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Abstract 
Synthetic Innovations Towards the Total Synthesis of Natural Product Derivatives for 
Drug Development 
 
Makeda A. Tekle-Smith 
   
 In order to provide scalable, efficient and selective routes towards pharmaceutically 
relevant compounds, we have focused on improving the economical viability and practicality of 
strained-silane Lewis acid activation. Towards these goals, the Leighton group has developed a 
new mode of anion catalysis to activate silane Lewis acids. Weakly coordinating anions have 
been used to access hyper-coordinate silicon species with unprecedented levels of reactivity, 
which have facilitated previously unattainable complex fragment couplings. A highly 
enantioselective and efficient method for anion catalyzed nucleophilic addition to aldehydes has 
enabled the synthesis of rationally designed, structurally simplified D-ring modified analogs of 
spongistatin 1. The completion of a step-economical route towards extremely potent, linker-
handle equipped spongistatin 1 analogs and their application to targeted drug delivery will be 
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 CHAPTER 1: Introduction 
 Non-aromatic polyketides are an essential class of compounds used in the pharmaceutical 
industry to combat unmet medical needs. The versatile architectural structures and 
unprecedented biological activity of non-aromatic polyketides have inspired and challenged 
medicinal chemists for generations (Figure 1.1). However, the inherent complexity of these 
molecules has at times limited their utility due to practical and economic concerns. Therefore, it 
is of critical importance that new approaches towards the synthesis and therapeutic development 
of non-aromatic polyketides are discovered. 
 
Figure 1.1: Non-aromatic polyketides of interest. 
Natural products and their direct derivatives make up 47% of all FDA approved drugs 
between 1981 and 2014.
1
 However, unaltered natural product drugs only make up 4 of the 47% 
of FDA approved natural product sourced drugs. It is clear that modification of the extraordinary 
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compounds we find in nature is both necessary and beneficial to extract the most desired drug-
like properties. A beautiful illustration of natural product synthetic modification is laid out in the 
Bristol-Myers Squibb synthesis of ixabepilone. Ixabepilone, which is the lactam analogue of 
epothilone B, was designed to increase metabolic stability while retaining potent antimitotic 
activity against paclitaxel-resistant cell lines.
2
 A simple lactone to lactam conversion was able to 
optimize the natural product, epothilone B, for medicinal use beyond the natural purpose it was 
initially created to perform (Figure 1.2). 
 
Figure 1.2: Structural modification of epothilone B to the more stable analog, ixabepilone. 
 In an effort to exploit the biological activity, particularly pertaining to cancer, of non-
aromatic polyketides, the Leighton group has approached the total synthesis of this class of 
molecules with a new vision. We have endeavored to 1) simplify the synthesis of natural 
products through rationally designed modifications and 2) create more efficient, step-economical 
routes towards non-aromatic polyketides by developing novel carbon-carbon bond forming 
methods. To maximize biologic control of our natural product derivatives, we also envision 
incorporating synthetic handles as a key part of our drug design process for downstream targeted 
drug delivery functionalization. The aforementioned goals have motivated the Leighton group’s 







, and targeted drug delivery payload innovation
16,17
. This thesis will 
describe innovations in each of the previously described areas which were necessary in the 
development of the natural product, spongistatin 1, as a viable anti-cancer therapeutic. 
1.1. Spongistatin 1 
1.1.1. Isolation and biological activity 
 
Figure 1.3: Initially reported structures of spongistatin, altohyrtin and cinachyrolide. 
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The spongipyran family is a class of complex marine natural products that exhibit 
extraordinary cytoxicity. In 1982, spongistatin 4 and 5 were first discovered by the Pettit natural 
product isolation group
18
. Spongistatins 1-9, altohyrtin A-C, and cinachydrolide A were 






 groups, respectively (Figure 
1.3). 
The structural assignment of altohyrtin C was first proposed using extensive NMR 
studies by the Kitagawa group and was later confirmed with the first synthesis of altohyrtin C by 
Evans and coworkers.
23,24
 Structural determination and verification also conclusively showed 
that altohyrtin C and spongistatin 2 were in fact the same compound.  The macrocyclic 
compounds that comprise the spongipyran family differ subtly in the E ring and AB fragment 
architectures as well as in the EF side chain substitution (Figure 1.3, Table 1.1). A more notable 
change is observed in spongistatins 5, 7, 8, and 9 which incorporate a G ring into the macrocyclic 
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 = Ac 0.03 0.13  5 (1.5): R = Cl, R
1 
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 = Ac 2.0 0.85  7 (1.7): R = R
1 
= H 2.0 1.00 




 = Ac 1.0 0.83  8 (1.8): R = H, R
1 
= Ac 3.0 0.23 




 = H 0.10 0.10  9 (1.9): R = Cl, R
1 
= Ac 0.3 0.04 
6 (1.6): R = R
2
 = H, R
1 
= Ac 0.80 1.10     
 
 Spongistatin 1 stands out in this exciting class of natural products as the most cytotoxic 
member in the spongistatin family. When tested against the 60 cell line in vitro screen of the 
National Cancer Institute, spongistatin 1 was shown to potently kill several solid tumor cell lines, 
including melanoma, lung, colon, and brain cancer cells (Table 1.1).
26
 Spongistatin 1 has also 
been successful in inhibiting growth of chemoresistant cell lines
26
 and has exhibited curative 
responses against human melanoma and ovarian xenografts without observed toxicity at 25 
μg/kg.
27
 In addition to being known as a potent anti-cancer agent, Spongistatin 1 has also been 
shown to be a powerful antifungal. Spongistatin 1 was fungicidal for a variety yeasts and 
filamentous fungi, including strains resistant to known antifungals: amphotericin B, ketoconazole 
and flucytosine.
27
 Spongistatin 1’s described potency coupled with its cell selectivity (10,000-
6 
 
fold more cytotoxic toward cancer cells than normal cells
27
) makes this molecule a highly sought 
after therapeutic target.  
1.1.2. Spongistatin 1 mechanism of action and SAR studies 
 It is worth examining in more detail the structural features of spongistatin 1 and their role 
in connection to biological activity. First, we must explore the mechanism by which 
spongistatins cause cell death. Spongistatin 1 targets tubulin, thus causing microtubule 
destabilization and subsequent cell arrest during mitosis.
26
 Microtubule-targeting agents (MTAs) 
can either stabilize or destabilize microtubule development to induce apoptosis. Whereas taxol 
and vinblastine, two of the most successful antimitotic FDA approved drugs, can be classified as 
stabilizing MTAs; spongistatin has been classified as a destabilizing MTA.
26
 Destabilizing agents 
shift the dynamic equilibrium of tubulin polymerization by inhibiting polymerization resulting in 
shorter spindles and hampered function.
28
 Destabilizing agents are a desirable target in order to 
help combat drug resistance against taxol and vinblastine. 
 
Figure 1.4: Structure activity relationship analysis of spongistatin 1. Red arrays indicate critical structural 
motifs and blue arrays indicate non-critical structural motifs. 
Upon examination of the structural variations of the spongistatin family, it is clear that 
certain areas of the molecule are critical to the desired biological function. Direct comparison of 
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1.1 and 1.2 highlight the importance of the C50 chloride in maintaining activity (Table 1.1). The 
affect of the chlorodiene side chain was further examined by Paterson and coworkers with a 




Figure 1.5: Paterson’s truncated side chain analog (1.10) and Smith’s CD spiroketal replacement analog 
(1.11). 
 Directly comparing 1.1, 1.3, and 1.4 indicates that the C5 acetate has some importance 
whereas the C15 acetate is non-essential for binding to tubulin. First Kishi, followed by Smith 
both observed the C23 epimer of spongistatins retained the potency of the parent compound
30,31
 
indicating that the CD spiroketal has limited structural significance. This hypothesis was 
bolstered by Smith’s synthesis of a simplified spongistatin 1 analog which completely removed 
the CD spiroketal and replaced it with an alkanoate strap. Despite a dramatic change to its 
molecular architecture, 1.11 still retains modest bioactivity (IC50 = 60-300 nM).
32
 The specific 
design of the CD spiroketal seems to hold little sway when binding to tubulin; however, Smith’s 
analog would suggest that the rigidity the CD spiroketal imparts is beneficial to overall activity. 
 A variety of other simplified spongistatin analogs have been explored (Figure 1.6). These 
compounds were found to be only weakly cytotoxic, with the best activity in the micromolar 
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range against certain cell lines (Figure1.6).
33,34
 Whereas the CD fragment’s only importance 
seems to arise from being molecular scaffolding, the same cannot be said of the AB fragment and 
EF fragments. Analogs 1.12 and 1.13 show that although both the AB fragment and EF fragment 
have some binding affinity on their own, both are required in order to maintain the desired 
picomolar potency of the parent compound. 
 




1.1.3. Spongistatin 1 crystal structure 
 Until recently, all structure activity relationship data was obtained through analysis of 
naturally occurring spongistatins and their analogs’ structural perturbations. However, work from 
Steinmetz and coworkers in 2018 has produced a high-resolution (2.4Å) crystal structure of 
spongistatin 1complexed with tubulin.
35
 Excitingly, this affords us the opportunity to examine 
the predictions of structural importance proposed in section 1.1.2.  
 There are six distinct tubulin-binding sites that have been structurally characterized to 
date, which are referred to as the taxane, laulimalide/peloruside, colchicine, vinca, pironetin and 
maytansine sites. Spongistatin 1 has been found to be a ligand of the maytansine binding site.
35
 
Most notably, the binding site interactions deemed critical involve the chlorodiene side chain, the 
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B ring, the F ring as well as the unsaturated alkyl linker between the E and D rings (Figure 1.7).  
This data confirms the findings obtained from the experimental structure activity relationship 
studies previously performed. Clearly the southwestern hemisphere of spongistatin 1 is not 
amenable to modification whereas the northeastern CD fragment can tolerate structural 
manipulation. 
 
Figure 1.7:Left: Crystal structure of spongistatin 1(purple) bound to the maytansine binding site of tubulin 
(grey). Key interacting residues are labeled in black. Hydrogen bond interactions are indicated with dashed 
lines. PDB ID 6FII. Right: Molecular structure of spongistatin 1 where tubulin-interacting moieties are 
depicted with red circles.
35
  
1.2. Previous syntheses of spongistatins 
 Spongistatin 1 appears to be an ideal candidate for drug development do to its incredible 
potency and known mechanism of action. However, spongistatin 1 has largely been discounted 
as a viable therapeutic target due to its limited natural material availability and highly complex 
molecular structure. Since its isolation in 1993, the efficient synthesis of spongistatin 1 has been 
a compelling challenge to the total synthesis community. 
 Spongistatin is a 42 membered macrolactone with 24 stereocenters; however, it is not 
simply the size of spongistatin that makes its synthesis so daunting. Three key structural motifs 
10 
 
have hampered the synthesis of spongistatin and drastically extended synthesis step counts and 
practicality. Installation of the highly sensitive chlorodiene side chain, selective formation of the 
singly anomeric CD spiroketal, and creation of the completely substituted F ring are all 
formidable synthetic tasks.  
1.2.1. Bond disconnection strategies 
 A universal bond disconnection strategy has emerged from the 7 groups that reported 















 have all used a Wittig olefination and subsequent 
macrolactonization to complete the synthesis of spongistatins 1 and 2. This retrosynthetic 
strategy provides two fragments of approximately equal complexity. Strategies begin to differ 
when constructing the polypropionate linker between the AB and CD fragments. Regardless of 
the AB-CD coupling strategy employed, each route was faced with the task of generating three 
main fragments: AB, CD, and EF.  
 
Figure 1.8: Retrosynthetic analysis of spongistatin 1 and 2. 
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1.2.2. Overview of AB-CD coupling strategies 
 The overwhelmingly popular AB-CD coupling strategy is an anti-aldol reaction between 
an α-chiral-β-γ-unsaturated AB aldehyde and two equivalents of a CD ketone, first pioneered by 
Evans and coworkers in the first synthesis of spongistatin 2 (Scheme 1.1).
36
 This reaction follows 
the Felkin-Ahn model to obtain the desired diastereoselectivity in a 70% yield and 90:10 dr.
36
  
An anti-aldol reaction is clearly a beneficial strategy in obtaining material in rather high 
selectivities. 6 of the 7 groups have used this reaction with success; nevertheless, this reaction 
does leave room for improvement. In particular, the α-chiral-β-γ-unsaturated AB aldehyde is 
highly unstable and prone to epimerization, thus necessitating immediate use of the intermediate. 
Use of excess CD ketone is also undesirable, and even with up to 80% recovery, the reaction 
yield with regards to the precious CD ketone material is untenable. 
 
Scheme 1.1: Evans’ anti-aldol AB-CD coupling strategy. 
 Additionally, the AB and CD fragments (1.17 and 1.18) have been joined using a Lewis 
acid catalyzed crotyl stannane coupling in Nakata’s formal synthesis of spongistatin 2 (Scheme 
1.2).
47
 Although this strategy ends up giving the undesired diastereomer and subsequently 
requires further downstream chemistry to set the correct stereochemistry, it is a creative 
alternative to the anti-aldol reaction. Formation and isolation of the AB crotyl stannane is also 
step intensive and costly. Despite these drawbacks, a crotylation strategy to install AB-CD bridge 




Scheme 1.2: Nakata’s AB-CD coupling strategy. 
1.2.3. Synthetic strategies towards the CD fragment synthesis 
 Spongistatin 1 is characterized by two 6,6-spiroketals, the doubly anomeric AB spiroketal 
and the singly anomeric CD spiroketal (Figure 1.8). A major synthetic challenge of spongistatin 
is the formation of the contrathermodynamic singly anomeric CD spiroketal. In the fully 
elaborated spongistatin macrocycle, the singly anomeric spiroketal is stabilized by the constraints 
of the macrocycle and by hydrogen bonding. These favorable forces, however, are not present 
when synthesizing the CD fragment. Since the doubly anomeric spiroketal is generally the more 
stable isomer, selective formation of the singly anomeric spiroketal and preventing isomerization 
in downstream chemistry are significant challenges that have plagued the synthesis of the CD 
fragment.  
Most strategies to prepare the CD spiroketal rely on acid-mediated spiroketalization with 
subsequent reequilibration of the undesired doubly anomeric spiroketal as was described by 
Evans (Scheme 1.3).
30,48–52
 This step presents a major restriction in the synthesis of the CD 
fragment and significantly impedes scalability. Due to the limitations of recycling material, a 







, and Roush 
56
have pursued beautiful strategies for selective 
formation of singly anomeric spiroketals. However, forming the spiroketal selectively is only a 
temporary success in the saga of installing this type of functionality. Preventing isomerization of 
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the singly anomeric spiroketal remains just as challenging as introducing it and greatly restricts 
the type of allowed downstream chemistry.  
 
Scheme 1.3: Evans acid-mediated spiroketalization and subsequent reequilibration.
48
 
The challenges associated with the CD fragment have justified the development of 
spongistatin 1 analogs with the CD spiroketal excised. However, as was discussed in section 
1.1.2, the structural scaffolding that the CD spiroketal provides remains a critical component in 
the thermodynamic favorability of spongistatin-tubulin binding. What makes spongistatin a 
worthy medicinal target is its picomolar potency and favorable pharmacological properties. 
Therefore it is necessary to retain, if not improve upon, the natural biological activity of the 
compound. In order to accomplish a practical, scalable, and efficient synthesis of a highly potent 
spongistatin, the CD spiroketal either needs to be installed late in the synthetic route or needs to 
be modified to increase stability and ease of synthesis. 
1.2.4. Overview of EF-chlorodiene aldehyde coupling strategies 
 The EF side chain of spongistatin 1 is one of the most intricate and challenging 
areas of the molecule to construct. The demands of the EF side chain arise from inherent 
sensitivity of the chlorodiene moiety. Preventing elimination of the C47 alcohol into tetraene 
conjugation has been an impediment to coupling strategies. Structural fragility coupled with the 
14 
 
stereochemical requirements of the C47 alcohol combine to make a uniquely challenging 
synthetic array.  
There have been several creative strategies to approach EF side chain installation. The 
first approach that will be discussed is the installation of a functionalized chlorodiene fragment 
that can attach directly to the F-ring. This approach was first used in the Evans synthesis of 
spongistatin 2
57
 in order to attach the more stable diene side chain and adapted for later syntheses 
of spongistatin 1.
58 Aldehyde 1.20 was obtained in a multiple step sequence and subsequently 
underwent an indium promoted allylation and dehydration to give the chlorodiene 1.22 (Scheme 
1.9). Using Trost’s palladium-catalyzed π-allyl chemistry, the allyl stannane 1.23 was obtained in 
a 67% yield. Similarly to Nakata’s synthesis of crotyl stannane AB fragment 1.17, generating and 
isolating allyl or crotyl stannanes is both step intensive and yield inefficient.  
 
Scheme 1.4: Crimmins’ synthesis of allyl stannane 1.23.
58
 
Once 1.23 was completed, chlorodiene side chain installation was achieved through 
direct addition to the F ring (Scheme 1.5). Selective epoxidation of enol ether 1.24 was carried 
out, which was treated immediately with 1.23 and Bu3SnOTf to afford the desired product 1.26 
in a 75% yield as a single diastereomer. Epoxide opening to achieve desired connectivity and 
selectivity is a tactful approach towards this major synthetic challenge. Drawbacks associated 
with this coupling strategy include a long synthetic sequence to achieve intermediate coupling 





Scheme 1.5:Chlorodiene side chain installation endgame.
58
  
 Other syntheses of spongistatin 1 have relied on multi-step coupling strategies, wherein 
the sensitive chlorodiene moiety is introduced and further synthetic manipulation is done to 
achieve desired stereochemistry and functionality of the complete side chain. Paterson and 




Scheme 1.6: Paterson’s boron-mediated aldol approach. 
The Smith group used an umpolung approach with a nucleophile equivalent of the side 
chain and allyl halide EF fragment.
31
 Alcohol elimination and enantioselective ketone reduction 
were then required to generate the chlorodiene and C47 stereocenter, respectively. The problems 
associated with this area of the molecule have pushed groups towards new synthetic innovation 
in order to meet the demands of spongistatin 1. Nevertheless, there has yet to be an established 
ideal EF-chlorodiene installation route. The ultimate side chain formation would use a readily 
available chlorodiene containing intermediate that can be coupled with a stable EF fragment 





Scheme 1.7: Smith’s umpolung chlorodiene side chain approach. 
1.3. Leighton group strategies towards natural product drug development 
1.3.1. Overall goals 
The unanswered challenges associated with the total synthesis of spongistatin 1, that we 
believe will have a meaningful impact on drug development, fall into two main categories: 1) 
inherent structural weaknesses with regards to pharmaceutical needs and 2) a dearth of methods 
for complex fragment coupling reactions which are scalable and impart high stereocontrol. We 
believe progress in these two areas will lead to a usable synthesis of a spongistatin 1 lead 
compound. As discussed, SAR studies of spongistatin have shown that a drastically simplified 
analog is not a feasible approach to exploit the biological activity imparted by spongistatin’s 
unique tubulin binding mode. Therefore it will be necessary to include the inherent structural 
complexity of the naturally occurring compound in our proposed drug target; however, this does 
not negate our ability to synthetically simplify our proposed synthesis. Generating a compound 
as structurally complex as spongistatin 1 raises an immediate concern over the economic 
viability of use in a commercial space. One way in which we envision combating that issue is 
through the use of targeted drug delivery applications, such as antibody-drug conjugates (ADCs), 
which can maximize material use for desired therapeutic effect.  
 Herein we will describe and implement a retrosynthetic strategy in which we not only 
look for new and more efficient bond disconnections, but also for possible structural 
manipulations. These two considerations, in combination, have the potential to tackle the 
17 
 
problems that have prevented spongistatin 1’s clinical use for over 25 years. With spongistatin 1 
as our flagship warhead, we hope to introduce a new class of payloads to the ADC community. 
We believe this strategy towards natural product analog development can be widely applied in 
the field of total synthesis, in order to more efficiently take advantage of creative synthetic work 
for medicinal use. 
1.3.2. Overview of strained silane chemistry 
 In accordance with our goal to develop new methods for complex fragment couplings, we 
envision using strained silane-mediated aldehyde allylations and crotylations as an ideal way to 
install the desired stereochemical arrays of spongistatin 1. The Leighton group first established 





Scheme 1.8: A new reagent for the enantioselective allylation of aldehydes. 
It is well precedented that silicon, when constrained into a 4 or 5 membered ring, exhibits 
a substantial increase in Lewis acidity.
60
 Increasing the Lewis acidity of a silane facilitates 
carbonyl electron pair donation, thus generating a formal positive charge on the carbonyl carbon 
which subsequently lowers the activation barrier for nucleophilic addition. Strain-release Lewis 
acidity has been demonstrated by Utimoto’s experiments comparing 1.33 and 1.34, where acyclic 
species exhibit much lower Lewis acidity, and thus reactivity, than their strained silacycle 
counterparts (Figure 1.9).
61
 This phenomenon has been rationalized by Denmark and coworkers 
who propose that because the A-Si-B bond angle has been compressed from its ideal tetrahedral 
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geometry, addition of a nucleophile is favored so that silicon can rehybridize to the trigonal 
bipyramidal species (Figure 1.10).
62
 The trigonal bipyramidal geometry is able to better 
incorporate the A-Si-B bond angle, effectively relieving the strain of the initial silane complex 
and driving the reaction forward.  
 
Figure 1.9: Utimoto’s strained silane Lewis acidity experiments. 
 
Figure 1.10: Denmark’s rationale for strain-release Lewis acidity. 
Leighton and coworkers have exploited strain-release Lewis acidity to build a library of 
chiral strained silane Lewis acid reagents for various applications.
8–12,14,15,63
Notably, the 
development of 1.35 enabled the highly selective crotylation of aldehydes including aliphatic 
aldehydes.
12
 This was a marked advance for the field of crotyltrichlorosilane addition to 
aldehydes, which until now had been dominated by Denmark’s chiral Lewis base-catalyzed 
crotylations.
64,65
Denmark’s crotylation methodology is incompatible with the majority of 
aliphatic aldehydes, thus making it widely unusable for non-aromatic polyketide synthesis. Up 
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until now the industry standard crotylation methodology for non-aromatic polyketide synthesis 
has either been the Brown crotylation
66
 or the Roush crotylation
67
. 1.35 is seen as a highly 
desirable alternative to the Brown and Roush crotylation reagents because it is a bench stable 
crystalline solid that is inexpensively prepared. The method also does not require toxic reagents 
or produce toxic byproducts, and the chiral ligand is easy to separate and purify away from the 
homoallylic alcohol products. 
 
Figure 1.11: Highly diastereo- and enantioselective reagents for aldehyde crotylations.
12
 
 A further advance in asymmetric crotylations arose with the discovery that both Brønsted 
acids and Lewis acids, such as scandium triflate, effectively catalyze the reactions depicted in 
Figure 1.11. This discovery reduced reaction times and dramatically increased the aldehyde 
scope of the reaction.
63
 The improvement in reactivity is attributed to Lewis acid interaction with 
one of the nitrogens in 1.35 which facilitates N to Si π-type donation. The result of this 
interaction is that the silicon becomes more electropositive and more readily accepts the 
aldehyde substrate to promote crotyl transfer. Mixtures of the E-1.35 and Z-1.35 with Sc(OTf)3 




The one drawback to the EZ-CrotylMix is the need to isolate and purify the strained 
silane complexes away from the DBU•HCl salts formed during the complexation reaction. If 
DBU•HCl salts are present when Sc(OTf)3 is introduced, the catalyst is deactivated through 
chloride-triflate ligand exchange. In an effort to obviate the need for Sc(OTf)3 and develop a 
more reactive one-pot approach to aldehyde crotylations, the tridentate ligand 1.36 was 
developed.
15
 Conformational restraints of the tridentate ligand 1.36 renders the strained silane 
complex more Lewis acidic enabling facile allylation and crotylation of a wide scope of 
aldehydes in high yields and selectivities (Figure 1.12). 
 
Figure 1.12: One-pot crotylation procedure.
15
 
 The strength of the Leighton strained silane allylations and crotylations is highlighted in 




. We envision using the Leighton 
one-pot crotylation procedure to tackle the formidable challenges laid out in both the AB-CD 
fragment coupling as well as the EF-chlorodiene side chain coupling of spongistatin 1. 
Furthermore, we strive to use the wealth of knowledge on silane-mediated asymmetric 
allylations, collected by the Denmark and Leighton groups, to push the frontier of this field. 
1.3.3. Overview of targeted drug delivery 
 Targeted drug delivery is an exceptionally intriguing concept for the total synthesis 
community. Not only are there incredible therapeutic benefits to selectively delivering cytotoxic 
agents to diseased tissue and bypassing healthy tissue, but this “smart” delivery approach also 
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requires less drug material to obtain desired biologic effects. That being said, one of the main 
challenges associated with targeted drug delivery is obtaining potent chemical payloads. The 
amount of drug delivered to tumor targets is less than 5% due to blood circulation, extravasation, 
and tumor microenvironment heterogeneity.
70
 Therefore it is of vital importance to have highly 
cytoxic agents, such as spongistatin 1, as chemical payloads. 
One promising targeted drug delivery approach is antibody-drug conjugation. ADCs 
deliver warheads directly to tumor cells through recognition of tumor specific antigens. Once 
bound to a tumor cell, the ADC enters the cell through receptor-mediated endocytosis at which 
time the drug is cleaved from the antibody, usually in the lysosome (Figure 1.13). The ability of 
ADCs to directly target tumor cells decreases non-specific toxicity of the drug toward normal 









The origin of ADCs can be traced back over a century to when Paul Ehrlich proposed the 
concept of selectively delivering a cytotoxic drug to a tumor via a targeting agent.
72
 This so 
called ‘magic bullet’ has been sought after ever since (Figure 1.14). Nearly 50 years later, this 
concept was realized when methotrexate (MTX) was linked to an antibody targeting leukemia 
cells.
73
 In 1972 noncovalent-linked ADCs were first tested in animal models and soon after 
covalently linked ADCs were tested. In 1975, the landmark development of mouse mAbs greatly 
advanced the field of ADCs. The first human clinical trial followed less than a decade later, with 
the antimitotic vinca alkaloid vindesine as the cytotoxic payload. Further advances in antibody 
engineering enabled the production of humanized mAbs with reduced immunogenicity in 
humans compared with the murine mAbs used for early ADCs. Finally, in 2001, the first FDA 




Figure 1.14: ADC development timeline. 
There are currently four approved ADCs on the market: Mylotarg, Adcetris, Kadcyla, and 
Besponsa. Although there are significantly high barriers towards achieving a successful ADC, the 
future of ADC is promising with 60 ADCs currently undergoing clinical trials. Our goal is to 
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increase the pool of available highly cytotoxic drug payloads to increase the variety of potential 
conjugates and hopefully develop more effective ADCs. 
1.4. Summary and Outlook 
 Natural product synthesis has been a major driving force for synthetic innovation since 
the first complex molecules were engineered in a flask.
75
 In particular, non-aromatic polyketide 
total synthesis has necessitated the advent of high-utility asymmetric reactions.
76
 The previous 
work that has been done on the total synthesis of spongistatin 1 is a prime example of how 
instrumental natural product synthesis is in developing new tools for the synthetic community 
and new lead compounds for the pharmaceutical industry. The work that will be laid out in the 
following chapters aspires to continue the incredible total synthesis legacy of useful reaction 
development as well as disrupt current complex-molecule design and synthesis practices.  
In order to pave a path towards spongistatin 1 drug candidacy, we have (1) developed 
novel methods for the installation of chiral alcohols, (2) applied these methods in the total 
synthesis of spongistatin 1 analogs, as well as (3) developed spongistatin 1 analogs as payloads 
for targeted drug delivery applications. Specifically, we report the anion catalysis of silanes to 
access highly reactive 6-coordinate intermediates for carbonyl activation and subsequent carbon-
carbon or carbon-hydrogen bond formation. The medicinal utility and importance of fundamental 
research into silicon Lewis acidity and methods development is illustrated in the synthesis of a 
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  CHAPTER 2: Synthesis of linker-equipped spongistatin 1 analogs 
2.1. Introduction 
Among the large group of natural products known to express their anti-cancer activity by 
disrupting microtubule dynamics, spongistatin 1
1–3
 is particularly notable for its extraordinary 
potency, with an average GI50 value against the NCI panel of 60 human cancer cell lines of 0.12 
nM
1,4
. While the clinical utility of this class of compounds is well established, such ultra-potency 
is often associated with dose-limiting toxicities that render them unsuitable for use as standalone 
chemotherapeutics. Conversely, antibody-drug conjugates (ADCs) target tumor-specific antigens, 
thereby selectively delivering their cytotoxic payload to the cancer cells and effectively 
increasing its therapeutic index and minimizing off-target toxicities
5–8
. Very little drug material is 
delivered to the cancer cells using ADCs; therefore, it is not only possible but advantageous to 
employ ultra-potent cytotoxins that might otherwise be too toxic for use as cancer drugs as ADC 
payloads. Thus, spongistatin 1, which has been shown to exhibit significant in vivo antitumor 
activity in an orthotopic pancreatic cancer mouse model
9
 and in a melanoma xenograft model
10
, 
is an attractive candidate for development and evaluation as the drug component of ADCs and 
other selective cancer cell-targeting conjugates. 
2.1.1. Antibody-drug conjugates 
The three most basic requirements for a drug to be a candidate for development as an 
ADC payload are: 1) sub-nanomolar potency with a clinically validated mechanism of action, 2) 
access to a supply of the compound either from natural sources or by chemical synthesis, and 3) 
a functional group that can be used in selective conjugation reactions, located in a region of the 
molecule that is not critical for activity such that chemical modification does not result in any 
30 
 
significant loss of potency. While spongistatin 1 meets the first criterion, it is not available from 
natural sources, and it does not have a functional group that can serve as a synthetically selective 
and pharmacologically innocent linker attachment point. The latter two challenges can be 
addressed only by chemical synthesis, and though several ground breaking syntheses of 
spongistatin 1 and 2 have been reported
11–30
, spongistatin’s size and structural and stereochemical 
complexity necessitate unusually long synthetic sequences that could render such ADC payload 
development efforts prohibitively laborious. We therefore set out not only to develop a more 
step-economical and efficient synthesis of the spongistatins but also to design, where possible, 
structurally simplified yet equipotent analogs
31
 to render the synthesis and development efforts 
less time- and resource-intensive. 
2.1.2. Spongistatin 1 analog design 
Ideally, the design of structurally simplified and pharmacologically innocent linker-
equipped analogs would be guided by structural biological information regarding the interaction 
of spongistatin 1 (2.1) with its receptor, but such information
32
 wasn’t available until after this 
work was completed. We thus turned to Smith’s remarkable report that a “diminutive congener” 
(2.2) in which the entire C(12)-C(28) region was replaced with a simple linear alkanoate strap 
retained some significant potency (Figure 2.1)
33
. This suggested to us that the deleted portion of 
the molecule primarily plays an indirect scaffolding role to favor the biologically active 
conformation and reduce the entropic cost of binding, and in turn that more subtle structural 




Figure 2.1: Smith’s simplified analog 2.2 retains some significant potency suggesting that the C(12)-C(18) 
fragment and the CD-spiroketal are not in contact with the receptor in the bound conformation, and that 
their role is to serve as scaffolding to lock the compound in its active conformation. 
That the CD spiroketal is located in this part of the molecule was of particular interest 
because it occurs in its thermodynamically less stable singly anomeric form and all attempts to 
access it directly by way of an acid-mediated spiroketalization reaction of dihydroxy ketones 
(2.3), as discussed in subsection 1.2.3, lead to the doubly anomeric form as the major product 
necessitating an inefficient and laborious separation/equilibration/separation sequence (Figure 
2.2). Given that the primary role of the CD spiroketal is to properly orient the RAB and REF 
groups, we hypothesized that a redesigned CD* spiroketal in which the D-ring oxygen atom has 
been relocated to the anomeric position and the C(25) hydroxyl group has been deleted would be 
both readily accessible by spiroketalization of dihydroxyketone 2.4 and isostructural with the 




Figure 2.2: CD fragment spiroketal D-ring redesign. 
Another important advantage might accrue to the D-ring redesign: ADC payloads must be 
chemically stable in the low pH environments of the endosome and lysosome, and whereas the 
natural CD spiroketal might well be susceptible to isomerization to the presumably far less 
potent doubly anomeric form in such environments, the redesigned CD* spiroketal should be 
immune to isomerization. In seeking to identify a group that may be amenable to modification to 
incorporate a linker functional group with no deleterious impact on potency, we noted that the 
C(15)-OAc group is also located within the deleted region (Figure 2.1). Our focus on this group 
as a pharmacologically innocent linker group installation site was further supported by the fact 
that spongistatins 4 and 6, which differ from spongistatins 1 and 2 only in having a C(15)-OH 
group, are ~equipotent with spongistatins 1 and 2, respectively, while spongistatin 9, in which 
the C(15)-oxygen is cyclized on to the C(13) alkene to form a THF ring is also ~equipotent with 
spongistatin 1 (Table 1.1).
33
 In stark contrast, the C(5)-OAc appears to be important for activity 
in that spongistatin 3 with a free alcohol at C(5) is about an order of magnitude less potent than 
spongistatin 1. Together, these data establish that the C(15)-acetate is not critical for activity, and 
our aims thus evolved as 1) the development of more step-economical methods and strategies for 
33 
 
the synthesis of the spongistatins, 2) synthesis and evaluation of the D-ring-redesigned analog 
2.5 (R = Me), and 3) synthesis and evaluation of azide-equipped ester analogs (R = linker-N3). 
 
Figure 2.3: D-ring modified analog 2.5, where R is the proposed site for linker incorporation without a 
significant loss of potency. 
2.1.3. Spongistatin 1 retrosynthesis 
Retrosynthetic disconnection by way of macrolactonization and Wittig reactions
14
 leads 
to two major fragments of approximately equal complexity, the ABCD* aldehyde 2.6, and the EF 
phosphonium salt 2.7 (Figure 2.4). Within both of these fragments may be found homoallylic 
alcohols (highlighted in red) that could in principle be the products of a syn-crotylation reaction 
of a crotylmetal(loid) derived from 2.8 with aldehyde 2.9a or 2.9b, and an alkallylation reaction 
of a allylmetal(loid) derived from 2.11 with aldehyde 2.10, respectively. While we saw in these 
hypothetical transformations great potential to streamline the synthesis, such direct (i.e. 
generation and use, without isolation, of the active crotyl-/allylmetal species) and highly 
stereocontrolled complex fragment coupling reactions wherein the crotyl or allyl donor is 
stereochemically and functionally complex were unknown. The critical methodological 
challenge was thus the generation of versions of 2.8 and 2.11 possessed of the necessary 
reactivity to efficiently and highly stereoselectively couple with aldehydes 2.9 and 2.10 from 
simple and readily available precursors and in a way that does not require their isolation. We 
34 
 
were optimistic that our diamine- and diaminophenol-activated crotyl- and allylsilanes
34,35
 
would, uniquely, be well-suited for the proposed reactions due both to their reliably excellent 
reactivity and broad generality and to the fact that the requisite crotyl- and allylsilanes appeared 
accessible from the precursors diene 2.8
36
 and allyl chloride 2.11 by way of mild, functional 
group-tolerant, and chemoselective transition metal-catalyzed hydrosilylation and allylic 
substitution reactions, respectively. 
 
Figure 2.4: The target molecules may be split into the ABCD* (2.6) and EF (2.7) fragments, which may be 
coupled with a Wittig reaction, followed by macrolactonization to complete the synthesis. A direct complex 
fragment coupling syn-crotylation reaction of 2.8 with CD* spiroketal aldehyde 2.9a or 2.9b was envisioned as 
the key step in the synthesis of the ABCD* fragment, while a direct complex fragment coupling alkallylation 
reaction of 2.10 with aldehyde 2.11 was envisioned as a critical step in the synthesis of the EF fragment. 
2.2. Synthesis of CD* aldehydes 
2.2.1. CD* aldehyde retrosynthetic plan 
Not knowing at the outset which of the C(17) diastereomeric aldehydes 2.9a and 2.9b 
would perform best in the critical fragment coupling crotylation reaction, we developed a 
flexible and efficient route to both. The first generation synthesis of aldehyde subunit 2.9a, 
developed by Dr. Linda Suen, envisioned forming the CD* spiroketal through a spiroketalization 
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of the polyketide fragment 2.12, which could be accessed from a Mukaiyama aldol reaction of 
aldehyde 2.13 and methyl ketone 2.14 (Figure 2.5).  
 
Figure 2.5: Retrosynthetic plan for the synthesis of the CD* aldehyde. 
2.2.2. Synthesis of 2.9a
1
 
Starting from the PMB aldehyde 2.15 allylation, TES protection, and oxidative cleavage 
furnished this TES PMB aldehyde 2.18. The Leighton one-pot crotylation with cis-crotyl 
trichlorosilane furnished the resulting diol 2.20 which was protected with an acetonide. PMB 
deprotection followed by swern oxidation resulted in the desired aldehyde subunit 2.13a 
(Scheme 2.1A).  
                                                     
1
 Synthesis of 2.9a was carried out by former graduate student Dr. Linda Suen. 
2





Scheme 2.1: A) Synthesis of aldehyde subunit 2.13a. B) Synthesis of 2.9a. 
 Use of 2.13a and 2.14 in a 5 step sequence involving a Mukaiyama aldol, methyl ether 
formation, spiroketalization, TES protection, and ozonolysis furnished 2.9a (Scheme 2.1B). This 
5 step sequence will be discussed in detail in subsection 2.2.3.  
2.2.3. Synthesis of 2.9b 
In order to synthesize the C(17) diastereomer 2.9b, the same retrosynthetic strategy was 
applied. However, interestingly a subtle change in stereochemistry had quite substantial effects 
on the synthetic approach to this fragment. The first three steps of this synthesis (allylation, TES 
protection, and oxiditative cleavage) were identical to that of the 2.9a synthesis. The Leighton 
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one-pot crotylation with trans-crotyl trichlorosilane successfully installed C(17) stereocenter of 
2.24 in an 82% yield >20:1 dr. Acetonide protection furnished the anti-diol acetonide 2.25.  
 
Scheme 2.2: Synthesis of aldehyde subunit 2.13b. 
The importance of the new stereocenter emerged during the attempted PMB deprotection 
of 2.25. Initial attempts to deprotect the PMB ether with standard DDQ conditions resulted in 
acetonide migration to the less sterically strained primary alcohol. The acidic 2,3-dichloro-5,6-
dicyanohydroquinone byproduct, which can produce HCN, of the DDQ deprotection was 
considered the most likely cause of the undesired reaction pathway. To combat this problem the 
ratio of CH2Cl2 to pH 7 buffer was decreased from 20:1 to 7.5:1. Buffering the reaction 
prevented acid mediated acetonide migration to give the desired free alcohol 2.26 in a 94% yield. 
Similarly, when Swern oxidation conditions were attempted on 2.27, acetonide migration to the 
less hindered primary alcohol was observed before aldehyde formation could occur. The ketone 
2.13c was the only product isolated indicating that milder oxidation conditions were required. 
Oxidation with Dess–Martin periodinane, which can be performed under neutral pH, gave only 




Scheme 2.3: Illustrations of the importance the C(17) stereocenter on the synthesis of 2.9b. A. PMB 
deprotection optimization to minimize undesired acetonide migration. B. Ketone 2.13c synthesis via swern 
oxidation of 2.27. 
After the synthesis of the aldehyde subunit 2.13b, as described in scheme 2.2, 2.13b and 
2.27 were coupled through an aldol reaction under Mukaiyama aldol conditions. The anti aldol 
product 2.28 was formed smoothly upon addition of 2.13b. The alcohol was then converted to 
the methyl ether 2.29 by treatment with Meerwein salt. Addition of PPTS then resulted in 
selective spiroketalization to form the doubly anomeric spiroketal 2.30. Finally TES protection 
and ozonolysis of the terminal olefin provided the final CD* aldehyde 2.9b in 25% overall yield 
with a longest linear sequence of 12 steps (Scheme 2.4). Synthesis of the CD* fragment enabled 
critical analysis of the AB-CD* coupling which will be discussed in section 2.3. 
 
Scheme 2.4: Full elaboration of the CD* fragment 2.9b. 
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2.2.4. Synthesis of 2.9b via 2.38 
To facilitate the most step-economical synthesis of spongistatin 1, a variation of the CD* 
anti-aldehyde synthesis was carried out.
2
 With mild, functional group tolerant reaction conditions 
in hand, we envisioned bringing the C(15) aldehyde through the synthesis masked as an acetal. 
By inverting the synthetic strategy of aldehyde subunit 2.13b, we remove the PMB deprotection/ 
DMP oxidation sequence and replace it with a simple oxidative cleavage. We also proposed a 
single pot TES triflate mediated TES protection and acetal deprotection reaction as the final step 
for the CD* fragment synthesis.  
Beginning with the commercially available 2.32, a one-pot hydroformylation/allylation 
was carried out to set the C(16) and (C17) stereocenters. TES protection of 2.33 followed by 
oxidative cleavage reveals aldehyde 2.35. Leighton allylation and in situ TES deprotection gives 
2.36 which can subsequently be acetonide protected. Finally, oxidative cleavage of 2.37’s alkene 
will give the desired aldehyde subunit 2.38 (Scheme 2.5). 
 
Scheme 2.5: Synthesis of the aldehyde subunit 2.38. 
2.38 was taken on to participate in the Mukaiyama aldol coupling with 2.27 in a 70% 
yield and 9:1 dr.  The alcohol 2.39 was then converted to the methyl ether 2.40 by treatment with 
                                                     
2
 The synthesis of 2.38 was carried out with graduate student Tyler Casselman. 
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Meerwein salt. Addition of PPTS then resulted in selective spiroketalization to form the doubly 
anomeric spiroketal 2.41. However, when the single pot TES triflate mediated TES protection 
and acetal deprotection was attempted the reaction stalled after TES protection of the C(17) 
alcohol. It is hypothesized that once TES protection occurs the steric environment surrounding 
the acetal has become too congested to allow facile deprotection under the said conditions. This 
hypothesis was given credence once TES protected 2.41 was isolated and subjected to TMSOTf 
conditions which easily furnished the desired aldehyde 2.9b in 90% yield. Upon further 
optimization of this reaction, we were able generate a one-pot protocol, using both TESOTf and 
TMSOTf, to obviate the need for isolation of the TES protected 2.41 intermediate. Finally, 
purification of 2.9b by column chromatography resulted in isolation of a single diastereomer in 
82% yield (Scheme 2.6). 
 
Scheme 2.6: Completion of a more step-economical synthesis of 2.9b. 
2.3. AB-CD* coupling  




Figure 2.6: Proposed AB-CD* coupling strategy. 
 With the CD* aldehyde and AB fragment
3,36
 in hand, we were prepared to attempt the 
critical AB-CD* coupling. We envision coupling the AB and CD* fragments through a complex 
crotylation reaction between AB diene 2.8, which can then be converted to the crotylsilane 2.42, 
and the CD* aldehyde 2.9 (Figure 2.6). The first generation AB-CD* coupling, developed by Dr. 
Linda Suen and Dr. Samuel Reznik, was relatively successful using the Sc(OTf)3 catalyzed 
Leighton crotylation
34
 to produce 2.43 in a range of yields (50-77%) (Scheme 2.7). While we 
were gratified by this proof-of-concept result, the requirement for isolation of the intermediate 
crotylsilane 2.42 (necessary because the DBU•HCl salts poison the Sc(OTf)3 catalyst) was 
deemed highly problematic. Crotylsilanes, such as 2.42, are prone to degradation when exposed 
to moisture both rendering the isolation technically difficult and risky and leading to significant 
variability in the yield of the reaction. Another limitation that we hoped to overcome was the use 
of 1.3 equivalents of the AB diene. When yields are calculated in regards to the AB diene, the 
reaction is left wanting. We approached solving these problems by applying the newly develop 
one-pot tridentate ligand allylation methodology
35
. 
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Scheme 2.7: First generation AB-CD* coupling. 
2.3.2. One-pot AB-CD* coupling 
 
Scheme 2.8: Proposed reaction for an optimized, one-pot AB-CD* coupling. 
 
 When the proposed protocol (Scheme 2.8) was employed to generate and react (without 
isolation) crotylsilane 2.45 with 2.9a, we were surprised to find that the reaction produced, at 
best, trace amounts of the desired product. Based on a computational model for the first 
generation crotylsilylation reaction
37
 and on Evans’ comprehensive model for merged 1,2- and 
1,3-stereoinduction in related aldol reactions
38
, we constructed transition state model A for the 
reaction of crotylsilane 2.45 (Figure 2.7). This exercise revealed that the tethering of the phenol 
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to the silane with diaminophenol ligand 2.46, which induces the greater reactivity in the silane, 
also has the unintended consequence of generating a prohibitive steric interaction between the t-
Bu group on the phenol ring and the -OTES group on the aldehyde. We hypothesized that we 
could alleviate this interaction by employing diaminophenol (R,R)-2.46a with a methyl group in 
place of the t-Bu group and by employing CD* aldehyde 2.9b (C(17)-R), to result in a reaction 
that would proceed smoothly by way of transition structure B.  
 
Figure 2.7: Transition state A: The -OTES group on aldehyde 2.9a is shown to have a prohibitive steric 
interaction with the t-Bu substituent of ligand 2.46. Transition state B: Changing the C(17) stereocenter 
minimizes the unfavorable steric clash in the six-membered transition state. 
Gratifyingly, this proved to be the case with the crotylsilane formed from diene 2.8 and 
(R,R)-2.46a reacting with aldehyde 2.9b to give the desired product 2.48 as a single diastereomer 
in 69% yield from diene 2.8 and in 81% yield from aldehyde 2.9b (Scheme 2.9). Crucially, 
because no isolation of the crotylsilane is necessary, the reaction is robust, reproducible, and 




Scheme 2.9: One-pot AB-CD* coupling with aldehyde 2.9b. 
2.4. Synthesis of ABCD* aldehyde 
 Completion of the ABCD* fragment synthesis comprised a 5-step sequence as described 
in Scheme 2.10. This chemistry was initially worked out using 2.44, and entailed, 1. acetylation 
of the C(15) alcohol, 2. deprotection of the TMSE ester, TFA group, and the C(17) and C(28) 
silyl ethers, 3. esterification of the C(1) acid with tri-iso-propylsilyl chloride (TIPSCl), 4. double 
oxidation of the C(17) and C(28) alcohols, and 5. protection of the tertiary carbinol as its TES 
ether to produce the completed ABCD* fragment 2.6a in 50% yield over the 5 steps. Overall, the 
route to ABCD* fragments 2.6a comprises just 18 steps in the longest linear sequence (LLS) and 




Scheme 2.10: Final five-step sequence to complete the synthesis of 2.6a. 
Interestingly, when the above five-step sequence was carried out on 2.48, the importance 
of the C(17) stereocenter again emerged (Scheme 2.11). Global deprotection which should have 
revealed the polyol 2.52, instead led to a mixture of desired product and acetate migration 
product. In contrast to the C(17)-S stereocenter present in 2.44, the C(17)-R alcohol is oriented in 
a 1,3-syn relationship with the C(15) acetate, which readily forms a chair-like transition state to 
undergo acetate migration (Scheme 2.11B). Using TASF as a mild fluoride source and buffering 
the reaction with pH 7 buffer minimizes the acetate migration product to acceptable levels. TIPS 




Scheme 2.11: A. Final five-step sequence to complete the synthesis of 2.6a starting from 2.48. B. Proposed 
transition state for the observed acetate migration process. 
The D-ring redesign had the intended impact on the ease and scalability of the synthesis 
of aldehydes 2.9, while the ease and scalability of the single step conversion of 2.8 and 2.9b to 
2.48 – the first example of a direct and highly stereoselective complex fragment coupling 
crotylation reaction – made possible the rapid and far less resource- and time-intensive synthesis 
of the ABCD* fragments. 
2.5. Synthesis of linker-equipped ABCD* aldehydes 
2.5.1. Linker Synthesis  
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 With a successful route to the ABCD* fragment in hand, we know turned our attention to 
one of the main goals of this project: developing a novel payload for antibody-drug conjugation. 
In accordance with the spongistatin 1 analog design, described in section 3.1.2., we wanted to 
replace the C(15)-OAc with an azide-bearing group. We chose 2.55 and 2.60 as potential linker 
candidates for 1) ease of synthesis, 2) robust architecture and 3) steric bulk to prevent ester 
hydrolysis. It was critical that the linker acids could be produced on scale without adding undue 
burden to the total step count. The molecular architecture of the candidates also needed to be able 
to survive downstream chemistry, thus not creating a liability for total synthesis completion. 
Finally, steric bulk around the ester attachment point was hypothesized as desirable in order to 
discourage premature release of the drug payload. With these considerations in mind we set out 
to synthesize 2.55 and 2.60. 
 
Scheme 2.12: A. Synthesis of linker-handle 2.55. B. Synthesis of linker-handle 2.60. 
2.55 and 2.60 were prepared as described in Scheme 2.12. Formation of 2.55 by a SN2 
reaction between NaN3 and chloroacid 2.54 was easily carried out in a 79% yield (Scheme 
2.12A). 2.60 was prepared starting from anhydride 2.56. Lactone 2.57 was easily converted to 
the methyl ester 2.58, which cleanly underwent SN2 to afford azide 2.59. Saponification of the 
methyl ester afforded our desired azidoacid 4.77 in 50% yield over four steps (Scheme 2.12B). 
2.5.2. Full elaboration of linker handle equipped ABCD* aldehydes 
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 By synthesizing linker functional group handles as the carboxylic acids, we were able to 
easily adapt the acetate installation reaction to, instead, install our azide-bearing groups. Using 
the 5-step sequence starting from 2.48, we synthesized two azide-bearing ester linker candidates 
at C(15), 2.6b and 2.6c. Each carboxylic acid was reacted with 2,4,6-trichlorobenzoyl chloride to 
form its mixed anhydride, which were then used for the acylation of 2.48 to provide the 
corresponding esters 2.61b and 2.61c. The final global deprotection, TIPS protection, double 
DMP oxidation, TES protection sequence was performed as previously described. A simple 
adaption of our synthesis was able to furnish linker handle equipped ABCD* aldehydes which 
highlights the flexibility and utility of the rationally designed ABCD* fragment synthesis. 
 
Scheme 2.13: Synthesis of linker-handle equipped ABCD* fragments. 2.6b was synthesized using 2.55 and 
2.6c was synthesized using 2.60. 
2.6. Completion of spongistatin 1 analogs 
2.6.1. Spongistatin 1 analog endgame 
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Wittig coupling of EF fragment 2.7 with aldehydes 2.6a-c proceeded smoothly and 
delivered 2.63a-c, in 58-63% yields (Scheme 2.14). Selective deprotection of the TIPS ester and 
the C(41) and C(42) TES groups was carried out with n-Bu4NF•3H2O to give the hydroxy acids 
2.64a-c in 79-84% yields, which were subjected to macrolactonization employing the Yamaguchi 
protocol
39
 to give the macrolactones 2.65a-c in 77-87% yields. Global deprotection of the 
remaining silyl ether protecting groups as well as E-ring ketal hydrolysis was effected with 
aqueous HF to deliver the target structures 2.5a-c in 82-83% yields. With this 4 step sequence the 
ABCD* and EF hemispheres were joined to realize the fully elaborated, rationally designed 
spongistatin 1 analogs in a 22 step longest linear sequence. 
 
Scheme 2.14: Four steps couple the ABCD* and EF fragments and produce the spongistatin 1 analogs 2.5a-c. 
2.6.2. Biological activity 
These compounds were evaluated for in vitro cytotoxicity against the 1A9 (A2780, 
ovarian), PC3 (prostate), and Ca46 (lymphoma) cell lines, using paclitaxel as a reference 
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compound in the absence of a sample of spongistatin 1. First and most critically, the data reveal 
that 2.5a is characterized by potencies in a similar range (i.e. low picomolar) to the parent natural 
product, consistent with our hypothesis regarding the primary role of the CD spiroketal as 
scaffolding and validating the D-ring redesign. Second, the data show that whereas the benzoate 
derivative 2.5b is more than an order of magnitude less potent than 2.5a, the aliphatic ester 2.5c 
is only slightly (~three-fold) less potent than 2.5a. While caution must be exercised when 
attempting to rationalize such small changes in potency, these data are consistent with the 
hypothesis that whereas the change from an acetate to a benzoate results in significant local 
conformational changes in the vicinity of C(15), the extension of an acetate to a higher order 
alkyl ester does not. While further optimization of the structure of the C(15)-azide bearing acyl 
group to minimize any loss in potency may be desirable, these results constitute a proof-of-
concept that the C(15)-acetate may be structurally modified without a significant loss of activity. 
The crystal structure of spongistatin also confirms that the C(15)-acetate is solvent exposed and 






Figure 2.8: Cell growth inhibition assays with three human cancer cell lines establish that the D-ring modified 
analog 5a is approximately equipotent with spongistatin 1, while 5c represents a proof-of-concept result that 
the C(15) acetate may be structurally modified with only a minimal reduction in potency.   
2.7. Summary and outlook 
Some 70% of all ADCs currently in clinical development use either a maytansinoid or an 
auristatin as the payload
40
, mainly because they are two of the only drugs that meet the basic 
criteria, including that they are readily available in significant quantity. Even within the 
microtubule-targeting drug class, it may be that certain payloads perform more effectively 
against certain cancers than others
41
, and an expanded pool of potential payloads for ADC 
development could advance the field in significant ways
42
. Many of these drugs are structurally 
complex natural products that are unavailable in quantity from natural sources and/or that do not 
have a synthetically selective and pharmacologically innocent linker functional group. While 
ideally the limits of chemical synthesis would never prevent efforts to develop such compounds, 
the reality is that, especially with compounds as complex as the spongistatins, lengthy syntheses 
are often required that do not readily lend themselves to these kinds of drug development efforts. 
Indeed, the previous syntheses of spongistatin 1 and 2 have all required ≥ 30 steps in the longest 
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linear sequence and ≥ 105 total steps. Due to the development of powerful and uniquely enabling 
new methodologies and strategies including the direct diaminophenol-activated fragment 
coupling crotylsilylation and n-Bu4NBr-catalyzed alkallylsilylation reactions, the synthesis 
described here proceeds in 22 steps in the longest linear sequence (1.4% overall yield) and 68 
total steps. This is important not only in advancing the frontiers of step-economy and efficiency 
in the synthesis of non-aromatic polyketide natural products
43–45
, but also in facilitating the 
compound development efforts necessary to begin evaluating whether the spongistatins, properly 
configured for use in ADCs and other conjugates, can serve as effective payloads. In the present 
case, this step economy and efficiency have allowed us to validate the D-ring redesign of the CD 
fragment. The efficient synthesis and evaluation of linker functional group-equipped analogs 5b 
and 5c has also been rendered a far less laborious and time- and resource-intensive effort and 
have allowed us to secure a crucial proof-of-concept result in the form of 5c, a highly potent 
linker-equipped analog of the spongistatins.  
Developing a rationally designed and validated strategy for installation of a synthetic 
handle in highly complex molecules is of great utility not only towards the therapeutic area 
previously described, but also for drug discovery in general. I envision exploiting spongistatin’s 
documented antifungal properties
46
 to develop a new class of antifungals to help alleviate the 
drug resistance crisis. Using the newly developed analogs, we can easily generate siderophore-
drug conjugates to take advantage of iron uptake pathways to selectively deliver cytotoxic cargo.  
Thus we can create a novel antifungal platform to generate more potent and selective 
therapeutics with fewer side effects. In effect, our synthesis of spongistatin 1 analogs has 
generated highly potent medicinal lead intermediates which can now be further functionalized to 
target a broad array of therapeutic needs. 
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2.8. Experimental procedures and characterization 
General Information. All reactions were carried out under an atmosphere of nitrogen in flame-
dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were 
purified by passage through an activated alumina column. Thin-layer chromatography (TLC) 
was carried out on glass backed silica gel TLC plates (250 μm) from Silicycle; visualization by 
UV light, cerium ammonium molybdate (CAM), phosphomolybdic acid (PMA), p-anisaldehyde 
stain, or potassium permanganate (KMnO4) stain. HPLC analysis was carried out on an Agilent 
1200 Series using a Chiralpak OD-H (250 × 4.5 mm ID) column. Diastereomeric ratios for all 
compounds were determined by 
1
H NMR analysis of the unpurified reaction mixtures. 
1
H NMR 
spectra were recorded on a Bruker AVIII 400 (400 MHz) and AVIII 500 (500 MHz) spectrometer 
and are reported in ppm, relative to residual protonated solvent peak (CDCl3, 7.26 ppm) unless 
otherwise indicated. Data are reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, 
ddt = doublet of doublet of triplets, td = triplet of doublets; coupling constant(s) in Hz; 
integration). Proton decoupled 
13
C NMR spectra were recorded on a Bruker AVIII 400 (100 
MHz) and AVIII 500 (125 MHz) spectrometer and are reported in ppm from CDCl3 internal 
standard (77.00 ppm) unless otherwise indicated. High-resolution mass spectra were obtained 
from the Columbia University Mass Spectrometry Facility on a Waters XEVO G2XS QToF mass 
spectrometer equipped with a UPC2 SFC inlet, electrospray ionization (ESI) probe, atmospheric 
pressure chemical ionization (APCI) probe. Infrared spectra were recorded on a Perkin Elmer 
Paragon 1000 FT-IR spectrometer. Optical rotations were recorded on a Jasco DIP-1000 digital 
polarimeter. pH 7.00 buffered silica gel was prepared as follows: A 1000 mL round bottom flask 
charged with silica gel (250 g) and 25.0 mL of pH 7.00 buffer solution (potassium dihydrogen 
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phosphate/sodium hydroxide, Fluka Analytical) was stirred on rotavapor under atmospheric 
pressure overnight.  
SAFETY STATEMENT. No unexpected or unusually high safety hazards were encountered. 
2.8.1. Preparation of 2.9a. 
 
Alcohol 2.16 was prepared using a modified literature procdure.
5
 To a cooled (0 °C) 
solution of (S,S)-2.46 (20.3 g, 70.0 mmol) in CH2Cl2 (250 mL) was added DBU (31.4 mL, 210 
mmol). Allyltrichlorosilane (11.2 mL, 77 mmol) was then added slowly. The ice/water bath was 
removed and after 1 h the mixture was re-cooled to 0 °C. 3-((4-methoxybenzyl)oxy)propanal 
(13.6 g, 70.0 mmol, prepared as described here
47
) was added and the resulting mixture was 
stirred at 0 °C for 1 h. The mixture was concentrated and the residue was suspended in Et2O (250 
mL). The mixture was stirred vigorously for 20 min to ensure complete precipitation of the 
DBU•HCl salts. The mixture was then filtered through a frit, and the filtrate was treated with 
TBAF (70.0 mL, 70.0 mmol, 1 M in THF). After 2.5 h, 1 M HCl (350 mL, 350 mmol) was added 
and the mixture was transferred to a separatory funnel. The layers were separated and the 
aqueous layer was extracted with Et2O (3 x 100 mL). The combined organic layers were washed 
with H2O (2 x 50 mL) and saturated aqueous NaHCO3 (1 x 100 mL), dried over MgSO4, filtered 
and concentrated. The residue was purified by chromatography on silica gel to provide pure 2.16 
as a pale yellow oil (12.3 g, 52.2 mmol, 75% yield, 97% ee). 
1
H NMR (400 MHz, CDCl3) δ 7.28 
(m, 2H), 7.01 – 6.79 (m, 2H), 5.86 (ddt, J = 17.4, 10.4, 7.1 Hz, 1H), 5.20 – 5.05 (m, 2H), 4.48 (s, 
2H), 3.93 – 3.85 (m, 1H), 3.83 (s, 3H), 3.72 (dt, J = 9.3, 5.3 Hz, 1H), 3.65 (ddd, J = 9.3, 6.7, 5.4 





spectroscopic data is in agreement with data reported in literature.
48
 The enantiomeric excess was 
determined by chiral HPLC analysis: OD-H column, 98:2 hexanes:iPrOH, 1 mL/min, 254 nm, 
where the desired R-enantiomer 2.16 has been established to elute second.
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To recover (S,S)-2.46, the combined aqueous layers from above were treated with 3 M NaOH 
(240 mL) and extracted with CH2Cl2 (5 x 100 mL). The combined organic layers were washed 
with water (2 x 100 mL), dried over MgSO4, filtered, and concentrated. The residue was 
dissolved in minimal hot 9:1 MeOH:H2O (during the dissolution process the temperature should 
not be allowed to exceed 80 °C, as the ligand may start to undergo decomposition at higher 
temperatures). The hot saturated solution was allowed to cool to room temperature, and distilled 
water (10.0 mL) was added to ensure complete crystallization of 2.46. The white solid was 
collected by filtration through a frit with a cold 1:1 MeOH:H2O rinse and then dried in vacuo at 
45 °C to give recovered diaminophenol 2.46. 
 
To a cooled (0 °C) solution of 2.16 (17.8 g, 75.2 mmol) in CH2Cl2 (225 mL) was added 
Et3N (13.6 mL, 97.7 mmol) followed by the slow addition of TESCl (12.6 mL, 75.2 mmol) and 
DMAP (0.28 g, 2.2 mmol). The resulting solution was stirred at room temperature for 2 h. 
MeOH (3.0 mL) was added to quench unreacted TESCl and the resulting mixture was 
concentrated. The residue was suspended in hexanes and the Et3N•HCl salts were removed by 
filtration. The filtrate was concentrated to give crude 2.17 as a pale orange oil (26.6 g, 76 mmol), 




H NMR (500 MHz, CDCl3) δ 7.34 – 7.24 (m, 2H), 6.95 – 6.84 (m, 2H), 5.84 (ddt, J = 16.3, 
11.1, 7.1 Hz, 1H), 5.11 – 5.01 (m, 2H), 3.92 (m, 1H), 3.83 (s, 3H), 3.61 – 3.46 (m, 2H), 2.38 (s, 
1H), 2.25 (m, 2H), 1.81 (m, 1H), 1.71 (m, 1H), 0.98 (t, J = 8.0 Hz, 9H), 0.62 (q, J = 7.7 Hz, 6H). 
 
To a solution of unpurified 2.17 (15.5 g, 44.2 mmol) in dioxane:H2O (330 mL:110 mL) 
were sequentially added 2,6-lutidine (6.7 mL, 57.5 mmol), OsO4 (168 mg, 0.66 mmol), and 
NaIO4 (21.7 g, 102 mmol). The resulting reaction mixture was stirred at room temperature for 
2.5 h. The reaction mixture was cooled to 0 ºC and carefully quenched with saturated aqueous 
Na2S2O3 (250 mL). The layers were separated and the aqueous layer was extracted with Et2O (3 
x 100 mL). The combined organic layers were dried over MgSO4, filtered and concentrated. The 
residue was purified by silica gel column chromatography eluting with 5:95  15:85 




 -6.1° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2953, 2876, 1724, 1612, 1513, 1461, 1366, 1247, 1174, 1094, 1027, 820, 742 
1
H NMR (500 MHz, CDCl3) δ 9.78 (t, J = 2.3 Hz, 1H), 7.30 – 7.16 (m, 2H), 6.92 – 6.82 (m, 
2H), 4.47 – 4.33 (m, 3H), 3.79 (s, 3H), 3.58 – 3.42 (m, 2H), 2.63 – 2.45 (m, 2H), 1.93 – 1.73 (m, 
1H), 0.94 (t, J = 8.0 Hz, 9H), 0.60 (q, J = 8.0 Hz, 6H) 
13
C NMR (126 MHz, CDCl3) δ 202.0, 159.3, 130.5, 129.4, 113.9, 72.8, 66.2, 65.7, 55.3, 51.3, 
37.9, 6.9, 5.0 
HRMS (FAB+) calculated for C19H31O4Si [M+H]
+
















To a cooled (0 °C) solution of (S,S)-2.46 (8.02 g, 27.6 mmol) in CH2Cl2 (100 mL) was 
added DBU (12.4 mL, 82.8 mmol). The cis-crotyltrichlorosilane (4.6 mL, 30.4 mmol, prepared 
as described here
5
) was then added slowly. The ice/water bath was removed and after 1 h the 
mixture was re-cooled to 0 °C. Aldehyde S14 (9.13 g, 25.9 mmol) was added and the resulting 
solution was stirred at 0 °C for 1 h. The mixture was concentrated and the residue was 
resuspended in Et2O (100 mL). The mixture was stirred vigorously for 20 min to ensure 
complete precipitation of the DBU•HCl salts. The mixture was then filtered through a frit, and 
the filtrate was treated with TBAF (52.0 mL, 52.0 mmol, 1 M in THF). After 2.5 h, 1 M HCl 
(140 mL, 140 mmol) was added and the mixture was transferred to a separatory funnel. The 
layers were separated and the aqueous layer was extracted with Et2O (3 x 50 mL). The combined 
organic layers were washed with H2O (2 x 25 mL) and saturated aqueous NaHCO3 (1 x 50 mL), 
dried over MgSO4, filtered, and concentrated. The residue was purified by chromatography on 
silica gel to provide 2.20 as a pale yellow oil (7.24 g, 24.6 mmol, 95% yield, 15:1 dr).  
OR [α]D
19
 -6.1° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 3378, 2938, 2863, 1612, 1513, 1421, 1301, 1246, 1174, 1089, 1035, 915, 
820, 570 
1
H NMR (500 MHz, CDCl3) δ 7.28 – 7.19 (m, 2H), 6.95 – 6.80 (m, 2H), 5.78 (ddd, J = 17.1, 
10.6, 7.5 Hz, 1H), 5.09 – 4.98 (m, 2H), 4.44 (s, 2H), 4.09 – 3.98 (m, 1H), 3.88 – 3.81 (m, 1H), 
3.80 (s, 3H), 3.75 – 3.69 (m, 1H), 3.69 – 3.64 (m, 1H), 3.64 – 3.54 (m, 2H), 2.35 – 2.15 (m, 1H), 
59 
 
1.86 – 1.65 (m, 2H), 1.58 (dt, J = 14.3, 2.3 Hz, 1H), 1.48 (dt, J = 14.4, 10.1 Hz, 1H), 1.03 (d, J = 
6.9 Hz, 3H) 
13
C NMR (126 MHz, CDCl3) δ 159.4, 141.0, 130.0, 129.5, 115.1, 114.0, 75.8, 73.1, 72.7, 68.5, 
55.4, 44.2, 40.0, 37.1, 15.0 
HRMS (FAB+) calculated for C17H27O4 [M+H]
+














To a solution of 2.20 (9.27 g, 31.5 mmol) in dimethoxypropane (210 mL) was added 
camphor sulfonic acid (0.37 g, 1.6 mmol). The resulting solution was stirred at room temperature 
for 1 h. Saturated aqueous NaHCO3 (75 mL) was added. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed 
with H2O (1 x 75 mL), dried over Na2SO4, filtered, and concentrated to give crude S16 as a pale 
yellow oil (10.4 g, 31.2 mmol) that was used without further purification. Purification for a 
characterization sample was achieved by silica gel column chromatography eluting with 0:100 




 -16.3° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2859, 1612, 1512, 1461, 1378, 1301, 1247, 1200, 1174, 1097, 1035, 915, 
872, 817, 522 
1
H NMR (400 MHz, CDCl3) δ 7.31 – 7.20 (m, 2H), 6.93 – 6.80 (m, 2H), 5.72 (ddd, J = 17.1, 
10.4, 7.7 Hz, 1H), 5.11 – 4.95 (m, 2H), 4.42 (s, 2H), 4.04 – 3.91 (m, 1H), 3.80 (s, 3H), 3.64 – 
3.42 (m, 3H), 2.24 – 2.10 (m, 1H), 1.82 – 1.60 (m, 2H), 1.46 (dt, J = 12.9, 2.5 Hz, 1H), 1.41 (s, 
3H), 1.37 (s, 3H), 1.11 (dt, J = 12.6, 11.5 Hz, 1H), 1.02 (d, J = 6.7 Hz, 3H) 
13
C NMR (101 MHz, CDCl3) δ 159.3, 140.4, 130.8, 129.4, 115.0, 113.9, 98.6, 72.7, 72.6, 66.3, 
66.1, 55.4, 43.5, 36.8, 34.8, 30.4, 20.0, 15.9 
HRMS (FAB+) calculated for C20H29O4 [M+H]
+


















To a solution of unpurified PMB ether 2.21 (4.00 g, 12.0 mmol) in CH2Cl2 (106 mL) was 
added pH 7 buffer solution (14 mL). The resulting mixture was cooled to 0 °C. DDQ (4.07 g, 
17.9 mmol) was added in 3 portions at a rate of 1 portion per 3 min. The resulting mixture was 
stirred at 0 °C for 5 min and then at room temperature for 1 h. The reaction mixture was filtered 
through celite, onto pH 7 buffer solution (100 mL), rinsing with CH2Cl2. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic 
layers were washed with saturated NaHCO3 solution (1 x 100 mL) and H2O (1 x 100 mL), dried 
over Na2SO4, filtered, and concentrated. The residue was purified by chromatography with pH 7 
buffered silica gel eluting with 10:90  30:70 EtOAc:Hexanes to give 2.22 as a pale yellow oil 
(2.46 g, 11.4 mmol, 95% yield from 2.20 over 2 steps).  
OR [α]D
21
 -27.7° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 3418, 2946, 1379, 1257, 1200, 1100, 1053, 998, 965, 916, 874 
1
H NMR (400 MHz, CDCl3) δ 5.70 (ddd, J = 17.2, 10.4, 7.8 Hz, 1H), 5.08 – 4.94 (m, 2H), 4.05 
(dddd, J = 11.7, 7.3, 4.6, 2.6 Hz, 1H), 3.83 – 3.66 (m, 2H), 3.59 (ddd, J = 11.6, 7.3, 2.4 Hz, 1H), 
2.60 (s, 1H), 2.24 – 2.08 (m, 1H), 1.80 – 1.62 (m, 2H), 1.48 – 1.40 (m, 1H), 1.43 (s, 3H), 1.37 (s, 
3H), 1.23 (dt, J = 13.0, 11.5 Hz, 1H), 1.01 (d, J = 6.7 Hz, 3H)
 
13
C NMR (101 MHz, CDCl3) δ 140.1, 115.2, 98.7, 72.4, 69.6, 61.0, 43.4, 38.3, 34.5, 30.3, 19.9, 
15.8 
HRMS (FAB+): calculated for C12H23O3 215.1647 [M+H]
+


















To a cooled (-78 °C) solution of oxalyl chloride (4.4 mL, 52.4 mmol) in CH2Cl2 (175 
mL) was added DMSO (7.4 mL, 105 mmol). After 20 min a solution of 2.22 (5.61 g, 26.2 mmol) 
in CH2Cl2 (90 mL) was added slowly. After 20 min Et3N (24.5 mL, 175 mmol) was added 
dropwise, and the mixture was then allowed to warm to room temperature. After 30 min the 
reaction mixture was quenched with water (100 mL) and the mixture was concentrated to remove 
the bulk of the CH2Cl2, and the residue was extracted with Et2O (3 x 100 mL). The combined 
ether layers were washed with water (1 x 100 mL), dried over Na2SO4, filtered, and concentrated 
to give 2.13a as a pale yellow oil (5.6 g, 26 mmol) which was used without further purification.  
OR [α]D
22
 -18.1° (c 0.8, CHCl3) 
IR (thin film, cm
-1
) 2924, 2854, 1717, 1380, 1259, 1201, 1102, 965, 917, 771 
1
H NMR (400 MHz, CDCl3) δ 9.77 (dd, J = 2.3, 1.7 Hz, 1H), 5.70 (ddd, J = 17.1, 10.4, 7.8 Hz, 
1H), 5.11 – 4.95 (m, 2H), 4.35 (dddd, J = 12.0, 7.4, 5.0, 2.6 Hz, 1H), 3.62 (ddd, J = 11.5, 7.3, 2.4 
Hz, 1H), 2.60 (ddd, J = 16.6, 7.3, 2.3 Hz, 1H), 2.45 (ddd, J = 16.6, 5.0, 1.8 Hz, 1H), 2.25 – 2.12 
(m, 1H), 1.55 (dt, J = 12.9, 2.5 Hz, 1H), 1.44 (s, 3H), 1.37 (s, 3H), 1.18 (dt, J = 12.8, 11.5 Hz, 
1H), 1.02 (d, J = 6.8 Hz, 3H) 
13
C NMR (101 MHz, CDCl3) δ 201.2, 140.0, 115.4, 98.9, 72.3, 64.9, 50.1, 43.5, 34.5, 30.2, 19.8, 
15.8 
HRMS (FAB+) calculated for C12H21O3 [M+H]
+




















To a cooled (-78 °C) solution of i-Pr2NH (4.5 mL, 32.1 mmol) in THF (170 mL) was 
added n-BuLi (11.1 mL, 27.8 mmol, 2.5 M in hexanes). After 5 min the solution was warmed to 
0 °C, held at that temperature for 10 min, and then re-cooled to -78 °C. A solution of 2.14
49
 (10.7 
g, 21.4 mmol) in THF (25 mL) was added slowly, with a THF rinse (15 mL). After 20 min 
TMSCl (4.6 mL, 36.4 mmol) was added slowly. After 1 h the reaction mixture was warmed to 
room temperature and concentrated to give a thick cloudy oil. [CAUTION: over concentration 
will result in isomerization of the enol ether product]. The residue was resuspended in pentane 
and the iPr2NH•HCl salts were removed by filtration. The filtrate was concentrated to give the 
enol ether as a pale yellow oil that was used immediately in the next step without further 
purification. 
 
To a cooled (-78 °C) solution of the enol ether 2.27 and unpurifed aldehyde 2.13a (4.13 g, 
19.5 mmol) in CH2Cl2 (200 mL) was added BF3•Et2O (2.52 mL, 20.4 mmol) over 20 min by 
syringe pump. After 1 h the reaction was quenched by the addition of saturated aqueous NaHCO3 
(100 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 50 
mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. Analysis 
of the residue by 
1
H NMR spectroscopy revealed a 7:1 dr for the reaction. The residue was 
purified by silica gel column chromatography eluting with 5:95  20:80 EtOAc:Hexanes to give 





-4.7° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2952, 2930, 2857, 1706, 1470, 1427, 1380, 1254, 1200, 1103, 999, 917, 834, 
776, 703, 505 
1
H NMR (400 MHz, CDCl3) δ 7.71 – 7.54 (m, 4H), 7.48 – 7.29 (m, 6H), 5.72 (ddd, J = 17.7, 
10.4, 7.7 Hz, 1H), 5.13 – 4.94 (m, 2H), 4.35 – 4.19 (m, 1H), 4.16 – 4.00 (m, 1H), 3.73 – 3.42 (m, 
5H), 3.32 (d, J = 3.5 Hz, 1H), 2.66 (dd, J = 16.8, 6.8 Hz, 1H), 2.58 – 2.45 (m, 2H), 2.40 (dd, J = 
16.8, 6.3 Hz, 1H), 2.34 – 2.23 (m, 1H), 2.18 (hept, J = 6.8, 6.4 Hz, 1H), 1.68 – 1.44 (m, 5H), 
1.43 (s, 3H), 1.38 (s, 3H), 1.27 – 1.13 (m, 1H), 1.05 (s, 9H), 1.03 (d, J = 6.7 Hz, 3H), 0.85 (s, 
9H), -0.01 (d, J = 1.6 Hz, 6H)
 
13
C NMR (101 MHz, CDCl3) δ 211.4, 140.3, 135.7, 135.7, 133.7, 129.8, 127.8, 115.1, 98.8, 
72.6, 66.4, 66.0, 64.5, 61.2, 49.9, 45.7, 43.5, 42.7, 34.7, 34.4, 33.7, 30.4, 27.1, 26.1, 19.9, 19.45, 
18.4, 15.9, -5.2 
HRMS (FAB+): calculated for C41H66O6Si2Na [M+Na]
+






















To a solution of 2.28a (10.8 g, 15.2 mmol) in CH2Cl2 (150 mL) was added 4 Å MS (11.0 
g), proton sponge (32.6 g, 152 mmol) and Me3O•BF4 (18.1 g, 122 mmol). After 5 h the mixture 
was filtered through celite, with EtOAc rinses. The filtrate was washed with 1 M AcOH (1 x 500 
mL) and saturated aqueous NaHCO3 (1 x 300 mL), dried over MgSO4, filtered, and concentrated. 
The residue was purified by silica gel column chromatography eluting with 5:95  20:80 
EtOAc:Hexanes to give 2.29a (7:1 dr) as a colorless oil (10.20 g, 14.1 mmol, 93% yield).  
OR [α]D
19
 -8.4° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2930, 2855, 1713, 1470, 1378, 1253, 1199, 1090, 835, 703, 505 
1
H NMR (400 MHz, CDCl3) δ 7.71 – 7.52 (m, 4H), 7.49 – 7.31 (m, 6H), 5.72 (ddd, J = 17.3, 
10.4, 7.7 Hz, 1H), 5.12 – 4.93 (m, 2H), 4.02 – 3.91 (m, 1H), 3.91 – 3.81 (m, 1H), 3.68 – 3.47 (m, 
5H), 3.32 (s, 3H), 2.64 (ddd, J = 24.3, 16.4, 7.0 Hz, 2H), 2.49 – 2.35 (m, 2H), 2.28 (h, J = 6.1 
Hz, 1H), 2.18 (h, J = 7.0 Hz, 1H), 1.68 – 1.45 (m, 4H), 1.45 – 1.39 (m, 1H), 1.41 (s, 3H), 1.37 (s, 
3H), 1.17 – 1.07 (m, 1H), 1.06 (s, 9H), 1.02 (d, J = 6.7 Hz, 3H), 0.85 (s, 9H), -0.01 (d, J = 1.7 
Hz, 6H) 
13
C NMR (101 MHz, CDCl3) δ 209.0, 140.3, 135.7, 135.7, 133.8, 129.8, 127.8, 115.0, 98.6, 
74.0, 72.6, 66.1, 65.7, 61.3, 58.2, 48.8, 46.1, 43.5, 42.6, 35.1, 34.5, 33.7, 30.4, 27.1, 26.1, 20.0, 
19.5, 18.4, 15.8, -5.2 
HRMS (FAB+) calculated for C42H68O6Si2Na [M+Na]
+






















To a solution of ketone 2.29a (70 mg, 0.1 mmol) in MeOH (1.0 mL) was added 
pyridinium p-toluene sulfonate (PPTS) (25 mg, 0.1 mmol). After 20 h additional PPTS (25 mg, 
0.1 mmol) was added. After 2 h the reaction mixture was quenched by the addition of saturated 
aqueous NaHCO3 (3.0 mL). The mixture was extracted with CH2Cl2 (3 x 2.0 mL). The combined 
organic layers were dried over MgSO4, filtered, and concentrated. The residue was purified by 
silica gel column chromatography eluting with 5:95  20:80 EtOAc:Hexanes. The product 




 +32.4° (c 1.8, CHCl3) 
IR (thin film, cm
-1
) 3501, 3061, 2926, 2858, 1636, 1420, 1380, 1106, 710 
1
H NMR (500 MHz, CDCl3) δ 7.74 – 7.57 (m, 4H), 7.48 – 7.29 (m, 6H), 5.84 (ddd, J = 17.6, 
10.4, 7.6 Hz, 1H), 5.12 – 5.02 (m, 2H), 3.92 – 3.80 (m, 1H), 3.76 – 3.59 (m, 5H), 3.48 (dd, J = 
10.0, 5.2 Hz, 1H), 3.42 (dd, J = 10.0, 5.7 Hz, 1H), 3.33 (s, 3H), 2.28 (h, J = 6.9 Hz, 1H), 2.14 – 
2.07 (m, 1H), 2.07 – 1.96 (m, 2H), 1.74 – 1.55 (m, 4H), 1.45 – 1.35 (m, 1H), 1.35 – 1.22 (m, 
2H), 1.18 (q, J = 11.7 Hz, 1H), 1.08 (d, J = 6.8 Hz, 3H), 1.05 (s, 9H) 
13
C NMR (126 MHz, CDCl3) δ 141.2, 135.8, 133.8, 129.7, 127.8, 115.0, 98.3, 75.5, 72.7, 70.3, 
68.3, 60.4, 55.6, 44.1, 41.7, 39.6, 38.2, 38.0, 33.0, 28.1, 27.1, 19.5, 15.3 
HRMS (FAB+) calculated for C33H48O5SiNa [M+Na]
+




























To a cooled (0 °C) solution of 2.30a (4.79 g, 8.7 mmol) in CH2Cl2 (90 mL) was 
sequentially added Et3N (2.66 mL, 19.1 mmol), TESCl (2.91 mL, 17.3 mmol), and DMAP (0.21 
g, 1.7 mmol). The resulting mixture was warmed to room temperature and stirred 15 h. Excess 
TESCl was quenched by the addition of MeOH (0.80 mL) and the reaction mixture was 
concentrated. The residue was resuspended in hexanes and the Et3N•HCl salts were removed by 
filtration. The filtrate was concentrated and the residue purified by silica gel column 
chromatography eluting with 5:95 EtOAc:Hexanes to give 2.31a as a colorless oil (5.38 g, 8.1 
mmol, 93% yield).  
OR [α]D
18
 +21.5° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 3071, 2953, 2932, 2876, 1639, 1461, 1385, 1239, 1092, 1004, 824, 739, 703, 
614, 505 
1
H NMR (400 MHz, CDCl3) δ 7.72 – 7.56 (m, 4H), 7.51 – 7.28 (m, 6H), 6.02 – 5.80 (m, 1H), 
5.13 – 4.92 (m, 2H), 3.88 – 3.71 (m, 2H), 3.70 – 3.58 (m, 3H), 3.50 (dd, J = 9.9, 5.3 Hz, 1H), 
3.42 (dd, J = 9.8, 6.3 Hz, 1H), 3.35 (s, 3H), 2.50 – 2.35 (m, 1H), 2.28 – 2.14 (m, 1H), 2.13 – 1.99 
(m, 2H), 1.81 – 1.53 (m, 4H), 1.34 (qd, J = 12.2, 6.3 Hz, 1H), 1.24 (dd, J = 12.9, 11.6 Hz, 2H), 
1.06 (s, 9H), 1.10 – 1.02 (m, 1H), 1.02 – 0.92 (m, 12H), 0.62 (q, J = 7.9 Hz, 6H) 
13
C NMR (101 MHz, CDCl3) δ 141.5, 135.7, 134.0, 133.9, 129.7, 127.8, 114.4, 97.7, 73.4, 72.8, 
68.7, 65.4, 60.3, 55.6, 43.1, 41.9, 40.6, 38.8, 37.5, 33.0, 28.7, 27.0, 19.5, 14.6, 7.1, 5.4 
HRMS (ESI+) calculated for C39H62O5Si2Na [M+Na]
+




























A cooled (-78 °C) solution of 2.31a (1.15 g, 1.7 mmol) in CH2Cl2 (17 mL) was sparged 
with O2 for 5 min. Ozone was then bubbled through the solution until it turned blue (~8 min.). 
The solution was sparged with O2 for 5 min resulting in a cloudy white mixture. PPh3 (0.54 g, 
2.1 mmol) was added and the resulting mixture was warmed to room temperature. After 12h, the 
mixture was concentrated [CAUTION!!!! It is imperative to make sure that the ozonides 
have been completely reduced before concentration]. The residue was resuspended in hexanes 
and residual PPh3O was removed by filtration. The filtrate was concentrated and the residue was 
purified by silica gel column chromatography eluting with 5:95  15:85 EtOAc:Hexanes to give 
2.9a as a colorless oil (1.07 g, 1.6 mmol, 94% yield).  
OR [α]D
16
 14.1° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2930, 2876, 1727, 1589, 1461, 1385, 1240, 1104, 822, 703, 614, 505 
1
H NMR (400 MHz, CDCl3) δ 9.78 (d, J = 1.0 Hz, 1H), 7.75 – 7.56 (m, 4H), 7.51 – 7.30 (m, 
6H), 4.52 – 4.40 (m, 1H), 3.72 – 3.52 (m, 4H), 3.52 – 3.39 (m, 2H), 3.34 (s, 3H), 2.61 – 2.51 (m, 
1H), 2.25 – 2.12 (m, 1H), 2.09 (ddd, J = 12.5, 4.7, 1.7 Hz, 1H), 2.05 – 1.95 (m, 1H), 1.85 – 1.57 
(m, 4H), 1.42 – 1.29 (m, 1H), 1.29 – 1.18 (m, 2H), 1.11 (d, J = 6.9 Hz, 3H), 1.16 – 1.08 (m, 1H) 
1.05 (s, 9H), 0.95 (t, J = 7.9 Hz, 9H), 0.67 – 0.53 (m, 6H) 
13
C NMR (101 MHz, CDCl3) δ 205.1, 135.7, 133.9, 129.7, 127.8, 97.8, 73.1, 68.6, 68.5, 65.2, 
60.5, 55.7, 51.2, 41.8, 41.2, 38.9, 37.5, 33.1, 28.6, 27.0, 19.5, 7.6, 7.0, 5.2 
HRMS (FAB+) calculated for C38H60O6Si2Na [M+Na]
+































2.8.2. Preparation of 2.9b. 
 
To a metal cylinder of a Parr bomb (without a glass liner) was added 2-vinyl-1,3-
dioxolane (1.50 mL, 15.0 mmol) in toluene (3.50 mL), Rh(acac)(CO)2 (1.16 mg, 0.450 mmol), 
and (S,S)-Ph-BPE (6.83 mg, 1.35 mmol).
50
 The Parr bomb was charged to 500 psi with H2/CO 
(1:1) and vented (repeated 5 times). The bomb was then pressurized to 150 psi and heated to 70 
°C (oil bath, external temperature. After 12 h, the bomb was allowed to cool to room temperature 
and de-pressurized. Analysis of an aliquot by 
1
H NMR spectroscopy indicated full conversion of 
the dioxolane and a 9:1 branched to linear aldehyde ratio. This solution was used directly in the 
allylation step without purification. 
To a cooled (0 °C) solution of (S,S)-2.46
35,51
 (4.79 g, 16.5 mmol) in CH2Cl2 (50.0 mL) 
was added DBU (7.40 mL, 49.5 mmol) and allyltrichlorosilane (2.61 mL, 18.0 mmol). The 
reaction mixture was allowed to warm to room temperature for 1 h. The reaction mixture was 
cooled to -78 °C, and the solution of the aldehyde from above was added, rinsing with CH2Cl2 
(5.0 mL). After 3h, the reaction mixture was quenched by the addition of n-Bu4NF (4.73 g, 15.0 
mmol). After 1h, the reaction mixture was concentrated to dryness and re-suspended in Et2O 
(60.0 mL) in order to fully precipitate the DBU•HCl salts. The mixture was filtered, 
concentrated, and purified by silica gel flash column chromatography 0:100  20:80 
EtOAc:Hexanes to afford alcohol 2.33 (1.70 g, 65% yield, 8:1 dr) as a colorless oil. The 
moderate diastereoselectivity reflects the only moderately enantioselective hydroformylation 
79 
 
reaction. The mixture was carried forward and the minor diastereomer could be separated at a 
later stage. 
Recovery of (S,S)-2.46: After elution of 2.33, the chromatography column was flushed with 
CH2Cl2/MeOH/Et3N (100:5:1) and the filtrate was concentrated to give a beige solid. The residue 
was dissolved in minimal boiling hexanes (about 70 °C), and the resulting solution was allowed 
to cool to room temperature slowly. The resulting white solid was collected by filtration through 
a frit, with cold hexane rinses, and then dried in vacuo (with gentle warming with an oil bath set 
to 40 °C) to give recovered diaminophenol (S,S)-2.46 (4.42 g, 92% yield) as white crystals. 
OR [α]D
23
 -1.8º (c 1.0, CHCl3) 




H NMR (500 MHz, CDCl3) δ 5.92 (dddd, J = 16.8, 10.3, 7.8, 6.2 Hz, 1H), 5.23 – 5.02 (m, 2H), 
4.91 (d, J = 4.5 Hz, 1H), 4.05 – 3.95 (m, 2H), 3.94 – 3.83 (m, 2H), 3.73 (td, J = 7.8, 3.6 Hz, 1H), 
3.28 – 3.01 (m, 1H), 2.41 (dddt, J = 14.1, 6.5, 3.4, 1.5 Hz, 1H), 2.25 – 2.14 (m, 1H), 1.89 (pd, J 
= 7.1, 4.5 Hz, 1H), 0.96 (d, J = 7.0 Hz, 3H) 
13
C NMR (125 MHz, CDCl3) δ 135.0, 117.6, 106.7, 71.9, 65.1, 64.9, 41.4, 39.0, 11.3 
HRMS (ASAP+) calculated for C9H16O3 [M+H]
+
: 172.1099; found 172.1095 
80 
 




To a cooled (0 °C) solution of 2.33 (1.50 g, 7.69 mmol) in CH2Cl2 (28 mL) was added 
Et3N (1.39 mL, 9.99 mmol) followed by the slow addition of TESCl (1.29 mL, 7.69 mmol) and 
DMAP (28.2 mg, 0.231 mmol). The resulting mixture was stirred at room temperature for 2 h. 
MeOH (0.3 mL) was added to quench unreacted TESCl and the resulting solution was 
concentrated. The residue was resuspended in hexanes and the Et3N•HCl salts were removed by 
filtration. The filtrate was concentrated and purified by silica gel column chromatography eluting 
with 0:100  10:90 EtOAc:Hexanes to give product 2.34 as a pale yellow oil (2.10 g, 7.38 
mmol, 96% yield). This material was carried forward as an 8:1 mixture of diastereomers. 
OR [α]D
23
 -22.8º (c 1.0, CHCl3) 




H NMR (500 MHz, CDCl3) δ 5.90 (dddd, J = 16.9, 10.2, 7.6, 6.4 Hz, 1H), 5.13 – 5.01 (m, 2H), 
4.89 (d, J = 4.4 Hz, 1H), 4.05 – 3.93 (m, 2H), 3.93 – 3.79 (m, 3H), 2.37 – 2.17 (m, 2H), 1.99 – 
1.89 (m, 1H), 0.98 (t, J = 7.9 Hz, 9H), 0.91 (d, J = 7.0 Hz, 3H), 0.68 – 0.57 (m, 6H) 
13
C NMR (125 MHz, CDCl3) δ 135.5, 116.9, 105.1, 72.9, 65.0, 65.0, 42.4, 38.5, 8.8, 7.1, 5.2 
HRMS (ASAP+) calculated for C15H31O3Si [M+H]
+








To a solution of 2.34 (2.0 g, 6.48 mmol) in dioxane:H2O (60 mL:20 mL) were 
sequentially added 2,6-lutidine (1.05 mL, 9.08 mmol), OsO4 (26 mg, 0.10 mmol), and NaIO4 
(3.43 g, 16.1 mmol). The reaction mixture was stirred at room temperature for 4 h. The reaction 
mixture was cooled to 0 °C and carefully quenched by the slow addition of saturated aqueous 
Na2S2O3 (70 mL). The layers were separated and the aqueous layer was extracted with Et2O (3 x 
200 mL). The combined organic layers were dried over MgSO4, filtered and concentrated. The 
residue was purified by silica gel column chromatography eluting with 0:100  15:85 
EtOAc:Hexanes to give pure 2.35 as a colorless oil (1.74 g, 6.14 mmol, 88% yield). This 
material was carried forward as an 8:1 mixture of diastereomers. 
OR [α]D
22
 +6.2º (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2954, 2877, 1726, 1460, 1410, 1239, 1080, 1006, 816, 733 
1
H NMR (500 MHz, CDCl3 δ 9.82 (d, J = 2.6 Hz, 1H), 4.75 (d, J = 4.7 Hz, 1H), 4.46 (dt, J = 6.9, 
4.7 Hz, 1H), 4.00 – 3.78 (m, 4H), 2.68 – 2.51 (m, 2H), 2.02 (dtd, J = 11.7, 7.0, 3.4 Hz, 1H), 1.02 
– 0.87 (m, 13H), 0.62 (q, J = 7.9 Hz, 7H) 
13
C NMR (126 MHz, CDCl3) δ 202.5, 105.0, 68.3, 65.0, 65.0, 47.7, 43.3, 8.7, 6.9, 5.1 
HRMS (ASAP+): calculated for C14H29O4Si [M+H]
+








Diol 2.35 was prepared using a modified literature procdure.
5
 To a cooled (0 °C) solution 
of (R,R)-2.46 (1.80 g, 6.20 mmol) in CH2Cl2 (25 mL) was added DBU (2.47 mL, 18.6 mmol). 
The allyltrichlorosilane (1.08 mL, 7.44 mmol) was then added slowly. The ice/water bath was 
removed and after 1 h the mixture was recooled to 0 °C. Aldehyde S3 (1.70 g, 5.89 mmol) was 
added and the resulting solution is stirred at 0 °C for 3 h. The mixture was concentrated and the 
residue was resuspended in Et2O (100 mL). The mixture was stirred vigorously for 20 min to 
ensure complete precipitation of the DBU•HCl salts. The mixture was then filtered through a frit, 
and the filtrate was treated with TBAF (24.8 mL, 24.8 mmol, 1 M in THF). The mixture was 
filtered through a plug of silica gel, rinsing with EtOAc. The filtrate was concentrated and the 
residue was purified by chromatography on silica gel eluting with 0:100  20:80 
EtOAc:Hexanes to provide pure 2.36 as a pale yellow oil (1.05 g, 4.83 mmol, 82% yield). This 
material was carried forward as an 8:1 mixture of diastereomers. 
OR [α]D
22
 +9.6º (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 3389, 2896, 1641, 1405, 1160, 1104, 1049, 996, 923, 601 
1
H NMR (500 MHz, CDCl3) δ 5.85 (ddt, J = 17.2, 10.1, 7.2 Hz, 1H), 5.21 – 5.05 (m, 2H), 4.87 
(d, J = 4.8 Hz, 1H), 4.01 (dq, J = 8.3, 4.8, 3.9 Hz, 4H), 3.95 – 3.83 (m, 2H), 2.29 (qt, J = 13.7, 
6.9 Hz, 2H), 1.99 – 1.83 (m, 1H), 1.75 – 1.61 (m, 2H), 0.93 (d, J = 7.0 Hz, 3H) 
13
C NMR (126 MHz, CDCl3) δ 135.1, 117.7, 107.4, 70.7, 68.1, 65.2, 64.8, 42.2, 41.6, 38.9, 11.8 








To a solution of 2.36 (1.00 g, 4.34 mmol) in dimethoxypropane (30 mL) was added 
camphor sulfonic acid (CSA) (50 mg, 0.21 mmol). The mixture was stirred at room temperature 
for 1 h. Saturated aqueous NaHCO3 (10 mL) was added. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed 
with H2O (1 x 15 mL), dried over Na2SO4, filtered, and concentrated. Purification of the residue 
by silica gel column chromatography eluting with 0:100  15:85 EtOAc:Hexanes gave pure 
2.37 as a clear oil (1.05 g, 4.12 mmol, 95% yield). Separation of the minor diastereomer from the 
first step was possible at this stage, and 2.37 was isolated and taken forward as a single 
diastereomer (≥20:1 dr).  
OR [α]D
22
 +9.56º (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2859.39, 1612.08, 1512.49, 1460.63, 1378.20, 1300.69, 1247.24, 1199.51, 
1174.41, 1096.76, 1035.17, 915.21, 872.23, 817.36, 522.38 
1
H NMR (500 MHz, CDCl3) δ 5.80 (ddt, J = 17.1, 10.3, 6.8 Hz, 1H), 5.06 (dd, J = 23.2, 13.6 Hz, 
2H), 4.99 (d, J = 2.9 Hz, 1H), 3.99 – 3.79 (m, 6H), 2.30 (dt, J = 13.9, 6.8 Hz, 1H), 2.17 (ddt, J = 
20.4, 14.1, 6.8 Hz, 1H), 1.91 (dpd, J = 14.0, 7.0, 3.0 Hz, 1H), 1.69 (ddd, J = 12.7, 9.8, 6.1 Hz, 
1H), 1.62 – 1.46 (m, 1H), 1.44 – 1.12 (m, 8H), 0.85 (t, J = 6.9 Hz, 3H) 
13
C NMR (126 MHz, CDCl3) δ 134.6, 116.8, 104.0, 100.4, 67.4, 66.3, 65.1, 65.1, 41.5, 40.2, 
35.9, 24.7, 24.5, 7.7  
HRMS (ASAP+) calculated for C14H25O4 [M+H]
+









To a solution of 2.37 (190 mg, 0.367 mmol) in dioxane:H2O (6.0 mL:2.0 mL) were 
sequentially added 2,6-lutidine (0.20 mL, 0.734 mmol), OsO4 (2.8 mg, 0.006 mmol), and NaIO4 
(361 mg, 0.844 mmol). The mixture was stirred at room temperature for 4 h. The reaction 
mixture was cooled to 0 °C and carefully quenched by the slow addition of saturated aqueous 
Na2S2O3 (3.5 mL). The layers were separated and the aqueous layer was extracted with Et2O (3 x 
10 mL). The combined organic layers were dried over MgSO4, filtered and concentrated. The 
residue was purified by silica gel column chromatography eluting with 0:100  30:70 
EtOAc:Hexanes to give pure 2.38 as a colorless oil (180 mg, 0.337 mmol, 92% yield). 
OR [α]D
22
 +13.2º (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2984, 2886, 1725, 1460, 1381, 1223, 1172, 1053 
1
H NMR (500 MHz, CDCl3) δ 9.74 (d, J = 2.3 Hz, 1H), 4.97 (d, J = 3.1 Hz, 1H), 4.33 (tt, J = 
9.7, 5.4 Hz, 1H), 3.99 – 3.79 (m, 6H), 2.61 (ddd, J = 16.7, 8.7, 2.6 Hz, 1H), 2.49 (dd, J = 16.6, 
4.3 Hz, 1H), 1.94 (hd, J = 9.6, 8.4, 4.3 Hz, 1H), 1.88 – 1.73 (m, 1H), 1.60 (ddd, J = 12.7, 9.5, 6.1 
Hz, 1H), 1.33 (d, J = 10.2 Hz, 7H), 0.85 (d, J = 6.9 Hz, 3H) 
13
C NMR (126 MHz, CDCl3) δ 200.9, 103.9, 100.7, 67.2, 65.1, 65.1, 62.3, 49.1, 41.3, 35.8, 24.6, 
24.2, 7.7 
HRMS (ASAP+) calculated for C13H23O5 [M+H]
+










To a cooled (-78 °C) solution of the enol ether 2.38 and aldehyde 2.27 (90 mg, 0.35 
mmol) in CH2Cl2 (5 mL) was added BF3•Et2O (51 μL, 0.39 mmol) over 20 min by syringe pump. 
After 1 h the reaction was quenched by the addition of saturated aqueous NaHCO3 (2.5 mL). The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 15 mL). The 
combined organic layers were dried over Na2SO4, filtered, and concentrated. Analysis of the 
residue by 
1
H NMR spectroscopy revealed a 9:1 dr for the reaction. The residue was purified by 
silica gel column chromatography eluting with 0:100  40:60 EtOAc:Hexanes to give 2.39as a 
colorless oil in 9:1 dr (170 mg, 0.25 mmol, 70% yield).  
OR [α]D
21 
+2.9º (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 3519, 2930, 2857, 1707, 1471, 1428, 1381, 1224, 1100, 938, 836, 777, 703, 
505 
1
H NMR (500 MHz, CDCl3) δ 7.62 (dd, J = 7.5, 3.4 Hz, 4H), 7.39 (dt, J = 14.5, 7.2 Hz, 6H), 
4.98 (d, J = 3.1 Hz, 1H), 4.22 (s, 1H), 4.11 – 4.04 (m, 1H), 4.00 – 3.89 (m, 2H), 3.89 – 3.80 (m, 
3H), 3.66 – 3.61 (m, 1H), 3.61 – 3.48 (m, 3H), 3.29 (d, J = 3.7 Hz, 1H), 2.66 (dd, J = 16.8, 6.7 
Hz, 1H), 2.54 – 2.45 (m, 2H), 2.40 (dd, J = 16.9, 6.4 Hz, 1H), 2.27 (p, J = 6.2 Hz, 1H), 1.94 (tp, 
J = 7.2, 3.5, 3.1 Hz, 1H), 1.71 (ddd, J = 12.6, 9.7, 6.1 Hz, 1H), 1.66 – 1.55 (m, 4H), 1.54 – 1.42 
(m, 2H), 1.34 (d, J = 7.4 Hz, 6H), 1.26 (s, 1H), 1.05 (s, 9H), 0.97 (d, J = 6.9 Hz, 1H), 0.85 (s, 
12H), -0.02 (d, J = 2.2 Hz, 6H) 
13
C NMR (126 MHz, CDCl3) δ 211.5, 135.7, 135.7, 133.7, 129.8, 127.8, 104.1, 100.7, 67.6, 
66.0, 65.3, 65.2, 64.8, 63.9, 61.2, 49.8, 45.8, 41.9, 41.5, 36.3, 34.3, 33.7, 27.1, 26.1, 24.8, 24.6, 
19.5, 18.4, 7.8, -5.2 
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HRMS (ESI+) calculated for C42H68O8Si2Na [M+Na]
+








To a solution of 2.39 (150 mg, 0.22 mmol) in CH2Cl2 (4 mL) was added 4 Å MS (170 
mg), proton sponge (330 mg, 1.54 mmol), and Me3O•BF4 (195 mg, 1.32 mmol). After 1.5 h the 
mixture was filtered through celite, with EtOAc rinses. The filtrate was washed with 1 M AcOH 
(1 x 75 mL) and saturated aqueous NaHCO3 (1 x 50 mL). The organic layer was dried over 
MgSO4, filtered, and concentrated. The residue was purified by silica gel column 
chromatography eluting with 0:100  20:80 EtOAc:Hexanes to give 2.40 as a colorless oil (125 
mg, 0.18 mmol, 83% yield).  
OR [α]D
22
 +7.4º (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2929, 2856, 1711, 1464, 1428, 1379, 1253, 1224, 1092, 834, 703, 505 
1
H NMR (500 MHz, CDCl3) δ 7.66 – 7.59 (m, 4H), 7.41 (d, J = 7.0 Hz, 2H), 7.37 (t, J = 7.3 Hz, 
4H), 4.98 (d, J = 3.0 Hz, 1H), 4.00 – 3.87 (m, 3H), 3.87 – 3.77 (m, 4H), 3.63 (dd, J = 10.0, 4.7 
Hz, 1H), 3.60 – 3.48 (m, 3H), 3.32 (s, 3H), 2.65 (ddd, J = 28.2, 16.3, 6.8 Hz, 2H), 2.49 – 2.37 
(m, 2H), 2.28 (h, J = 6.1 Hz, 1H), 1.93 (pd, J = 7.0, 3.1 Hz, 1H), 1.79 – 1.64 (m, 1H), 1.64 – 1.38 
(m, 6H), 1.33 (d, J = 2.1 Hz, 6H), 1.05 (s, 9H), 0.85 (s, 11H), -0.01 (d, J = 2.2 Hz, 6H) 
13
C NMR (126 MHz, CDCl3) δ 209.1, 135.8, 135.7, 133.8, 129.8, 127.8, 104.1, 100.6, 74.4, 
67.5, 66.1, 65.3, 65.2, 63.4, 61.3, 57.9, 48.5, 46.1, 41.7, 41.6, 36.8, 34.4, 33.7, 27.1, 26.1, 24.8, 
24.6, 19.5, 18.4, 7.8, -5.2 
HRMS (ESI+) calculated for C42H74O8Si2N [M+H]
+








To a solution of ketone 2.40 (35 mg, 0.048 mmol) in MeOH (0.55 mL) was added 
pyridinium p-toluene sulfonate (12 mg, 0.048 mmol). After 2 h, the reaction mixture was 
quenched by the addition of saturated aqueous NaHCO3 (1.0 mL). The mixture was extracted 
with CH2Cl2 (4 x 5 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated. Purification of the residue by silica gel column chromatography eluting with 0:100 
 50:50 EtOAc:Hexanes gave product 2.41 as a colorless oil (18 mg, 0.036 mmol, 75% yield). 
OR [α]D
21
 +38.3° (c 0.5, CHCl3) 
IR (thin film, cm
-1
) 3488, 3070, 2929, 2856, 1673, 1464, 1427, 1386, 1058, 704 
1
H NMR (500 MHz, CDCl3) δ 7.64 (dt, J = 6.6, 1.6 Hz, 4H), 7.44 – 7.34 (m, 7H), 4.94 (d, J = 
4.5 Hz, 1H), 4.05 – 3.96 (m, 4H), 3.96 – 3.89 (m, 1H), 3.89 – 3.81 (m, 2H), 3.80 – 3.61 (m, 4H), 
3.52 (dd, J = 9.9, 5.0 Hz, 1H), 3.42 (dd, J = 10.0, 6.2 Hz, 1H), 3.33 (s, 3H), 3.29 (d, J = 3.8 Hz, 
1H), 2.15 (s, 1H), 2.09 (ddd, J = 12.5, 4.7, 1.8 Hz, 1H), 2.01 – 1.90 (m, 1H), 1.86 (td, J = 7.1, 4.5 
Hz, 1H), 1.79 – 1.69 (m, 2H), 1.69 – 1.55 (m, 4H), 1.43 – 1.35 (m, 1H), 1.35 – 1.25 (m, 3H), 
1.25 – 1.13 (m, 4H), 1.05 (s, 10H), 0.97 (d, J = 7.0 Hz, 3H) 
13
C NMR (126 MHz, CDCl3) δ 135.8, 135.8, 134.0, 133.9, 129.7, 127.8, 106.5, 97.7, 73.4, 69.5, 
68.7, 65.1, 65.0, 65.0, 60.3, 55.7, 42.6, 41.8, 40.7, 38.7, 37.7, 33.0, 28.6, 27.1, 19.5, 11.2 
HRMS (ESI+) calculated for C34H51O7Si [M+H]
+






To a cooled (-78 °C) solution of alcohol 2.41 (8 mg, 0.0136 mmol) in CH2Cl2 (200 µL) 
was added 2,6-lutidine (12 µL, 0.136 mmol) and TESOTf (3.2 µL, 0.014 mmol). After 4h, 
TMSOTf (6 µL, 0.0325 mmol) was added, and the reaction mixture was warmed to 0 °C. After 
3h, the reaction mixture was quenched by the addition of water (150 µL). The mixture was 
stirred vigorously for 2h, and then the layers were separated and the aqueous layer was extracted 
with CH2Cl2 (5 x 0.5 mL). The combined organic layers were dried over Na2SO4, filtered, and 
concentrated. The crude product was purified by chromatography with pH 7.0 buffered silica gel 
eluting with 0:100  15:85 EtOAc:Hexanes to provide aldehyde 2.9b (8 mg, 0.011 mmol, 82% 
yield) as a colorless oil. 
OR [α]D
25
 +27.5° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2954, 2933, 2876, 1724, 1461, 1428, 1385, 1239, 1187, 1107, 1093, 975, 
822, 740, 703, 505 
1
H NMR (500 MHz, CDCl3) δ 9.79 (d, J = 1.8 Hz, 1H), 7.72 – 7.57 (m, 4H), 7.49 – 7.32 (m, 
6H), 4.19 – 4.18 (m, 1H), 3.81 – 3.71 (m, 1H), 3.71 – 3.56 (m, 3H), 3.52 (dd, J = 9.9, 5.1 Hz, 
1H), 3.42 (dd, J = 9.9, 6.4 Hz, 1H), 3.34 (s, 3H), 2.67 – 2.65 (m, 1H), 2.18 – 2.03 (m, 2H), 2.02 – 
1.98 (m, 1H), 1.85 (ddd, J = 14.1, 8.1, 5.8 Hz, 1H), 1.74 – 1.59 (m, 3H), 1.45 – 1.31 (m, 1H), 
1.29 – 1.20 (m, 2H), 1.20 – 1.10 (m, 4H), 1.05 (s, 9H), 0.97 (t, J = 8.0 Hz, 9H), 0.63 (q, J = 8.0 
Hz, 6H)  
13
C NMR (126 MHz, CDCl3) δ 204.5, 135.7, 135.7, 133.9, 133.9, 129.7, 127.8, 97.7, 73.1, 71.9, 
68.6, 66.1, 60.5, 55.7, 52.3, 42.4, 41.6, 38.6, 38.1, 33.1, 28.6, 27.0, 19.5, 10.6, 7.1, 5.4 
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HRMS (ESI+) calcd for C38H60O6Si2Na [M+Na]
+







2.8.3. Preparation of 2.6a 
 
A 100 mL-capacity, septum-adapted pressure tube was charged with Pd(PPh3)4 (24 mg, 
0.02 mmol), evacuated, and then back-filled with N2. A solution of diene 2.8
36
 (1.19 g, 2.1 mmol) 
in benzene (24 mL) was added followed by trichlorosilane (0.43 mL, 4.2 mmol) and the tube was 
tightly sealed. The tube was heated with an oil bath set at 70 °C. After 15 h the oil bath was 
removed and the sealed tube was allowed to cool to room temperature. The resulting light brown 
solution was transferred by cannula into a 250 mL round bottom flask, rinsing with benzene (3 x 
5 mL). The flask was attached to a vacuum line equipped with a manometer and a -78 °C cold 
finger, and then placed in a warm (~35 °C) water bath. All volatiles were evaporated by 
application of vacuum until a viscous oil remained. 
The residue was dissolved in CH2Cl2 (21.0 mL) and (R,R)-diamine
52
 (1.11 g, 2.11 mmol) was 
added. The resulting white slurry was cooled to 0 °C and DBU (1.26 mL, 8.4 mmol) was added 
over 10 min. After 5 min, the mixture was warmed to room temperature. After 2 h, the flask was 
attached to a vacuum line equipped with a manometer and a -78 °C coldfinger, and then placed 
in a room temperature water bath. All volatiles were removed by careful application of vacuum, 
102 
 
and the residue was treated with Et2O (25.0 mL). The mixture was stirred vigorously for 3 h 
during which time to precipitate the DBU•HCl. The DBU•HCl salts were removed by syringe 
transfer on to an oven-dried, air-free filter frit and filtering into a 250 mL round bottom flask. 
The residual DBU•HCl salts were rinsed with Et2O (3 x 5.0 mL) and the resulting supernatants 
were again filtered through the air-free frit into the flask. The flask was attached to a vacuum line 
equipped with a manometer and a -78 °C coldfinger, and then placed in a room temperature 
water bath. All volatiles were removed by careful application of vacuum until the resulting 
yellow oil became opaque and foamy. The residue was dissolved in CH2Cl2 (11.0 mL) and used 
without further purification. 
To the above solution (cooled to 0 °C) was added aldehyde 9a (1.06 g, 1.58 mmol) as a solution 
in CH2Cl2 (5.0 mL) rinsing with CH2Cl2 (2 x 2.5 mL). Sc(OTf)3 (78 mg, 0.16 mmol) was added 
in one portion. The N2 inlet was removed and the septum was parafilmed. The reaction solution 
was stirred for 15 h during which time the ice/water bath was allowed to warm to room 
temperature. The reaction mixture was re-cooled to 0 ºC and TBAF•3H2O (0.50 g, 1.6 mmol) 
was added. After 45 min the mixture was concentrated. Analysis of the residue by 
1
H NMR 
spectroscopy revealed that the product was formed with > 15:1 diastereoselectivity. The residue 
was purified by silica gel column chromatography eluting with 5:95  100:0 EtOAc:Hexanes to 
give pure 2.43as a beige foam (1.50 g, 1.21 mmol, 57% from 2.8, 77% from 2.9a).  
OR [α]D
19
 -13.5° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2953, 2932, 1778, 1736, 1379, 1247, 1216, 1165, 1107, 1000, 859, 741, 704 
1
H NMR (400 MHz, CDCl3) δ 7.74 – 7.56 (m, 4H), 7.51 – 7.31 (m, 6H), 5.17 (s, 1H), 5.08 – 
4.98 (m, 2H), 4.38 – 4.27 (m, 2H), 4.27 – 4.20 (m, 1H), 4.20 – 4.06 (m, 2H), 3.78 – 3.54 (m, 
5H), 3.49 (dd, J = 9.8, 5.3 Hz, 1H), 3.42 (dd, J = 9.8, 6.2 Hz, 1H), 3.34 (s, 3H), 2.99 – 2.78 (m, 
103 
 
2H), 2.56 – 2.32 (m, 3H), 2.32 – 2.16 (m, 3H), 2.13 – 1.99 (m, 2H), 2.03 (s, 3H), 1.99 – 1.74 (m, 
4H), 1.74 – 1.56 (m, 4H), 1.56 – 1.43 (m, 1H), 1.53 (s, 3H), 1.43 – 1.17 (m, 6H), 1.05 (s, 9H), 
1.08-1.01 (m, 3H), 0.98 (t, J = 7.8 Hz, 11H), 0.81 (d, J = 6.9 Hz, 3H), 0.63 (q, J = 7.9 Hz, 6H), 
0.04 (s, 10H) 
13
C NMR (101 MHz, CDCl3) δ 171.1, 170.6, 156.6, 156.2, 148.1, 135.8, 134.0, 133.9, 129.7, 
127.8, 115.9, 113.7, 113.0, 97.7, 96.8, 84.3, 73.4, 71.7, 71.2, 68.7, 66.5, 65.4, 63.5, 62.6, 61.5, 
60.2, 55.6, 42.7, 41.9, 41.6, 41.1, 40.1, 40.0, 39.9, 39.5, 38.8, 37.7, 37.4, 33.8, 32.8, 28.7, 27.0, 
26.5, 21.6, 19.5, 17.4, 10.9, 10.2, 7.1, 5.2, -1.4 
HRMS (ESI+) calculated for C64H101O14Si3F3Na [M+Na]
+














































To a solution of diene 2.8 (838 mg, 1.49 mmol) in C6H6 (15 mL) in a 100 mL-capacity, 
septum-adapted pressure tube was added Pd(PPh3)4 (34 mg, 0.029 mmol). The tube was 
evacuated and back-filled with N2 (3x). HSiCl3 (0.40 mL, 3.0 mmol) was added and the reaction 
vessel was sealed with a teflon lined screw cap and heated at 80 °C for 12 h. The reaction 
mixture was cooled to room temperature. The reaction vessel was attached to a vacuum line 
equipped with a manometer and a -78 °C cold finger, and then placed in a warm (~35 °C) water 
bath. All volatiles were evaporated by application of vacuum until a viscous oil remained.  
The resulting hydrosilylated product was dissolved in CH2Cl2 (11.0 mL) and the solution 
was cooled to 0 °C. A solution of diaminophenol (R,R)-2.46 (351 mg, 1.41 mmol) and DBU 
(0.63 mL, 4.2 mmol) in CH2Cl2 (2.0 mL) was added, rinsing with CH2Cl2 (2 x 1 mL). The 
mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was cooled 
back to 0 °C and aldehyde 2.9b (850 mg, 1.27 mmol) was added as a solution in CH2Cl2 (2.0 
mL), rinsing with CH2Cl2 (3 x 0.5 mL). The N2 inlet was removed and the septum was 
parafilmed. The mixture was stirred for 12 h during which time the ice/water bath was allowed to 
warm to room temperature. The reaction mixture was cooled to 0 °C and treated with 
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TBAF•3H2O (400 mg, 1.3 mmol). After 1.5 h the reaction mixture was filtered through a plug of 
silica gel, rinsing with EtOAc. The filtrate was concentrated, and analysis of the residue by 
1
H 
NMR spectroscopy revealed that the product was formed with ≥20:1 diastereoselectivity. The 
residue was purified by silica gel column chromatography eluting with 0:100  60:40 
EtOAc:Hexanes to give 2.48 as a beige foam (1.27 g, 1.03 mmol, ≥20:1 dr, 69% from 2.8, 81% 
from 2.9b).  
OR [α]D
26
 -4.5° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2954, 1777, 1734, 1379, 1247, 1215, 1163, 1134, 1094, 1060, 998, 837, 753, 
704, 505 
1
H NMR (500 MHz, CDCl3) δ 7.68 – 7.57 (m, 4H), 7.45 – 7.33 (m, 6H), 5.15 (d, J = 1.9 Hz, 
1H), 5.07 – 5.01 (m, 1H), 5.00 (s, 1H), 4.41 (dt, J = 9.2, 2.8 Hz, 1H), 4.35 – 4.29 (m, 2H), 4.20 – 
4.04 (m, 2H), 3.83 – 3.75 (m, 1H), 3.75 – 3.59 (m, 3H), 3.50 (dd, J = 9.9, 4.9 Hz, 1H), 3.41 (dd, 
J = 9.9, 6.1 Hz, 1H), 3.34 (s, 4H), 2.84 (dd, J = 15.2, 2.2 Hz, 1H), 2.54 – 2.42 (m, 2H), 2.33 (dd, 
J = 14.3, 8.9 Hz, 1H), 2.29 – 2.15 (m, 3H), 2.14 – 2.04 (m, 2H), 2.02 (s, 3H), 2.02 – 1.98 (m, 
1H), 1.96 – 1.84 (m, 3H), 1.81 – 1.78 (m, 1H), 1.73 – 1.56 (m, 4H), 1.55 – 1.43 (m, 5H), 1.42 – 
1.35 (m, 2H), 1.34 – 1.14 (m, 5H), 1.13- 1.04 (s, 4H), 1.04 (s, 9H), 1.02 – 0.91 (m, 11H), 0.85 (d, 
J = 6.9 Hz, 3H), 0.64 (q, J = 7.7 Hz, 6H) 
13
C NMR (126 MHz, CDCl3) δ 171.0, 170.5, 156.6, 156.2, 148.3, 135.7, 133.9, 129.7, 127.7, 
115.6, 113.9, 113.3, 97.6, 96.8, 84.2, 73.4, 72.0, 71.0, 68.6, 66.5, 66.4, 63.5, 62.6, 61.4, 60.5, 
55.6, 42.7, 42.1, 41.9, 41.1, 39.9, 39.9, 38.9, 38.8, 38.6, 37.7, 33.8, 32.8, 28.6, 27.0, 26.5, 21.6, 
19.5, 17.4, 10.5, 10.0, 7.2, 5.6, -1.4 
HRMS (ESI+) calculated for C64H101O14Si3F3Na [M+Na]
+















































To a cooled (0 °C) solution of 2.44 (1.08 g, 0.874 mmol) in THF (9.0 mL) at 0 ºC was 
added Et3N (1.22 mL, 8.73 mmol), Ac2O (0.50 mL, 5.24 mmol), and DMAP (0.32 g, 2.62 
mmol), sequentially. The resulting mixture was warmed to room temperature and stirred for 15 h. 
Saturated aqueous NaHCO3 (20 mL) was added and the aqueous layer was extracted with EtOAc 
(3 x 10 mL). The combined organic layers were washed with H2O (1 x 20 mL), dried over 
Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column 
chromatography eluting with 5:95  30:70 EtOAc:Hexanes to give 2.49 as a beige foam (1.07 g, 
0.837 mmol, 96% yield). 
OR [α]D
20
 -2.1° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2953, 2882, 1779, 1735, 1379, 1246, 1216, 1165, 1100, 999, 859, 838, 704 
1
H NMR (400 MHz, CDCl3) δ 7.69 – 7.56 (m, 4H), 7.49 – 7.29 (m, 6H), 5.20 – 5.12 (m, 1H), 
5.08 – 4.99 (m, 1H), 4.97 (s, 1H), 4.82 (s, 1H), 4.30 – 4.18 (m, 2H), 4.18 – 4.10 (m, 2H), 4.10 – 
4.03 (m, 1H), 3.76 – 3.51 (m, 4H), 3.46 (dd, J = 9.9, 5.7 Hz, 1H), 3.37 (dd, J = 9.9, 6.6 Hz, 1H), 
3.33 (s, 3H), 2.85 (dd, J = 15.2, 2.2 Hz, 1H), 2.68 – 2.56 (m, 1H), 2.56 – 2.40 (m, 2H), 2.34 – 
2.22 (m, 2H), 2.22 – 2.11 (m, 1H), 2.11 – 2.03 (m, 1H), 2.02 (s, 3H), 1.99 – 1.86 (m, 3H), 1.89 
(s, 3H), 1.85 – 1.55 (m, 6H), 1.53 (s, 3H), 1.51 – 1.41 (m, 1H), 1.41 – 1.11 (m, 6H), 1.08 (d, J = 
6.8 Hz, 3H), 1.03 (s, 9H), 0.97 (t, J = 8.0 Hz, 14H), 0.89 (d, J = 6.8 Hz, 3H), 0.60 (q, J = 7.9 Hz, 
6H), 0.04 (s, 9H) 
13
C NMR (101 MHz, CDCl3) δ 171.1, 170.6, 170.0, 156.6, 156.2, 147.8, 135.7, 135.7, 133.8, 
133.7, 129.8, 129.8, 127.8, 115.9, 113.5, 113.1, 97.6, 96.8, 84.3, 73.8, 73.1, 68.7, 67.6, 66.3, 
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65.3, 63.3, 62.6, 61.6, 60.1, 55.6, 42.9, 42.3, 41.9, 41.9, 41.0, 40.1, 39.0, 38.2, 37.7, 37.4, 33.8, 
33.0, 28.9, 27.0, 26.5, 21.6, 21.0, 19.4, 17.5, 10.8, 8.4, 7.2, 5.6, -1.4 
HRMS (ESI+) calculated for C66H103O15SiF3Na [M+Na]
+














































To a solution of 2.49 (426 mg, 0.333 mmol) in DMF (4.0 mL) was added distilled H2O 
(192 μL) and tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF) (1.01 g, 3.7 mmol), 
and the vial containing the TASF was rinsed with DMF (2.0 mL). After 15 min the reaction 
mixture was heated to 50 °C (oil bath, external temperature). After 10 h, TLC analysis indicated 
complete conversion to product. The reaction mixture was cooled to room temperature and the 
excess TASF was quenched by the addition of pH 7 buffer (8.0 mL). The mixture was extracted 
with EtOAc (5 x 3 mL) and the combined organic layers were washed with H2O (1 x 3 mL), 
dried over Na2SO4, filtered, and concentrated. Filtration through a plug of silica gel eluting with 
0:100  10:90 MeOH:CH2Cl2 gave a beige foam, which was azeotroped with toluene (4 x) 
before being used immediately in the next step. 
To a solution of this material in CH2Cl2 (3.0 mL) was added Et3N (60 μL, 0.43 mmol) 
and TIPSCl (68 μL, 0.32 mmol). After 20 min saturated aqueous NaHCO3 (3 mL) was added. 
The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 1 mL). The 
combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was 
purified by silica gel column chromatography eluting with 0:100  5:95 MeOH:CH2Cl2 to give 
2.50 as a beige foam (212 mg, 0.239 mmol, 72% yield over 2 steps from 2.49).  
OR [α]D
20
 +16.4° (c 1.0, CHCl3) 
IR (thin film, cm
-1





H NMR (400 MHz, CDCl3) δ 5.09 – 5.02 (m, 2H), 5.00 (dd, J = 9.8, 2.6 Hz, 1H), 4.86 (s, 1H), 
4.41 – 4.22 (m, 2H), 4.03 (s, 1H), 3.87 – 3.72 (m, 2H), 3.72 – 3.54 (m, 3H), 3.52 – 3.36 (m, 2H), 
3.33 (s, 3H), 2.97 (d, J = 2.5 Hz, 1H), 2.66 – 2.52 (m, 2H), 2.46 (dd, J = 17.2, 4.7 Hz, 1H), 2.35 
(dd, J = 14.4, 8.1 Hz, 1H), 2.21 – 2.07 (m, 2H), 2.07 – 1.98 (m, 2H), 2.05 (s, 3H), 2.01 (s, 3H), 
1.98 – 1.91 (m, 1H), 1.90 – 1.69 (m, 5H), 1.69 – 1.61 (m, 3H), 1.61 – 1.56 (m, 1H), 1.56 – 1.46 
(m, 3H), 1.46 – 1.38 (m, 1H), 1.35 – 1.16 (m, 8H), 1.14 (s, 3H), 1.09-1.01 (m, 3H), 1.05 (d, J = 
7.5 Hz, 18H), 0.99 – 0.85 (m, 1H), 0.95 (d, 3H).  
13
C NMR (101 MHz, CDCl3) δ 171.4, 171.1, 170.4, 147.5, 113.3, 98.3, 97.9, 75.2, 73.0, 68.7, 
68.1, 67.8, 66.2, 65.0, 61.4, 60.2, 55.6, 46.3, 43.9, 42.3, 41.6, 41.5, 40.7, 39.7, 38.8, 38.5, 37.7, 
34.1, 33.2, 30.1, 28.3, 21.7, 20.9, 17.9, 17.9, 12.0, 11.9, 9.4 
HRMS (FAB+) calculated for C46H81O14Si [M+H]
+














































To a solution of 2.50 (102 mg, 0.115 mmol) in CH2Cl2 (7.7 mL) was added Dess-Martin 
periodinane (147 mg, 0.35 mmol). After 1.5 h the reaction mixture was cooled to 0 °C and 10 mL 
of a 1:1 solution of saturated aqueous NaHCO3 and saturated aqueous Na2S2O3 was added 
slowly. The mixture was warmed to room temperature and after 30 min the layers were separated 
and the aqueous layer was extracted with CH2Cl2 (3 x 5.0 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated. The residue was filtered through a plug of 
pH 7 buffered silica gel with 0:100  70:30 EtOAc:Hexanes to give a beige foam (88 mg), 
which was used immediately in the next step without further purification. 
To a solution of 61 mg of this product in CH2Cl2 (1.4 mL) was added 2,6-di-tert-
butylpyridine (155 μL, 0.69 mmol). The mixture was cooled to -78 °C and TESOTf (78 μL, 0.35 
mmol) was added slowly. After 2h, the reaction mixture was quenched by the addition of 
saturated aqueous NaHCO3 (3.0 mL) and the mixture was warmed to room temperature over 10 
minutes. The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 2 mL). 
The combined organic layers were dried over MgSO4, filtered, and concentrated. The residue 
was purified by silica gel column chromatography with pH 7 buffered silica gel eluting with 
0:100  60:40 EtOAc:Hexanes to give 2.6a as a beige foam (58 mg, 0.058 mmol, 72% yield 
over 2 steps from 2.50).  
OR [α]D
20
 +13.3° (c 1.0, CHCl3) 
IR (thin film, cm
-1





H NMR (400 MHz, CDCl3) δ 9.57 (s, 1H), 5.29 (dd, J = 9.7, 2.9 Hz, 1H), 5.06 – 5.01 (m, 1H), 
4.99 (s, 1H), 4.84 (s, 1H), 4.29 – 4.09 (m, 3H), 3.88 – 3.76 (m, 1H), 3.74 – 3.62 (m, 2H), 3.33 (s, 
3H), 2.94 – 2.76 (m, 2H), 2.76 – 2.61 (m, 2H), 2.53 – 2.34 (m, 3H), 2.33 – 2.24 (m, 2H), 2.16 – 
2.07 (m, 1H), 2.06 – 1.94 (m, 2H), 2.01 (s, 3H), 1.92 (s, 3H), 1.90 – 1.79 (m, 3H), 1.79 – 1.69 
(m, 1H), 1.63 – 1.37 (m, 56H), 1.37 – 1.15 (m, 8H), 1.20 (s, 3H), 1.13 – 1.00 (m, 25H), 0.93 (t, J 
= 7.9 Hz, 9H), 0.55 (qd, J = 7.9, 2.1 Hz, 6H) 
13
C NMR (101 MHz, CDCl3) δ 209.2, 203.0, 171.1, 170.7, 169.6, 147.2, 113.9, 97.1, 97.0, 73.8, 
72.8, 70.6, 66.8, 64.4, 64.2, 61.3, 59.6, 55.8, 48.7, 48.5, 47.8, 45.4, 43.4, 42.4, 42.2, 41.3, 38.7, 
38.0, 37.0, 35.0, 34.2, 32.1, 24.9, 21.7, 20.9, 17.9, 12.9, 12.1, 12.1, 7.5, 7.5, 7.1 
HRMS (ESI+) calculated for C52H90O14Si2Na [M+Na]
+






















































 2.8.4. Preparation of 2.55 and 2.60 
 
To a solution of 2.54 (3.00 g, 16.3 mmol) in DMF (50 mL) was added NaN3 (2.11 g, 32.5 
mmol). The mixture was heated at 80 °C for 12 h and the cooled to room temperature. Water (30 
mL) was added to the reaction vessel and the mixture was extracted with EtOAc (3 x 20 mL). 
The combined organic layers were dried over MgSO4, filtered, and concentrated. The crude 
product was purified by silica gel column chromatography eluting with 0:100  70:30 
EtOAc:Hexanes to afford the desired product 2.55 as a pale yellow solid (2.37 g, 79% yield). 
The 
1




H NMR (300 MHz, CDCl3) δ 8.15 – 7.99 (m, 2H), 7.41 – 7.28 (m, 2H), 3.56 (t, J = 7.1 Hz, 




To a cooled (-20 °C) solution of 3,3-dimethylglutaric anhydride 2.56 (5.00 g, 35.0 mmol) 
in THF (175 mL) was added a LiAlH4 (0.80 g, 21 mmol) in 3 equal portions in 5 min increments. 
The reaction mixture was slowly warmed to 0 °C and stirred for 1 h. Excess LiAlH4 was 
quenched by the slow addition of 6 M HCl (45.0 mL), and the mixture was warmed to room 
temperature. After 20 min the mixture was extracted with EtOAc (3 x 50 mL) and the combined 
organic layers were dried over MgSO4, filtered, and concentrated to provide crude S30, which 
was used without additional purification.  
1
H NMR (500 MHz, CDCl3) δ 4.40 – 4.32 (m, 2H), 2.32 (s, 2H), 1.69 (t, J = 6.1 Hz, 2H), 1.08 
(s, 6H). 
A mixture of lactone 2.57 (205 mg, 1.6 mmol) and 33% HBr in AcOH (0.46 mL) was 
stirred at 75 °C for 1 h. Upon cooling to room temperature, MeOH (0.60 mL) was added and the 
resulting mixture was stirred for 48 h. All volatiles were removed in vacuo and the resulting 
residue was dissolved in EtOAc (5.0 mL) and washed with saturated NaHCO3 (3 x 2.0 mL). The 
organic layer was dried over Mg2SO4, filtered, and concentrate to afford crude 2.58 as a colorless 
oil. NMR analysis of the crude indicated an 85:15 mixture of product 2.58 to side products (2.57 
and bromoacid) that was used without further purification.  
1
H NMR (400 MHz, CDCl3) δ 3.67 (s, 3H), 3.46 – 3.36 (m, 2H), 2.22 (s, 2H), 2.01 – 1.91 (m, 
2H), 1.03 (s, 6H). 
To a solution of crude 2.58 in DMF (4 mL) was added NaN3 (210 mg, 3.2 mmol) and the 
resulting mixture was stirred at 70 °C for 2 h. The reaction mixture was quenched by the addition 
of H2O (4 mL) and extracted with EtOAc (3 x 2 mL). The combined organic layers were dried 
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over MgSO4, filtered, and concentrated to provide the crude product 2.59, which was used 
without further purification.  
1
H NMR (400 MHz, CDCl3) δ 3.65 (s, 3H), 3.35 – 3.23 (m, 2H), 2.23 (s, 2H), 1.71 – 1.61 (m, 
2H), 1.02 (s, 6H). 
To a solution of crude 2.59 in MeOH (0.4 mL) was added 1 M NaOH (2.4 mL, 2.4 
mmol). The resulting reaction mixture was stirred at room temperature for 12 h. The reaction 
mixture was concentrated in vacuo and the resulting residue was treated with 1 M HCl until pH 
1. The product was extracted with EtOAc (3 x 2 mL) and the combined organic layers were dried 
over MgSO4, filtered, and concentrated. The crude product was purified by silica gel column 
chromatography eluting with 0:100  50:50 EtOAc:Hexanes to afford the desired product 2.60 
as a colorless oil (138 mg, 50% yield over 4 steps).  
IR (thin film, cm
-1
) 2963, 2092, 1702, 1472, 1409, 1249, 898, 670 
1
H NMR (400 MHz, CDCl3) δ 3.40 – 3.24 (m, 2H), 2.28 (s, 2H), 1.78 – 1.66 (m, 2H), 1.08 (s, 
6H) 
13
C NMR (101 MHz, CDCl3) δ 177.7, 47.7, 45.8, 39.8, 32.6, 27.6 
HRMS (APCI-) calculated for C7H12N3O2 [M-H]
-

















2.8.5. Preparation of 2.6b 
 
To a cooled (0 °C) solution of alcohol 2.48 (400 mg, 0.324 mmol) in toluene (6.5 mL) was 
sequentially added benzoic acid S.55 (309 mg, 1.6 mmol), Et3N (0.27 mL, 1.9 mmol), DMAP 
(198 mg, 1.6 mmol), and 2,4,6-trichlorobenzoyl chloride (278 μL, 1.8 mmol). The reaction 
mixture immediately became thick and cloudy upon addition of the 2,4,6-trichlorobenzoyl 
chloride. The mixture was warmed to room temperature. After 12 h the reaction mixture was 
quenched by the addition of saturated aqueous NaHCO3 (10 mL). The mixture was extracted 
with EtOAc (3 x 3 mL) and the combined organic layers were dried over MgSO4, filtered, and 
concentrated. The residue was purified by silica gel column chromatography eluting with 0:100 
 50:50 EtOAc:Hexanes to afford the desired product 2.61bas a beige foam (378 mg, 0.268 
mmol, 83% yield).  
OR [α]D
24
 +1.6° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2954, 2097, 1777, 1733, 1428, 1378, 1248, 1215, 1114, 1098, 999, 752, 667, 
504 
1
H NMR (400 MHz, CDCl3) δ 7.91 – 7.78 (m, 2H), 7.73 – 7.59 (m, 4H), 7.52 – 7.34 (m, 6H), 
7.00 (d, J = 8.1 Hz, 2H), 5.19 – 5.07 (m, 1H), 5.07 – 4.96 (m, 1H), 4.87 (s, 1H), 4.72 (s, 1H), 
4.34 – 4.21 (m, 2H), 4.19 – 4.06 (m, 2H), 4.03 (dd, J = 10.3, 2.5 Hz, 1H), 3.67 – 3.52 (m, 2H), 
3.44 – 3.37 (m, 2H), 3.35 – 3.26 (m, 2H), 3.31 (s, 3H), 3.21 (d, J = 4.2 Hz, 2H), 2.90 – 2.77 (m, 
1H), 2.72 (q, J = 7.6 Hz, 1H), 2.65 (td, J = 7.1, 2.7 Hz, 2H), 2.53 – 2.38 (m, 2H), 2.34 – 2.18 (m, 
3H), 2.13 – 1.95 (m, 4H), 1.95 – 1.84 (m, 1H), 1.91 (s, 3H), 1.83 – 1.67 (m, 3H), 1.58 (dd, J = 
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15.0, 4.2 Hz, 2H), 1.53 (s, 3H), 1.50 – 1.14 (m, 14H), 1.14 – 1.06 (m, 1H), 1.06 – 1.01 (m, 1H), 
1.04 (s, 9H), 1.00 – 0.83 (m, 16H), 0.64 – 0.55 (m, 6H), 0.04 (s, 9H) 
13
C NMR (101 MHz, CDCl3) δ 171.0, 170.5, 164.9, 156.6, 156.2, 146.4, 143.1, 135.8, 135.8, 
135.7, 134.0, 133.9, 129.8, 129.8, 129.7, 129.0, 128.8, 127.8, 127.8, 115.9, 114.4, 113.0, 97.5, 
96.7, 84.3, 77.4, 74.5, 73.5, 70.5, 68.1, 66.4, 66.4, 63.3, 62.6, 61.4, 60.1, 55.5, 51.9, 42.9, 42.2, 
41.8, 41.6, 41.0, 40.0, 38.6, 38.4, 38.1, 37.9, 37.7, 35.2, 33.8, 32.2, 28.1, 27.0, 26.5, 21.5, 19.5, 
17.4, 11.5, 9.7, 7.2, 5.6, -1.4 
HRMS (ESI+) calculated for C73H108N3O15F3Si3Na [M+Na]
+


















































To a solution of 2.61b(378 mg, 0.268 mmol) in DMF (5.4 mL) was added pH 7 buffer 
(150 μL) followed by tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF) (740 mg, 
2.69 mmol). After 23 h the reaction mixture was quenched by the addition of pH 7 buffer (10 
mL). The mixture was extracted with EtOAc (5 x 5 mL) and the combined organic layers were 
dried over Na2SO4, filtered, and concentrated. Filtration through a plug of silica gel eluting with 
0:100  10:90 MeOH:CH2Cl2 gave a beige foam (166 mg), which was used immediately in the 
next step. 
To a solution of this material in CH2Cl2 (3.9 mL) was added Et3N (50 μL, 0.36 mmol) 
and TIPSCl (45 μL, 0.21 mmol). After 45 min the reaction mixture was quenched by the addition 
of saturated aqueous NaHCO3 (5 mL). The product was extracted with CH2Cl2 (3 x 2 mL) and 
the combined organic layers were dried over MgSO4, filtered, and concentrated. The residue was 
purified by silica gel column chromatography eluting with 0:100  10:90 MeOH:CH2Cl2 to 
afford the desired product 2.62b as a beige foam (190 mg, 0.187 mmol, 70% yield over 2 steps 
from 2.61b).  
OR [α]D
23
 +3.8° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 3529, 2945, 2869, 2098, 1718, 1383, 1271, 1184, 1097, 993, 757 
1
H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 5.23 (dd, J = 
8.7, 3.1 Hz, 1H), 5.06 – 4.99 (m, 1H), 4.96 (s, 1H), 4.82 (s, 1H), 4.39 – 4.27 (m, 2H), 4.09 (s, 
1H), 4.07 – 3.99 (m, 1H), 3.96 – 3.84 (m, 1H), 3.67 – 3.48 (m, 5H), 3.29 – 3.19 (m, 2H), 3.25 (s, 
3H), 2.94 (t, J = 7.0 Hz, 2H), 2.81 – 2.75 (m, 1H), 2.73 (d, J = 4.1 Hz, 1H), 2.65 (dd, J = 16.9, 
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7.7 Hz, 1H), 2.48 (dd, J = 17.0, 5.3 Hz, 1H), 2.37 (dd, J = 14.4, 8.2 Hz, 1H), 2.30 – 2.18 (m, 
2H), 2.01 (ddd, J = 12.1, 4.4, 1.7 Hz, 1H), 1.98 – 1.91 (m, 1H), 1.97 (s, 3H), 1.90 – 1.50 (m, 
12H), 1.47 – 1.37 (m, 1H), 1.33 – 1.08 (m, 15H), 1.05 (dd, J = 7.6, 1.2 Hz, 18H), 1.00 (d, J = 7.0 
Hz, 3H) 
13
C NMR (101 MHz, CDCl3) δ 171.1, 170.4, 165.7, 147.2, 143.5, 130.0, 129.3, 129.0, 113.9, 
98.3, 97.7, 77.4, 75.7, 73.1, 69.0, 68.2, 67.8, 66.2, 66.2, 64.8, 61.6, 60.2, 55.5, 52.1, 46.3, 44.1, 
42.5, 41.7, 41.6, 40.7, 39.3, 38.6, 37.7, 36.9, 36.6, 35.4, 34.1, 33.2, 30.1, 28.4, 21.6, 18.0, 17.9, 
13.1, 12.0, 11.7 
HRMS (ESI+) calculated for C53H85N3O14SiNa [M+Na]
+


















































To a solution of 2.62b(190 mg, 0.187 mmol) in CH2Cl2 (12 mL) was added Dess-Martin 
periodinane (229 mg, 0.540 mmol). After 1.5 h the reaction mixture was cooled to 0 °C and 40 
mL of a 1:1 solution of saturated aqueous NaHCO3 and saturated aqueous Na2S2O3 was added 
slowly. The mixture was warmed to room temperature and after 30 min the layers were separated 
and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated. The residue (189 mg) was used immediately 
in the next step without further purification.  
To a solution of this product (189 mg) in CH2Cl2 (3.7 mL) was added 2,6-di-tert-
butylpyridine (356 μL, 1.86 mmol). The mixture was cooled to -78 °C and TESOTf (210 μL, 
0.93 mmol) was added dropwise. After 1 h the mixture was warmed to -45 °C. After 1 h excess 
TESOTf was quenched by the addition of saturated aqueous NaHCO3 (10 mL). The mixture was 
warmed to room temperature and extracted with CH2Cl2 (3 x 10 mL). The combined organic 
layers were washed with saturated CuSO4 (10 mL), dried over Na2SO4, filtered, and 
concentrated. The residue was purified by column chromatography using pH 7 buffered silica gel 
and eluting with 0:100  5:95 acetone:CH2Cl2 to afford the desired product 2.6b as a beige 
foam (119 mg, 0.106 mmol, 57% yield over 2 steps from 2.62b).  
OR [α]D
23
 +12.2° (c 1.0, CHCl3) 
IR (thin film, cm
-1




H NMR (500 MHz, CDCl3) δ 9.48 (s, 1H), 7.91 (d, J = 7.8 Hz, 2H), 7.26 (m, 2H), 5.58 – 5.48 
(m, 1H), 5.03 (s, 1H), 4.90 (s, 1H), 4.79 (s, 1H), 4.31 – 4.14 (m, 2H), 4.14 – 4.04 (m, 1H), 3.80 
(t, J = 12.1 Hz, 1H), 3.68 – 3.56 (m, 2H), 3.53 (t, J = 7.1 Hz, 2H), 3.26 (s, 3H), 3.10 – 2.99 (m, 
1H), 2.96 – 2.89 (m, 2H), 2.89 – 2.82 (m, 1H), 2.75 – 2.66 (m, 1H), 2.65 – 2.56 (m, 2H), 2.46 – 
2.28 (m, 4H), 2.06 (dd, J = 12.6, 4.5 Hz, 1H), 2.01 – 1.92 (m, 1H), 1.95 (s, 3H) 1.90 – 1.81 (m, 
2H), 1.81 – 1.70 (m, 3H), 1.65 – 1.23 (m, 15H), 1.23 – 1.11 (m, 11H), 1.07 (dd, J = 7.8, 2.3 Hz, 
18H), 1.07 – 0.99 (m, 1H), 0.94 (t, J = 7.9 Hz, 9H), 0.62 – 0.50 (m, 6H) 
13
C NMR (126 MHz, CDCl3) δ 209.1, 203.0, 171.1, 170.7, 165.0, 146.6, 143.6, 130.1, 129.0, 
128.9, 114.5, 97.1, 74.7, 72.7, 70.5, 66.8, 64.4, 64.1, 61.4, 59.5, 55.7, 52.1, 49.1, 48.1, 47.8, 45.4, 
43.4, 42.5, 42.1, 41.3, 38.6, 38.5, 36.8, 35.4, 34.9, 34.2, 32.2, 24.9, 21.7, 17.9, 13.2, 12.5, 12.1, 
7.5, 7.1 
HRMS (ESI+) calculated for C59H95N3O14Si2Na [M+H]
+



















































2.8.6. Preparation of 2.6c 
 
To a cooled (0 °C) solution of alcohol 2.48 (400 mg, 0.324 mmol) in toluene (6.5 mL) 
was added acid S33 (166 mg, 0.97 mmol), Et3N (180 μL, 1.3 mmol), DMAP (119 mg, 0.97 
mmol), and 2,4,6-trichlorobenzoyl chloride (167 μL, 1.1 mmol). The reaction mixture 
immediately became thick and cloudy upon addition of 2,4,6-trichlorobenzoyl chloride. The 
mixture was warmed to room temperature. After 1.5 h the reaction mixture was quenched by the 
addition of saturated aqueous NaHCO3 (10 mL). The mixture was extracted with EtOAc (3 x 3 
mL) and the combined organic layers were dried over MgSO4, filtered, and concentrated. The 
residue was purified by silica gel column chromatography eluting with 0:100  50:50 




 +14.4° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 2655, 2095, 1777, 1734, 1378, 1248, 1215, 1163, 1106, 1074, 999, 977, 838, 
742, 702, 505 
1
H NMR (500 MHz, CDCl3) δ 7.68 – 7.58 (m, 4H), 7.46 – 7.31 (m, 6H), 5.06 – 4.97 (m, 2H), 
4.97 – 4.90 (m, 1H), 4.86 (s, 1H), 4.30 – 4.19 (m, 2H), 4.18 – 4.04 (m, 2H), 3.97 (d, J = 10.2 Hz, 
1H), 3.72 – 3.57 (m, 4H), 3.54 (dd, J = 10.0, 4.2 Hz, 1H), 3.39 (dd, J = 9.9, 6.5 Hz, 1H), 3.32 (s, 
3H), 3.25 – 3.12 (m, 2H), 2.90 – 2.80 (m, 1H), 2.63 (q, J = 7.1 Hz, 1H), 2.43 (ddd, J = 19.6, 
15.8, 4.2 Hz, 2H), 2.33 – 2.22 (m, 2H), 2.21 – 1.85 (m, 12H), 1.83 – 1.76 (m, 1H), 1.73 – 1.16 
(m, 20H), 1.11 (d, J = 6.9 Hz, 3H), 1.08 – 1.03 (m, 2H), 1.05 (s, 9H), 1.02 – 0.89 (m, 21H), 0.62 




C NMR (126 MHz, CDCl3) δ 171.0, 170.5, 170.5, 156.6, 156.3, 146.7, 135.8, 135.8, 133.9, 
133.8, 129.8, 129.7, 127.8, 115.6, 114.3, 113.3, 97.5, 96.7, 84.3, 74.0, 73.3, 70.3, 68.5, 66.6, 
66.4, 63.2, 62.6, 61.4, 60.3, 55.6, 47.7, 45.9, 42.9, 42.0, 41.9, 41.2, 41.0, 40.0, 39.6, 38.6, 38.5, 
37.9, 37.7, 37.6, 36.8, 33.8, 32.8, 32.0, 28.7, 27.7, 27.3, 27.1, 26.4, 24.8, 23.5, 21.6, 19.5, 17.4, 
11.3, 10.2, 7.2, 5.6, -1.4 
HRMS (ESI+) calculated for C71H112N3O15F3Si3Na [M+Na]
+






















































To a solution of 2.61c (439 mg, 0.316 mmol) in DMF (6.3 mL) was added pH 7 buffer 
(0.17 mL) followed by tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF) (0.87 g, 
3.2 mmol). After 23 h the reaction mixture was quenched by the addition of pH 7 buffer (10 mL). 
The mixture was extracted with EtOAc (5 x 5 mL) and the combined organic layers were dried 
over Na2SO4, filtered, and concentrated. Filtration through a plug of silica gel eluting with 0:100 
 10:90 MeOH:CH2Cl2 gave a beige foam (228 mg), which was used immediately in the next 
step. 
To a solution of this material in CH2Cl2 (5.4 mL) was added Et3N (70 μL, 0.50 mmol) 
and TIPSCl (64 μL, 0.30 mmol). After 45 min the reaction mixture was quenched by the addition 
of saturated aqueous NaHCO3 (6 mL). The product was extracted with CH2Cl2 (3 x 3 mL) and 
the combined organic layers were dried over MgSO4, filtered, and concentrated. The residue was 
purified by silica gel column chromatography eluting with 0:100  6:94 MeOH:CH2Cl2 to 




 +18.1° (c 1.0, CHCl3) 
IR (thin film, cm
-1
) 3485, 2945, 2869, 2095, 1718, 1552, 1464, 1370, 1324, 1184, 1091, 1053, 
993, 884, 754, 667 
1
H NMR (500 MHz, CDCl3) δ 5.08 – 5.01 (m, 3H), 4.87 (s, 1H), 4.39 – 4.26 (m, 2H), 4.12 (s, 
1H), 4.02 – 3.88 (m, 2H), 3.71 – 3.59 (m, 3H), 3.41 (s, 2H), 3.36 – 3.30 (m, 4H), 3.28 (t, J = 8.0 
Hz, 2H), 3.08 – 2.99 (m, 1H), 2.68 (q, J = 7.7 Hz, 2H), 2.48 (dd, J = 17.1, 5.5 Hz, 1H), 2.33 (dd, 
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J = 14.4, 8.5 Hz, 1H), 2.26 – 2.17 (m, 1H), 2.20 (s, 2H), 2.14 – 1.87 (m, 7H), 2.04 (s, 3H), 1.87 – 
1.74 (m, 2H), 1.74 – 1.48 (m, 11H), 1.42 (d, J = 14.0 Hz, 1H), 1.34 – 1.16 (m, 10H), 1.15 (s, 
3H), 1.10 – 0.99 (m, 30H), 0.92 (d, J = 7.0 Hz, 3H) 
13
C NMR (126 MHz, CDCl3) δ 171.2, 171.1, 170.5, 147.6, 113.7, 98.3, 97.9, 74.9, 73.1, 69.3, 
68.3, 67.8, 66.5, 66.2, 64.6, 61.6, 60.4, 55.7, 47.7, 46.2, 45.8, 44.0, 42.5, 41.7, 41.4, 40.4, 39.7, 
38.8, 38.7, 37.6, 36.7, 34.0, 33.3, 32.2, 30.0, 28.3, 27.6, 27.5, 21.7, 18.0, 17.9, 13.2, 12.0, 11.9 
HRMS (ESI+) calculated for C51H89N3O14SiNa [M+Na]
+






















































To a solution of 2.62c (154 mg, 0.154 mmol) in CH2Cl2 (10 mL) was added Dess-Martin 
periodinane (190 mg, 0.447 mmol). After 1.5 h the reaction mixture was cooled to 0 °C and 35 
mL of a 1:1 solution of saturated aqueous NaHCO3 and saturated aqueous Na2S2O3 was added 
slowly. The mixture was warmed to room temperature and after 30 min the layers were separated 
and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated. The residue (152 mg) was used immediately 
in the next step without further purification. 
To a solution of this product (152 mg) in CH2Cl2 (3.1 mL) was added 2,6-di-tert-
butylpyridine (333 μL, 1.54 mmol). The mixture was cooled to -78 °C and TESOTf (174 μL, 
0.769 mmol) was added dropwise. After 1 h the mixture was warmed to -45 °C. After 1 h excess 
TESOTf was quenched by the addition of saturated aqueous NaHCO3 (10 mL). The mixture was 
warmed to room temperature and extracted with CH2Cl2 (3 x 10 mL). The combined organic 
layers were washed with saturated aqueous CuSO4 (10 mL), dried over Na2SO4, filtered, and 
concentrated. The residue was purified by column chromatorgraphy using pH 7 buffered silica 
gel and eluting with 0:100  8:92 acetone:CH2Cl2 to afford the desired product 2.6c as a beige 
foam (136 mg, 0.123 mmol, 80% yield over 2 steps from 2.62c). 
OR [α]D
22
 +11.4° (c 0.5, CHCl3) 
IR (thin film, cm
-1
) 2947, 2871, 2095, 1725, 1463, 1370, 1214, 1181, 1145, 1065, 994, 755, 667 
1
H NMR (500 MHz, CDCl3) δ 9.56 (s, 1H), 5.42 – 5.31 (m, 1H), 5.04 (s, 1H), 4.98 (s, 1H), 4.82 
(s, 1H), 4.27 – 4.09 (m, 3H), 3.83 (t, J = 12.0 Hz, 1H), 3.74 – 3.62 (m, 2H), 3.33 (s, 3H), 3.26 (t, 
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J = 8.0 Hz, 2H), 2.92 – 2.77 (m, 2H), 2.74 – 2.61 (m, 2H), 2.52 – 2.44 (m, 1H), 2.44 – 2.21 (m, 
4H), 2.16 – 2.06 (m, 3H), 2.04 – 1.95 (m, 5H), 1.90 – 1.79 (m, 3H), 1.78 – 1.70 (m, 1H), 1.65 – 
1.52 (m, 7H), 1.51 – 1.39 (m, 3H), 1.36 – 1.17 (m, 11H), 1.08 (t, J = 6.0 Hz, 25H), 0.97 (s, 6H), 
0.92 (t, J = 7.8 Hz, 9H), 0.59 – 0.49 (m, 6H).  
13
C NMR (126 MHz, CDCl3) δ 208.8, 203.0, 171.1, 170.7, 170.2, 147.0, 114.1, 97.1, 97.0, 73.3, 
72.8, 70.5, 66.8, 64.3, 64.2, 61.3, 59.6, 55.8, 48.9, 48.4, 47.8, 47.7, 45.8, 45.3, 43.4, 42.4, 42.1, 
41.2, 39.7, 38.6, 37.6, 37.0, 35.0, 34.1, 32.3, 32.1, 27.5, 27.5, 24.9, 21.7, 17.9, 12.9, 12.1, 12.0, 
7.5, 7.0.  
HRMS (ESI+) calculated for C57H99N3O14Si2Na [M+Na]
+




















































2.8.7. Preparation of 2.5a 
 
Phosphonium salt 2.7 (90 mg, 0.060 mmol) was azeotroped with dry benzene (3x) and placed 
under vacuum for 24 h. Aldehyde 6a (90 mg, 0.090 mmol) was azeotroped with dry benzene (3x) 
and placed under vacuum for 24 h. The dried Wittig salt was charged with dry 10% HMPA/THF 
solution (0.63 mL) and cooled to -78 ºC. LiHMDS (66 μL, 0.066 mmol) was added dropwise and 
the resultant orange solution was stirred 30 min at this temperature. A solution of the dried 
aldehyde in 10% HMPA/THF (0.45 mL) was added dropwise to the reaction mixture. The yellow 
solution was allowed to warm to 0 ºC over 1 h and stirred at 0 ºC for 1 h. The reaction was 
quenched by the addition of a 4:1 mixture of NH4Cl (sat. aq.) and Na2S2O3 (sat. aq.) (5 mL). 
Et2O (7 mL) was added the layers were separated. The aqueous layer was extracted with Et2O (3 
x 4 mL) and the combined organic layers were washed with NaHCO3 (sat. aq) (5 mL) and brine 
(5 mL), dried over MgSO4, filtered and concentrated. Purification by flash column 
chromatography (10%  40% EtOAc/Hexanes, then 0%  10% MeOH/CH2Cl2) on pH 7 




 +8.2° (c 1.00, CH2Cl2) 






H NMR (500 MHz, C6D6) δ 6.55 – 6.42 (m, 2H), 5.63 (dd, J = 9.1, 3.5 Hz, 1H), 5.48 – 5.40 (m, 
1H), 5.24 – 4.99 (m, 8H), 4.59 – 4.50 (m, 2H), 4.42 – 4.26 (m, 1H), 4.03 – 3.95 (m, 2H), 3.91 (s, 
1H), 3.81 (td, J = 10.9, 5.3 Hz, 1H), 3.67 – 3.49 (m, 4H), 3.19 (s, 3H), 3.14 (s, 3H), 2.98 (dd, J = 
9.1, 7.0 Hz, 1H), 2.93 (dd, J = 15.8, 3.9 Hz, 1H), 2.81 (dd, J = 17.1, 7.5 Hz, 1H), 2.77 – 2.65 (m, 
2H), 2.61 – 2.48 (m, 3H), 2.47 – 2.32 (m, 3H), 2.29 – 2.20 (m, 2H), 2.14 – 1.90 (m, 6H), 1.83 – 
1.73 (m, 6H), 1.69 – 1.59 (m, 2H), 1.51 – 1.17 (m, 29H), 1.18 – 1.00 (m, 72H), 0.97 – 0.77 (m, 
16H), 0.71 – 0.60 (m, 5H), 0.29 (s, 12H), 0.26 (s, 3H), 0.18 (d, J = 3.5 Hz, 6H), 0.13 (s, 3H) 
13
C NMR (126 MHz, C6D6) δ 208.5, 170.6, 170.2, 168.8, 148.0, 144.4, 138.9, 138.9, 135.1, 
129.4, 128.6, 126.6, 115.6, 115.1, 113.8, 101.6, 97.6, 97.3, 81.8, 80.8, 77.8, 77.4, 74.7, 73.2, 
71.8, 71.7, 71.3, 70.8, 67.7, 67.0, 64.9, 64.7, 61.8, 60.0, 55.3, 49.1, 48.9, 47.9, 47.1, 47.0, 45.6, 
42.8, 42.7, 42.4, 42.3, 40.4, 39.4, 39.1, 38.8, 37.7, 34.6, 33.0, 32.2, 32.2, 32.0, 30.3, 30.2, 29.9, 
29.4, 29.3, 28.1, 27.2, 26.2, 23.1, 23.1, 21.4, 20.6, 18.6, 18.4, 18.1, 16.2, 14.4, 13.4, 13.0, 12.3, 
10.8, 7.7, 7.7, 7.5, 7.5, 7.4, 6.3, 6.2, 6.2, 1.4, -4.0, -4.2, -4.4, -4.5 
HRMS (ESI+) calculated for C109H203ClO21Si7NH4 [M+NH4]
+








Wittig product 2.63a (68 mg, 0.033 mmol) was dissolved in THF (7 mL) and cooled to 0 
ºC. TBAF3H2O (99 μL, 1M in THF) was added in 6 portions over 1 h and stirring was 
continued at 0 ºC for 3 h. The reaction was quenched by the addition of NH4Cl (sat. aq.) (10 mL) 
and EtOAc (10 mL). The layers were separated and the aqueous layer was extracted with EtOAc 
(3 x 10 mL). The combined organic layers were washed with brine (15 mL). The combined 
aqueous layers were back-extracted with CH2Cl2 (2 x 10 mL). The combined organic layers were 
dried over Na2SO4, filtered and concentrated. Purification by flash column chromatography (0% 
 5% MeOH/CH2Cl2) on silica gel afforded seco-acid 2.64a as a white solid (46 mg, 0.0274 
mmol, 83% yield).  
OR [α]D
25
 +25.4° (c 1.00, CH2Cl2) 
IR (ATR) 3448, 2951, 2930, 2876, 2860, 1734, 1590, 1551, 1461, 1371, 1241, 1182, 1144, 1106, 




H NMR (500 MHz, C6D6) δ 6.56 – 6.40 (m, 2H), 5.63 (dd, J = 9.0, 3.5 Hz, 1H), 5.53 – 5.40 (m, 
2H), 5.24 – 4.93 (m, 12H), 4.58 – 4.35 (m, 2H), 4.34 – 4.24 (m, 4H), 4.02 – 3.87 (m, 3H), 3.86 – 
3.78 (m, 1H), 3.66 – 3.46 (m, 4H), 3.23 – 3.17 (m, 7H), 3.14 (s, 3H), 3.03 – 2.95 (m, 1H), 2.89 – 
2.66 (m, 3H), 2.62 – 1.85 (m, 12H), 1.83 – 1.68 (m, 7H), 1.63 (d, J = 13.4 Hz, 2H), 1.55 – 1.39 
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(m, 3H), 1.39 – 0.76 (m, 93H), 0.67 (q, J = 7.9 Hz, 6H), 0.29 – 0.23 (m, 3H), 0.20 – 0.08 (m, 
10H) 
13
C NMR (126 MHz, C6D6) δ 208.7, 170.1, 169.1, 167.4, 148.0, 144.4, 143.7, 138.9, 138.9, 
135.1, 129.4, 126.6, 115.7, 115.1, 113.8, 101.7, 97.7, 97.6, 81.7, 81.2, 80.8, 77.8, 77.4, 76.9, 
74.9, 73.3, 72.2, 71.8, 71.7, 71.3, 70.9, 67.7, 66.7, 64.9, 64.6, 61.7, 60.0, 55.8, 55.3, 53.3, 49.2, 
49.0, 48.0, 47.1, 47.1, 45.2, 42.7, 42.4, 42.2, 40.6, 40.4, 39.0, 38.7, 37.7, 34.4, 32.9, 32.4, 32.2, 
32.2, 30.2, 30.2, 30.1, 29.9, 29.9, 29.8, 29.7, 29.3, 28.1, 27.8, 26.2, 26.2, 25.1, 23.1, 21.3, 18.6, 
18.4, 16.2, 16.1, 14.4, 13.4, 13.1, 10.8, 7.7, 7.5, 7.5, 7.3, 6.4, 6.3, 6.2, 6.2, 6.0, -4.0, -4.2, -4.4, -
4.4, -4.5 
HRMS (ESI+) calculated for C88H155ClO21Si4NH4 [M+NH4]
+









Seco-acid 2.64a (40 mg, 0.023 mmol) was dissolved in toluene (2.3 mL) and i-Pr2NEt 
(0.24 mL, 1.38 mmol) and 2,4,6-trichlorobenzoyl chloride (72 μL, 0.46 mmol) were added. This 
was stirred for 4 h at rt, then diluted with toluene (6.9 mL). The mixture was taken up into a 12 
mL gas-tight syringe and added to a 90 ºC solution of DMAP (141 mg, 1.15 mmol) in toluene 
(34 mL) over 24 h by syringe pump. The vial containing starting material which was sealed and 
stored at 0 ºC was rinsed with toluene (2.3 mL) and added to the reaction at over 8 h by syringe 
pump. The starting material vial was rinsed with an additional portion of toluene (2.3 mL) and 
added to the reaction over 4 h by syringe pump. The reaction mixture was allowed to stir at 90 ºC 
for 20 h. The reaction mixture was cooled to rt and diluted with Et2O (50 mL). This was washed 
with NaHCO3 (sat. aq) (50 mL) and brine (50 mL). The combined aqueous layers were extracted 
with EtOAc (2 x 50 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated. Purification by flash column chromatography (10%  40% EtOAc/Hexanes) on 
silica gel afforded lactone 2.65a as a white solid (31 mg, 0.0186 mmol, 81% yield).  
OR [α]D
24
 +23.9° (c 1.00, CH2Cl2) 
IR (ATR) 2928, 2876, 2856, 1735, 1647, 1583, 1550, 1461, 1370, 1246, 1143, 1110, 1029, 1005, 






H NMR (500 MHz, C6D6) δ 6.55 – 6.26 (m, 3H), 5.70 (d, J = 10.4 Hz, 1H), 5.41 (q, J = 7.7 Hz, 
2H), 5.23 – 4.93 (m, 14H), 4.84 (q, J = 15.7 Hz, 1H), 4.41 (dq, J = 22.9, 12.2, 9.5 Hz, 6H), 4.03 – 
3.74 (m, 5H), 3.64 – 3.39 (m, 5H), 3.28 – 3.05 (m, 10H), 2.68 (s, 1H), 2.61 – 2.46 (m, 5H), 2.45 
– 2.05 (m, 5H), 2.11 – 1.54 (m, 16H), 1.55 – 0.54 (m, 162H), 0.32 – -0.02 (m, 17H) 
13
C NMR (126 MHz, C6D6) δ 208.8, 171.5, 170.3, 168.5, 148.2, 143.5, 142.8, 139.0, 138.9, 
134.5, 130.0, 128.6, 126.5, 126.5, 126.4, 117.2, 116.2, 115.6, 115.2, 113.4, 101.8, 101.7, 97.7, 
97.6, 97.1, 97.0, 80.9, 80.1, 79.7, 79.2, 78.9, 76.8, 75.0, 73.2, 73.1, 72.8, 72.3, 72.2, 71.7, 71.5, 
71.3, 71.2, 70.4, 67.0, 65.4, 64.6, 63.5, 60.3, 55.7, 55.3, 51.4, 48.4, 48.1, 47.0, 46.6, 46.4, 45.7, 
44.2, 42.5, 40.5, 40.3, 39.3, 39.0, 38.6, 38.4, 38.2, 37.8, 36.9, 36.1, 34.8, 33.4, 33.0, 32.8, 32.5, 
32.4, 32.3, 30.6, 30.2, 29.9, 29.6, 27.7, 26.2, 26.1, 25.6, 25.1, 23.2, 21.5, 20.6, 18.5, 18.3, 14.6, 
14.4, 13.9, 12.7, 10.8, 10.6, 7.7, 7.6, 7.2, 6.2, -4.1, -4.3, -4.5, -4.7 
HRMS (ESI+) calculated for C88H153ClO20Si4Na [M+Na]
+








Lactone 2.65a (26 mg, 0.015 mmol) was dissolved in MeCN (1.08 mL) and cooled to -20 
ºC. A freshly prepared solution of HF in MeCN (1.08 mL) [prepared by mixing 48% aqueous HF 
(1.25 mL) and MeCN (5 mL)] was added over 2 h by syringe pump at -20 ºC. The reaction was 
allowed to stir an additional 18 h at this temperature. The reaction was quenched by the dropwise 
addition of Et3N (2.53 mL) and warmed to rt. The reaction mixture was diluted with a 2:1 
mixture of EtOAc/CH2Cl2 (13 mL), then washed with NaHCO3 (sat. aq) (13 mL) and brine (13 
mL). The combined aqueous layers were extracted with a 2:1 mixture of EtOAc/CH2Cl2 (2 x 13 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. 
Purification by flash column chromatography (0%  5% MeOH/CH2Cl2) on silica gel afforded 
spongistatin 1 analog 2.5a as a white solid (15 mg, 0.0125 mmol, 83% yield).  
OR [α]D
22
 +18.2° (c 0.50, MeOH) 





H NMR (500 MHz, CD3CN) δ 6.50 – 6.34 (m, 1H), 6.25 – 6.06 (m, 1H), 5.45 (d, J = 6.9 Hz, 
2H), 5.36 (s, 1H), 5.33 – 5.11 (m, 3H), 5.07 (s, 1H), 4.97 – 4.79 (m, 6H), 4.81 – 4.67 (m, 1H), 
4.48 – 4.22 (m, 3H), 4.21 – 4.08 (m, 2H), 4.08 – 3.96 (m, 1H), 3.93 – 3.47 (m, 4H), 3.47 – 3.31 
(m, 1H), 3.27 (d, J = 18.9 Hz, 6H), 3.19 – 3.03 (m, 1H), 3.03 – 2.69 (m, 3H), 2.66 – 2.47 (m, 
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1H), 2.44 – 2.30 (m, 1H), 2.30 – 2.22 (m, 2H), 1.87 – 1.78 (m, 4H), 1.73 – 1.45 (m, 6H), 1.28 (d, 
J = 13.7 Hz, 11H), 1.14 (dd, J = 7.0, 2.7 Hz, 3H), 1.09 – 0.97 (m, 7H), 0.88 (d, J = 7.1 Hz, 1H), 
0.84 – 0.73 (m, 6H) 
13
C NMR (126 MHz, CD3CN) δ 210.7, 172.8, 171.6, 170.1, 148.1, 144.1, 139.2, 139.0, 135.8, 
129.0, 126.9, 126.8, 99.3, 99.2, 99.1, 98.0, 81.1, 81.0, 80.3, 78.8, 78.6, 77.8, 74.9, 73.8, 73.2, 
73.0, 71.5, 70.6, 69.4, 69.3, 69.2, 67.0, 64.7, 63.4, 62.6, 62.3, 60.7, 56.1, 55.5, 50.6, 48.1, 46.8, 
45.1, 44.3, 44.0, 43.8, 42.9, 42.2, 40.4, 40.3, 40.1, 39.7, 39.6, 37.4, 37.3, 37.2, 36.8, 34.5, 33.8, 
33.2, 32.6, 32.5, 30.4, 30.2, 30.1, 29.4, 27.7, 27.1, 23.4, 21.8, 21.0, 14.4, 13.1, 12.8, 12.2, 11.3 
HRMS (ESI+) calculated for C63H95ClO20Na [M+Na]
+






2.8.8. Preparation of 2.5b 
 
Wittig salt 2.7 (45 mg, 0.03 mmol) was azeotroped with dry benzene (3x) and placed 
under vacuum for 24 h. Aldehyde 2.6b (51 mg, 0.045 mmol) was azeotroped with dry benzene 
(3x) and placed under vacuum for 24 h. The dried Wittig salt was charged with dry 10% 
HMPA/THF solution (0.31 mL) and cooled to -78 ºC. LiHMDS (33 μL, 0.033 mmol) was added 
dropwise and the resultant orange solution was stirred 30 min at this temperature. A solution of 
the dried aldehyde in 10% HMPA/THF (0.23 mL) was added dropwise to the reaction mixture. 
The yellow solution was allowed to warm to 0 ºC over 1 h and stirred at 0 ºC for 1 h. The 
reaction was quenched by the addition of a 4:1 mixture of NH4Cl (sat. aq.) and Na2S2O3 (sat. aq.) 
(2.5 mL). Et2O (3.5 mL) was added the layers were separated. The aqueous layer was extracted 
with Et2O (3 x 2 mL) and the combined organic layers were washed with NaHCO3 (sat. aq) (2.5 
mL) and brine (2.5 mL), dried over MgSO4, filtered and concentrated. Purification by flash 
column chromatography (10%  40% EtOAc/Hexanes, then 0%  10% MeOH/CH2Cl2) on pH 




 +20.2° (c 1.00, CH2Cl2) 






H NMR (500 MHz, C6D6) δ  8.14 (dd, J = 8.3, 3.5 Hz, 2H), 6.82 (d, J = 7.9 Hz, 2H), 6.47 (td, J 
= 15.0, 12.8, 4.7 Hz, 2H), 5.93 (dt, J = 8.7, 4.3 Hz, 1H), 5.41 (q, J = 7.8 Hz, 1H), 5.17 (h, J = 
6.9, 5.4 Hz, 5H), 5.09 – 5.02 (m, 3H), 4.61 – 4.48 (m, 2H), 4.36 (d, J = 10.6 Hz, 1H), 4.27 (d, J = 
8.5 Hz, 2H), 4.02 – 3.93 (m, 2H), 3.91 (d, J = 3.1 Hz, 1H), 3.68 (tt, J = 10.5, 4.6 Hz, 1H), 3.63 – 
3.44 (m, 5H), 3.20 – 3.13 (m, 4H), 3.04 (s, 3H), 2.93 (dt, J = 15.6, 3.7 Hz, 1H), 2.89 – 2.66 (m, 
6H), 2.60 – 2.46 (m, 4H), 2.35 (tdd, J = 16.8, 10.9, 4.6 Hz, 3H), 2.27 (t, J = 7.2 Hz, 2H), 2.23 – 
2.03 (m, 4H), 1.96 (dd, J = 17.9, 10.7 Hz, 2H), 1.82 (d, J = 2.5 Hz, 4H), 1.80 – 1.59 (m, 7H), 
1.51 (d, J = 13.0 Hz, 1H), 1.45 (q, J = 7.2, 5.7 Hz, 6H), 1.32 (p, J = 8.8, 7.2 Hz, 11H), 1.27 – 
0.90 (m, 107H), 0.89 – 0.79 (m, 19H), 0.78 (s, 3H), 0.66 (dh, J = 14.6, 7.1 Hz, 10H), 0.26 (d, J = 
4.3 Hz, 3H), 0.17 (d, J = 2.7 Hz, 7H), 0.12 (s, 3H) 
13
C NMR (126 MHz, C6D6) δ 208.1, 170.3, 169.8, 164.6, 147.2, 144.0, 143.3, 138.5, 138.5, 
134.7, 129.9, 129.1, 128.9, 128.7, 128.2, 126.1, 115.6, 115.2, 114.7, 114.0, 101.2, 97.2, 96.9, 
81.3, 80.8, 80.4, 80.0, 77.6, 77.4, 77.0, 76.9, 75.4, 72.7, 71.8, 71.4, 71.2, 71.0, 70.9, 70.4, 67.3, 
66.6, 64.5, 64.2, 61.4, 59.6, 54.8, 51.3, 48.6, 47.5, 46.6, 46.1, 45.2, 42.4, 42.1, 42.0, 41.9, 40.1, 
39.5, 38.7, 38.4, 37.0, 36.5, 34.7, 34.1, 32.6, 31.8, 29.8, 28.9, 27.7, 26.8, 25.8, 25.8, 24.7, 20.9, 
18.2, 18.0, 17.7, 15.8, 15.7, 13.1, 11.9, 10.5, 10.4, 7.4, 7.3, 7.1, 7.1, 7.0, 6.0, 5.9, 5.9, 5.8, 5.8, -
4.4, -4.6, -4.8 
HRMS (ESI+) calculated for C116H212ClO21Si7N4 [M+NH4]
+










Wittig product 2.63b (35 mg, 0.016 mmol) was dissolved in THF (3.4 mL) and cooled to 
0 ºC. TBAF3H2O (47 μL, 1M in THF) was added in 6 portions over 1 h and stirring was 
continued at 0 ºC for 3 h. The reaction was quenched by the addition of NH4Cl (sat. aq.) (3.5 
mL) and EtOAc (3.5 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (3 x 3.5 mL). The combined organic layers were washed with brine (5 mL). The 
combined aqueous layers were back-extracted with CH2Cl2 (2 x 3.5 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated. Purification by flash column 
chromatography (0%  5% MeOH/CH2Cl2) on silica gel afforded seco-acid 2.64b as a white 
solid (23 mg, 0.013 mmol, 81% yield).  
OR [α]D
23
 +21.5° (c 1.00, CH2Cl2) 
IR (ATR) 3439, 2952, 2928, 2876, 2854, 2099, 1729, 1553, 1461, 1382, 1248, 1179, 1144, 1101, 




H NMR (500 MHz, C6D6) δ 8.15 (d, J = 7.9 Hz, 2H), 6.86 – 6.80 (m, 2H), 6.55 – 6.33 (m, 2H), 
5.94 (s, 1H), 5.42 (s, 1H), 5.24 – 5.04 (m, 7H), 5.01 (s, 1H), 4.95 (s, 1H), 4.57 – 4.40 (m, 2H), 
4.33 (d, J = 29.6 Hz, 3H), 4.02 – 3.85 (m, 3H), 3.69 (s, 1H), 3.60 (d, J = 11.1 Hz, 2H), 3.53 (d, J 
= 10.1 Hz, 1H), 3.39 (d, J = 11.4 Hz, 1H), 3.28 – 3.12 (m, 6H), 3.11 – 2.97 (m, 5H), 2.86 (d, J = 
27.3 Hz, 2H), 2.77 (t, J = 7.0 Hz, 3H), 2.70 (s, 1H), 2.64 – 2.42 (m, 5H), 2.35 (d, J = 15.5 Hz, 
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3H), 2.27 (s, 3H), 2.21 – 2.14 (m, 2H), 1.89 (t, J = 10.6 Hz, 2H), 1.83 (s, 4H), 1.74 (t, J = 14.1 
Hz, 4H), 1.63 (d, J = 14.1 Hz, 3H), 1.53 – 1.39 (m, 8H), 1.36 (s, 8H), 1.34 – 1.28 (m, 10H), 1.25 
– 1.14 (m, 15H), 1.14 – 1.01 (m, 53H), 0.98 (s, 3H), 0.95 – 0.84 (m, 9H), 0.84 – 0.77 (m, 10H), 
0.68 (q, J = 7.9 Hz, 9H), 0.29 – 0.23 (m, 3H), 0.21 – 0.09 (m, 10H) 
13
C NMR (126 MHz, C6D6) δ 209.2, 170.8, 170.5, 167.7, 165.5, 165.4, 147.9, 147.8, 144.7, 
144.2, 144.1, 144.1, 143.4, 139.4, 139.3, 139.2, 135.4, 130.6, 129.8, 129.7, 129.5, 128.9, 126.9, 
126.8, 116.1, 116.0, 115.5, 114.9, 102.1, 102.0, 97.9, 82.0, 81.1, 77.8, 77.2, 76.2, 73.5, 73.4, 
72.6, 72.1, 72.0, 71.7, 71.2, 68.0, 67.2, 65.1, 65.0, 64.8, 62.0, 60.3, 56.1, 55.5, 55.5, 52.0, 49.5, 
49.4, 48.3, 47.4, 46.8, 45.6, 42.6, 40.8, 39.9, 39.4, 39.3, 39.0, 37.7, 35.5, 34.7, 33.3, 33.1, 32.7, 
32.6, 30.6, 30.2, 29.6, 28.4, 28.2, 28.1, 27.4, 27.1, 26.6, 23.5, 21.7, 21.6, 18.9, 18.8, 16.5, 14.7, 
14.3, 13.9, 13.6, 11.2, 11.1, 8.0, 8.0, 8.0, 7.9, 7.8, 7.6, 7.6, 6.7, 6.6, 6.6, 1.8, -3.7, -3.9, -4.1, -4.1 
HRMS (ESI+) calculated for C95H164ClO21Si4N4 [M+NH4]
+








Seco-acid 2.64b (21 mg, 0.011 mmol) was dissolved in toluene (1.1 mL) and i-Pr2NEt 
(115 μL, 0.66 mmol) and 2,4,6-trichlorobenzoyl chloride (34 μL, 0.22 mmol) were added. This 
was stirred for 4 h at rt, then diluted with toluene (3.3 mL). The mixture was taken up into a 6 
mL gas-tight syringe and added to a 90 ºC solution of DMAP (67 mg, 0.55 mmol) in toluene (16 
mL) over 24 h by syringe pump. The vial containing starting material which was sealed and 
stored at 0 ºC was rinsed with toluene (1.1 mL) and added to the reaction at over 8 h by syringe 
pump. The starting material vial was rinsed with an additional portion of toluene (1.1 mL) and 
added to the reaction over 4 h by syringe pump. The reaction mixture was allowed to stir at 90 ºC 
for 20 h. The reaction mixture was cooled to rt and diluted with Et2O (25 mL). This was washed 
with NaHCO3 (sat. aq) (25 mL) and brine (25 mL). The combined aqueous layers were extracted 
with EtOAc (2 x 25 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated. Purification by flash column chromatography (10%  40% EtOAc/Hexanes) on 
silica gel afforded lactone 2.65b as a white solid (15 mg, 0.0085 mmol, 77% yield).  
OR [α]D
25
 +16.9° (c 1.00, CH2Cl2) 







H NMR (500 MHz, C6D6) δ 8.25 – 8.09 (m, 2H), 6.83 (d, J = 8.2 Hz, 2H), 6.53 – 6.33 (m, 2H), 
6.03 (d, J = 10.4 Hz, 1H), 5.49 – 5.29 (m, 1H), 5.07 (ddq, J = 48.4, 24.6, 9.4, 8.3 Hz, 8H), 4.67 
(d, J = 10.7 Hz, 1H), 4.54 – 4.23 (m, 4H), 4.03 – 3.79 (m, 3H), 3.69 (d, J = 6.0 Hz, 1H), 3.63 (d, 
J = 10.3 Hz, 1H), 3.58 (s, 1H), 3.51 (d, J = 3.5 Hz, 2H), 3.42 (s, 1H), 3.27 (d, J = 4.0 Hz, 1H), 
3.18 (d, J = 1.9 Hz, 1H), 3.11 – 3.00 (m, 2H), 2.98 – 2.88 (m, 1H), 2.87 – 2.68 (m, 5H), 2.65 – 
2.38 (m, 4H), 2.32 – 2.21 (m, 4H), 2.19 – 2.08 (m, 3H), 2.01 (d, J = 18.5 Hz, 1H), 1.84 (d, J = 
6.1 Hz, 3H), 1.73 – 1.55 (m, 4H), 1.44 (ddd, J = 7.3, 4.6, 2.6 Hz, 5H), 1.38 – 1.28 (m, 5H), 1.28 
– 1.15 (m, 11H), 1.15 – 0.90 (m, 43H), 0.84 (dq, J = 15.9, 7.6 Hz, 13H), 0.71 – 0.54 (m, 9H), 
0.28 (d, J = 12.3 Hz, 2H), 0.21 – 0.01 (m, 12H). 
13
C NMR: We were unable to generate a useful 
13
C NMR spectrum for this compound due to a 
lack of a minimally sufficient amount of material. 
HRMS (ESI+) calculated for C95H162ClO20Si4N4 [M+NH4]
+








Lactone 2.65b (13 mg, 0.0072 mmol) was dissolved in MeCN (0.52 mL) and cooled to -
20 ºC. A freshly prepared solution of HF in MeCN (0.52 mL) [prepared by mixing 48% aqueous 
HF (1.25 mL) and MeCN (5 mL)] was added over 2 h by syringe pump at -20 ºC. The reaction 
was allowed to stir an additional 18 h at this temperature. The reaction was quenched by the 
dropwise addition of Et3N (1.21 mL) and warmed to rt. The reaction mixture was diluted with a 
2:1 mixture of EtOAc/CH2Cl2 (6 mL), then washed with NaHCO3 (sat. aq) (6 mL) and brine (6 
mL). The combined aqueous layers were extracted with a 2:1 mixture of EtOAc/CH2Cl2 (2 x 6 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. 
Purification by flash column chromatography (0%  5% MeOH/CH2Cl2) on silica gel afforded 
spongistatin 1 analog 2.5b as a white solid (8 mg, 0.006 mmol, 83% yield).  
OR [α]D
22
 +18.2° (c 0.50, MeOH) 





H NMR (500 MHz, CD3CN) δ 7.98 – 7.81 (m, 2H), 7.43 – 7.33 (m, 2H), 6.50 – 6.42 (m, 1H), 
6.22 – 6.14 (m, 1H), 5.55 – 5.45 (m, 2H), 5.39 (d, J = 4.3 Hz, 1H), 5.29 (dd, J = 10.8, 6.4 Hz, 
1H), 5.17 (t, J = 10.6 Hz, 1H), 4.95 (d, J = 12.8 Hz, 2H), 4.87 – 4.78 (m, 2H), 4.76 (d, J = 4.9 
Hz, 1H), 4.37 (s, 1H), 4.31 (t, J = 11.1 Hz, 1H), 4.23 – 4.07 (m, 2H), 4.00 (t, J = 10.4 Hz, 2H), 
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3.85 – 3.77 (m, 1H), 3.71 (s, 1H), 3.59 (t, J = 6.9 Hz, 2H), 3.50 (d, J = 25.7 Hz, 2H), 3.42 (d, J = 
10.2 Hz, 1H), 3.30 – 3.26 (m, 1H), 2.96 (t, J = 6.9 Hz, 2H), 2.91 – 2.73 (m, 3H), 2.60 (d, J = 9.3 
Hz, 1H), 2.55 (d, J = 11.2 Hz, 1H), 2.46 – 2.31 (m, 2H), 1.79 (s, 2H), 1.71 (d, J = 4.3 Hz, 2H), 
1.58 (d, J = 12.8 Hz, 4H), 1.50 (d, J = 14.5 Hz, 2H), 1.41 (d, J = 6.1 Hz, 1H), 1.38 (s, 3H), 1.30 
(s, 7H), 1.26 – 1.15 (m, 8H), 1.11 (s, 3H), 1.06 – 0.99 (m, 3H), 0.90 (q, J = 6.9 Hz, 3H), 0.84 (t, J 
= 5.6 Hz, 3H) 
13
C NMR: We were unable to generate a useful 
13
C NMR spectrum for this compound due to a 
lack of a minimally sufficient amount of material. 
HRMS (ESI+) calcd for C70H100ClO20N3Na [M+Na]
+
: 1360.6486, found 1360.6436 






2.8.9. Preparation of 2.5c 
 
Wittig salt 2.7 (35 mg, 0.023 mmol) was azeotroped with dry benzene (3x) and placed 
under vacuum for 24 h. Aldehyde 6c (38 mg, 0.035 mmol) was azeotroped with dry benzene (3x) 
and placed under vacuum for 24 h. The dried Wittig salt was charged with dry 10% HMPA/THF 
solution (0.24 mL) and cooled to -78 ºC. LiHMDS (25 μL, 0.025 mmol) was added dropwise and 
the resultant orange solution was stirred 30 min at this temperature. A solution of the dried 
aldehyde in 10% HMPA/THF (0.18 mL) was added dropwise to the reaction mixture. The yellow 
solution was allowed to warm to 0 ºC over 1 h and stirred at 0 ºC for 1 h. The reaction was 
quenched by the addition of a 4:1 mixture of NH4Cl (sat. aq.) and Na2S2O3 (sat. aq.) (2.5 mL). 
Et2O (3.5 mL) was added the layers were separated. The aqueous layer was extracted with Et2O 
(3 x 2 mL) and the combined organic layers were washed with NaHCO3 (sat. aq) (2.5 mL) and 
brine (2.5 mL), dried over MgSO4, filtered and concentrated. Purification by flash column 
chromatography (10%  40% EtOAc/Hexanes, then 0%  10% MeOH/CH2Cl2) on pH 7 




 +11.7° (c 0.50, CH2Cl2) 






H NMR (500 MHz, C6D6) δ 6.55 – 6.40 (m, 2H), 5.69 (dd, J = 9.1, 3.3 Hz, 1H), 5.49 – 5.40 (m, 
1H), 5.27 (s, 1H), 5.22 – 5.11 (m, 4H), 5.07 (d, J = 7.1 Hz, 3H), 4.52 (p, J = 6.0, 4.9 Hz, 2H), 
4.42 (q, J = 6.5 Hz, 1H), 4.30 (d, J = 7.8 Hz, 2H), 4.07 – 3.94 (m, 2H), 3.91 (s, 1H), 3.85 (tt, J = 
10.8, 4.6 Hz, 1H), 3.64 (dt, J = 11.3, 5.6 Hz, 1H), 3.61 – 3.54 (m, 2H), 3.54 – 3.45 (m, 2H), 3.18 
(d, J = 1.2 Hz, 3H), 3.16 (s, 3H), 3.08 (t, J = 10.6 Hz, 1H), 2.97 (dd, J = 9.1, 7.0 Hz, 1H), 2.94 – 
2.80 (m, 4H), 2.78 – 2.64 (m, 3H), 2.64 – 2.48 (m, 4H), 2.45 (dd, J = 15.2, 4.0 Hz, 1H), 2.42 – 
2.31 (m, 3H), 2.31 – 2.16 (m, 3H), 2.16 – 2.07 (m, 2H), 2.05 (s, 2H), 2.01 – 1.91 (m, 6H), 1.76 
(t, J = 13.9 Hz, 4H), 1.64 (td, J = 14.3, 4.7 Hz, 3H), 1.56 – 1.44 (m, 6H), 1.44 – 1.25 (m, 18H), 
1.21 (q, J = 8.0 Hz, 15H), 1.16 – 0.96 (m, 84H), 0.94 – 0.76 (m, 28H), 0.65 (pd, J = 7.9, 6.0 Hz, 
8H), 0.49 (s, 2H), 0.30 – 0.22 (m, 3H), 0.22 – 0.14 (m, 6H), 0.12 (s, 3H) 
13
C NMR (126 MHz, C6D6) δ 207.9, 170.3, 169.8, 169.5, 147.6, 144.0, 143.3, 138.6, 138.5, 
138.5, 138.5, 134.7, 129.0, 126.1, 115.6, 115.3, 114.8, 114.8, 113.6, 101.2, 97.3, 96.9, 81.4, 80.8, 
80.4, 77.6, 77.4, 77.0, 76.9, 73.9, 72.9, 71.8, 71.4, 71.2, 70.9, 70.4, 67.3, 66.6, 64.5, 64.2, 61.4, 
59.7, 55.0, 48.7, 48.6, 47.5, 47.3, 46.7, 46.6, 45.2, 45.2, 42.4, 42.2, 42.1, 41.9, 40.1, 39.4, 38.8, 
38.7, 38.4, 37.5, 34.2, 32.6, 31.8, 31.7, 29.9, 29.9, 28.9, 27.7, 27.1, 27.0, 26.8, 25.8, 21.0, 18.2, 
18.0, 17.7, 15.8, 15.7, 13.0, 12.6, 11.9, 10.5, 10.4, 7.4, 7.3, 7.2, 7.1, 7.0, 5.9, 5.8, 5.8, -4.4, -4.6, -
4.8, -4.9 
HRMS (ESI+) calculated for C114H216ClO21Si7N4 [M+NH4]
+









Wittig product 2.63c (20 mg, 0.0091 mmol) was dissolved in THF (1.95 mL) and cooled 
to 0 ºC. TBAF3H2O (27.3 μL, 1M in THF) was added in 6 portions over 1 h and stirring was 
continued at 0 ºC for 3 h. The reaction was quenched by the addition of NH4Cl (sat. aq.) (2 mL) 
and EtOAc (2 mL). The layers were separated and the aqueous layer was extracted with EtOAc 
(3 x 2 mL). The combined organic layers were washed with brine (5 mL). The combined aqueous 
layers were back-extracted with CH2Cl2 (2 x 2 mL). The combined organic layers were dried 
over Na2SO4, filtered and concentrated. Purification by flash column chromatography (0%  
5% MeOH/CH2Cl2) on silica gel afforded seco-acid 2.64c as a white solid (13 mg, 0.0072 mmol, 
79% yield).  
OR [α]D
26
 +41.5° (c 1.00, CH2Cl2) 
IR (ATR) 3449, 2953, 2930, 2876, 2095, 1734, 1553, 1461, 1383, 1246, 1181, 1144, 1108, 1005, 




H NMR (500 MHz, C6D6) δ 6.55 – 6.31 (m, 2H), 5.69 (t, J = 9.7 Hz, 1H), 5.55 – 5.37 (m, 1H), 
5.27 – 4.90 (m, 10H), 4.52 (s, 1H), 4.47 – 4.37 (m, 3H), 4.30 (s, 2H), 3.97 (t, J = 10.7 Hz, 1H), 
3.92 (s, 1H), 3.85 (tt, J = 10.7, 4.6 Hz, 1H), 3.63 (dd, J = 11.1, 5.3 Hz, 1H), 3.59 – 3.46 (m, 1H), 
3.42 – 3.31 (m, 1H), 3.22 (dd, J = 14.1, 3.4 Hz, 3H), 3.18 – 3.11 (m, 6H), 3.09 – 2.95 (m, 3H), 
2.85 (dt, J = 14.7, 7.5 Hz, 3H), 2.78 – 2.63 (m, 3H), 2.63 – 2.51 (m, 2H), 2.47 (dd, J = 15.6, 7.6 
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Hz, 3H), 2.36 (dt, J = 16.7, 6.9 Hz, 2H), 2.24 (dd, J = 12.3, 4.6 Hz, 3H), 2.11 (d, J = 13.7 Hz, 
1H), 2.05 (dd, J = 7.4, 4.9 Hz, 2H), 1.99 – 1.93 (m, 4H), 1.90 (t, J = 14.4 Hz, 2H), 1.82 – 1.67 
(m, 4H), 1.61 (t, J = 12.0 Hz, 3H), 1.49 (ddd, J = 23.6, 15.8, 6.9 Hz, 6H), 1.40 – 1.25 (m, 18H), 
1.25 – 1.13 (m, 15H), 1.12 – 0.94 (m, 54H), 0.94 – 0.71 (m, 28H), 0.66 (qd, J = 7.8, 3.1 Hz, 
11H), 0.25 (dd, J = 7.2, 4.0 Hz, 4H), 0.19 – 0.07 (m, 11H) 
13
C NMR: We were unable to generate a useful 
13
C NMR spectrum for this compound due to a 
lack of a minimally sufficient amount of material. 
HRMS (ESI+) calculated for C93H168ClO21Si4N4 [M+NH4]
+









Seco-acid 2.64c (10 mg, 0.0058 mmol) was dissolved in toluene (0.58 mL) and i-Pr2NEt 
(61 μL, 0.35 mmol) and 2,4,6-trichlorobenzoyl chloride (18 μL, 0.12 mmol) were added. This 
was stirred for 4 h at rt, then diluted with toluene (1.74 mL). The mixture was taken up into a 6 
mL gas-tight syringe and added to a 90 ºC solution of DMAP (35 mg, 0.29 mmol) in toluene (8.5 
mL) over 24 h by syringe pump. The vial containing starting material which was sealed and 
stored at 0 ºC was rinsed with toluene (0.56 mL) and added to the reaction at over 8 h by syringe 
pump. The starting material vial was rinsed with an additional portion of toluene (0.56 mL) and 
added to the reaction over 4 h by syringe pump. The reaction mixture was allowed to stir at 90 ºC 
for 20 h. The reaction mixture was cooled to rt and diluted with Et2O (12 mL). This was washed 
with NaHCO3 (sat. aq) (12 mL) and brine (12 mL). The combined aqueous layers were extracted 
with EtOAc (2 x 12 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated. Purification by flash column chromatography (10%  40% EtOAc/Hexanes) on 
silica gel afforded lactone 2.65c as a white solid (9.1 mg, 0.005 mmol, 87% yield).  
OR [α]D
25
 +13.7° (c 1.00, CH2Cl2) 







H NMR (500 MHz, C6D6) δ 6.52 – 6.29 (m, 2H), 5.72 (t, J = 14.0 Hz, 1H), 5.45 – 5.33 (m, 1H), 
5.26 – 4.96 (m, 7H), 4.82 (q, J = 9.8 Hz, 1H), 4.59 – 4.47 (m, 1H), 4.41 (d, J = 29.6 Hz, 2H), 
3.96 (d, J = 4.3 Hz, 1H), 3.88 (d, J = 22.7 Hz, 2H), 3.72 – 3.60 (m, 1H), 3.54 (dd, J = 22.4, 12.7 
Hz, 2H), 3.45 (d, J = 3.1 Hz, 1H), 3.21 – 3.11 (m, 4H), 3.09 (q, J = 9.1, 8.2 Hz, 2H), 2.99 (s, 
1H), 2.94 – 2.80 (m, 2H), 2.69 (d, J = 22.6 Hz, 1H), 2.63 – 2.45 (m, 3H), 2.44 – 2.28 (m, 2H), 
2.28 – 2.18 (m, 2H), 2.17 – 2.07 (m, 2H), 2.07 – 1.94 (m, 4H), 1.80 – 1.44 (m, 8H), 1.42 – 1.23 
(m, 29H), 1.17 (tt, J = 7.8, 5.2 Hz, 9H), 1.14 – 0.71 (m, 62H), 0.63 (dqd, J = 19.5, 7.9, 4.8 Hz, 
8H), 0.28 (d, J = 2.9 Hz, 3H), 0.20 – 0.03 (m, 10H) 
13
C NMR: We were unable to generate a useful 
13
C NMR spectrum for this compound due to a 
lack of a minimally sufficient amount of material. 
HRMS (ESI+) calculated for C93H166ClO20Si4N4 [M+NH4]
+










Lactone 2.65c (6.8 mg, 0.0038 mmol) was dissolved in MeCN (0.27 mL) and cooled to -
20 ºC. A freshly prepared solution of HF in MeCN (0.27 mL) [prepared by mixing 48% aqueous 
HF (1.25 mL) and MeCN (5 mL)] was added over 2 h by syringe pump at -20 ºC. The reaction 
was allowed to stir an additional 18 h at this temperature. The reaction was quenched by the 
dropwise addition of Et3N (0.64  mL) and warmed to rt. The reaction mixture was diluted with a 
2:1 mixture of EtOAc/CH2Cl2 (4 mL), then washed with NaHCO3 (sat. aq) (4 mL) and brine (4 
mL). The combined aqueous layers were extracted with a 2:1 mixture of EtOAc/CH2Cl2 (2 x 4 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. 
Purification by flash column chromatography (0%  5% MeOH/CH2Cl2) on silica gel afforded 
spongistatin 1 analog 2.5c as a white solid (4.1 mg, 0.0031 mmol, 82% yield).  
OR [α]D
22
 +18.2° (c 0.50, MeOH) 





H NMR (400 MHz, CD3CN) δ 6.46 (dd, J = 14.9, 7.1 Hz, 1H), 6.16 (dd, J = 15.0, 5.6 Hz, 1H), 
5.49 (s, 1H), 5.39 (s, 1H), 5.30 (dd, J = 17.8, 8.7 Hz, 1H), 5.25 – 5.14 (m, 1H), 4.98 – 4.89 (m, 
3H), 4.87 (s, 1H), 4.81 – 4.69 (m, 1H), 4.37 (ddd, J = 35.8, 27.1, 14.7 Hz, 3H), 4.21 – 4.11 (m, 
2H), 4.08 – 3.98 (m, 1H), 3.83 – 3.75 (m, 1H), 3.71 (s, 1H), 3.66 – 3.52 (m, 2H), 3.42 (dd, J = 
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19.2, 9.6 Hz, 1H), 3.28 (s, 3H), 3.21 – 3.09 (m, 2H), 3.07 – 2.94 (m, 1H), 2.92 – 2.82 (m, 2H), 
2.78 (d, J = 15.2 Hz, 1H), 2.67 – 2.46 (m, 2H), 2.45 – 2.35 (m, 1H), 2.35 – 2.23 (m, 2H), 2.14 (s, 
24H), 2.07 – 2.00 (m, 2H), 1.95 (s, 31H), 1.84 (s, 2H), 1.71 (dd, J = 15.1, 4.3 Hz, 3H), 1.65 – 
1.46 (m, 9H), 1.37 (d, J = 2.1 Hz, 3H), 1.18 (dd, J = 6.9, 2.8 Hz, 4H), 1.12 – 1.01 (m, 8H), 0.96 
(s, 7H), 0.94 – 0.88 (m, 5H), 0.83 (dd, J = 16.3, 6.9 Hz, 5H) 
13
C NMR: We were unable to generate a useful 
13
C NMR spectrum for this compound due to a 
lack of a minimally sufficient amount of material. 
HRMS (ESI+) calculated for C68H108ClO20N4 [M+NH4]
+







2.9. Biological data 
2.9.1. In Vitro Cell Growth Inhibition Assays 
Assay protocols 
PC3, human prostate cancer, and Ca46, Burkitt’s lymphoma, cell lines were obtained 
from the NCI anticancer drug screen. A2780(1A9) cells, human ovarian cancer, were the kind 
gift of Dr. Tito Fojo, Medical Oncology Branch, NCI, NIH. All cells were maintained in RPMI 
medium supplemented with 10% fetal bovine serum. Growth inhibition was determined by the 
resazurin method, following exposure to serial dilutions of each compound for 4 days prior to 
assay and GI(50) determinations as described.
54
 Each compound was tested with an initial 10-
dose dilution series, followed by narrower,  replicate 6-dose series, each of which was a separate 
experiment. The results presented are mean values based on multiple determinations of the 
GI(50), where the number of replicates, n, is shown. The standard deviation was determined 
from the replicate determinations of GI(50). 
 


























2.5a 0.1 0.03 9 0.06 0.02 6 0.15 0.09 9 0.1 0.04 3 
2.5b 2.5 0.5 9 1.4 0.8 6 2.7 1.1 9 2.4 0.06 3 
2.5c 0.3 0.09 7 0.06 0.08 5 0.5 0.06 8 0.3 0.07 3 
paclit
axel 
2.9 0.9 8 1.1 1.1 6 3 1.4 9 1.2 0.5 3 
a
s.d. = standard deviation. 
b
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 CHAPTER 3: Direct, mild, and general n-Bu4NBr-catalyzed aldehyde 
allylsilylation with allyl halides 
3.1. Introduction 
We have recently embarked on a program to synthesize structural variants of natural 
products for improved medicinal use as well as for potential warheads in targeted drug delivery 
applications, as discussed in Chapter 2.
1
  A critical component of our effort has been the 
utilization of our group’s strained silane chemistry for the rapid and scalable synthesis of 
molecular fragments,
2
 and for their union.
3
  Herein, we describe our approach to improve the 
operational simplicity of our silane chemistry by generating the requisite trichlorosilanes in situ 
(Figure 3.1).  We believe this tactic greatly improves the overall method by avoiding the need for 
air-free handling techniques as well as offers a wider scope of potential strained silane 
nucleophiles that can be utilized for target-oriented synthesis.  
The impetus for this work began during our studies toward a concise synthesis of the EF 
fragment of spongistatin 1.  The chlorodiene side-chain of this molecule is a key structural 
feature and crucial for its bioactivity.
4
 Due to its sensitivity, it has often been incorporated at a 




 additions have been 
very successful; however, these require additional functional group manipulations to install the 
methylene unit or to set the stereochemistry of the side-chain alcohol.  Additionally, methods for 
direct addition to the requisite chlorodiene aldehyde, such as reactions using an allyl stannane, 
have been plagued by poor diastereoselectivity.
7
 We wondered, therefore, if the application of 
our strained silane methodology for late-stage coupling of an allyl trichloro-silane with 
chlorodiene aldehyde 3.2 might offer a concise approach with improved stereoselectivity.  Due to 
the sensitivity of chlorosilanes to moisture, however, we wished to avoid isolation of complex 
intermediates prone to decomposition.  Based on prior work in our lab demonstrating a highly 
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active tridentate ligand motif capable of tolerating the presence of exogenous salts in solution,
8
 
we hypothesized that we could telescope the synthesis of trichlorosilane intermediates from allyl 
bromides to avoid potential loss of material in complex fragment couplings (Figure 3.1a). 
 
Figure 3.1: (a) Hypothetical direct complex fragment coupling allylation of aldehyde 1 with stereochemically 
and functionally complex allyl chloride 3.3. (b) Desirable attributes of a “universal” and direct aldehyde 
allylation reaction. (c) Our allylsilylation method entails preformation and isolation of the allyl 
trichlorosilanes and has a limited scope with respect to the allyl donor. 
3.1.1. Overview of aldehyde allyl halide additions 
Prior work involving enantioselective coupling of allyl halides and aldehydes has, until 
now, relied on chromium-mediated Nozaki-Hiyama-Kishi (NHK) reactions (Figure 3.2).
9
 
Enantioselectivity was first achieved in this reaction using chiral pyridine ligands as reported by 
Kishi.
10





Furstner’s breakthrough in making this process catalytic,
14,15
 a chiral chromium salen complex 
has been used to obtain the coupled product in a catalytic and enantioselective fashion.
16,17
 
Despite these improvements, however, high yields and enantioselectivity across a wide scope of 
substrates has yet to be achieved. The toxicity associated with the chromium salts also makes this 
reaction less desirable, especially on large scale. 
 
Figure 3.2: Generic Nozaki-Hiyama-Kishi reaction to generate homoallylic alcohols. 
As an alternative to NHK reactions, asymmetric aldehyde allylations are a well known 
way to produce the highly sought after homoallylic alcohol products. Despite major progress on 





reactions, including the Krische approach which heretofore uniquely obviates preformation and 
isolation of the active allylmetal(loid) species,
37,38
 the full potential of this reaction type remains 
unfulfilled. For example, direct fragment coupling allylation reactions with complex and high 
MW allyl donors (e.g. the hypothetical synthesis of the EF half of spongistatin 1 by way of a 
direct coupling of (E)-4-chloropenta-2,4-dienal (1) and complex allyl chloride 3.3 (Figure 3.1a) 
are essentially unknown.
39,40
 More generally, the development of a “universal” Type 1
41
 aldehyde 
allylation reaction that can directly and efficiently couple any allyl-X donor in a practical and 
sustainable way and with reliably high levels of both efficiency and stereoselectivity would 
greatly expand the utility of this reaction type in the synthesis of a broad array of structurally 
diverse targets (Figure 3.1b).  
3.1.2. Development of the Leighton group one-pot asymmetric allylation 
The Leighton group exploits strain-release lewis acidity to promote allylations and 
crotylations of various types of aldehydes and hydrazones. This phenomenon has been 
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demonstrated by Utimoto’s experiments where acyclic species exhibit much lower Lewis acidity 
than their strained silacycle counterparts (Figure 1.10).
42
 The driving force behind strain-release 
lewis acidity has been rationalized by Scott Denmark, who proposed that the compression of the 
strained silicon bond angle from its ideal tetrahedral bond angle favors nucleophilic addition so 
that the silicon can rehybridize to the less-strained trigonal bipyramidal species which better 
tolerates the ~95° strained bond angle.
43
 The Leighton group has used this concept to develop 





Figure 3.3: A selection of silane Lewis acid reagents developed by the Leighton group. 
A library of ligands has been developed in order to tune the properties of the 5-membered 
silacycles (Figure 3.3). The ease of synthesis of the pseudoephedrine and 1,2-
diaminocyclohexane derived ligands has enabled the exploration of subtle steric and electronic 
effects that can change the reactivity of the desired silane lewis acids. Former graduate student, 
Dr. Linda Suen, synthesized the most reactive and enantioselective ligand 3.4 for the allylation of 
aldehydes. The extraordinary reactivity of the tridentate ligand silane complex 3.7 is attributed to 
conformational constraints that attenuate stereoelectronic deactivation of silicon. This discovery 
led to a facile one-pot crotylation procedure with an impressive substrate scope.
8
  
3.1.3. Limitations of current allylation methods  
In terms of an ideal allylation procedure, the Leighton allylsilylation methodology
8
 is 
characterized by many of the attributes listed in Figure 3.1b, but the scope with respect to the 
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allyl donor is limited to simple low MW and alkyl-substituted (i.e. electron-rich) allyl fragments 
by the requirement for pre-formation (by way of the Benkeser-Furuya reaction
8,9
) and isolation 
of the allyl trichlorosilanes and by limited allylsilane reactivity, respectively (Figure 3.1c).  
Another limitation of the current methodology arises when a deep exploration of the 
carbonyl scope is undertaken. As was described in Chapter 2, certain challenging stereochemical 
arrays cause the Leighton allylation procedure to fail (Section 2.3). Although 3.7 is the most 
reactive silane complex we have discovered to date, more reactivity is still necessary to 
accomplish sterically demanding reactions. Expanding the scope of the carbonyl coupling partner 
beyond aldehydes to ketones, imines, and dicarbonyls would be decidedly advantageous. 
Currently, ketones are not a viable coupling partner due their significantly diminished reactivity 
compared to aldehydes. Ketones are less reactive than aldehydes due to both steric and electronic 
factors. To more fully realize a “universal” and direct allylation reaction, we set out to address 
these serious limitations. 
3.1.4. Plans towards a universal allylation method 
 We first set out to address the limitation of having to pre-form and isolate the allyl 
trichlorosilanes. The Benkeser-Furuya reaction is an efficient way to generate trichlorosilanes 
from allyl halides. The strength of the Benkeser-Furuya reaction lies in its use of inexpensive and 
readily available starting materials which include allyl halides, trichlorosilane, a tertiary amine, 
and a copper(I) catalyst. In particular, the Furuya variation of the Benkeser reaction, which 
exploits a copper catalyst to accelerate the carbon-silicon bond formation, allows for mild 
reaction conditions and an expanded scope. We hypothesized that the mild reaction conditions 
and predictable byproducts of this reaction could be compatible with our second-generation 
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allylsilylation methodology. If we could telescope these processes, we could avoid the inefficient 
and restrictive problem of generating and isolating highly reactive allyl trichlorosilanes. 
 
Figure 3.4: Limitations associated with synthesizing trichlorosilanes using the Benkeser-Furuya reaction and 
proposed plan to obviate the limitations. 
3.2. Telescoping the Benkeser-Furuya reaction 
3.2.1. Initial results 
In accordance with traditional Benkeser-Furuya conditions, we started with trans-crotyl 
chloride to generate trans-crotyl trichlorosilane. The previously described Leighton tridentate 
ligand and DBU were then added to generate the desired strained silane complex in situ. Upon 
addition of hydrocinnamaldehyde, the desired homo-allylic alcohol was obtained in a 34% yield. 
With this proof of concept in hand, we moved forward to optimize the yield and selectivity of the 
reaction. 
 
Scheme 3.1: Initial attempt to telescope the Benkeser-Furuya reaction with the Leighton crotylation reaction. 
3.2.2. Optimizing conditions for allyl bromides 
We began our optimization studies by splitting the overall reaction sequence into three 
parts: 1) the conversion of an allyl halide to the corresponding trichlorosilane, 2) formation of a 
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strained silane complex in situ, followed by 3) coupling with an aldehyde. Focusing on part one 
of the reaction, we hypothesized that an allyl bromide substrate would have a higher reactivity 
than an allyl chloride during the silylation. Subjection of trans-crotyl bromide to the conditions 
(Table 3.1, entry 2) did indeed produce a more effective reaction. A screen of catalyst conditions 
(Table 3.1, entries 3-6) illuminated that 0.05 mmol CuBr provided the best reaction results. 
However, when trans-crotyl chloride was tried again with the improved catalyst conditions, no 
improvement was observed (Table 3.1, entry 7).  









1 Cl CuCl 5% 34% 




4 Br CuBr 5% 76% 
5 Br CuBr 10% 71% 
6 Br CuBr 20% 75% 
7 Cl CuBr 5% 27% 
a
Unless otherwise noted, reactions were performed using 1 mmol allyl halide, 1.2 mmol HSiCl3, 1.4 mmol Et3N, 1 




Utilizing methallyl bromide and hydrocinnamaldehyde as model coupling partners, we 
investigated copper catalyzed silylation conditions reported by Furuya
49
 (Table 3.2, entries 1–3).  
Gratifyingly, copper bromide and triethylamine were found to give rapid and clean conversion to 
the desired chlorosilane by 
1
H NMR.  Next, we investigated the complexation of tridentate 




use of Et3N provided product (Table 3.2, entry 4), we found DBU was more effective for cleanly 
forming the silane and resulted in a higher yield (Table 3.2, entry 5).  Finally, we noted that 
lowering the temperature of the aldehyde-coupling step provided a boost to the stereoselectivity 
(Table 3.2, entry 6).   

















1 iPr2NEt 70% -- -- -- 
2 DBU 47% -- -- -- 
3 Et3N >95% -- -- -- 
4 Et3N >95% Et3N 62% 94% 
5 Et3N >95% DBU 80% 93% 
6
e
 Et3N >95% DBU 82% 98% 
a









Enantiomeric excess determined by HPLC 
analysis. 
e
Performed at –30ºC. 
 
3.2.3. Allyl bromide scope 
Excited by the prospect of easily generating a range of trichlorosilanes in situ, we 
investigated the scope of the allyl bromide coupling partner with hydrocinnamaldehyde (Table 
3.3).  Crotyl (Table 3.3, entry 1), methallyl (Table 3.3, entry 2), prenyl (Table 3.3, entry 3), and 
cinnamyl (Table 3.3, entry 4) groups were all incorporated with good yields and exceptional 
levels of enantioselectivity. A variety of functional groups can also be introduced under the 
reaction conditions.  Protected allylic alcohol (Table 3.3, entry 5), vinyl bromide (Table 3.3, 
entry 6), and primary alkyl chloride (Table 3.3, entry 7) moieties were all well tolerated.  Finally, 
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we found that chiral quaternary centers could be incorporated with slightly longer reaction times 
(Table 3.3, entry 8).  




































70 % 95% 
a
Unless otherwise noted, reactions were performed using 1 mmol allyl halide, 0.05 mmol CuBr, 1.2 mmol HSiCl3, 





Enantiomeric excess determined by HPLC analysis. 
d




3.2.4. Investigation of anion dependence 
Encouraged by the excellent scope and functional group tolerance of the allyl bromides, 
we returned to the reactivity problem encountered with allyl chlorides. Allyl chlorides are of 
particular interest because of their commercial availability and ease of synthesis. Unfortunately, 
as previously discussed, trans-crotyl chloride showed poor conversion to the desired product 
(Table 3.1, entry 7). Upon closer inspection of each of the reaction steps, it was determined that 
the difference in reactivity between the allyl bromide and allyl chloride arose during the coupling 
step with the aldehyde. NMR analysis showed complete conversion of trans-crotyl chloride to 
the corresponding trichlorosilane. Clean complexation of trans-crotyl trichlorosilane with the 
tridenate ligand was also observed via NMR. From these observations, we inferred that the lack 
of bromide ions present in the reaction mixture when starting with trans-crotyl chloride, 
negatively affects conversion to the desired product. Concluding that the bromide ions were 
playing a non-innocent role in the coupling step, we hypothesized that the addition of an 
exogenous source, tetrabutylammonium bromide (n-Bu4NBr), would produce the same effect. 
Upon addition of 1.00 mmol n-Bu4NBr, we were pleased to observe both an increase in yield and 
retention of enantioselectivity (85% yield, 97% ee). 
3.3. Development of an anion catalyzed allylation method 
3.3.1. Optimization of anion catalysis 
Encouraged by the excellent reactivity observed in the crotylation of 
hydrocinnamaldehyde in the presence of 1 equiv. n-Bu4NBr, we wanted to further explore its role 
in the reaction. Indeed, it was found that as little as 5 mol% of n-Bu4NBr had a dramatic impact 
on the efficiency of the reaction with crotyl chloride (entry 4), and we note that the n-Bu4NBr 
has no impact on the Benkeser-Furuya reaction and that there is no Finkelstein reaction under 
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these conditions (see Figure S2). A survey of other salts revealed that n-Bu4NI is equally 
effective (Table 3.4, entry 5) while n-Bu4NOTf, n-Bu4NBF4, and n-Bu4NPF6 were found to be 
competent but less efficient catalysts (Table 3.4, entries 6-8). It should noted that Et4NCl was 
found to not be beneficial to the reaction (Table 3.4, entry 9). 
Table 3.4: Reaction optimization. 
  
entry X CuY additive yield 
1 Cl CuCl - 34% 
2 Cl CuBr - 27% 
3 Br CuBr - 76% 
4 Cl CuBr n-Bu4NBr 86% 
5 Cl CuBr n-Bu4NI 86% 
6 Cl CuBr n-Bu4NOTf 76% 
7 Cl CuBr n-Bu4NBF4 77% 
8 Cl CuBr n-Bu4NPF6 54% 
9 Cl CuBr Et4NCl 27% 
 
3.3.2. Substrate scopes 
With optimized conditions identified, we set out to explore the scope of the reaction with 
respect to the allyl chloride starting material (Table 3.5). Methallyl chloride (Table 3.5, entry 1), 
and functionalized methallyl chlorides (Table 3.5, entries 2 and 3) work well in the reaction, as 
do trans-crotyl chloride (Table 3.5, entries 4 and 5), a substituted trans-crotyl chloride (Table 3.5, 
entry 6), and trans-cinnamyl chloride (Table 3.5, entry 7). Entry 6 is particularly noteworthy as 
the product of that reaction was an intermediate in our synthesis of a “methyl-extended” linker-
equipped analog of dictyostatin
50
 that was previously prepared by an only moderately 
diasteroselective and inefficient process. 3,3-Disubstituted allyl chlorides also work well and 
allow the establishment of all-carbon quaternary centers (Table 3.5, entries 8 and 9). Halogens 
are well tolerated at the 2-position of the allyl chloride leading to usefully functionalized alkene 
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products (Table 3.5, entries 10 and 11), while heteroatom (Cl, BPin) substitution is also well 
tolerated at the 3-position (Table 3.5, entries 12-15). Control reactions with no n-Bu4NBr 
established that the catalysis is in most cases critical for synthetically useful results (Table 3.5, 
entries 4a, 5, 6, 9, 12, and 13), and whereas the reactions with simple alkyl-substituted (i.e. 
electron-rich) allyl donors are efficient when run with isolated allyltrichlorosilanes (cf. Figure 
3.1c), reactions with electronically deactivated allyl donors (Table 3.5, entries 10-15) are not. 
Thus, in addition to enabling the significant practical advance of the fully telescoped procedure 
that obviates the technically difficult and tedious isolation of the allyltrichlorosilanes, the n-




Table 3.5: Exploration of scope for allyl chlorides. 
 
a
The values in parentheses are the yields of the reactions with no added n-Bu4NBr under otherwise identical 
conditions. 
b
These reactions were conducted with benzaldehyde. 
c
This reaction was conducted with aldehyde 4, and 
treated with 1 M HCl prior to workup and product isolation to hydrolyze the ketal.  
More hindered and functionalized aldehydes of the type that are often employed in 
polyketide natural product syntheses are well tolerated in the reaction as well (Table 3.6). Entry 2 
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is particularly noteworthy as the product of that reaction was an intermediate in our synthesis of 
a “methyl-extended” linker-equipped analog of dictyostatin
50
 that was prepared by an only 
moderately diasteroselective and inefficient process. Together with the results described in Table 
3.5, significant generality and functional group tolerance has been demonstrated for the allyl 
chloride and aldehyde substrates. 
Table 3.6: Aldehyde scope. 
 
a
These reactions were treated with 1 M HCl prior to workup and product isolation to hydrolyze the ketal.  
3.4. Mechanistic investigations  
In considering the mechanism of the catalysis, we were cognizant of Berrisford’s report 
that tetraalkylammonium salts accelerate the DMF-promoted allylation of benzaldehyde with 
allyltrichlorosilane,
51
 and Denmark’s demonstration that n-Bu4NI or n-Bu4NOTf led in a few 
cases to a modest increase in the efficiency of Lewis base-catalyzed reactions with aliphatic 
aldehydes that suffered from silylchlorohydrin formation.
52–55
These effects were attributed to an 
increase in the ionic strength of the medium that would be expected to favor formation of the 
active ionic species 3.8 and to disfavor the formally neutral silylchlorohydrin 3.9 (Figure 3.5). 
However, the mechanistic data we have produced suggests that our system is not governed by the 




Figure 3.5: Mechanistic scheme for Denmark’s LB-catalyzed allylation and aldol reactions. 
3.4.1. Silylchlorohydrin 
At the outset, we were optimistic that the Benkeser-Furuya reaction could be effectively 
telescoped
56
 with the allylation reaction given that its only byproduct is Et3N•HCl. This turned 
out not to be the case, however, as the fully telescoped reaction with dihydrocinnamaldehyde led 
to the isolation of the product in only 34% yield (Table 3.1, entry 1), a result that may be 
attributed to silylchlorohydrin formation in direct analogy to the observations of Denmark.
52
 If 
silylchlorohydrin formation was indeed causing the reaction progress to stall, it would confirm 
experimental observations in which addition of excess chloride inhibited yield. To 
experimentally probe silylchlorhydrin formation the experiment outlined in Figure 3.6 was 
performed. An unreactive silane complex 3.10 was formed and subjected to excess Et3N•HCl 
salts and hydrocinnamaldehyde. Proton NMR of 3.11 did indeed show formation of the 
silylchlorohydrin, thus confirming the hypothesis that additional chloride anion negatively 
impacts reaction yields by promoting an unproductive pathway. 
Figure 3.6: Formation an observation of the unproductive silylchlorohydrin pathway. 
3.4.2. Rate studies 
We have measured the rate of conversion of the trans-crotylation of benzaldehyde 
starting from trans-crotyltrichlorosilane with 5 mol% n-Bu4NBr and with no additive (Figure 
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3.7). As chloride ion is present in these reactions and may also be catalyzing the reaction, we also 
endeavored to prepare a sample of chloride-free crotylsilane 3.12 in an attempt to measure the 
true coordinating anion-free background reaction. Though complete removal of the DBU•HCl 
salts by trituration is difficult, we were able to isolate a sample of 3.12 contaminated only with 






 prior to using it 
in these experiments. As shown, the data establish that chloride and bromide greatly accelerate 
the reaction relative to the anion-free non-coordinating background reaction, strongly implying a 
direct role for the anion component of the tetrabutylammonium salts in the catalysis.  
 
Figure 3.7: Rate measurements of the crotylation of PhCHO under various conditions. Each data point is the 
average of 3 experiments (2 experiments in the case of chloride-free silane 10), measuring the disappearance 
of PhCHO (measuring the appearance of product provides similar results) against a quantitative internal 
standard by 
1
H NMR spectroscopy.  
3.4.3. Proposed mechanism of anion catalysis 
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The rate data, discussed in subsection 3.4.2, strongly imply a direct role for the anion in 
our system, however, our allylsilane (A, Figure 3.8) has no ionizable substituent, rendering the 
Denmark mechanism highly implausible in our reactions. We propose instead that the catalyst X
-
 
activates the allylsilane by forming allylsilicate B, which binds (C) and allylates (D) the 
aldehyde by way of a 6-coordinate silicate at a greatly accelerated rate (kX-) over the anion-free 
non-coordinating background reaction (k0) before releasing the catalyst and generating the 
product E (Figure 3.8). 
 
Figure 3.8: Proposed mechanism of the anion-catalyzed allylation reaction. 
A propensity to form dianion G would be expected to inhibit the reaction and this may 
provide an explanation for the poorer performance of certain anions. Indeed, treatment of 
crotylsilane 10 with excess n-Bu4NBr led to 
29
Si NMR resonances consistent with 5- and 6-
coordinate silicates, thus providing direct spectroscopic evidence for the formation of both B and 
G (Figure 3.9). Though it has been shown that strong nucleophiles (e.g. fluoride, catecholate) 
may be used to pre-form 5-coordinate allylsilicates that are activated for aldehyde allylsilylation 
reactions,
57–62
 the effective use of more weakly coordinating anions as catalysts reported here is 
without precedent. We suggest that the key to accessing this mode of nucleophilic catalysis is the 
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pre-activation of the silane by ligand 3.4, which induces Lewis acidity
8
 sufficient for the 
reversible binding of weakly nucleophilic anions. 
 
Figure 3.9: Spectroscopic evidence for the formation of B and G. 
3.5. Synthetic method application towards the EF chlorodiene side chain fragment coupling 
As previously stated, asymmetric allylations are an incredibly important reaction in 
natural product synthesis. In order to complete the EF fragment of spongistatin 1, we required a 
chemoselective and enantioselective carbon-carbon bond forming step that could utilize two 
intermediates with easily attainable functional group handles. Both the practical improvements 
and the increased reactivity of the newly developed anion catalyzed allylation have finally 
generated a method that is ideal for complex fragment couplings in total synthesis.  
3.5.1. Proposed complex fragment coupling 
 Upon examination of the chlorodiene side chain, we saw the C47 homoallylic alcohol as 
the linchpin of the structural array. While installing this stereocenter has proved labor intensive 
in the past, we saw it as an opportunity for construction of the entire side chain. We envisioned 
installing the EF side chain through the direct allylation of allyl halide donor 3.3 with 
chlorodiene aldehyde 3.2 (Figure 3.10). Using the newly developed allylation method previously 
described, this type of complex fragment coupling should be possible for the first time in high 
yields and selectivities. The proposed reaction would have to be tolerant of the sensitivity of both 
the chlorodiene aldehyde as well as the highly functionalized and precious allyl halide. Entry 6 
(Table 3.5) which incorporated both an alkyl chloride and a ketal functionality gave us 
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confidence that such an ambitious reaction could be possible, however we also endeavored to 
prepare a model system to further test the limitations of the allylation methodology. 
 
Figure 3.10: Proposed EF fragment coupling. 
3.5.2. Model coupling 
To demonstrate that the n-Bu4NBr catalysis can enable direct complex fragment coupling 
reactions, we used diallyl chloride 3.13 to allylate aldehyde 3.14 to give 3.15 in 89% yield and 
95% ee (Scheme 3.2). Alcohol acetylation produced 3.16, which, like allyl chloride 3.3 
comprises stereochemical complexity near the allyl chloride as well as an acid-sensitive ketal. 
Initial attempts to allylate aldehyde 3.2 with 3.16 were unsuccessful due to ketal degradation 
presumably caused by adventitious HCl generated in the Benkeser-Furuya reaction. While 
simply using excess Et3N could in principle be a simple solution to this problem, in practice 
excess Et3N negatively impacts the ligand complexation. Fortunately, we found that 2,6-di-t-Bu-
pyridine is an effective and otherwise innocent base, and when the CuBr loading was increased 
to 25 mol% these modified conditions led to the isolation of 3.17 in 77% yield and ≥ 20:1 dr. In 
addition to serving as a meaningful model for the spongistatin 1 EF fragment synthesis (Figure 
3.10), this 3-step sequence also demonstrates the direct use of 3.13 as a linchpin reagent, 




Scheme 3.2 Model fragment coupling allylation reaction for the synthesis of the EF-half of spongistatin 1. 
3.5.3. EF chlorodiene coupling optimization 
With a promising model reaction in hand, our attention turned to the synthesis of the EF 
coupling partners. Our synthesis of the chlorodiene-bearing EF fragment commenced with a 
double cross-metathesis reaction between diene 3.18 and tert-butyl acrylate using the second-
generation Hoveyda-Grubbs (HG-II) catalyst
63
 (Scheme 3.3). By using the acrylate as the solvent 
we have been able to reduce the catalyst loading to an extraordinarily low level, with just 0.69 
mol% catalyst resulting in isolation of 3.19 in 58% yield
64
. Double Sharpless asymmetric 
dihydroxylation (AD)
65
 then delivered tetraol 3.20 in 65% yield as a 4.5:1 mixture of 
diastereomers
66
. Diastereoselective lactonization to establish the C(40) stereocenter was most 
effectively carried out using dry HCl in MeOH and was accompanied by transesterification to 
deliver lactone 3.21. Without isolation, this material was subjected to triple benzyl ether 
protection with 2,4,6-tris(benzyloxy)-1,3,5-triazene (TriBOT)
67
 giving lactone 3.22 as a single 
diastereomer (the minor meso diastereomer from the double AD reaction does not undergo the 
lactonization reaction) in 62% yield over 2 steps. Petasis methylenation
68,69
 of both carbonyls 
gave bis enol ether 3.23 in 55% yield, both setting up a hydroboration/B-alkyl Suzuki reaction 
for the allyl sidechain introduction and converting the methyl ester to a methyl ketone in masked 





 was followed by B-alkyl Suzuki coupling
71
 with vinyl bromide 3.24 and acidic 
hydrolysis of the methyl enol ether to deliver the fully elaborated F-ring methyl ketone 3.25 in 
49% yield. Introduction of the E-ring commenced with a diastereoselective aldol reaction of 
methyl ketone 3.25 with aldehyde 3.26 to give 3.27 in 84% yield with 11:1 
diastereoselectivity
72,73
. Acid-promoted ketalization delivered 3.28 in 70% yield, and alcohol 
protection was carried out in 87% yield. Four protecting group and functional group 
manipulations (1. reductive removal of all 5 benzyl groups
74
, 2. persilylation of all 5 alcohols, 3. 
selective deprotection of the two primary alcohols, and 4. chlorination of both primary alcohols) 
delivered allyl chloride 3.3 in 55% yield over 4 steps, setting up the critical complex fragment 




Scheme 3.3: Synthesis of allyl chloride 3.3. 
Alkallysilanes derived from complex and sterically hindered alkallyl chlorides such as 
3.3 react very slowly under the first-generation tridentate ligand allylation conditions, and the 
attempted coupling of 3.3 with aldehyde 3.2 led mainly to decomposition. However, we were 
pleased to observe that this reaction was greatly accelerated by weakly coordinating anions (e.g. 
Br
-
), which are effective catalysts that operate, the evidence suggests, by adding to the allylsilane 
and accessing small equilibrium concentrations of the more highly activated allylsilicate
75
. When 
the coupling of 3.2 and 3.3 was repeated in the presence of 20 mol% n-Bu4NBr, the desired 
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product 3.31 was produced as a single diastereomer (≥20:1 dr) in 60% yield, presumably through 
the intermediacy of the anion activated allylsilicate. As was suggested by the model system, 
when the reaction is performed in the absence of 2,6-di-t-Bu-pyridine rapid degradation of both 
starting material and product is observed. The mass balance of the reaction lay with starting 
material 3.3, suggesting that the Benkeser-Furuya reaction was stalling in regards to the in situ 
allyltrichlorosilane formation. In order to pinpoint the cause of the sluggish conversion, a NMR 
tube reaction was performed of the silylation. Upon closer inspection, it was observed that 
trichlorosilane (boiling point = 31.8 ºC) was evaporating from the reaction mixture before it was 
consumed. We were able to improve the yield by portion-wise addition of trichlorosilane over the 
course of the reaction, thus providing the desired product as a single diastereomer (≥20:1 dr) in 
71% yield (94% based on recovered allyl chloride 3.3) (Scheme 3.4).  
 
Scheme 3.4: Optimized EF fragment coupling reaction. 
3.5.4. EF fragment completion 
Successful installation of the chlorodiene side chain cleared the last major challenge in 
finishing the EF fragment of spongistatin. However, careful handling and immediate TBS 
protection of 3.31 was required because of the propensity of the C47 alcohol to eliminate into 
tetraene conjugation. Alcohol protection was followed by a one-pot Finkelstein reaction and 
phosphonium salt formation
5
 to deliver the fully elaborated EF fragment 3.1 in 83% yield over 2 
steps (Scheme 3.5). Overall, this synthesis of the EF fragment comprises just 16 steps in the 
longest linear sequence and a 2% overall yield, which is the shortest EF fragment synthesis to 
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date. This step-economy derives in large part from the development of a 6-step synthesis of F-
ring methyl ketone 3.25, and the direct fragment coupling alkallylation reaction to install the 
chlorodiene sidechain and C(47) stereocenter in a single step. 
 
Scheme 3.5: Completion of the EF fragment synthesis. 
3.6. Summary and outlook 
We have discovered that tetraalkylammonium salts catalyze aldehyde allylsilylation 
reactions with our diaminophenol-ligated allylsilanes. This catalysis allows both for a significant 
expansion in scope with respect to the allyl donor and for the direct use of allyl chlorides without 
preformation and isolation of the allyltrichlorosilanes, which in turn allows, uniquely, for the 
direct use of stereochemically and/or functionally complex allyl donors in fragment coupling 
allylation reactions. This concept has been realized in the direct and efficient synthesis of the EF 
fragment of spongistatin 1. The result is the most significant progress yet reported toward the 
realization of a “universal” direct aldehyde allylation reaction possessed of the attributes outlined 
in Figure 3.1b. Mechanistically, we have secured evidence that the catalyst plays a direct role in 
accelerating the carbon-carbon bond-forming event by accessing the more reactive 5-coordinate 
allylsilicate. This may have implications for the design of catalytic enantioselective variants of 
this reaction as well as for the catalysis of a range of otherwise difficult transformations. Efforts 
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along these lines and to further elucidate the mechanistic details of catalysis will be illustrated in 
later chapters. 
3.7. Experimental procedures 
General Information. All reactions were carried out under an inert atmosphere of argon in 
flame-dried glassware with magnetic stirring unless otherwise indicated.  Degassed solvents 
were purified by passage through an activated alumina column.  Et3N was distilled from CaH2; 
DBU was distilled from CaH2 onto 4 Å molecular sieves and stored under inert atmosphere.  All 















 and aldehyde 3.2
8
 were conducted as 
previously described, and all spectroscopic data were consistent with those reported for these 
compounds.  All other reagents were purchased from commercial sources and used without 
further purification unless otherwise noted.  Flash chromatography was performed with Silicycle 
SiliaFlash® P60 silica gel.  Thin-layer chromatography (TLC) was carried out on glass backed 
silica gel TLC plates (250 nm) from Silicycle; visualization by UV, phosphomolybdic acid 
(PMA), or Potassium Permanganate (KMnO4). 
Diastereomeric ratios for all compounds were determined by 
1
H NMR analysis of the 






F NMR data were obtained using Bruker AVIII 500 
(500 MHz) spectrometer and are reported in ppm.  
1
H NMR spectra were internally referenced to 
CDCl3 (7.26 ppm); 
13
C NMR spectra were internally referenced to CDCl3 (77.23 ppm); 
19
F NMR 
spectra were internally referenced to an α,α,α-trifluorotoluene (–63.72 ppm) internal standard.  
Data are reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = triplet, m = 
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multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, ddt = doublet of 
doublet of triplets, td = triplet of doublets; coupling constant(s) in Hz; integration).  Infrared 
spectra were recorded on a Perkin-Elmer Spectrum Two (Diamond ATR) IR spectrometer.  
Optical rotations were recorded on a Jasco DIP-1000 polarimeter.  HPLC analysis was carried 
out on an Agilent 1200 Series using a Chiralpak OD-H (250 x 4.5 mm ID) column. Mass 
Spectroscopy Data was obtained on a Waters XEVO G2-XS QToF mass spectrometer.   




To a –78 ºC solution of the ethyl (2E)-7–chlorhept-2-enoate
11
 in dry CH2Cl2 under N2 
was slowly added DIBAL solution (1M in CH2Cl2, 49.85 mL, 49.85 mmol).  The resulting 
mixture was stirred 3 hrs at this temperature, and then slowly quenched with MeOH (2 mL).  
Saturated aqueous Rochelle’s salt (60 mL) was added and the mixture was stirred vigorously for 
1 hr.  The layers were separated and the aqueous phase was extracted with CH2Cl2 (3 x 150 mL).  
The organics were combined, washed with brine (100 mL), dried over Na2SO4, filtered, and 
concentrated.  The material was then passed through a silica plug (EtOAc) to afford the crude 
allylic alcohol, which was used in the next step without any further purification.   
To a solution of the crude allylic alcohol (2 g, 13.46 mmol) in dry MeCN (40 mL) at -20 
ºC was added PPh3 (7.06 g, 26.92 mmol). CCl4 (8.28 g, 53.84 mmol) was added portion-wise 
over 30 min.  The reaction mixture was stirred at -20 ºC for 2 hr and then concentrated in vacuo. 
The resulting residue was triturated in hexanes and filtered through a pad of celite three times. 
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The crude material was purified by silica gel flash column chromatography (0 – 3% 
EtOAc/hexanes) to afford allylic chloride (1.29g, 53% yield over two steps) as a clear oil.  IR 




H NMR (500 MHz, CDCl3) δ 5.78 – 
5.66 (m, 2H), 4.05 (d, J = 6.6 Hz, 2H), 3.56 (t, J = 6.6 Hz, 2H), 2.12 (q, J = 7.26 Hz, 2H), 1.80 
(p, J = 6.6 Hz, 2H), 1.57 (p, J = 7.26 Hz, 2H).  
13
C NMR (125 MHz, CDCl3) δ 135.1, 126.6, 




To a 0 ºC solution of 2,2,6,6-Tetramethylpiperdine (20.4 mL, 119.8 mmol) in dry benzene 
(310 mL) under N2 was added n-butyllithium (2.22M, 54 mL, 119.8 mmol) dropwise.  The 
resulting mixture was stirred 30 min, and then cooled to –78 ºC.  Diethylaluminum chloride 
(25% in toluene, 62.3 mL, 114.6 mmol) was added slowly, and then the mixture was warmed to 
0 ºC for 45 min.  A solution of the triethyl-[2-(2-methyloxiran-2-yl)ethoxy]silane
i
 in dry benzene 
(10 mL) was then added and the reaction mixture was stirred 3 hrs at 0 ºC.  Upon completion, 
saturated aqueous Rochelle’s salt (200 mL) was added and the mixture was stirred vigorously for 
1 hr.  The layers were separated, and the aqueous phase was extracted with Et2O (3 x 75 mL).  
The organics were combined, dried over Na2SO4, filtered, and concentrated.  The resultant crude 
allylic alcohol was used directly in the next step without further purification.  
To a solution of the crude allylic alcohol (500 mg, 2.31 mmol) in dry MeCN (7 mL) at -
20 ºC was added Et3N (322 μL, 2.31 mmol), PPh3 (1.21 g, 4.62 mmol). CCl4 (0.89 mL, 9.24 
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mmol) was added in 4 portions over 1 hr.  The reaction mixture was stirred for an additional hour 
at -20 ºC. The reaction was concentrated then resuspended in hexanes and filtered (3x).  The 
crude material was purified by silica gel flash column chromatography (0 – 5% EtOAc/hexanes) 
to afford the allylic chloride (329 mg, 61% yield) as a clear oil.  IR (ATR) 2953, 2875, 1643, 




H NMR (500 MHz, CDCl3) δ 5.21 (t, J = 1.2 Hz, 1H), 5.04 (q, J 
= 1.3 Hz, 1H), 4.11 (d, J = 1.0 Hz, 2H), 3.80 (t, J = 6.7 Hz, 2H), 2.44 (td, J = 6.7, 1.2 Hz, 2H), 
1.00 (t, J = 7.9 Hz, 9H), 0.64 (q, J = 8.0 Hz, 6H). 
13
C NMR (125 MHz, CDCl3) δ 142.9, 115.9, 
61.7, 48.6, 36.5, 6.8, 4.4. HRMS with ESI, APCI, or ASAP was unable to identify an intact mass. 
3.7.2. Preparation of homoallylic alcohols 
General Procedure A for telescoped silane reactions: A 2-dram vial, equipped with a stir bar, 
was charged with copper (I) bromide (7.2 mg, 0.050 mmol, 0.052 equiv) in an argon-atmosphere 
glove box
4
. The vial was capped with a septum and transferred out of the glove box. The vessel 
was charged with CH2Cl2 (3 mL) and Et3N (195 μL, 1.40 mmol, 1.47 equiv) and n-Bu4NBr (16 
mg, 0.050 mmol, 0.052 equiv). In a separate vial under Ar atmosphere, allyl chloride (1.00 
mmol, 1.05 equiv), CH2Cl2 (2 mL), and Cl3SiH (121 μL, 1.20 mmol, 1.26 equiv) were 
sequentially added. To the cooled 0 ºC solution of CuBr, was added the allyl chloride solution 
dropwise via syringe. The allyl chloride vial was then rinsed with 1 mL CH2Cl2, this solution was 
added to the reaction flask, and the resulting mixture was stirred 2 hrs at 0 ºC.  A solution of the 
(R,R)-3.4 (290 mg, 1.00 mmol, 1.05 equiv) and DBU (449 μL, 3.00 mmol, 3.15 equiv) in CH2Cl2 
(2 mL + 0.5 mL rinse) was added dropwise via syringe to the reaction mixture.  The cooling bath 
was removed and the mixture was stirred 1 hr at room temperature.  The silane solution was then 
                                                     
4
 The copper (I) bromide degrades slowly over time upon repeated exposure to air, and because we were 
performing many experiments over weeks and months, it was more convenient to store it and weigh it out in the 
glovebox. For occasional use this is not necessary and the copper(I) bromide may be weighed out in air with no 
deleterious impact on the performance of the reactions. 
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re-cooled to –78 ºC and the aldehyde (0.95 mmol, 1.0 eqiuv) was added.  The reaction was then 
conducted at 0 ºC for the indicated time. Upon consumption of the aldehyde, the reaction mixture 
was treated with n-Bu4NF (1M in THF, 2.0 mL, 2.0 mmol, 2.0 equiv) and stirred 1 hr at 0ºC.  
The mixture was then passed through a silica plug with EtOAc and concentrated to give the 
crude product, which was purified by flash column chromatography. 
General Procedure B for telescoped silane reaction substrates containing acid-sensitive 
functionality:  A 2-dram vial, equipped with a stir bar, was charged with copper (I) bromide (7.2 
mg, 0.050 mmol, 0.052 equiv) in an argon-atmosphere glove box. The vial was capped with a 
septum and transferred out of the glove box.  The vessel was then charged with CH2Cl2 (3 mL) 
and Et3N (98 μL, 0.70 mmol, 0.74 equiv) and n-Bu4NBr (16 mg, 0.050 mmol, 0.052 equiv).  In a 
separate vial under Ar atmosphere, the allyl chloride (1.00 mmol, 1.05 equiv) was charged with 
CH2Cl2 (2 mL), Et3N (98 μL, 0.70 mmol, 0.74 equiv), and Cl3SiH (121 μL, 1.20 mmol, 1.26 
equiv) sequentially (base must be added first to prevent acid-mediated degradation).  To the 
cooled 0 ºC solution of CuBr, was added the allyl chloride solution dropwise via syringe. The 
allyl chloride vial was then rinsed with 1 mL CH2Cl2, this solution was added to the reaction 
flask, and the resulting mixture was stirred 2 hrs at 0 ºC.  A solution of the (R,R)-3.4 (290 mg, 
1.00 mmol, 1.05 equiv) and DBU (449 μL, 3.00 mmol, 3.15 equiv) in CH2Cl2 (2 mL + 0.5 mL 
rinse) was added dropwise via syringe to the reaction mixture.  The cooling bath was removed 
and the mixture was stirred 1 hr at room temperature.  The silane solution was then re-cooled to –
78 ºC and the aldehyde (0.95 mmol, 1.0 equiv) was added.  The reaction was then conducted at 
the indicated temperature and time.  Upon consumption of the aldehyde, the reaction mixture 
was treated with n-Bu4NF (1M in THF, 1.2 mL, 1.2 mmol, 1.2 equiv) and stirred 1 hr at –40 ºC.  
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The mixture was then passed through a silica plug with EtOAc and concentrated to give the 
crude product, which was purified by flash column chromatography.   
General Procedure C for telescoped silane reaction for acidic workup with (R,R)-3  Ligand 
recovery:  General Procedure A or B was used until complete consumption of the aldehyde was 
achieved. The reaction mixture was then concentrated and the residue was suspended in Et2O (25 
mL). The mixture was stirred vigorously for 20 min to ensure complete precipitation of the 
DBU•HCl salts. The mixture was then filtered through a frit, and the filtrate was treated with n-
Bu4NF (1M in THF, 1.2 equiv) and stirred 1 hr at 0 ºC. The mixture was then treated with 
aqueous HCl (1M, 5 equiv) and transferred to a separatory funnel. The layers were separated and 
the aqueous layer was extracted with Et2O (3x). The combined organic layers were washed with 
H2O (2x) and saturated aqueous NaHCO3 (1x), dried over MgSO4, filtered and concentrated. The 
mixture was then passed through a silica plug with EtOAc and concentrated to give the crude 
product, which was purified by flash column chromatography. 
3.4 Ligand Recovery: The combined aqueous layers were treated with aqueous NaOH (1M, 10 
equiv) and extracted with CH2Cl2 (5x). The combined organic layers were washed with H2O 
(2x), dried over MgSO4, filtered and concentrated. The residue was dissolved in minimal hot 9:1 
MeOH:H2O (temperature should not be allowed to exceed 80 °C). The hot saturated solution was 
allowed to cool to room temperature, and distilled water (10 mL) was added to ensure complete 
crystallization. The white solid was collected by filtration through a frit, rinsing with cold 1:1 





Prepared using Procedure A with methallyl chloride (91 mg, 1.0 mmol) and 
hydrocinnamaldehyde (127 mg, 0.95 mmol) with a 12 hr reaction time at 0 °C.  Purified by silica 
gel flash column chromatography (5–10% EtOAc/Hexanes) to give the product as a pale yellow 
oil (162 mg, 90% yield, 97% ee).  
[Daicel Chiracel OD-H, 95:5 Hexanes:IPA, 1 mL/min, 254 nm; t1= 7.51 min, t2=10.84 min], 
[α]D
23




H NMR (500 MHz, CDCl3) δ 7.29 (t, J = 7.6 Hz, 2H), 7.22 (d, J = 7.6 Hz, 2H), 7.19 (t, J = 7.6 
Hz, 1H), 4.89 (p, J = 1.7 Hz, 1H), 4.81 (dt, J = 2.2, 1.1 Hz, 1H), 3.76 (dtt, J = 9.4, 6.5, 3.4 Hz, 
1H), 2.84 (dt, J = 13.7, 7.9 Hz, 1H), 2.71 (dt, J = 13.7, 8.2 Hz, 1H), 2.24 (dd, J = 13.8, 3.2 Hz, 
1H), 2.15 (dd, J = 13.8, 9.4 Hz, 1H), 1.85 – 1.75 (m, 2H), 1.74 (s, 3H).  
13
C NMR (125 MHz, 
CDCl3) δ 142.8, 142.3, 128.6, 128.6, 126.0, 113.8, 68.2, 46.5, 39.0, 32.3, 22.6.  HRMS (APCI+) 
calcd for [C13H17O+] requires m/z 189.1279, found 189.1283. 
(R)-5-methylene-1-phenyl-7-((triethylsilyl)oxy)heptan-3-ol: 
 
Prepared using Procedure B with allyl chloride (279 mg, 1.0 mmol) and 
hydrocinnamaldehyde (127 mg, 0.95 mmol).  Purified by silica gel flash column chromatography 
(5% EtOAc/Hexanes) to give the product as a clear oil (197 mg, 62% yield, 94% ee).  
[Daicel Chiracel OD-H, 98:2 Hexanes:IPA, 1 mL/min, 254 nm; t1= 7.80 min, t2= 11.97 min], 
OR [α]D
23





H NMR (500 MHz, CDCl3) δ 7.28 (tt, J = 7.6, 1.5 Hz, 2H), 7.21 (dd, J = 7.6, 
1.2 Hz, 2H), 7.18 (tt, J = 7.3, 1.2 Hz, 1H), 4.91 – 4.96 (m, 2H), 3.73 – 3.79 (m, 1H), 3.74 (t, J = 
6.6, 2H), 2.83 (ddd, J = 13.7, 9.6, 6.0 Hz, 1H), 2.69 (ddd, J = 13.7, 9.6, 6.9 Hz, 1H), 2.24 – 2.35 
(m, 4H), 2.13 (dd, J = 13.7, 9.8 Hz, 1H), 1.73–1.85 (m, 2H), 0.96 (t, J = 8.0 Hz, 9H), 0.60 (q, J = 
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8.0 Hz, 6H).  
13
C NMR (125 MHz, CDCl3) δ 144.3, 128.6, 128.5, 125.9, 114.6, 68.7, 62.4, 45.5, 




Prepared using Procedure A with 3-benzyloxy-2-chloromethyl-1-propene, (197 mg, 1.0 
mmol) and hydrocinnamaldehyde (127 mg, 0.95 mmol) with a 12 hr reaction time at 0 °C. 
Purified by silica gel flash column chromatography (10–20% EtOAc/Hexanes) to give the 
product as a clear oil (248 mg, 88% yield, 95% ee). 
[Daicel Chiracel OD-H, 90:10 Hexanes:IPA, 1 mL/min, 254 nm; t1= 11.90 min, t2=19.94 min], 
OR [α]D
23





H NMR (500 MHz, CDCl3) δ 7.25 – 7.38 (m, 7H), 7.21 (dd, J = 7.4, 1.2 Hz, 2H), 
7.18 (tt, J = 7.4, 1.8 Hz, 1H), 5.18 (q, J = 1.4 Hz, 1H), 5.06 (s, 1H), 4.52 (ABq, 2H, ΔνAB = 8.1 
Hz, JAB = 11.9 Hz), 3.97 (ABq of ABX, 2H, ΔνAB = 19.6 Hz,  JAB = 11.8 Hz, JBX = 1.2 Hz, JAX = 
1.1 Hz), 3.71 – 3.79 (X of ABX, m, 1H), 2.82 (ddd, J = 13.7, 9.3, 6.3 Hz, 1H), 2.69 (ddd, J = 
13.7, 9.2, 7.1 Hz, 1H), 2.63 (broad s, 1H), 2.40 (ddd, J = 14.1, 3.3, 1.2 Hz, 1H), 2.20 (ddd, J = 
14.1, 9.0, 0.9 Hz, 1H), 1.72 – 1.86 (m, 2H).  
13
C NMR (125 MHz, CDCl3) δ 143.1, 142.4, 137.9, 
128.6, 128.5, 127.9, 127.9, 125.9, 116.6, 73.6, 72.4, 69.4, 42.8, 39.1, 32.3.  HRMS (APCI+) 
calcd for [C20H25O2+] requires m/z 297.1855, found 297.1861. 




Prepared using Procedure A with trans-crotyl chloride (90.6 mg, 1 mmol) and 
hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 12 hr reaction time at 0 °C.  Purified by 
silica gel flash column chromatography (10% EtOAc/Hexanes) to give the product as a clear oil 
(153 mg, 84% yield, 97% ee). 
[Daicel Chiracel OD-H, 96:4 Hexanes:IPA, 1 mL/min, 254 nm; t1= 8.14 min, t2=13.10 min], OR 
[α]D
23




H NMR (500 MHz, CDCl3) δ 7.31 (t, J = 7.6 Hz, 2H), 7.21 (dd, J = 7.6, 1.2 Hz, 2H), 7.19 (tt, J 
= 7.2, 1.4 Hz, 1H), 5.75 (ddd, J = 16.6, 10.8, 8.2 Hz, 1H), 5.09 – 5.16 (m, 2H), 3.42 (dddd, J = 
9.1, 6.1, 4.2, 3.2 Hz, 1H), 2.85 (ddd, J = 13.7, 10.2, 5.2 Hz, 1H), 2.68 (ddd, J = 13.7, 9.9, 6.6 Hz, 
1H), 2.23 (dqd, J = 14.1, 6.8, 1.0 Hz, 1H), 1.85 (dddd, J = 13.8, 10.0, 6.6, 3.2 Hz, 1H), 1.70 
(dddd, J = 13.8, 9.9, 9.1, 5.2 Hz, 1H), 1.59 (d, J = 4.2 Hz, 1H), 1.03 (d, J = 6.8 Hz, 3H).  
13
C 
NMR (125 MHz, CDCl3) δ 142.5, 140.4, 128.7, 128.6, 126.0, 116.7, 74.21, 44.6, 36.3, 32.4, 
16.5. HRMS (APCI+) calcd for [C13H17O+] requires m/z 189.1279, found 189.1279. 




Prepared using Procedure C with trans-crotyl chloride (1.81 g, 20 mmol) and 
hydrocinnamaldehyde (2.55 g, 19 mmol).  Purified by silica gel flash column chromatography 
(10% EtOAc/Hexanes) to give the product as a clear oil (3.29 g, 91% yield, 97% ee). Ligand 
recovery was achieved according to Procedure C and purified by recrystalization in hot 9:1 
MeOH:H2O. The hot saturated solution was allowed to cool to room temperature, and distilled 
water (10 mL) was added to ensure complete crystallization. The white solid was collected by 
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filtration through a frit, rinsing with cold 1:1 MeOH:H2O and then dried in vacuo to give (R,R)-
3.4 (5.35 g, 92% yield). 
(1S, 2S)-2-Methyl-1-phenylbut-3-en-1-ol: 
 
Prepared using Procedure A with trans-crotyl chloride (90.6 mg, 1 mmol) and 
benzaldehyde (100.8 mg, 0.95 mmol) with a 12 hr reaction time at 0 °C.  Purified by silica gel 
flash column chromatography (10% EtOAc/Hexanes) to give the product as a clear oil (146 mg, 
90% yield, 91% ee). 
[Daicel Chiracel OD-H, 99:1 Hexanes:IPA, 0.5 mL/min, 254 nm; t1= 32.9 min, t2=37.2 min]. 
1
H 
NMR (500 MHz, CDCl3) δ 7.41 – 7.32 (m, 4H), 7.35 – 7.27 (m, 1H), 5.84 (ddd, J = 17.2, 10.3, 
8.2 Hz, 1H), 5.28 – 5.18 (m, 2H), 4.39 (dd, J = 7.9, 2.6 Hz, 1H), 2.51 (dtd, J = 7.9, 6.9, 1.0 Hz, 
1H), 2.15 (d, J = 2.7 Hz, 1H), 1.25 (d, J = 26.9 Hz, 0H), 1.04 (d, J = 6.8 Hz, 0H), 0.90 (d, J = 6.8 
Hz, 3H).
 13
C NMR (126 MHz, CDCl3) δ 142.7, 141.0, 128.6, 128.4, 128.0, 127.1, 126.8, 117.2, 







Prepared using Procedure A with the allyl chloride (167 mg, 1 mmol) and 
hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 12 hr reaction time at 0 °C.  Purified by 
silica gel flash column chromatography (5–15% EtOAc/Hexanes) to give the  product as a clear 
oil (186 mg, 86% yield, 95% ee). 
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[Daicel Chiracel OD-H, 90:10 Hexanes:IPA, 1 mL/min, 254 nm; t1= 6.68 min, t2=14.67 min], 
OR [α]D
23





H NMR (500 MHz, CDCl3) δ 7.29 (t, J = 7.6 Hz, 2H), 7.21 (d, J = 7.1 Hz, 2H), 7.19 (t, J 
= 7.1 Hz, 1H), 5.64 (ddd, J = 17.2, 10.3, 9.2 Hz, 1H), 5.21 (dd, J = 10.3, 2.0 Hz, 1H), 5.12 (dd, J 
= 17.2, 2.0 Hz, 1H), 3.52 (t, J = 6.7 Hz, 2H), 3.47 – 3.54 (m, 1H), 2.82 (ddd, J = 13.7, 9.8, 5.4 
Hz, 1H), 2.67 (ddd, J = 13.7, 9.8, 6.6 Hz, 1H), 2.04 (tt, J = 9.0, 4.8 Hz, 1H), 1.67 – 1.87 (m, 4H), 
1.54 (d, J = 4.4 Hz, 1H), 1.43 – 1.52 (m, 2H), 1.31 – 1.40 (m, 2H).  
13
C NMR (125 MHz, 
CDCl3) δ 142.4, 138.4, 128.6, 128.5, 126.0, 118.5, 73.2, 50.6, 45.1, 36.8, 32.8, 32.4, 30.2, 24.9.  
HRMS (APCI+) calcd for [C16H22OCl+] requires m/z 265.1359, found 265.1352. 
(4R, 5S)-9-chloro-4-hydroxy-5-vinylnonan-2-one: 
 
Prepared using Procedure A with allyl chloride (167 mg, 1 mmol) and 2-(2-methyl-1,3-
dioxolan-2-yl)acetaldehyde (124 mg, 0.95 mmol) with a modified work-up.  Upon completion, 
the reaction was concentrated in vacuo then suspended in Et2O (10 mL).  The reaction was 
cooled to 0 °C and 1N HCl (10 mL, 10 mmol) was added.  The solution was slowly warmed to rt 
and stirred 12 hrs.  The reaction was extracted with EtOAc (3 x 15 mL).  Organics were 
combined, washed with H2O (10 mL) and brine (10 mL), and dried over Na2SO4.  The solution 
was then filtered and concentrated in vacuo.  The resulting crude residue was purified by flash 
column chromatography (30% EtOAc/Hexanes) to give the product as a yellow oil (172 mg, 
83% yield).  The ee of the compound was determined to be 94% based on 
19
F NMR analysis of 




H NMR (500 MHz, CDCl3) δ 5.86 – 5.52 (m, 1H), 5.23 – 
4.96 (m, 2H), 4.07 (dt, J = 9.2, 3.5 Hz, 1H), 3.54 (t, J = 6.7 Hz, 2H), 2.67 – 2.43 (m, 2H), 2.11 (s, 
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3H), 2.00 (dq, J = 9.0, 4.6 Hz, 1H), 1.79 (dqd, J = 14.5, 6.9, 5.4 Hz, 2H), 1.64 – 1.35 (m, 4H).
 
13
C NMR (126 MHz, CDCl3) δ 139.9, 135.7, 135.6, 135.6, 132.9, 132.9, 129.8, 129.6, 129.6, 
127.8, 127.6, 115.2, 79.8, 77.3, 77.0, 76.8, 69.0, 42.6, 41.2, 37.8, 26.9, 26.8, 26.77, 26.7, 26.7, 






Prepared using Procedure A with trans-cinnamyl chloride (152.6 mg, 1 mmol) and 
hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 12 hr reaction time at 0 °C.  Purified by 
silica gel flash column chromatography (10% EtOAc/Hexanes) to give the product as a clear oil 
(231 mg, 96% yield, 97% ee). 
[Daicel Chiracel OD-H, 95:5 Hexanes:IPA, 1 mL/min, 254 nm; t1= 8.94 min, t2=13.14 min], OR 
[α]D
23




H NMR (500 MHz, CDCl3) δ 7.34 (t, J = 7.5 Hz, 2H), 7.28 (d, J = 7.5 Hz, 2H), 7.25 (t, 8 Hz, 
1H), 7.20 (d, 7.5 Hz, 2H), 7.19 (t, J = 8.0 Hz, 1H), 7.14 (d, J = 7.5 Hz, 2H), 6.14 (ddd, J = 16.9, 
10.3, 9.1 Hz, 1H), 5.29 – 5.21 (m, 2H), 3.84 (tt, J = 7.3, 3.4 Hz, 1H), 3.30 (dd, J = 9.1, 7.3 Hz, 
1H), 2.86 (ddd, J = 14.0, 9.8, 5.4 Hz, 1H), 2.66 (ddd, J = 14.0, 9.6, 6.9 Hz, 1H), 1.88 (d, J = 3.4 
Hz, 1H), 1.62 – 1.78 (m, 2H).  
13
C NMR (125 MHz, CDCl3) δ 142.2, 138.4, 128.9, 128.6, 128.5, 
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128.1, 126.9, 125.9, 118.1, 73.4, 57.6, 36.2, 32.2.  HRMS (ASAP+) calcd for [C18H21O+] 
requires m/z 253.1592, found 253.1587. 
(R)-4,4-dimethyl-1-phenylhex-5-en-3-ol: 
 
Prepared using Procedure A with prenyl chloride (105 mg, 1 mmol) and 
hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 12 hr reaction time at 0 °C.  Purified by 
silica gel flash column chromatography (10% EtOAc/Hexanes) to give the product as a pale 
yellow oil (181 mg, 93% yield, 92% ee). 
 [Daicel Chiracel OD-H, 95:5 Hexanes:IPA, 1 mL/min, 254 nm; t1= 6.43 min, t2=11.26 min], 
OR [α]D
23
 +26.3° (c2.00, CH2Cl2).  IR (ATR) 3430, 2958, 2926, 2865, 1634, 1602, 1496, 1454, 




H NMR (500 MHz, CDCl3) δ 7.29 (t, J = 7.6 Hz, 2H), 7.21 (d, J = 7.6 
Hz, 2H), 7.19 (t, J = 7.4 Hz, 1H), 5.80 (dd, J = 17.5, 10.8 Hz, 1H), 5.09 (dd, J = 10.8, 1.3 Hz, 
1H), 5.05 (dd, J = 17.5, 1.3 Hz, 1H), 3.29 (ddd, J = 10.7, 5.0, 1.8 Hz, 1H), 2.92 (ddd, J = 14.5, 
10.1, 4.9 Hz, 1H), 2.62 (ddd, J = 13.6, 9.7, 6.9 Hz, 1H), 1.89 – 1.79 (m, 1H), 1.63 – 1.51 (m, 
2H), 1.50 (broad s, 1H, –OH) 1.00 (s, 6H).  
13
C NMR (125 MHz, CDCl3) δ 145.5, 142.6, 128.7, 
128.6, 126.0, 113.8, 77.8, 41.9, 33.5, 33.5, 23.3, 22.2.  HRMS (APCI+) calcd for [C14H19O+] 










Prepared using Procedure A with geranyl chloride (20:1 trans:cis, 172.7 mg, 1 mmol) and 
hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 24 hr reaction time at 0 °C.  Purified by 
silica gel flash column chromatography (5% EtOAc/Hexanes) to give the product as a clear oil 
(214 mg, 83% yield, 95% ee). 
[Daicel Chiracel OD-H, 96:4 Hexanes:IPA, 1 mL/min, 254 nm; t1= 6.05 min, t2=11.30 min], OR 
[α]D
23





H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.5 Hz, 2H), 7.21 (d, J = 6.7 Hz, 
3H), 7.19 (tt, J = 7.0, 1.4 Hz, 1H), 5.74 (dd, J = 17.6, 10.8 Hz, 1H), 5.22 (dd, J = 10.8, 1.4 Hz, 
1H), 5.03 – 5.11 (m, 2H), 3.31 (ddd, J = 10.6, 3.8, 1.8 Hz, 1H), 2.93 (ddd, J = 13.6, 10.2, 4.9 Hz, 
1H), 2.61 (ddd, J = 13.6, 9.8, 6.7 Hz, 1H), 1.75 –1.98 (m, 2H), 1.67 (d, J = 1.4 Hz, 3H), 1.57 – 
1.66 (m, 2H), 1.57 (d, J = 0.7 Hz, 3H), 1.37 (ddd, J = 13.4, 11.6, 5.7 Hz, 1H), 1.29 (ddd, J = 
13.4, 11.8, 5.1 Hz, 1H), 0.97 (s, 3H).  
13
C NMR (125 MHz, CDCl3) δ 144.3, 142.6, 131.5, 128.7, 
128.5, 125.9, 124.9, 115.5, 76.5, 45.3, 37.6, 33.5, 33.0, 25.9, 22.9, 17.8, 16.8.  HRMS (APCI+) 
calcd for [C19H27O+] requires m/z 271.2062, found 271.2067. 
(R)-5-chloro-1-phenylhex-5-en-3-ol: 
 
Prepared using Procedure A with 2,3-dichloropropene, (110.9 mg, 1 mmol) and 
hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 12 hr reaction time at 0 °C. Purified by 
silica gel flash column chromatography (15% EtOAc/Hexanes) to give the product as a clear oil 
(233 mg, 74% yield, 98% ee).  
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[Daicel Chiracel OD-H, 90:10 Hexanes:IPA, 1 mL/min, 254 nm; t1= 6.91 min, t2=9.15 min], OR 
[α]D
23




H NMR (500 MHz, CDCl3) δ 7.32 (t, J = 7.5 Hz, 2H), 7.20 – 7.24 (m, 3H), 5.32 (q, J = 1.5 Hz, 
1H), 5.28 (d, J = 1.5 Hz, 1H), 3.96 – 4.03 (m, 1H), 2.87 (ddd, J = 13.8, 8.9, 6.9 Hz, 1H), 2.74 
(ddd, J = 13.8, 8.9, 7.6 Hz, 1H), 2.48 – 2.56 (m, 2H), 1.82 – 1.87 (m, 2H), 1.80 (d, J = 3.4 Hz, 
1H).  
13
C NMR (125 MHz, CDCl3) δ 141.8, 139.2, 128.5, 128.4, 125.9, 115.3, 68.1, 47.4, 38.2, 




Prepared using Procedure A with 2-bromo-3-chloropropene (155.4 mg, 1 mmol) and 
hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 12 hr reaction time at 0 °C.  Purified by 
silica gel flash column chromatography (15% EtOAc/Hexanes) to give the product as a pale 
yellow oil (173 mg, 71% yield, 99% ee). 
[Daicel Chiracel OD-H, 90:10 Hexanes:IPA, 1 mL/min, 254 nm; t1= 7.00 min, t2=9.31 min], OR 
[α]D
23




H NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.6 Hz, 2H), 7.22 (d, J = 7 Hz, 2H), 7.20 (tt, J = 7.3, 
1.4 Hz, 1H), 5.70 (q, J = 1.5 Hz, 1H), 5.55 (d, J = 1.5 Hz, 1H), 3.95 – 4.02 (m, 1H), 2.85 (ddd, J 
= 13.7, 8.8, 6.8 Hz, 1H), 2.72 (ddd, J = 13.7, 8.8, 7.4 Hz, 1H), 2.53 – 2.63 (m, 2H), 1.80 – 1.86 
(m, 2H), 1.76 (d, J = 3.7 Hz, 1H).  
13
C NMR (125 MHz, CDCl3) δ 142.0, 130.7, 128.7, 128.6, 
126.1, 120.0, 68.8, 49.6, 38.2, 32.2.  HRMS (ASAP+) calcd for [C12H16BrO+] requires m/z 





Prepared using Procedure A with trans-1,3-dichloropropene (111 mg, 1 mmol) and 
hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 24 hr reaction time at 0 °C.  The reaction 
2O (1 equiv) at -40 ºC. Purified by silica gel flash 
column chromatography (15% EtOAc/Hexanes) to give the product as a clear oil (156 mg, 78% 
yield, 95% ee). 
[Daicel Chiracel OD-H, 94:6 Hexanes:IPA, 1 mL/min, 254 nm; t1= 8.6 min, t2= 12.4 min], OR 
[α]D
23





H NMR (500 MHz, CDCl3) δ 7.19-7.36 (m, 5H), 5.98 (ddd, J = 16.9, 10.2, 
8.8 Hz, 1H), 5.31-5.39 (m, 2H), 4.41 (dd, J = 8.8, 3.9 Hz, 1H), 3.83 (dq, J = 8.5, 4.5 Hz, 1H), 
2.91 (ddd, J = 14.3, 8.6, 6.1 Hz 1H), 2.72 (ddd, J = 13.8, 9.1, 7.6 Hz, 1H), 2.22-2.16 (m, 1H), 
1.85 (tdd, J = 8.9, 4.9, 3.3 Hz, 2H) 
13
C NMR (125 MHz, CDCl3) δ 141.5, 133.8, 128.5, 126.0, 




Prepared using Procedure A with trans-1,3-dichloropropene (111 mg, 1 mmol) and 
benzaldehyde (100.8 mg, 0.95 mmol) with a 24 hr reaction time at 0 °C.  The reaction was 
quenched by addition of TBAF 3H2O (1 equiv) at -40 ºC. Purified by silica gel flash column 
chromatography (15% EtOAc/Hexanes) to give the product as a clear oil (128 mg, 74% yield, 
93% ee).  
222 
 
[Daicel Chiracel OD-H, 92:8 Hexanes:IPA, 0.5 mL/min, 220 nm; t1= 16.5 min, t2= 17.4 min], 
1
H NMR (500 MHz, CDCl3) δ 7.43 – 7.30 (m, 5H), 5.95 (ddd, J = 17.0, 10.2, 8.5 Hz, 1H), 5.31 
– 5.23 (m, 2H), 4.97 (dd, J = 4.7, 2.4 Hz, 1H), 4.61 (ddt, J = 8.5, 4.6, 0.9 Hz, 1H), 2.53 (s, 
1H).
13
C NMR (126 MHz, CDCl3) δ 139.2, 133.3, 128.3, 128.2, 126.7, 120.1, 77.3, 77.2, 77.0, 





Prepared using Procedure A with cis-1,3-dichloropropene (111 mg, 1 mmol) and 
hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 24 hr reaction time at 0 °C. The reaction 
was quenched by addition of TBAF 3H2O (1 equiv) at -40 ºC. Purified by silica gel flash column 
chromatography (15% EtOAc/Hexanes) to give the product as a clear oil (143 mg, 72% yield, 
96% ee). 
[Daicel Chiracel OD-H, 90:10 Hexanes:IPA, 1 mL/min, 254 nm; t1= 6.7 min, t2= 9.3 min], OR 
[α]D
21





H NMR (500 MHz, CDCl3) δ 7.19-7.36 (m, 5H), 5.93 (ddd, J = 16.9, 10.1, 
8.7 Hz, 1H), 5.28-5.39 (m, 2H), 4.37 (dd, J = 8.7, 6.0, 1H), 3.70 (dtd, J = 9.2, 5.7, 3.4 Hz, 1H), 
2.90 (ddd, J = 14.5, 9.6, 5.2 Hz, 1H), 2.75 (ddd, J = 13.8, 9.4, 7.1 Hz, 1H), 2.25 (d, J = 5.4 Hz, 
1H), 1.81-1.93 (m, 2H).  
13
C NMR (125 MHz, CDCl3) δ 141.5, 135.1, 128.5, 128.4, 126.0, 






Prepared using Procedure A with trans-2-chloromethylvinylboronic acid pinacol ester 
(202.5 mg, 1 mmol) and hydrocinnamaldehyde (127.1 mg, 0.95 mmol) with a 12 hr reaction time 
at 0 °C.  Purified by silica gel flash column chromatography on boric acid impregnated silica
84
 
(50% EtOAc/Hexanes) to give the product as a yellow oil (273 mg, 95% yield). The ee of the 
compound was determined to be 94% based on 
19











H NMR (500 MHz, CDCl3) δ  7.18-7.33 (m, 5H), 5.86 (dt, J = 18.6, 9.7 Hz, 1H), 
5.13-5.19 (m, 2H), 3.86 (q, J = 6.5 Hz, 1H), 2.86 (dt, J = 15.1, 7.2 Hz, 1H), 2.71 (dt, J = 13.5, 
8.7 Hz, 1H), 2.20 (s, 1H), 2.08 (dd, J = 9.8, 7.0 Hz, 1H), 1.78-1.85 (m, 2H), 1.27 (d, J = 5.4 Hz, 
12H).  
13
C NMR (125 MHz, CDCl3) δ 142.4, 135.2, 128.4, 128.3, 125.7, 117.6, 83.6, 70.9, 38.0, 
32.2, 24.7, 24.6. HRMS (ESCl+) calcd for [C18H27BO3Na+] requires m/z 325.1951, found 
325.1960.  
 





Prepared using a modified Procedure A with chloride 3.13 (125 mg, 1.00 mmol), (S,S)-3 
(290mg, 1.00 mmol), and aldehyde 3.14 (150 mg, 0.95 mmol). Prior to addition of the allyl 
chloride and Cl3SiH solution to the copper (I) bromide solution, 2,6-di-tert-butylpyridine (383 
mg, 2.00 mmol) was added dropwise to the allyl chloride solution.  After addition of aldehyde 
3.14, the reaction was stirred 12 hr at 0 °C. Upon consumption of the aldehyde, the reaction 
mixture was treated with n-Bu4NF (1M in THF, 1.2 mL, 1.2 mmol, 1.2 equiv).  The mixture was 
stirred 1 hr at –40 °C, and then filtered through a silica plug eluting with EtOAc.  After 
concentration in vacuo, the crude residue was purified by silica gel flash column chromatography 
(45% EtOAc/Hexanes) to give 3.15 as a pale yellow oil (211 mg, 89% yield). The ee of the 
compound was determined to be 95% based on HPLC of the corresponding benzoate protected 
alcohol. 
[Daicel Chiracel OD-H, 98:2 Hexanes:IPA, 1 mL/min, 254 nm; t1= 7.0 min, t2= 7.5 min],OR 
[α]D
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H NMR (500 MHz, CDCl3) δ 5.29 (t, J = 1.2 Hz, 1H), 5.10 (q, J = 1.2 Hz, 1H), 4.18 – 4.07 (m, 
2H), 4.02 – 3.91 (m, 4H), 3.84 (d, J = 5.5 Hz, 1H), 2.47 (ddd, J = 14.5, 3.6, 1.3 Hz, 1H), 2.25 
(ddd, J = 14.4, 9.3, 1.0 Hz, 1H), 1.75 – 1.66 (m, 2H), 1.59 – 1.43 (m, 4H), 1.35 (s, 3H). 
13
C 
NMR (500 MHz, CDCl3) δ 142.3, 117.4, 110.0, 69.4, 64.6, 48.2, 41.5, 39.0, 37.4, 23.8, 20.2. 
HRMS (ASAP+) calcd for [C12H20O3Cl] requires m/z 247.1101, found 247.1096. 




A 25 mL round bottom flask, equipped with a stir bar, was charged with THF (6.00 mL) 
and alcohol-3.15 (143 mg, 0.573 mmol, 1 equiv) and cooled to 0 °C. Triethylamine (87.0 mg, 
0.860 mmol, 1.5 equiv) followed by acetic anhydride (58.5 mg, 0.860 mmol, 1.5 equiv) and 4-
(dimethylamino)pyridine (21.0 mg, 0.172 mmol, 0.30 equiv). The reaction mixture was stirred 
for 1 hour at room temperature. The reaction mixture was concentrated and then purified by 
silica gel flash column chromatography (25% EtOAc/Hexanes) to afford the alcohol acetylation 
product-3.16 as a pale yellow oil (135 mg, 81% yield). 
OR [α]D
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H NMR (500 MHz, CDCl3) δ 5.20 (t, J = 1.2 Hz, 1H), 5.08 (ddd, J = 4.1, 2.4, 
1.1 Hz, 1H), 5.02 (q, J = 1.2 Hz, 1H), 4.16 (dd, J = 11.8, 1.1 Hz, 1H), 4.05 (dd, J = 11.8, 0.9 Hz, 
1H), 4.01 – 3.88 (m, 4H), 2.54 (ddd, J = 14.7, 4.2, 1.3 Hz, 1H), 2.42 – 2.31 (m, 1H), 2.04 (s, 3H), 
1.73 – 1.57 (m, 4H), 1.52 – 1.39 (m, 2H), 1.33 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.7, 
141.5, 117.5, 109.8, 77.3, 77.2, 77.0, 76.8, 71.6, 64.7, 64.6, 48.0, 38.8, 38.1, 34.3, 23.8, 21.1, 
19.9. HRMS (ESI+) calcd for [C14H23O4 m/z 313.1183, found 313.1178. 
 (4S,8S,E)-11-chloro-8-hydroxy-1-(2-methyl-1,3-dioxolan-2-yl)-6-methylenedodeca-9,11-
dien-4-yl acetate (3.17): 
 
Prepared using a modified Procedure A with chloride 3.16 and the chlorodiene aldehyde 
3.2 (46 mg, 0.4 mmol, 2.0 equiv).  A 2-dram vial, equipped with a stir bar, was charged with 
copper (I) bromide (1.4 mg, 0.010 mmol, 0.050 equiv) in an argon-atmosphere glove box. The 
vial was capped with a septum and transferred out of the glove box. The vessel was charged with 
CH2Cl2 (1.0 mL) and Et3N (39 μL, 0.28 mmol, 1.4 equiv) and n-Bu4NBr (3.2 mg, 0.010 mmol, 
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0.050 equiv). In a separate vial under Ar atmosphere, allyl chloride 3.16 (58 mg, 0.20 mmol, 1.0 
equiv), CH2Cl2 (0.75 mL), 2,6-di-t-Bu-pyridine (259 μL, 1.2 mmol, 6.0 equiv) and Cl3SiH (24 
μL, 0.24 mmol, 1.2 equiv) were sequentially added. The rest of Procedure A was followed 
without modification until the reaction was quenched at –40 °C and quenched by addition of 
TBAF 3H2O (76 mg, 0.24 mmol, 1.2 equiv).  The mixture was stirred 1 hr at –40 °C, and then 
filtered through a silica plug eluting with EtOAc.  After concentration in vacuo, the crude residue 
was purified by silica gel flash column chromatography using pH 7 buffered silica (30% 
EtOAc/Hexanes) to give 3.17 as a pale yellow oil (57 mg, 77% yield, ≥20:1 dr).  
OR [α]D
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H NMR (400 MHz, C6D6) δ 6.37 (dd, J = 14.9, 1.4 Hz, 1H), 6.24 (dd, J = 
14.9, 4.8 Hz, 1H), 5.22 – 5.11 (m, 2H), 5.15 (s, 1H), 4.96 (s, 1H), 4.83 (s, 1H), 4.81 (s, 1H), 4.29 
– 4.20 (m, 1H), 3.57 – 3.48 (m, 4H), 2.30 – 2.04 (m, 4H), 1.74 – 1.57 (m, 3H), 1.69 (s, 3H), 1.57 
– 1.41 (m, 4H), 1.28 (s, 3H). 
13
C NMR (126 MHz, C6D6) δ 170.0, 142.2, 138.5, 137.6, 126.2, 
115.6, 115.1, 109.6, 71.8, 69.0, 64.3, 64.3, 44.3, 41.4, 38.9, 34.4, 23.7, 20.4, 20.0. HRMS (ESI+) 
calcd for [C19H29O5 m/z 395.1601, found 395.1605. 






A flame dried 2-dram vial, equipped with a stir bar, was charged with (R,R)-3.4 and 
dissolved in dry CD2Cl2 under Ar atmosphere. The reaction mixture was cooled to 0 °C and DBU 
(449 μL, 3.00 mmol, 3.00 equiv) was added dropwise via syringe followed by 
methyltrichlorosilane (129 μL, 1.10 mmol, 1.10 equiv). The cooling bath was removed and the 
resulting mixture was stirred 1 hr at room temperature to afford 3.10 generated in situ.  A 
separate, flame dried 2-dram vial, equipped with a stir bar, was charged with Et3N·HCl (550 mg, 
4.00mmol, 4.00 equiv) and dissolved in CD2Cl2 (4 mL). The Et3N·HCl mixture was added 
dropwise via syringe to the reaction mixture of 3.10. The reaction mixture was cooled to 0ºC and 
hydrocinnamaldehyde (134 mg, 1.00 mmol, 1.00 equiv) was added dropwise via syringe. The 
reaction mixture was stirred for 1 hr at 0 °C and then an aliquot was transferred to an NMR tube 
under argon. Analysis by 
1
H NMR spectroscopy revealed complete disappearance of the 
aldehydic proton and the appearance of a new resonance (apparent doublet of doublets) at 6.0 
ppm. Analysis by 
29
Si NMR spectroscopy revealed a single resonance at -41.97 ppm. These data 








Finkelstein Exploration:  
 
Figure 3.11: A) Complete conversion of trans-crotyl chloride to trans-crotyltrichlorosilane without n-Bu4NBr.         
B) Attempted observation of Finkelstein product. 
In order to determine if n-Bu4NBr was facilitating a Finkelstein reaction during the 
Benkeser-Furuya silylation, several experiments were performed. Reaction A was performed to 
establish how the silylation worked starting from trans-crotyl chloride without the presence of n-
Bu4NBr. It was observed that the silylation went to completion after 2 hr without n-Bu4NBr 
present. Reaction B was performed in order to observe the possible formation of trans-crotyl 
bromide from a Finkelstein reaction. After stirring for 2 hr, only the trans-crotyl chloride was 
observed thus showing a Finkelstein reaction does not occur under these conditions. 
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A) A 2-dram vial, equipped with a stir bar, was charged with copper (I) bromide (7.2 mg, 0.050 
mmol, 0.050 equiv) in an argon atmosphere. The vessel was charged with CH2Cl2 (3 mL) and 
Et3N (195 μL, 1.40 mmol, 1.40 equiv). In a separate vial under argon atmosphere, trans-crotyl 
chloride (98 μL, 1.00 mmol, 1.00 equiv), CH2Cl2 (2 mL), and Cl3SiH (121 μL, 1.20 mmol, 1.20 
equiv) were sequentially added. To the cooled 0 ºC solution of CuBr, was added the allyl 
chloride solution dropwise via syringe. The allyl chloride vial was then rinsed with 1 mL 
CH2Cl2, this solution was added to the reaction flask, and the resulting mixture was stirred 2 hrs 
at 0 ºC.  An aliquot of the reaction mixture was transferred to an NMR tube under Ar 
atmosphere. Analysis by 
1
H NMR spectroscopy revealed complete formation of the trans-
crotyltrichlorosilane product. See the spectra below. 
B) A flame dried 2-dram vial, equipped with a stir bar, was charged with copper (I) bromide (7.2 
mg, 0.050 mmol, 0.050 equiv), n-Bu4NBr (322 mg, 1.00 mmol, 1.00 equiv), and CH2Cl2 (6 mL) 
under an argon atmosphere. The reaction mixture was cooled to 0 °C and Et3N (195 μL, 1.40 
mmol, 1.40 equiv) was added dropwise via syringe followed by trans-crotyl chloride (98 μL, 
1.00 mmol, 1.00 equiv). The reaction was stirred 2 hr at 0 °C and then an aliquot of the reaction 
mixture was transferred to an NMR tube under Ar atmosphere. Analysis by 
1
H NMR 








General Procedure for Rate Measurement Reactions:  
 
 
A flame dried 2-dram vial, equipped with a stir bar, was charged with (R,R)-3.4 (145 mg, 
0.50 mmol, 1.00 equiv) and dry CH2Cl2 under Ar atmosphere. The reaction mixture was cooled 
to 0 °C and DBU (224 μL, 1.50 mmol, 1.50 equiv) was added dropwise via syringe followed by 
trans-crotyltrichlorosilane (104.2 mg, 1.10 mmol, 0.55 equiv). The cooling bath was removed 
and the resulting mixture was stirred 1 hr at room temperature. The reaction mixture was cooled 
to -40 °C.  Benzaldehyde (53.3 mg, 0.50 mmol, 1.00 equiv) was added and the reaction was 
allowed to stir for 1, 2.5, 5, 10 or 20 minutes. At the desired time, the reaction mixture was 
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treated with n-Bu4NF (1M in THF, 1 mL, 2.00 mmol, 2.00 equiv) and stirred 1 hr at 0 °C.  The 
mixture was then passed through a silica plug with EtOAc and concentrated to give the crude 
product. Conversion data was obtained using trimethoxybenzene as a quantative internal 
standard. 
Spectroscopic Evidence for 5 and 6 Coordinate Silanes:  
A flame dried 2-dram vial, equipped with a stir bar, was charged with (R,R)-3.4 and 
dissolved in dry CD2Cl2 under Ar atmosphere. The reaction mixture was cooled to 0 °C and 
DBU (225 μL, 1.50 mmol, 3.00 equiv) was added dropwise via syringe followed by trans-
crotyltrichlorosilane (156 μL, 0.55 mmol, 1.10 equiv). The cooling bath was removed and the 
resulting mixture was stirred 1 hr at room temperature to afford silane-10 generated in situ. A 
separate, flame dried 2- dram vial, equipped with a stir bar, was charged with n-Bu4NBr (1.61 g, 
5.00 mmol, 10.0 equiv) and dissolved in CD2Cl2 (1 mL). The n-Bu4NBr mixture was added 
dropwise via syringe to the reaction mixture of silane-10 at 0 °C. An aliquot was transferred to 
an NMR tube under argon. Analysis by 
29
Si NMR spectroscopy revealed three resonances at -
14.2, -67.2 ppm and -105.3 ppm. These data are consistent with the four, five and six coordinate 




3.7.5. Synthesis of the EF fragment 
 
To a solution of 3-methyl-1,4-pentadiene 3.18 (5.62 mL, 45 mmol, 1 equiv) in t-butyl 
acrylate (135 ml, 0.9 mol, 20 equiv) was added Hoveyda-Grubbs 2nd Generation catalyst (65.6 
mg, 0.105 mmol, 0.23 mol %). The flask was fitted with a dry-ice condenser under constant 
nitrogen flow and the reaction mixture was heated to 50 °C. After 1.5 h, an additional portion of 
the HG-II catalyst (65.6 mg, 0.105 mmol, 0.23 mol %) was added. After 1.5 h, an additional 
portion of the HG-II catalyst (65.6 mg, 0.105 mmol, 0.23 mol %) was added. After 2 h, the 
reaction mixture was cooled to ambient temperature and concentrated. The residue was treated 
with toluene (100 mL) and the mixture was concentrated. The residue was purified by silica gel 
flash column chromatography (4% EtOAc/Hexanes) to yield dienoate 3.19 (7.55 g, 26.7 mmol, 
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58%) as a pale yellow oil. Dienoate 3.19 was previously characterized,
66
 and the data are 
reproduced here. 




H NMR (500 MHz, CDCl3) δ 
6.76 (dd, J = 15.7, 7.0 Hz, 2H), 5.73 (dd, J = 15.7, 1.3 Hz, 2H), 3.17-3.08 (m, 1H), 1.47 (s, 18H), 
1.20 (d, J = 6.9 Hz, 3H).
13
C NMR (126 MHz, CDCl3) δ 165.9, 148.4, 123.2, 80.6, 38.5, 28.3, 
18.6.HRMS (FAB+) calculated for C16H27O4 [M+H]
+
: 283.1904, found 283.1910. 
  
To a mechanically-stirred solution of K3Fe(CN)6 (148 g, 450 mmol, 6 equiv), K2CO3 
(62.1 g, 450 mmol, 6 equiv), NaHCO3 (37.8 g, 450 mmol, 6 equiv) and CH3SO2NH2 (14.3 g, 150 
mmol, 2 equiv) in H2 O (750 mL) was added a solution of (DHQD)2PHAL (3.00 g, 3.85 mmol, 
0.05 equiv) in t-BuOH (500 mL). The mixture was cooled to 0 °C and K2OsO4 •2H2O (1.10 g, 
3.00 mmol, 0.04 equiv) was added, followed 10 minutes later by a solution of dienoate 3.19 
(21.2 g, 74.9 mmol) in t-BuOH (250 mL). The bright orange suspension was stirred vigorously at 
0 °C for 18 h. Solid Na2SO3 (94 g, 749 mmol, 10 equiv) was added and the reaction mixture was 
stirred for a further 45 min. The layers of the cold reaction mixture were separated, and the 
aqueous layer was extracted with EtOAc (3 x 150 mL). The combined organic layers were stirred 
with solid NaCl, the resulting brine layer was removed. The organic phase was washed with 
additional brine (350 mL), dried over Na2SO4, filtered and concentrated. The residue was 
purified by silica gel flash column chromatography (50% EtOAc/Hexanes) to yield tetraol 3.20 
(16.4 g, 46.7 mmol, 62%) as the major product of a 4.5:1 mixture of diastereomers as a colorless 
gum that solidified to a colorless solid on standing. This mixture was used as is in the next step, 
but for the purposes of characterization, an analytically pure sample was obtained by careful 
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flash chromatography. Tetraol 28 was previously characterized,
66









NMR (400 MHz, CDCl3) δ 4.15 (dd, J = 5.7, 3.0 Hz, 1H), 4.12 (dd, J = 5.7, 1.6 Hz, 1H), 4.06 
(dt, J = 8.4, 3.3 Hz, 1H), 3.99 (td, J = 8.9, 1.3 Hz, 1H), 3.55 (d, J = 8.5 Hz, 1H), 3.52 (d, J = 5.7 
Hz, 1H), 3.34 (d, J = 5.7 Hz, 1H), 3.22 (d, J = 9.1 Hz, 1H), 2.26-2.14 (m, 1H), 1.50 (s, 18H), 
1.07 (d, J = 7.0 Hz, 3H).
13
C NMR (75 MHz, CDCl3) δ 173.0, 83.5, 83.3, 75.0, 74.2, 72.2, 71.9, 
40.0, 28.2, 13.1. HRMS (FAB+) calcd for [C16H30O8H+] requires m/z 351.2013, found 351.2018 
  
To a solution of tetraol 3.20 (20.83 g, 59.40 mmol) in methanol (300 mL) in a sealed-tube 
pressure apparatus was added TMS-Cl (37.7 mL, 297 mmol). The vessel was sealed and the 
reaction mixture was heated at 65 °C (oil bath, external temperature) for 18 h. [CAUTION!!! 
Always use a blast shield and proper personal protective equipment when running reactions in 
sealed tubes.] The reaction mixture was cooled and concentrated. The residue was re-dissolved 
in toluene (150 mL) and then concentrated. 
To the residue was added TriBOT
14
 (18.96 g, 47.52 mmol), flame-dried 5Å mol. sieves 
(14.36 g), 1,4-dioxane (585 mL), and triflic acid (3.93 mL, 44.55 mmol). After 1 h an additional 
portion of TriBOT (14.22 g, 35.64 mmol) was added. After 4 h an additional portion of TriBOT 
(14.22 g, 35.64 mmol) was added. After 18 h 1M NaOH (45 mL) was added and the mixture was 
stirred for 10 minutes. The reaction mixture was diluted with CH2Cl2 (450 mL) and filtered 
through Celite. The filtrate was washed with 1M NaOH (2 x 100 mL) and brine (150 mL), dried 
over Na2SO4, filtered, and concentrated. Purification of the residue by flash column 
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chromatography (5%  10%  20%  30% EtOAc/Hexanes) on silica gel gave lactone 3.22 as 
a pale yellow oil (18.6 g, 36.8 mmol, 62% yield over two steps) as well as a mix of doubly 
benzylated lactones (1.9 g, 4.58 mmol, 9% yield).  
OR [α]D
23





NMR (500 MHz, CDCl3) δ 7.56 – 7.17 (m, 20H), 5.06 (d, J = 11.2 Hz, 1H), 4.94 (d, J = 11.7 Hz, 
1H), 4.80 (d, J = 11.1 Hz, 1H), 4.66 (d, J = 11.2 Hz, 1H), 4.52 (d, J = 11.2 Hz, 1H), 4.42 (d, J = 
11.7 Hz, 1H), 4.38 (dd, J = 10.4, 2.2 Hz, 1H), 4.05 (d, J = 7.9 Hz, 1H), 4.03 (d, J = 2.2 Hz, 1H), 
3.85 (s, 3H), 3.44 (dd, J = 9.8, 7.8 Hz, 1H), 2.33 – 2.22 (m, 1H), 0.78 (d, J = 6.6 Hz, 3H).
13
C 
NMR (126 MHz, CDCl3) δ 170.1, 169.7, 137.8, 137.3, 136.5, 128.9, 128.7, 128.7, 128.6, 128.6, 
128.5, 128.5, 128.3, 128.2, 128.1, 81.9, 80.4, 79.9, 75.4, 74.5, 74.4, 73.2, 52.7, 35.7, 13.5.HRMS 
(ESI+) calculated for C62H82O9SiNa [M+Na]
+
: 527.2046, found 527.2041 
  
To a solution of lactone 3.22 (918 mg, 1.82 mmol) in toluene (15 mL) in a sealed-tube 
pressure apparatus was added Cp2TiMe2 (5.77 g of a 24% w/w solution in toluene, 6.38 mmol) 
and ethyl pivalate (0.14 mL, 0.91 mmol). The pressure apparatus was sealed and heated at 80 °C 
(oil bath, external temperature) for 12 h. [CAUTION!!! Always use a blast shield and proper 
personal protective equipment when running reactions in sealed tubes.] The reaction mixture 
was cooled to room temperature and hexane (100 mL) was added to precipitate the titanocene 
oxide byproduct. The reaction mixture was filtered through a pad of Celite and the filtrate was 
concentrated. Purification of the residue by silica gel flash column chromatography 0%  10% 





 –17.7° (c 1.00, CH2Cl2).IR (ATR) 3437, 3029, 2924, 2874, 1722, 1659, 1599, 1495, 




H NMR (500 MHz, CDCl3) δ 7.41 – 7.27 (m, 
15H), 4.91 (d, J = 11.1 Hz, 1H), 4.78 (dd, J = 14.0, 11.6 Hz, 2H), 4.65 (s, 2H), 4.58 (d, J = 11.1 
Hz, 1H), 4.43 (d, J = 2.5 Hz, 1H), 4.38 (d, J = 11.9 Hz, 1H), 4.28 (d, J = 2.5 Hz, 1H), 3.98 (d, J = 
8.1 Hz, 1H), 3.86 (d, J = 2.1 Hz, 1H), 3.64 (s, 3H), 3.45 (dd, J = 10.4, 2.1 Hz, 1H), 3.19 (dd, J = 
9.9, 8.1 Hz, 1H), 2.24 – 2.09 (m, 1H), 0.70 (d, J = 6.6 Hz, 3H).
13
C NMR (126 MHz, CDCl3) δ 
159.4, 158.2, 138.6, 138.3, 137.8, 128.7, 128.5, 128.5, 128.4, 128.3, 128.1, 128.0, 127.8, 127.8, 
94.3, 84.7 82.6, 82.3, 81.4, 76.5, 75.0, 73.1, 72.2, 55.1, 37.6, 12.9.HRMS (ESI+) calculated for 
C32H37O5 [M+H]
+
: 501.2641, found 501.2642 
  
To a cooled (0 °C) solution of enol ether 3.23 (1.70 g, 3.40 mmol) in THF (19 mL) was 
added 9-BBN (13.6 mL, 0.5 M in THF). After 6 h 3 M K3PO4 (3.4 mL, degassed) was added. 
After 20 min, a pre-prepared separate solution of Pd(dppf)Cl2CH2Cl2 (277 mg, 0.34 mmol) and 
vinyl bromide 3.24
15
 (2.32 g, 10.2 mmol) in degassed DMF (34 mL) was added dropwise. After 
12 h, saturated aqueous NaHCO3 (15 mL) and H2O (150 mL) were added. The resultant mixture 
was extracted with Et2O (3 x 50 mL). The combined organic layers were concentrated. The 
residue was dissolved in THF (85 mL) and 1M HCl (5 mL) was added. After 1 h saturated 
aqueous NaHCO3 (80 mL) was added. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated. Purification of the residue by flash column chromatography (5%  
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NMR (500 MHz, CDCl3) δ 7.41 – 7.20 (m, 20H), 5.07 (s, 1H), 4.94 – 4.83 (m, 3H), 4.78 (d, J = 
11.9 Hz, 1H), 4.65 (d, J = 11.0 Hz, 1H), 4.60 (d, J = 10.9 Hz, 1H), 4.48 (d, J = 11.9 Hz, 1H), 4.42 
(d, J = 11.9 Hz, 1H), 4.31 (d, J = 11.8 Hz, 1H), 3.99 – 3.85 (m, 2H), 3.75 (s, 1H), 3.37 – 3.23 (m, 
3H), 3.17 (t, J = 9.5 Hz, 1H), 2.69 (d, J = 15.0 Hz, 1H), 2.19 (s, 3H), 2.12 – 2.03 (m, 1H), 0.64 
(d, J = 6.5 Hz, 3H).
13
C NMR (126 MHz, CDCl3) δ 212.9, 142.9, 138.5, 138.4, 138.2, 136.7, 
128.9, 128.7, 128.6, 128.6, 128.5, 128.5, 128.2, 128.0, 127.9, 127.9, 127.9, 127.6, 113.9, 86.5, 
83.3, 83.1, 83.0, 78.2, 75.6, 75.1, 73.7, 73.0, 71.9, 38.1, 35.5, 27.9, 12.4.HRMS (ESI+) 
calculated for C41H46O6Na [M+Na]
+
: 657.3192, found 657.3195 
  
To a cooled (-78 °C) solution of methyl ketone 3.25 (5.23 g, 8.24 mmol) in Et2O (33 mL) 
was added Cy2BCl (3.6 mL, 16.48 mmol), followed by Et3N (3.42 mL, 24.72 mmol). The 
reaction mixture was warmed to 0 °C and stirred for 3 h to give an off-white slurry. The mixture 
was re-cooled to -78 °C and a solution of aldehyde 3.26 (9.01 g, 24.72 mmol) in Et2O (9 mL) 
was added. After 4 h the reaction mixture was warmed to -60 °C. After 14 h the reaction mixture 
was warmed to 0 °C. After 1 h the reaction mixture was quenched by the addition of saturated 
aqueous NH4Cl (150 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (3 x 100 mL). The combined organic layers were dried over Na2SO4, filtered, and 
concentrated down to a volume of ~100 mL. pH 7 buffered silica gel was added and the yellow 
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mixture was stirred at room temperature for 30 min, then filtered with EtOAc rinses (3 x 100 
mL) of the filter cake. The filtrate was concentrated. Purification of the residue by flash column 
chromatography (5%  20% EtOAc/Hexanes) on pH 7 buffered silica gel gave 3.27 as a pale 
yellow oil (6.89 g, 6.88 mmol, 84% yield, 11:1 dr).  
OR [α]D
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H NMR (500 MHz, C6D6) δ 7.37 (d, J = 7.5 Hz, 2H), 7.28 – 7.35 (m, 5H), 7.14 – 
7.24 (m, 8H), 7.00 – 7.13 (m, 10H), 5.29 (s, 1H), 5.05 (s, 1H), 4.85 (d, J = 11.0 Hz, 1H), 4.75 – 
4.79 (m, 1H), 4.76 (d, J = 10.6 Hz, 1H), 4.73 (d, J = 11.0 Hz, 1H), 4.49 (d, J = 11.6 Hz, 1H), 
4.44 (ABq, 2H, ΔνAB = 18.1 Hz, JAB = 11.9 Hz), 4.43 (d, J = 11.5 Hz, 1H), 4.36 (s, 2H), 4.22 (d, 
J = 11.5 Hz, 1H), 4.01 (ABq, 2H, ΔνAB = 37.3 Hz, JAB = 13.2 Hz), 4.00 – 4.03 (m, 1H), 3.84 (d, J 
= 2.5 Hz, 1H), 3.45 (dd, J = 17.2, 9.8 Hz, 1H), 3.43 (td, J = 9.4, 2.5 Hz, 1H), 3.37 (dd, J = 10.2, 
2.5 Hz, 1H), 3.34 (t, J = 6.4 Hz, 2H), 3.28 (d, J = 1.4 Hz, 1H), 3.21 (t, J = 9.3 Hz, 1H), 3.01 (dd, 
J = 10.4, 8.9 Hz, 1H), 2.75 (d, J = 14.5 Hz, 1H), 2.69 (dd, J = 17.3, 2.3 Hz, 1H), 2.35 (qq, J = 
10.1, 6.4 Hz, 1H), 2.20 (dd, J = 15.0, 9.7 Hz, 1H), 1.54 – 1.75 (m, 5H), 1.42 (p, J = 7.7 Hz, 2H), 
1.12 (d, J = 7.0 Hz, 3H), 1.01 (t, J = 7.9 Hz, 9H), 0.73 (t, J = 7.9 Hz, 3H), 0.63 (q, J = 7.9 Hz, 
6H).
13
C NMR (126 MHz, C6D6) δ 213.8, 144.8, 140.0, 140.0, 139.8, 139.7, 138.5, 129.3, 129.3, 
129.2, 129.2, 129.1, 129.1, 128.9, 128.8 128.7, 128.6, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 
128.2, 128.2, 114.0, 87.2, 84.7, 84.2, 83.4, 78.9, 78.0, 75.9, 75.4, 74.1, 73.9, 73.7, 72.8, 71.2, 
70.9, 45.9, 42.0, 38.9, 36.8, 35.7, 31.1, 23.2, 13.1, 8.1, 7.9, 6.4.HRMS (ESI+) calculated for 
C62H82O9SiNa [M+Na]
+




To a solution of alcohol 3.27 (6.89 g, 6.90 mmol) in dry MeOH (138 mL) was added 
trimethylorthoformate (13.8 mL, 124 mmol) and pyridinium p-toluene sulfonate (PPTS) (607 
mg, 2.42 mmol). After 2 h the reaction mixture was quenched by the slow addition of saturated 
aqueous NaHCO3 (175 mL) and the mixture was extracted with EtOAc (3 x 125 mL). The 
combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and 
concentrated. Purification of the residue by flash column chromatography (10  25% 
EtOAc/Hexanes with 1% Et3N) on silica gel afforded hemiketal 3.28 as a clear oil (4.47 g, 5.00 
mmol, 70% yield).  
OR [α]D
20





H NMR (500 MHz, C6D6) δ 7.40 (t, J = 7.0 Hz, 4H), 7.35 (d, J = 7.0 Hz, 2H), 
7.31 (d, J = 7.4 Hz, 2H), 7.24 (d, J = 7.0 Hz, 2H), 7.00 – 7.21 (m, 15 H), 5.39 (s, 1H), 5.17 (s, 
1H), 4.99 (d, J = 11.2 Hz, 1H), 4.92 (d, J = 11.4 Hz, 1H), 4.74 (d, J = 11.4 Hz, 1H), 4.58 (d, J = 
11.1 Hz, 1H), 4.55 (d, J = 11.6 Hz, 1H), 4.47 (d, J = 11.7 Hz, 2H), 4.37 (d, J = 12.1 Hz, 1H), 
4.36 (s, 2H), 4.22 (d, J = 12.7 Hz, 1H), 4.12 – 4.16 (m, 1H), 4.10 (d, J = 12.7 Hz, 1H), 3.90 – 
3.96 (m, 1H), 3.87 (d, J = 9.0 Hz, 1H), 3.58 (td, J = 9.0, 2.6 Hz, 1H), 3.56 (s, 1H), 3.38 (t, J = 6.1 
Hz, 2H), 3.27 (t, J = 9.1 Hz, 1H), 3.14 (dd, J = 10.2, 1.3 Hz, 1H), 3.06 (dd, J = 10.5, 8.7 Hz, 1H), 
2.95 (s, 3H), 2.83 (d, J = 14.1 Hz, 1H), 2.49 (ABX, 2H, ΔνAB = 22.8 Hz,  JAB = 15.3 Hz, JBX = 
3.3 Hz, JAX = 2.1 Hz), 2.32 (dd, J = 14.9, 9.4 Hz, 1H), 2.22 (ddt, J = 16.7, 10.4, 6.4 Hz, 1H), 
1.76 – 1.83 (m, 1H), 1.67 – 1.75 (m, 2H), 1.65 (p, J = 6.2 Hz, 2H), 1.40 – 1.50 (m, 1H), 1.23 – 
1.33 (m, 1H), 0.80 (d, J = 7.1 Hz, 3H), 0.71 (d, J = 6.5 Hz, 3H).
13
C NMR (126 MHz, C6D6) δ 
144.6, 140.2, 140.0, 140.0, 139.9, 139.7, 129.4, 129.2, 129.2, 129.1, 129.1, 128.9, 128.8, 128.7, 
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128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.2, 128.1, 115.1, 105.1, 87.7, 84.1, 
80.9, 78.8, 77.6, 75.8, 75.5, 75.3, 74.1, 73.7, 72.6, 71.3, 70.9, 68.6, 48.0, 39.4, 38.5, 37.0, 33.8, 
31.1, 30.8, 24.0, 13.8, 11.5.HRMS (ESI+) calculated for C57H70O9Na [M+Na]
+
: 921.4918, found 
921.4922. 
  
To a solution of 2,6-lutidine (4.23 mL, 36.48 mmol) in THF (24 mL) was added TBSOTf 
(2.51 mL, 10.94 mmol). The mixture was cooled to -78 °C. After 5 min the mixture was added 
dropwise to a cooled (-78 °C) solution of hemiketal 3.28 (3.28 g, 3.65 mmol) in THF (180 mL). 
After 1 h the reaction mixture was quenched by the addition of saturated aqueous NaHCO3 (150 
mL) and the mixture was diluted with EtOAc (150 mL). The layers were mixed well and then 
separated and the aqueous layer was extracted with EtOAc (3 x 150 mL). The combined organic 
layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated. 
Purification of the residue by flash column chromatography (10% EtOAc/Hexanes) on pH 7 
buffered silica gel afforded TBS ether as a pale yellow oil (3.15 g, 3.19 mmol, 87% yield).  
OR [α]D
21
 +18.0° (c 2.00, CH2Cl2).IR (ATR) 3029, 2931, 2853, 1494, 1454, 1360, 1250, 1209, 




H NMR (500 MHz, C6D6) δ 7.47 (d, J = 7.1 Hz, 2H), 7.35 (t, J = 7.0 Hz, 
4H), 7.31 (d, J = 7.0 Hz, 2H), 7.27 (d, J = 7.5 Hz, 2H), 7.02 – 7.22 (m, 15 H), 5.38 (s, 1H), 5.16 
(s, 1H), 5.07 (d, J = 11.3 Hz, 1H), 4.88 (d, J = 11.4 Hz, 1H), 4.80 (d, J = 11.5 Hz, 1H), 4.67 (d, J 
= 11.2 Hz, 1H), 4.53 (d, J = 11.2 Hz, 2H), 4.44 (ABq, 2H, ΔνAB = 24.5 Hz, JAB = 12.5 Hz), 4.36 
(s, 2H), 4.31 – 4.36 (m, 1H), 4.19 (ABq, 2H, ΔνAB = 50.5 Hz, JAB = 13.2 Hz), 3.86 (q, J = 3.1 Hz, 
1H), 3.65 (s, 1H), 3.55 (td, J = 7.7, 2.6 Hz, 1H), 3.38 (t, J = 5.9 Hz, 2H), 3.33 (t, J = 9.1 Hz, 1H), 
3.28 (d, J = 10.4 Hz, 1H), 3.20 (s, 3H), 3.05 (dd, J = 10.4, 8.7 Hz, 1H), 2.83 (d, J = 14.4 Hz, 1H), 
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2.51 (dd, J = 15.5, 3.9 Hz, 1H), 2.42 (dd, J = 14.7, 7.7 Hz, 1H), 2.14 (tq, J = 10.2, 6.4 Hz, 1H), 
1.97 (dd, J = 15.0, 1.6 Hz, 1H), 1.64 – 1.79 (m, 4H), 1.49 – 1.60 (m, 2H), 1.33 – 1.44 (m, 1H), 
1.09 (s, 9H), 0.89 (d, J = 7.1 Hz, 3H), 0.76 (d, J = 6.5 Hz, 3H), 0.20 (s, 3H), 0.10 (s, 3H).
13
C 
NMR (126 MHz, C6D6) δ 144.7, 140.2, 140.2, 140.1, 140.1, 129.2, 129.1, 129.1, 129.1, 128.9, 
128.8, 128.7, 128.6, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 128.1, 128.1, 114.7, 103.5, 
87.9, 83.6, 80.4, 78.9, 77.6, 75.8, 75.7, 75.1, 74.6, 73.6, 72.8, 71.7, 71.0, 67.9, 47.9, 39.7, 39.2, 
36.9, 33.8, 32.1, 31.1, 26.8, 24.0, 19.0, 13.9, 11.1, -3.6, -3.9.HRMS (ESI+) calculated for 
C63H84O9SiNa [M+Na]
+
: 1035.5782, found 1035.5789. 
 
Lithium di-tert-butylbiphenylide (LiDBB) was prepared as follows: a cooled (0 °C) 
solution of Li granules (415 mg, 29.61 mmol) and 4,4-di-tert-butyl-biphenyl (7.28 g, 27.33 
mmol) in THF (57 mL) was sonicated for 3.5 h, and then used as is. 
To a cooled (-78 °C) solution of TBS ether (960 mg, 0.949 mmol) in THF (57 mL) was 
added the LiDBB solution slowly by syringe. After 2 h the reaction mixture was warmed to -30 
°C. After 16 h the reaction mixture was quenched by the addition of saturated aqueous NH4Cl 
(150 mL). The mixture was diluted with ethyl acetate (150 ml) and warmed to room temperature. 
The layers were separated and the aqueous layer was extracted with ethyl acetate (75 ml) and 
methylene chloride (2 x 75 mL). The combined organic layers were dried over Na2SO4, filtered, 
and concentrated. Purification of the residue by flash column chromatography (1%  10% 
MeOH/CH2Cl2) on silica gel afforded pentaol 3.29 as an amorphous white solid (460 mg, 0.819 










H NMR (500 MHz, MeOH-d4) δ 5.15 (d, J = 1.9 Hz, 1H), 5.02 (s, 1H), 4.25 – 4.17 (m, 
1H), 4.08 (s, 2H), 3.86 (d, J = 2.8 Hz, 1H), 3.75 (s, 1H), 3.61 (t, J = 6.2 Hz, 2H), 3.41 – 3.34 (m, 
4H), 3.32 (d, J = 10.3 Hz, 1H), 3.22 (s, 3H), 3.12 (d, J = 17.1 Hz, 2H), 2.70 (d, J = 14.5 Hz, 1H), 
2.29 (dd, J = 14.6, 8.4 Hz, 1H), 2.10 (dd, J = 15.4, 3.9 Hz, 1H), 1.86 – 1.79 (m, 1H), 1.72 – 1.41 
(m, 5H), 1.07 (d, J = 6.5 Hz, 3H), 0.96 (s, 9H), 0.93 (d, J = 7.1 Hz, 3H), 0.13 (s, 3H), 0.09 (s, 
3H).
13
C NMR (126 MHz, MeOH-d4) δ 147.3, 113.5, 102.3, 80.0, 79.7, 79.6, 76.0, 71.9, 71.2, 
68.0, 66.7, 62.9, 48.0, 47.8, 40.1, 39.5, 36.6, 33.8, 33.6, 31.4, 26.4, 23.6, 18.9, 13.5, 10.4, 9.2, -
4.2, -4.7.HRMS (ESI+) calculated for C28H54O9SiNa [M+Na]
+
: 585.3435, found 585.3443. 
 
To a cooled (0 °C) solution of pentaol 3.29 (370 mg, 0.658 mmol) in DMF (36 mL) was 
added imidazole (1.57 g, 23.04 mmol) and TESCl (2.76 ml, 16.45 mmol). The reaction mixture 
was heated at 35 °C (oil bath, external temperature). After 14 h, the reaction mixture was diluted 
with Et2O (100 mL), cooled to 0 °C and then poured into a stirred solution of saturated aqueous 
NaHCO3 (150 mL). The layers were separated and the aqueous layer was extracted with Et2O (3 
x 50 mL). The combined organic layers were washed with water (2 x 50 mL) and brine (50 mL). 
The combined aqueous layers were extracted with Et2O (75 mL). The combined organic layers 
were dried over Na2SO4, filtered, and concentrated, and the residue was left on a high vacuum 
line overnight. To a solution of this material in THF (27 mL) and MeOH (82 ml) was added KF 
(2.86 g, 49.35 mmol). After 8 h the reaction mixture was diluted with CH2Cl2 (200 mL) and 
quenched by the addition of saturated aqueous NaHCO3 (300 mL). The layers were separated 
and the aqueous layer was extracted with CH2Cl2 (3 x 75 mL). The combined organic layers 
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were dried over Na2SO4, filtered, and concentrated. Purification of the residue by flash column 
chromatography (5% EtOAc/Hexanes with 1% Et3N) on silica gel afforded diol 3.30 as a 
colorless oil (440 mg, 0.487 mmol, 74% yield over 2 steps from 3.29).  
OR [α]D
22





H NMR (500 MHz, C6D6) δ 5.11 (d, J = 1.8 Hz, 1H), 5.02 (s, 1H), 4.32 – 4.21 (m, 
3H), 3.97 (d, J = 2.9 Hz, 1H), 3.88 (s, 1H), 3.64 (t, J = 6.5 Hz, 1H), 3.60 – 3.49 (m, 3H), 3.44 – 
3.38 (m, 3H), 3.13 (s, 3H), 2.74 – 2.65 (m, 2H), 2.34 (dd, J = 15.1, 3.7 Hz, 1H), 2.02 – 1.94 (m, 
1H), 1.74 – 1.54 (m, 3H), 1.41 – 1.28 (m, 1H), 1.18 (t, J = 8.0 Hz, 9H), 1.13 – 1.03 (m, 27H), 
1.00 (d, J = 7.2 Hz, 3H), 0.92 – 0.66 (m, 18H), 0.22 (s, 3H), 0.14 (s, 3H).
13
C NMR (126 MHz, 
C6D6) δ 148.7, 128.6, 111.9, 101.5, 82.1, 80.4, 77.7, 76.9, 71.6, 71.4, 67.7, 67.1, 62.6, 47.0, 40.3, 
38.9, 37.6, 33.4, 33.1, 30.2, 26.2, 23.0, 18.4, 16.2, 10.8, 7.6, 7.5, 7.4, 6.2, 6.1, -4.1, -4.6.HRMS 
(ESI+) calculated for C46H96O9Si4Na [M+Na]
+
: 927.6029, found 927.6010. 
 
To a solution of diol 3.30 (392 mg, 0.432 mmol) in CH2Cl2 (9 ml) was added Et3N (0.60 
ml, 4.32 mmol), PPh3 (566 mg, 2.16 mmol) and CCl4 (0.84 ml, 8.64 mmol). After 14 h the 
reaction mixture was quenched by the addition of saturated aqueous NaHCO3 (10 mL). The 
layers were separated and the aqueous layer was extracted with Et2O (2 x 7 ml). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated. Purification of the residue by 
flash column chromatography (0  2% EtOAc/Hexanes with 1% Et3N) on silica gel afforded 
dichloride 3.3 as a colorless oil (357 mg, 0.379 mmol, 87% yield).  
OR [α]D
24





H NMR (500 MHz, C6D6) δ 5.29 (d, J = 1.5 Hz, 1H), 5.10 (s, 1H), 4.39 (d, J = 11.9 Hz, 
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1H), 4.23 – 4.17 (m, 2H), 3.98 – 3.94 (m, 1H), 3.86 (s, 1H), 3.57 – 3.48 (m, 3H), 3.46 (d, J = 
10.6 Hz, 1H), 3.18 (td, J = 6.5, 2.1 Hz, 2H), 3.12 (s, 3H), 2.79 (dd, J = 13.8, 2.8 Hz, 1H), 2.45 
(dd, J = 13.7, 8.7 Hz, 1H), 2.25 (dd, J = 15.2, 3.7 Hz, 1H), 1.96 – 1.91 (m, 1H), 1.68 – 1.50 (m, 
5H), 1.14 (t, J = 8.0 Hz, 9H), 1.11 – 1.04 (m, 30H), 0.97 (d, J = 7.2 Hz, 3H), 0.84 – 0.70 (m, 
18H), 0.21 (s, 3H), 0.15 (s, 3H).
13
C NMR (126 MHz, C6D6) δ 144.1, 128.6, 115.6, 101.7, 81.0, 
80.6, 77.7, 76.9, 71.6, 71.3, 67.3, 49.4, 46.9, 44.9, 40.2, 39.0, 37.5, 33.1, 32.5, 30.3, 26.2, 24.0, 
18.4, 16.1, 10.7, 7.5, 7.5, 7.4, 6.2, 6.2, 6.1, -4.1, -4.6.HRMS (ESI+) calculated for 
C46H94Cl2O7Si4Na [M+Na]
+
: 963.5351, found 963.5353. 
 
In an argon-atmosphere glovebox, copper (I) bromide (2.5 mg, 0.017 mmol) was placed 
in a vial with a stir bar. The vial was capped with a septum and transferred out of the glove box. 
The vial was charged with CH2Cl2 (0.3 mL) and Et3N (13.5 μL, 0.097 mmol, 1.4 equiv) and then 
cooled to 0 °C. To a cooled (0 °C) solution of dichloride 3.3 (65 mg, 0.069 mmol) in CH2Cl2 (0.3 
mL) in a separate vial under an Ar atmosphere was added 2,6-di-t-butyl pyridine (89.5 μL, 0.414 
mmol) and Cl3SiH (8.4 μL, 0.083 mmol). This solution was mixed thoroughly by gentle swirling 
of the vial, and then was added dropwise by syringe to the CuBr/Et3N solution with a 0.1 mL 
CH2Cl2 rinse. After 5 h an additional portion of Cl3SiH (1.4 μL, 0.014 mmol) was added 
dropwise to the reaction vial. After 4 h a pre-prepared solution of (R,R)-3.4 (17.1 mg, 0.069 
mmol), n-Bu4NBr (4.5 mg, 0.014 mmol) and DBU (31 μL, 0.207 mmol) in CH2Cl2 (0.2 mL) was 
then added dropwise by syringe to the reaction mixture with a 0.1 mL CH2Cl2 rinse. After 2 h the 
reaction mixture was then cooled to -78 ºC and a solution of freshly prepared chlorodiene 
aldehyde 3.2
86
 (48.3 mg, 0.414 mmol) in CH2Cl2 (0.25 mL) was added dropwise by syringe with 
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a 0.1 mL CH2Cl2 rinse. The reaction mixture was then warmed to -10 °C and maintained at that 
temperature for 12 h. The reaction mixture was warmed to 0 °C and n-Bu4NF3H2O (83 μL, 1M 
in THF) was added. After 2 h, the mixture was then filtered through a plug of pH 7 buffered 
silica gel with EtOAc washes. The filtrate was concentrated. Purification of the residue by flash 
column chromatography on pH 7 buffered silica (0%  5% EtOAc/Hexanes) gave allyl chloride 
3.3 as a clear oil (16 mg, 0.017 mmol) and alcohol 3.31 as a clear oil (50 mg, 0.049 mmol, 71% 
yield, 94% yield based on recovered 3.3).  
OR [α]D
22
 +33.9° (c 1.00, CH2Cl2). IR (ATR) 3469, 2953, 2876, 1643, 1590, 1459, 1414, 1378, 




H NMR (500 MHz, C6D6) δ 6.64 (d, J = 14.8 Hz, 1H), 6.42 
(dd, J = 14.8, 4.2 Hz, 1H), 5.18 (s, 1H), 5.11 (s, 1H), 5.07 (s, 2H), 4.52 – 4.45 (m, 1H), 4.23 – 
4.17 (m, 1H), 3.93 (d, J = 3.1 Hz, 1H), 3.86 (s, 1H), 3.73 – 3.68 (m, 1H), 3.62 – 3.56 (m, 3H), 
3.18 (t, J = 6.5 Hz, 2H), 3.13 (s, 3H), 2.98 (d, J = 3.6 Hz, 1H), 2.62 (d, J = 6.7 Hz, 2H), 2.55 (dd, 
J = 13.5, 3.1 Hz, 1H), 2.33 – 2.24 (m, 2H), 2.07 – 1.98 (m, 1H), 1.70 (d, J = 14.8 Hz, 2H), 1.64 – 
1.45 (m, 5H), 1.31 – 1.21 (m, 7H), 1.17 (d, J = 7.8 Hz, 9H), 1.13 – 1.04 (m, 30H), 0.95 (d, J = 
7.4 Hz, 3H), 0.91 – 0.68 (m, 26H), 0.24 (s, 3H), 0.15 (s, 3H). 
13
C NMR (126 MHz, C6D6) δ 
145.7, 138.9, 138.1, 125.8, 114.4, 113.9, 101.2, 82.3, 79.4, 77.0, 76.2, 71.2, 70.9, 70.4, 67.0, 
46.7, 46.5, 44.4, 39.7, 38.6, 34.6, 32.7, 32.0, 31.6, 30.1, 29.0, 25.6, 25.3, 23.6, 22.7, 18.0, 16.3, 
13.9, 11.3, 10.3, 7.2, 7.0, 6.9, 5.8, 5.6, 5.5, -4.1, -4.6. HRMS (ESI+) calculated for 
C51H100NCl2O8Si4NH4 [M+NH4]
+
: 1040.6216, found 1040.6221. 
 
To a cooled (-78 °C) solution of alcohol 3.31 (238 mg, 0.23 mmol) in THF (23 mL) was 
added a pre-prepared solution of 2,6-lutidine (268 μL, 2.30 mmol) and TBSOTf (121 μL, 0.69 
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mmol) in THF (4.6 mL) slowly by syringe with a 0.5 mL THF rinse. The reaction mixture was 
warmed to 0 °C. After 3 h the reaction mixture was quenched by the addition of saturated 
aqueous NaHCO3 (50 mL) and extracted with Et2O (3 x 50 mL). The combined extracts were 
washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. Purification by flash 
column chromatography (0%  2% EtOAc/Hexanes) on pH 7 buffered silica gel gave TBS ether 
3.32 as a colorless oil (237 mg, 90% yield).  
OR [α]D
25
 +31.2° (c 1.00, CH2Cl2).IR (ATR) 2953, 2876, 1646, 1590, 1461, 1415, 1378, 1250, 




H NMR (500 MHz, C6D6) δ 6.56 – 6.41 (m, 2H), 5.23 – 5.10 
(m, 3H), 5.07 (s, 1H), 4.52 (q, J = 6.1 Hz, 1H), 4.23 (d, J = 7.9 Hz, 1H), 3.98 – 3.92 (m, 1H), 
3.89 (s, 1H), 3.63 – 3.44 (m, 4H), 3.17 (d, J = 12.7 Hz, 5H), 2.79 – 2.29 (m, 5H), 2.02 – 1.92 (m, 
1H), 1.74 (t, J = 14.9 Hz, 1H), 1.67 – 1.52 (m, 4H), 1.22 – 1.01 (m, 56H), 0.98 (t, J = 7.2 Hz, 
3H), 0.87 – 0.74 (m, 18H), 0.31 – 0.09 (m, 12H).
13
C NMR (126 MHz, C6D6) δ 144.0, 138.5, 
128.2, 126.2, 115.5, 114.7, 101.3, 81.4, 80.7, 77.6, 77.3, 71.8, 71.4, 71.2, 66.9, 46.6, 46.1, 44.5, 
40.1, 38.9, 32.3, 32.1, 30.1, 26.1, 25.8, 23.6, 18.2, 18.0, 15.7, 10.3, 7.5, 7.4, 7.3, 6.3, 6.2, 6.1, 5.4, 





To a solution of chloride 3.32 (235 mg, 0.206 mmol) in MeCN (11.1 mL) and MeOH (1.2 
mL) was added i-Pr2NEt (72 μL, 0.413 mmol), NaI (458 mg, 3.08 mmol), and PPh3 (2.16 g, 8.23 
mmol). The resulting mixture was heated at reflux for 12 h. The reaction mixture was cooled to 
room temperature and an additional portion of PPh3 (1.08 g, 4.12 mmol) was added. The reaction 
mixture was heated at reflux for 8 h. The reaction mixture was cooled to room temperature and 
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concentrated. The residue was suspended in CH2Cl2 and filtered through a cotton plug, washing 
with CH2Cl2. The filtrate was concentrated. Purification of the residue by flash column 
chromatography (0%  5% MeOH/CH2Cl2) on pH 7 buffered silica gel afforded phosphonium 
salt 3.1 as a yellow foam (274 mg, 0.184 mmol, 92% yield). Spectroscopic data was consistent 




H NMR (500 MHz, C6D6) δ 7.80 – 7.64 (m, 8H), 7.08 – 6.95 (m, 14H), 6.55 – 6.42 (m, 2H), 5.23 – 5.11 
(m, 3H), 5.06 (s, 1H), 4.53 (q, J = 6.0 Hz, 1H), 4.45 – 4.37 (m, 1H), 4.28 (s, 2H), 4.22 (dd, J = 13.8, 7.2 
Hz, 1H), 4.06 (s, 1H), 3.96 (d, J = 3.1 Hz, 1H), 3.64 – 3.48 (m, 4H), 3.35 (s, 2H), 2.79 – 2.66 (m, 2H), 
2.58 (dd, J = 13.2, 7.6 Hz, 1H), 2.43 – 2.31 (m, 2H), 2.01 (dt, J = 10.7, 6.9 Hz, 1H), 1.72 (dd, J = 31.3, 
12.4 Hz, 2H), 1.61 (d, J = 7.0 Hz, 1H), 1.48 (q, J = 8.2 Hz, 2H), 1.35 (s, 1H), 1.29 (s, 2H), 1.24 – 1.14 (m, 
9H), 1.14 – 1.06 (m, 22H), 1.03 (d, J = 2.8 Hz, 11H), 0.98 – 0.85 (m, 7H), 0.81 (qd, J = 7.9, 4.2 Hz, 12H), 










3.8. HPLC data 
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HPLC analysis was carried out on an Agilent 1200 Series using a Chiralpak OD-H (250 x 4.5 
mm ID) column. All racemic compounds were prepared by using the general procedure A or B 
with a 1:1 mixture of (R,R)-3.4 and (S,S)-3.4 ligand. The deviation from exactly 50:50 in the 
racemic traces is due to the error in this procedure.  
(R)-5-methyl-1-phenylhex-5-en-3-ol: 





Daicel Chiracel OD-H, 98:2 Hexanes:IPA, 1 mL/min, 254 nm
 
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 12/19/2015 12:17:56 PM       
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/19/2015 12:02:54 PM by Zack S
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/19/2015 1:10:11 PM by Zack S
                  (modified after loading)
Sample Info     : KSW4005Rac, Methallyl Bromide
                  1mL/min, 95:05 Hex:IPA, OD-H
                  254nm
                  
 


















































































HPLC 12/19/2015 1:12:34 PM Zack S Page 1 of 3
=====================================================================
                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   7.528 BB    0.1625 3588.80029  341.89218  48.3069
   2  11.254 BB    0.3037 3840.35937  196.77507  51.6931
 




Signal 2: A 1 B, Sig=254, 6 Ref=360,100
 
Peak RetTime Type  Width    Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.177 BB    0.1425   11.46958    1.14856   0.1575
   2   3.762 VB    0.0799   27.94481    5.26324   0.3838
   3   4.185 BV    0.0786   50.39346    9.69606   0.6921
   4   4.292 VB    0.0842   53.74519    9.46512   0.7382
   5   7.528 BB    0.1625 3442.48315  327.96960  47.2809
   6  10.378 BB    0.1758   14.09315    1.24754   0.1936
  7  11.254 BB    0.3036 3680.78760  188.71574  50.5539
 




Signal 3: DAD1 D, Sig=230,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.174 BV    0.1518   77.06551    7.26309   1.8463
   2   3.389 VV    0.1070   11.95285    1.68096   0.2864
   3   3.513 VV    0.1155   17.37770    2.08013   0.4163
   4   3.765 VB    0.0866   82.00634   13.95339   1.9647
   5   4.186 BV    0.0787   92.48394   17.76434   2.2157
   6   4.291 VB    0.0847  100.68365   17.61543   2.4122
   7   4.756 BB    0.0886    7.27088    1.23650   0.1742
   8   5.755 BB    0.0932   96.30459   15.78660   2.3073
Data File C:\CHEM32\1\DATA\KSW\KSW4005RAC00001.D
Sample Name: KSW4005Rac
HPLC 12/19/2015 1:12:34 PM Zack S Page 2 of 3
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 12/19/2015 12:52:18 PM       
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/19/2015 12:02:54 PM by Zack S
                (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/19/2015 1:10:11 PM by Zack S
                  (modified after loading)
Sample Info     : KSW4005Asym, Methallyl Bromide
                  1mL/min, 95:05 Hex:IPA, OD-H
                  254nm
                  
 























































































HPLC 12/19/2015 1:10:15 PM Zack S Page 1 of 3
=====================================================================
                         Area Percent Report                         
=============== =====================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   7.514 BB    0.1460   81.43776    8.79914   0.9897
   2  10.844 BB    0.3425 8147.20361  373.51385  99.0103
 




Signal 2: DAD1 B, Sig=254,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.146 BB    0.0915    9.12550    1.40990   0.1110
   2   3.758 BB    0.0814   34.44376    6.53964   0.4190
   3   4.184 BV    0.0822   64.06895   12.01354   0.7793
   4   4.289 VB    0.0844   67.43443   11.84580   0.8203
   5   5.407 BB    0.4114  115.18448    3.69756   1.4011
   6   7.514 BB    0.1461   78.19518    8.43670   0.9512
   7   8.462 BB    0.1706   12.13313    1.03615   0.1476
   8  10.202 BB    0.1680   22.20979    2.05712   0.2702
   9  10.844 BB    0.3425 7818.07373  358.36487  95.1003
 




Signal 3: DAD1 D, Sig=230,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.139 BB    0.2393  172.16046    8.99327   3.7885
   2   3.762 BB    0.1039  114.30759   16.29052   2.5154
   3   4.185 BV    0.0835  122.27593   22.45164   2.6908
   4   4.287 VB    0.0879  132.32736   22.72489   2.9119
   5   5.379 BB    0.4430   83.84813    2.29079   1.8451
   6   7.108 BV    0.1847   22.24497    1.89808   0.4895
Data File C:\CHEM32\1\DATA\KSW\KSW4005ASYM0001.D
Sample Name: KSW4005Asym
HPLC 12/19/2015 1:10:15 PM Zack S Page 2 of 3
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                           Location : Vial 61
Injection Date  : 8/11/2015 2:17:34 PM         
                              Inj Volume : 10.0 µl
Acq. Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 8/11/2015 2:10:40 PM by KSW
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/19/2015 1:20:58 PM by Zack S
                  (modified after loading)
Sample Info     : KSW4015Rac
                  96:4 Hex:iPrOH
                  1ml/min, OD-H
                 254, 23  nm
                  
 


















































                         Area Percent Report                        
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)
Use Multiplier & Dilution Factor with ISTDs
 
Data File C:\CHEM32\1\DATA\KSW\KSW4015RAC00 2.D
Sample Name: KSW4015Rac
HPLC 12/19/2015 1:21:16 PM Zack S Page 1 of 2
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
  1   7.5 7 BB    0.1997 1571.45374  122.44463  50.6843
   2  11.338 BB    0.3225 1529.02234   74.18581  49.3157
 




Signal 2: DAD1 D, Sig=230,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
# [min] [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
  1   3.329 BV    0.1822  101.47222    7.12253   3.9266
   2  3.513 VV 0.2053 144.51823    9.84029   5.5924
   3   3.820 VB 0.2313 118.82253    6.75238   4.5980
   4   4.395 BB 0.2259 97.12160    5.84260   3.7583
   5  4.921 BV 0.1288 37.95224    4.30765   1.4686
   6   5.103 VB   0.1471  109.74786  10.75063   4.2469
  7   7.560 BB    0.2193  937.36707   66.16142  36.2730
   8   8.330 BV    0.1893   29.11805    2.40395   1.1268
   9   8.739 VV    0.2068   22.47740    1.67282   0.8698
  10   9.042 VB    0.2490   44.76014    2.57250   1.7321
  11  11.340 BB    0.3430  940.84314   43.04659  36.4075




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4015RAC00002.D
Sample Name: KSW4015Rac















Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 8/13/2015 1:57:44 PM         
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 8/13/2015 1:21:33 PM by Chirag
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/19/2015 1:20:58 PM by Zack S
                  (modified after loading)
Sample Info     : KSW4016
                  98:02 Hex:iPrOH
                  1ml/min, OD-H
                  254, 230 nm
                  
 


























                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 12/19/2015 1:22:23 PM Zack S Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   7.801 BB    0.1960   69.67228    5.41860   3.0321
   2  11.967 MM    0.3781 2228.14941   98.21699  96.9679
 




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4016000002.D
Sample Name: KSW4016
HPLC 12/19/2015 1:22:23 PM Zack S Page 2 of 2
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 11/13/2015 3:50:00 PM        
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 11/13/2015 3:33:27 PM by KSW
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 11/13/2015 4:47:41 PM by Alex R
                  (modified after loading)
Sample Info     : KSW4057Rac
                  1 mL/min, 96:4 Hex:IPA, OD-H
                  254 nm
                  
 





























































HPLC 11/13/2015 4:47:46 PM Alex R Page 1 of 3
=====================================================================
                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :      1.00000  [ng/ul]   (not used in calc.)
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width    Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.562 BB    0.3689 3738.72192  149.96376  49.5733
   2  20.372 BB    0.7650 3803.07788   71.67668  50.4267
 




Signal 2: DAD1 D, Sig=230,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   2.961 BV    0.1304   20.43231    2.24121   0.3518
   2   3.160 VV    0.1300   63.74102    6.63744   1.0973
   3   3.379 VV    0.0981   28.70427    4.18140   0.4942
   4   3.501 VV    0.0942   36.90146    5.50335   0.6353
   5   3.687 VV    0.1476   64.46641    6.50585   1.1098
   6   4.091 VB    0.3377   72.40378    2.64180   1.2465
   7   4.998 BB    0.1592   12.32046    1.16674   0.2121
   8   6.828 BB    0.1529   10.65599    1.01157   0.1834
   9   8.424 BB    0.1684   80.09472    7.27779   1.3789
  10   9.294 BV    0.2640   21.63814    1.30136   0.3725
  11   9.743 VV    0.2259   52.44758    3.60170   0.9029
  12  10.260 VB    0.2465   45.81428    2.89687   0.7887
  13  11.563 BB    0.4077 2522.03198   93.78432  43.4181
  14  20.371 BB    0.7942 2777.05640   49.83135  47.8085
 








HPLC 11/13/2015 4:47:46 PM Alex R Page 2 of 3
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 11/13/2015 4:17:57 PM        
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 11/13/2015 3:33:27 PM by KSW
                 (modified after loading)
An lysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed : 11/13/2015 4:46:23 PM by Alex R
                  (modified after loading)
Sample Info   : KSW4057ASYM
         1 mL/min, 90:10 Hex:IPA, OD-H
                 254 nm
       

















































HPLC 11/13/2015 4:46:32 PM Alex R Page 1 of 3
=====================================================================
                         Area Percent Report                        
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :      1.00000  [ng/ul]   (not used in calc.)
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width    Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
  1  11.898 BB    0.3180   90.38309    4.43056   1.4784
   2  19.935 BB    0.8476 6023.27783  102.80289  98.5216
 
Totals :                  6113.66093  107.23345
 
 
Signal 2: DAD1 D, Sig=230,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
 #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
  1   2.958 BV    0.1290   13.51702    1.53164   0.2796
   2  .156 VV   0.097    36.18425    5.34341   0.7483
  3   3.298 VV    0.1111   25.45396    3.12384   0.5264
   4   3.557 VV    0.1266   57.21852    6.14773   1.1834
   5   3.692 VV    0.1227   57.22418    7.52496   1.1835
   6   4.088 VV    0.3471  106.25185    3.78986   2.1975
   7   4.663 VV    0.2427   52.19841    3.03485   1.0795
   8   4.968 VB    0.2014   30.18796    2.18146   0.6243
  9   8.408 BB    0.1591  77.17854    7.43719   1.5962
  10   9.723 BB    0.2267   75.61010    5.23033   1.5637
  11  11.899 BB    0.3212   78.68782    3.83827   1.6274
  12  19.935 BB    0.8952 4225.52051   67.98248  87.3902
 




Signal 3: DAD1 E, Sig=280,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.559 VV    0.1134   13.69974    1.67543  46.6479


















Daicel Chiracel OD-H, 99:1 Hexanes:IPA, 0.5 mL/min
 
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 11/20/2015 2:49:26 PM        
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 11/20/2015 2:41:11 PM by Fiene
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 11/20/2015 4:58:14 PM by LAC
                  (modified after loading)
Sample Info     : KSW4029Rac, trans-crotyl
                  1 mL/min, 96:4 Hex:IPA, OD-H
                  254nm
                  
 












































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 11/20/2015 4:58:24 PM LAC Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   7.982 BB    0.1783 2830.35767  245.80980  46.6920
   2   8.653 BB    0.1878  195.18132   16.05712   3.2199
   3  13.166 MM    0.3610 2855.96460  131.83694  47.1144
   4  14.715 BB    0.3405  180.25980    8.26410   2.9737
 




Signal 2: DAD1 B, Sig=254,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.186 BB    0.1786   15.33523    1.17279   0.2490
   2   3.949 BB    0.0927   77.97234   12.87159   1.2660
   3   4.413 BV    0.0869   45.50781    7.93663   0.7389
   4   4.509 VB    0.0973   52.61254    7.94491   0.8542
   5   7.982 BB    0.1783 2717.09595  235.95398  44.1158
   6   8.653 BB    0.1878  187.98909   15.46383   3.0523
   7  10.437 BV    0.1864   13.13071    1.09136   0.2132
   8  10.769 VB    0.1994   67.30133    5.18521   1.0927
   9  12.667 BV    0.2370   69.60372    4.58731   1.1301
 0  13. 66 VB    0.3366 2739.08618  126.51620  44.4728
  11  14.715 BB    0.3426  173.38023    7.94363   2.8151
 




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4029RAC00002.D
Sample Name: KSW4029Rac
HPLC 11/20/2015 4:58:24 PM LAC Page 2 of 2
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                           Location : Vial 1
Injection Date  : 9/18/2015 2:54:25 PM         
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 9/18/2015 2:23:24 PM by Alex R
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 11/20/2015 4:58:14 PM by LAC
                  (modified after loading)
Sample Info     : KSW4029
                  1ml/min, 96:4 Hex: IPA, OD-H
                  254 nm
                  
 



























































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 11/20/2015 4:59:01 PM LAC Page 1 of 2
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
Peak RetTime Type  Width     Area      Height  Area  
#  [min]        [min]   [mAU*s]     [mAU]     %
----|-------|----|-------|----------|----------|--------|
1   8.142 MM    0.2616  112.32067    7.15482  1.9497
 2  13.097 MM   0.4365 5648.69971  215.70390  98.0503




Signal 2: DAD1 E, Sig=280,16 Ref=360,100
 
Peak RetTime Type  Width     Area     Height Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   2.959 BV    0.0782    6.24236    1.17174   1.2948
   2   3.249 VV    0.1112   12.51812    1.56623   2.5966
   3   3.377 VV    0.1063   22.14255    3.06279   4.5930
   4   3.585 VB    0.1161   28.22318    3.42660   5.8543
   5   3.930 BV    0.0953   10.03415    1.55484   2.0814
   6   4.044 VB    0.1009    7.72810    1.08742   1.6030
   7   7.494 BB    0.1796   14.57368    1.29190   3.0230
   8  11.252 BB    0.1923   96.88204    7.83452  20.0960
   9  13.096 BB    0.3915  283.75266   10.90780  58.8580
 




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4029000001.D
Sample Name: KSW4029





















Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 8/21/2015 2:21:47 PM         
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 8/21/2015 2:13:51 PM by KSW
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 8/21/2015 3:32:22 PM by Chirag
                  (modified after loading)
Sample Info     : KSW4017Rac
                  90:10 Hex:iPrOH
                  1ml/min, OD-H
                  254, 230 nm
                  
 

































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 8/21/2015 3:32:56 PM Chirag Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.642 MM    0.1803 1360.24426  125.73959  49.5923
   2  15.113 MM    0.5558 1382.60742   41.46040  50.4077
 




Signal 2: DAD1 D, Sig=230,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   2.970 BV    0.1605   69.58830    5.94691   2.6541
   2   3.165 VV    0.1699  141.42337   10.86102   5.3938
   3   3.396 VV    0.0643   33.29639    7.42676   1.2699
   4   3.509 VV    0.0976   84.66295   12.40603   3.2290
   5   3.703 VV    0.1294  336.80960   34.65922  12.8457
  6   4.058 VV    0.1737   80.96604    6.14617   3.0880
   7   4.294 VB    0.1391   35.94507    3.40606   1.3709
   8   4.640 BV    0.1364   19.16376    1.92123   0.7309
   9   4.815 VV    0.1531   17.43072    1.65189   0.6648
  10   6.642 BB    0.1797  796.53247   68.47016  30.3793
 11   8.320 BB   0.1498   78.72284    8.06724   3.0024
  12   9.335 BV    0.2582   29.81107    1.75460   1.1370
  13   9.705 VB    0.2835   30.88133    1.64135   1.1778
  14  15.113 BB    0.5267  866.72595   25.48842  33.0564
 




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4017RAC00002.D
Sample Name: KSW4017Rac
HPLC 8/21/2015 3:32:56 PM Chirag Page 2 of 2
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 8/21/2015 2:51:57 PM         
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 8/21/2015 2:13:51 PM by KSW
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 8/21/2015 3:32:57 PM by Chirag
                  (modified after loading)
Sample Info     : KSW4018
                  90:10 Hex:iPrOH
                  1ml/min, OD-H
                 254, 230 nm
       



























































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 8/21/2015 3:33:48 PM Chirag Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.678 MM    0.2400   33.02640    2.29358   0.9482
   2  14.671 BB    0.5696 3450.02539   87.20641  99.0518
 




Signal 2: DAD1 D, Sig=230,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   2.964 BV    0.1582   50.04641    4.35197   1.7452
   2   3.162 VV    0.1132   58.62201    7.18511   2.0443
   3   3.303 VV    0.0716   20.90621    4.23472   0.7290
   4   3.397 VV    0.0733   32.48364    6.39529   1.1328
   5   3.511 VV    0.0858   60.71074   10.44572   2.1171
   6   3.713 VV    0.1088  262.95810   33.79087   9.1698
   7   4.058 VV    0.1478   44.19958    4.03590   1.5413
   8  4.299 VV    0.0883    9.97593    1.65672  0.3479
   9   4.647 VV    0.1739   17.04525    1.27530   0.5944
  10   4.802 VV    0.1321   11.31460    1.26749   0.3946
  11   6.456 BV    0.1365   13.83264    1.54440   0.4824
  12   6.676 VB    0.2062   30.77567    2.13467   1.0732
  13   8.290 BB    0.1498   82.12211    8.41698   2.8638
  14   9.661 BB    0.4032   83.42399    2.85252   2.9092
  15  14.671 BB    0.5991 2089.22217   49.63668  72.8551
 




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4018000003.D
Sample Name: KSW4018

















Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 7/22/2015 3:19:19 PM         
                                                Inj Volume : 5.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 7/22/2015 2:29:24 PM by Alex R
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/19/2015 1:05:12 PM by Zack S
                  (modified after loading)
Sample Info     : KSW4007Rac sample-Cinnamyl bromide
                  95:5 Hex:iPrOH
                  1ml/min, OD-H
                  210, 230 nm
                  
 










































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :      5.00000  [ng/ul]   (not used in calc.)




HPLC 12/19/2015 1:05:34 PM Zack S Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]       %
----|-------|----|-------|----------|----------|--------|
   1   8.828 BB    0.2154 1463.44568  104.48035  49.6672
   2  13.288 BB    0.3545 1483.05823   64.45059  50.3328
 
Totals :                  2946.50391  168.93094
 
 
Signal 2: DAD1 E, Sig=280,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]  [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   8.828 BB    0.2168 76.67307    5.42630  40.2585
   2  10.181 BB    0.1768 33.45036    2.93824  17.5637
   3  13.287 BB    0.3513   80.32844    3.45432  42.1778




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4007RAC00002.D
Sample Name: KSW4007Rac
HPLC 12/19/2015 1:05:34 PM Zack S Page 2 of 2
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 7/23/2015 3:14:11 PM         
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 7/23/2015 2:44:12 PM by KSW
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/19/2015 1:06:37 PM by Zack S
                  (modified after loading)
Sample Info     : KSW4007Asym sample-Cinnamyl bromide
                  95:5 Hex:iPrOH
                  1ml/min, OD-H
                  210, 230 nm
                  
 






















































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 12/19/2015 1:06:39 PM Zack S Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
 #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   8.937 MM    0.2028   41.35882    3.39940   0.7163
   2  13.136 MM    0.4649 5732.24658  205.51836  99.2837
 




Signal 2: DAD1 E, Sig=280,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.526 VB    0.1083   26.43449    3.41452   6.7516
   2   3.921 VV    0.0929    6.71191    1.07405   1.7143
   3  10.221 BB    0.1775   63.18818    5.52085  16.1389
   4  13.136 BB    0.4175  295.19348   10.51700  75.3952
 




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4007ASYM0002.D
Sample Name: KSW4007Asym
HPLC 12/19/2015 1:06:39 PM Zack S Page 2 of 2
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 71
Injection Date  : 12/4/2015 2:26:36 PM         
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed   : 12/4/ 015 1:32:21 PM by Fiene
            (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed : 12/4/201  2:59:07 PM by Fiene
                  (modified after loading)
Sample Info     : KSW4006Rac
                  1mL/min, 95:5 Hex:IPA, OD-H
              254 nm
                  
 






































































































Data File C:\CHEM32\1\DATA\KSW\KSW4006RAC0 2.D
Sample Name: KSW4006Rac
HPLC 12/4/2015 2:59:14 PM Fiene Page 1 of 3
                        Area Percent Report                         
=====================================================================
 
Sorted By : Signal
Multiplier:    :   1.
Dilution:                  :     1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)
Use Multiplier & Dilution Factor with ISTDs
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
Peak RetTime Type Width    Area     Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.420 BB    0.1429 1815.98096  191.06255  50.9089
   2  11.609 BB    0.3009 1751.13647   89.25835  49.0911
 




Signal 2: DAD1 B, Sig=254,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.266 VV    0.1767   21.06825    1.51034   0.5600
   2   3.554 VV    0.1222   10.41260    1.14355   0.2768
   3   3.790 VB    0.0968   34.50806    5.11174   0.9173
   4   6.420 BB    0.1433 1750.26196  183.52748  46.5257
   5   9.308 BB    0.2141  144.73553   10.54769   3.8474
   6  10.264 BB    0.1748   34.05552    3.03680   0.9053
   7  11.609 BB    0.3008 1681.51538   85.72801  44.6983
   8  13.022 BB    0.3017   85.36861    4.41256   2.2693
 




Signal 3: DAD1 D, Sig=230,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.007 BV    0.0998   54.99239    7.65692   1.9171
   2   3.149 VV    0.1393   84.82027    8.16120   2.9570
   3   3.351 VV    0.1762   59.38776    4.37841   2.0704
   4   3.788 VB    0.1287  118.81300   12.52299   4.1421
   5   4.376 BV    0.1059   26.04358    3.62310   0.9079
   6   5.462 BV    0.2093   62.48015    4.06470   2.1782
   7   5.746 VB    0.1374    9.87964    1.07314   0.3444
Data File C:\CHEM32\1\DATA\KSW\KSW4006RAC00002.D
Sample Name: KSW4006Rac



















Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 71
Injection Date  : 12/4/2015 2:43:55 PM         
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/4/2015 1:32:21 PM by Fiene
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 12/4/2015 2:59:07 PM by Fiene
                  (modified after loading)
Sample Info     : KSW4006ASYM
                  1mL/min, 95:5 Hex:IPA, OD-H
                  254 nm
                  
 















































































































HPLC 12/4/2015 3:03:29 PM Fiene Page 1 of 3
=====================================================================
                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.428 MM    0.1609  232.92827   24.13163   3.0417
   2  11.264 MM    0.4524 7424.83203  273.50693  96.9583
 




Signal 2: DAD1 B, Sig=254,16 Ref=360,100
 
Peak RetTime Type  Width     Area     Height     Area 
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.166 VV    0.0949    7.53710    1.08708   0.0995
   2   3.264 VB    0.1051    7.92076    1.01437   0.1046
   3   3.540 BV    0.0875   24.08815    4.16382   0.3181
   4   3.786 VB    0.0917   41.86256    6.62512   0.5527
   5   4.513 BV    0.0853    6.24353    1.15116   0.0824
   6   4.680 VB    0.0911    6.57686    1.14377   0.0868
   7   6.428 BB    0.1335  194.34663   22.34329   2.5661
   8   9.976 BV    0.1710   22.15340    1.97329   0.2925
   9  10.198 VB    0.1769   40.77969    3.47426   0.5384
  10  11.264 BB    0.4083 7117.55127  262.50009  93.9778
  11  12.976 BB    0.3241  104.59039    5.04042   1.3810
 




Signal 3: DAD1 D, Sig=230,16 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.005 BV    0.0923   46.77201    7.15380   0.9964
   2   3.152 VV    0.1186   60.67394    7.03596   1.2926
   3   3.337 VV    0.1036   27.42472    3.65148   0.5842
   4   3.538 VV    0.0907   53.09734    8.52201   1.1311
Data File C:\CHEM32\1\DATA\KSW\KSW4006ASYM0001.D
Sample Name: KSW4006ASYM
HPLC 12/4/2015 3:03:29 PM Fiene Page 2 of 3
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 10/15/2015 11:37:38 AM       
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 10/15/2015 11:03:02 AM by Nate
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 9/23/2015 11:30:06 AM by Chirag
                  (modified after loading)
Sample Info     : KSW4035Rac
                  1 mL/min, 96:4 Hex:IPA, OD-H
                  254, 280 nm
                  
 





































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 10/15/2015 11:56:21 AM Chirag Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.047 BB    0.1445 2059.64868  217.39651  49.3318
   2  11.484 MM    0.4387 2115.44800   80.36939  50.6682
 




Signal 2: DAD1 E, Sig=280,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
# [min] [min]   [mAU*s]    [mAU] %
----|-------|----|-------|----------|----------|--------|
  1   3.272 BV    0.0978   10.46186    1.52946   3.1183
   2  3.456 VV 0.1153   17.04809    2.17903   5.0814
   3   3.576 VB 0.1209   33.28419    3.84723   9.9209
   4   5.805 BV 0.1837   34.81889    2.64260  10.3783
   5  6.048 VV 0.1627  134.29738   12.76541  40.0294
   6  11.074 BV   0.1827   14.27183    1.21777   4.2539
  7  11.484 VB    0.3269   91.31474    4.02150  27.2178
 




                       *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4035RAC00002.D
Sample Name: KSW4035Rac
HPLC 10/15/2015 11:56:21 AM Chirag Page 2 of 2
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 61
Injection Date  : 10/15/2015 11:54:58 AM       
                                               Inj Volume : 10.0 µl
Acq. Method    : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 10/15/2015 11:03:02 AM by Nate
            (mo ified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 9/23/2015 11:30:06 AM by Chirag
                (modified after loading)
Sample Info     : KSW4035Asym
                  1 mL/min, 96:4 Hex:IPA, OD-H
                  254, 280 nm
                  
 
























































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 10/15/2015 12:12:00 PM Chirag Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.049 BB    0.1469  103.48177   10.69172   2.3406
   2  11.298 VB    0.4432 4317.66943  137.16760  97.6594
 




Signal 2: DAD1 E, Sig=280,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.254 VV    0.1332   10.45851    1.16034   4.3949
   2   3.510 VV    0.1624   15.06653    1.30796   6.3312
   3   4.554 BV    0.0872    8.03055    1.43660   3.3746
   4   4.691 VV    0.0931    7.89789    1.25967   3.3188
   5   6.045 VB    0.1654   11.71260    1.02410   4.9219
   6  11.292 BB    0.3766  184.80528    6.76629  77.6586
 




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4035ASYM0001.D
Sample Name: KSW4035Asym














Daicel Chiracel OD-H, 90:10 Hexanes:IPA, 1 mL/min, 254 nm
 
=====================================================================
Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 81
Injection Date  : 9/23/2015 10:57:15 AM        
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 9/23/2015 10:15:13 AM by KSW
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 9/23/2015 11:29:05 AM by Chirag
                  (modified after loading)
Sample Info     : KSW4030Rac, VinylBromide Product
                  1ml/min, 90:10 Hex/IPA
                  254nm
                  
 



































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 9/23/2015 11:29:08 AM Chirag Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.965 BV    0.1586 2077.71558  200.99156  49.9796
   2   9.356 BB    0.3811 2079.41040   92.21014  50.0204
 




Signal 2: DAD1 D, Sig=230,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
# [min] [min]   [mAU*s]    [mAU] %
----|-------|----|-------|----------|----------|--------|
  1   2.956 BV    0.1122   12.22972    1.61752   0.1417
   2   3.151 VV    0.1218   49.05033    5.51502   0.5685
   3   3.391 VV    0.0816   35.32709    6.09786   0.4094
   4   3.510 VV    0.0825   30.30690    5.16335   0.3512
   5   3.658 VV    0.1371  222.18774   21.39961   2.5750
   6   4.081 VV    0.1407   33.12431    3.20073   0.3839
  7   4.234 VV    0.1932   38.59872    3.01837   0.4473
   8   4.809 VB    0.3042   65.68883    2.83593   0.7613
   9   5.694 BV    0.1934   24.47210    1.72658   0.2836
  10   6.710 BV    0.1119   17.03462    2.31297   0.1974
  11   6.965 VV    0.1638 3898.28833  367.29303  45.1778
  12   7.496 VB    0.1744   91.45016    7.93812   1.0598
  13   8.372 BB    0.1472   33.78999    3.54427   0.3916
  14   9.355 BB    0.3894 4004.18042  174.70216  46.4050
  15  10.843 BB    0.2381   73.03850    4.83745   0.8465
 




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4030RAC00003.D
Sample Name: KSW4030Rac



















Acq. Operator   : KSW                          
Acq. Instrument : HPLC                            Location : Vial 81
Injection Date  : 9/23/2015 11:11:30 AM        
                                                Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 9/23/2015 10:15:13 AM by KSW
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\DEF_LC.M
Last changed    : 9/23/2015 11:26:28 AM by Chirag
                  (modified after loading)
Sample Info     : KSW4030Asym, VinylBromide Product
                  1ml/min, 90:10 Hex/IPA OD-H
                  254nm
                  
 

















































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Sample Amount:               :     10.00000  [ng/ul]   (not used in calc.)




HPLC 9/23/2015 11:26:49 AM Chirag Page 1 of 2
 
Signal 1: DAD1 A, Sig=254,4 Ref=360,100
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.998 BB    0.1474   47.34436    4.95790   1.9392
   2   9.313 BB    0.3773 2394.14575  105.29288  98.0608
 




Signal 2: DAD1 D, Sig=230,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
# [min] [min]   [mAU*s]    [mAU] %
----|-------|----|-------|----------|----------|--------|
  1   2.960 BV    0.1137   10.66375    1.35741   0.2106
   2   3.152 VB    0.1163   42.57287    5.15835   0.8406
   3   3.502 BV    0.1417   34.41743    3.09523   0.6796
   4   3.656 VB    0.1372  129.50935   14.63859   2.5572
   5   4.081 BV    0.2247   37.000 5    2.12934   0.7306
   6   4.782 VB    0.2187   22.86006    1.42863   0.4514
  7   6.998 BB    0.1487   95.86503   10.10106   1.8929
   8   8.355 BB    0.1450   38.45985    4.11540   0.7594
   9   9.313 BB    0.3873 4581.25928  198.49554  90.4580
  10  10.809 BB    0.2400   71.90754    4.66058   1.4198
 




                          *** End of Report ***
Data File C:\CHEM32\1\DATA\KSW\KSW4030ASYM0001.D
Sample Name: KSW4030Asym
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 CHAPTER 4: Stereoselective synthesis of 1,3-diol stereotetrads via 
nucleophilic anion catalysis  
4.1. Introduction 
We were inspired by the AB-CD* coupling reaction to address an inherent limitation in 
crotylation methodologies. Flexibility of stereocontrol at C(17) enabled transition state 
manipulation to bias diastereoselectivity and reactivity in our favor for the AB-CD* coupling 
(Figure 4.1).
1
 This example illuminates a greater problem in polyketide natural product synthesis. 
Certain stereotetrad arrays constitute significant synthetic challenges that are either plagued by 
poor yields and selectivities or require lengthy synthetic sequences to overcome. The anion 
catalysis methodology described in Chapter 2, accesses a novel silicate transition state that has 
never previously been reported with regards to metal-mediated crotylation reactions. We 
hypothesized that by exploiting our understanding of the anion catalysis reaction mechanism, we 
had the opportunity to overcome the limitations prescribed by the Felkin-Ahn model. 
 
Figure 4.1: Stereochemical limitations in synthesis of the ABCD* fragment. 
4.1.1. Overview of transition state models 
 Hoffmann’s overview
2
 of the six-membered cyclic transition state of diastereoselective 
aldehyde allylmetal additions provides us with a clear understanding of possible transition states 
and the factors that affect their favorability. The 6-membered transition states outlined in figure 






Figure 4.2: Possible transition for the metal-mediated crotylation of an aldehyde. C1, C2 denote chair-like 
transition states. B1, B2 denote boat-like transition states.
2
 
 Diastereoselectivity is obtained when one of the possible transition states (TS) is 
significantly more stable than the other potential TSs. In this context, significantly more stable is 
defined as approximately >2 kcal/mol more stable than the others.
4
 One of the factors affecting 
TS stability is the steric demand of both R (aldehyde substituent) and L (silicon bound ligand). 
1,3-diaxial interactions between R an L observed in the C2 TS suggest that the C1 TS is 
preferred as long as the 1,3-diaxial strain is greater than the C1 illustrated gauche-interaction 
between R and R
1
. When considering the forces impacting the boat-like conformations, the B1 
TS is clearly the highest energy conformer because of both the R/L 1,3-diaxial strain and the 
R/R
1
 interaction. Although the B2 TS is the more stable boat, boat TSs are inherently less 
favored than their chair counterparts because of the eclipsing interactions. However, because the 
energy differences between chair and boat conformations can be relatively small, boat transition 
states must be considered as possible pathways, particularly when analyzing challenging 
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stereochemical arrays.  Transition state analysis of the Z-crotylation and by analogy E-
crotylation of the simplest aldehyde, as just described, accurately predicts the products that are 




Figure 4.3: Felkin-Ahn stereoselectivity model. 
Aldehyde α and β stereocenters introduce further complexity in transition state analysis 
which warrants additional examination. Introduction of an α stereocenter on the substrate 
aldehyde requires the Felkin-Ahn model to accurately predict the diastereoselectivity of 
nucleophilic addition. The Felkin-Ahn model states that the approach of a nucleophile is favored 
when the developing C-C bond is anti to the largest α substituent (Figure 4.3).
6,7
 It is suggested 
that the controlling factors that determines α-substituted aldehyde diastereofacial selectivity is 
the minimization of syn-pentane interactions in the competing chairlike transition states (Figure 
4.4).
4,8–12
 Building on the C1 TS already discussed, we can examine the steric and electronic 
factors that influence E- and Z- crotyl addition to an  α-substituted aldehyde. 
In Figure 4.4A, the Felkin TS1 pathway is lowest in energy due to minimization of the 
syn-pentane interaction present in the anti-Felkin TS2. The nucleophile approaches from the 
more favored Felkin face which also minimizes undesired steric costs in the chair-like transition 
state to give the Felkin stereotetrad product. 4.5 would thus be described as a matched
13–15
 case, 
meaning it has the lowest reaction energy barrier to overcome. In contrast, the anti-Felkin 
product 4.8 is obtained when a Z-crotyl metal species is used with the same α-substituted 





interaction. Syn-pentane considerations override the competing Felkin/anti-Felkin facial 
selectivity. In this case both 4.7 and 4.8 would be described as a partially matched case. The anti-
Felkin product 4.6 must go through the highest energy TS2 pathway of the four transition states 
and is therefore described as a mismatched case and is the most challenging stereochemical array 
to obtain. 
 
Figure 4.4: A: E-crotyl addition to an α-substituted aldehyde. B: Z-crotyl addition to an α-substituted 
aldehyde. 
It is generally accepted that the stereocenter alpha to the carbonyl dictates 
diastereoselectivity in nucleophilic additions to aldehydes bearing multiple stereocenters.
7
 
However, stereocenters beta to the carbonyl can also play a critical role in determining 
diastereomeric ratios and reactivity.
16
 For example, the beta stereocenter on the α-methyl-β-
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alkoxy-CD* aldehyde 4.1, had a drastic impact on the effectiveness of the AB-CD* coupling 
reaction (Figure 4.1 and Chapter 2, Section 2.3).
1
 It has also been shown that the beta 
stereocenter can be mutually reinforcing by promoting addition to the same face as the alpha 
stereocenter or non-reinforcing by promoting addition to the opposite face of the alpha 
stereocenter.
17
 By analyzing the transition states of crotyl additions to α-methyl-β-alkoxy 
aldehydes, we can predict which stereotetrad arrays are challenging to access. Figure 4.5 outlines 
why the anti-anti-anti stereotetrad diastereomer 4.9g is unfavorable to synthesize. Crotyl addition 
to the α-methyl-β-alkoxy aldehyde is biased towards the Felkin pathway making TS3 more 
favorable than TS1 or TS2. The beta stereocenter then reinforces TS3 preference by introducing 
additional unfavorable steric interactions in either of the two possible anti-Felkin transition 
states, TS1 and TS2 (red arrows, Figure 4.5).  
 
Figure 4.5: Beta stereocenter transition state effects. 
 Using the TS analysis approach previously described, in which we consider each 
component factor and subsequently add them to gain a comprehensive model, every α-methyl-β-
alkoxy aldehyde crotylation product can be examined. This results in four of the possible eight 





Figure 4.6: All eight possible stereotetrad diastereomers. Highlighted in blue are the four stereochemically 
challenging substrates. 
4.1.2. Limitations of current crotylation methods  
 In 1999, Kishi reported impressive work towards a universal NMR database for the 
stereochemical assignment of acyclic compounds.
18
 The model system they examined contained 
two contiguous propionate units; therefore they were faced with the task of synthesizing all eight 
possible stereotetrad diastereomers (Figure 4.6). This offered an excellent opportunity to 
examine the strength of current methods to generate these stereotetrads.  
 Beginning with the Brown crotylation
19,20
, four diastereomers, 4.9b, 4.9d, 4.9e, and 4.9h, 
out of the eight were obtained stereospecifically. Three, 4.9a (2:1 dr), 4.9f (2:1 dr), and 4.9g 
(1:1), of the four remaining diastereomers were obtained as a mixture of diastereomers. The final 
diastereomer, 4.9c, was unable to be obtained with the Brown crotylation. 
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 Diastereomer 4.9c was instead prepared via zinc-mediated crotylation
21
 (5:1 dr), which 
was found also to be a stereoselective (5:1 dr) means for the preparation of diastereomer 4.9g. In 
addition, application of the tin-mediated crotylation developed by Keck
22
 improved the 
stereoselectivity in the formation of 4.9a (5:1 dr) and 4.9f (5:1 dr). For the case of 4.9a, although 
the stereoselectivity (4.9a:4.9b) could be improved up to 5:1, a significant amount of the linear 
product (3:2 regioselectivity) was also formed. 
 Previous studies
5
 of stereotetrad synthesis in the Leighton group have examined all eight 
diastereomers with the 2
nd
 generation EZ-CrotylMix methodology.
23
 As can be seen in Figure 
4.7, the Leighton crotylation performs better than the Brown crotylation on direct comparison. 
For this method, the most impressive result is the synthesis of 4.9a in 74% yield and 95:5 dr. 
However, the other 3 out of 4 predicted challenging diastereomers were only obtained as a 
mixture of diastereomers.  
.  
Figure 4.7: Diastereomeric ratios of stereotetrads generated using the Leighton EZ-CrotylMix methodology. 
R = TBS. 
                                                     
5
 This work was carried out by former Leighton graduate student Dr. Steven Ho. 
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 Although material is able to be obtained for the more challenging stereotetrads, 
improvement is clearly necessary to improve selectivity and eliminate side products. An ideal 
approach to achieve these stereochemical arrays in natural product synthesis would 1) use a 
single method to access every diastereomer and 2) be mild and tolerant of complex functionality. 
4.1.3. Plans towards a universal stereotetrad synthesis 
 We believed we could make an impact in the stereotetrad field using our more sterically 
and conformationally constricted tridentate ligand as well as our newly developed mild, one-pot 
allylation procedure. The tridentate ligand should provide a greater energetic cost override chiral 
ligand control in the transition state thus making the undesired transition states less favorable. 
We also hypothesized that anion-catalysis of the strained silane complex provides a unique 
opportunity to both accelerate the rate of reaction and tune the transition state for maximum 
stereocontrol. We began by investigating the most historically challenging stereochemical array 
4.9g. 
4.2. anti-anti-anti stereotetrad optimization 
4.2.1. Initial synthesis attempts 
 We began with attempting the crotylation of an α,β-anti-substituted aldehyde 4.11 with 
(R,R)-4.10 using the first generation Leighton crotylation method (Table 4.1). The desired 
product 4.9g was obtained in a 50% yield and a 1:1 dr (entry 1, Table 4.1). Also isolated in 34% 
yield was the crotylation product 4.12 resulting from the elimination of the β-stereocenter on 
aldehyde 4.11. 
 We probed both protecting group effects on the aldehyde and ligand substituent effects. 
Moving towards smaller protecting groups clearly improved the stereoselectivity of the reaction 
however only to a small extent (entry 3 and 4, Table 4.1). Confirmation of stereochemistry was 
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achieved through acetonide protection of the deprotected diol compound. Simply changing the 
protecting group was not sufficient to achieve the sought after high diastereoselectivity nor did it 
solve the problem of β-stereocenter elimination. Going to a smaller ortho-substituent (R) on the 
ligand phenol ring both improved the rate of crotylation and the yield thus minimizing 
elimination product, however diastereoselectivity decreased to 1:5 dr (entry 2, Table 4.1). This 
ligand effect is consistent with our transition state analysis wherein greater steric bulk at the 
ortho position raises the energy of the undesired transition state pathway (Felkin) thereby 
increasing the diastereoselectivity of the reaction. Unfortunately a larger R group also slows 
down the rate of reaction which we hypothesized increased the amount of elimination product.  
Table 4.1: anti-anti-anti reaction attempts. 
 
Further optimization studies of this reaction yielded little success. Lowering temperature 
only stunted conversion of the aldehyde to product without increasing selectivity. It was clear 
that more acid labile protecting groups generated more of the elimination product. To combat this 
problem we tried isolating the silane complex away from the DBU HCl salts. However, this only 
resulted in a poorer reaction with a depressed yield. Similarly, trying to add a scandium triflate 
additive to increase reactivity yielded no improvement. 2,6-di-tert-butylpyridine was added, in 
the hopes that free HCl was epimerizing the aldehyde’s α-stereocenter and/or playing an active 
role in the β-stereocenter elimination, with no response. Finally, when the α,β-anti-substituted 
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aldehyde 4.11 was subjected to reaction conditions with an unreactive silane 4.13, three 
aldehydes (4.11, 4.14, 4.15) were isolated. This experiment would suggest that the silane itself is 
acidic enough to degrade the starting aldehyde over extended reaction times. Moving forward we 
hypothesized that we needed a more reactive silane that could perform the carbon-carbon bond 
forming step at an accelerated rate in order to outcompete the starting material degradation 
inherent to the reaction. 
 
Figure 4.8: Acid stability study of 4.11. 
4.2.2. Anion catalysis 
 With the discovery of anion catalysis which accesses highly reactive six coordinate silane 
intermediates, we now had the opportunity to combat the problems associated with the first 
generation attempts at synthesizing the anti-anti-anti stereochemical array. To our delight, 
addition of 5 mol% TBAB to the reaction conditions gave a 70% yield and most interestingly 
improved the dr to 5:1 (Scheme 4.1). None of the elimination side reaction was observed to 
progress. 
 
Scheme 4.1: Bromide catalyzed synthesis of 4.9g. 
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4.2.3. Chiral anion catalysis
6
 
 We were particularly interested in the increase in diastereoselectivity from 1:5 to 5:1. If 
anion catalysis is affecting the diastereoselectivity determining step, then we can exploit that 
relationship to design a more effective anion catalyst. We began with the chiral tetrabutyl 
ammonium salt (-)-4.16
24,25
 which improved the diastereoselectivity to 16:1 starting with 
aldehyde 4.11 (Scheme 4.2). When the opposite enantiomer of 4.16 is employed a reversal of 
diastereoselective preference is observed (Scheme 4.3). 
 
Scheme 4.2: Chiral anion catalyzed synthesis of 4.9 g 
 
Scheme 4.3: (+)-4.16 effect on the diastereoselectivity of 4.9g. 
                                                     
6
 This work was done in collaboration with Leighton undergraduate student Roshan Bhaskar. 
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4.3. Synthesis of stereotetrad diastereomers 
4.3.1. Stereotetrad scope 
 With optimized conditions in hand for both an achiral (TBAB) and a chiral (4.16) anion 
catalyzed α-methyl-β-alkoxy aldehyde crotylation, we wanted to explore the generality of this 
methodology. α,β-anti- and α,β-syn-aldehydes were prepared and each reacted with both cis- and 
trans-crotyl trichlorosilanes in complex with both the (R,R)-4.10 and (S,S)-4.10 ligand 
enantiomers to generate all eight possible diastereomer combinations.  
 The four matched diastereomers, 4.9b, 4.9d, 4.9e, and 4.9h, were able to be obtained 
stereospecifically using TBAB as a catalyst. TBAB was deemed necessary to obtain the best 
results for these reactions despite the fact that their transition states are lower in energy. For 
example 4.9e is obtained in only a 25% yield and 12:1 dr in the absence of bromide anion. This 




Figure 4.9: Synthesis of all eight possible diastereomer tetrads. 
 For this method, the most impressive results arose from our attempts at synthesizing the 
four diastereomers that the Brown crotylation is not able to synthesize in high yields and 
selectivities. As previously discussed in section 4.2, we are able to achieve the synthesis of 4.9g 
in as of yet unprecedented stereoselectivity. Now we turned our attention to the remaining three 
diastereomers 4.9a, 4.9c, and 4.9f. Using (-)-4.16 as a catalyst were able to achieve the efficient 
synthesis each diastereomer (Figure 4.9). 4.9a was formed in a 70% yield and 10:1 dr. 
Excitingly, 4.9a was the same stereochemical array that we were unable to generate in the 
attempted AB-CD* coupling with a α,β-syn-CD* aldehyde. 4.9c and 4.9f were formed in a 75% 
yield and >20:1 dr and an 86% yield and 15:1 dr, respectively. 4.9c and 4.9f represent major 
improvements in both the Leighton crotylation methodology (see Figure 4.7) as well as for the 
field as a whole. 
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4.3.2. ABCD* coupling application
7
 
 Encouraged by the promising results obtained for the synthesis of 4.9a, we wanted to 
explore a model AB-CD* coupling reaction using our newly developed chiral anion catalysis 
method. In stark contrast to the uncatalyzed reaction which yielded only a trace amount of 
product, using the PCCP anion (-)-4.16 resulted in a 50% yield and a 2:1 dr (Figure 4.10). As is 
consistent with our previous studies, the opposite catalyst enantiomer completely shut down the 
reaction. Although the diastereomeric ratio is modest, this result is a promising proof of concept 
that this method can be applied to even the most complex of systems. Future work on this system 
will consist of modifying the chiral anion to improve diastereoselectivity. 
 
Figure 4.10: Model AB-CD* coupling. 
4.4. Mechanistic hypothesis 
4.4.1. Proposed transition state models 
 Going back to the transition state models for the anti-anti-anti reaction, A and B, it is 
clear that the Felkin-Ahn model is correct in that the Felkin pathway is preferred and can 
override the stereochemical control of the chiral tridentate ligand (Figure 4.11). Evidence of this 
preference is described in Table 4.1. However, the anion catalyzed crotylation clearly favors the 
anti-Felkin pathway. We propose the anion is playing a role in rehybridizing the silane geometry 
                                                     
7
 This work was done in collaboration with Leighton group research assistant Mario Rivera. 
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prior to the approach of aldehyde 4.11 thereby blocking the face of Felkin attack and increasing 
rate of aldehyde coordination to the desired face (Figure 4.11C and D).  
 
Figure 4.11: A: proposed undesired Felkin transition state to give 4.9h. B: proposed desired anti-Felkin 
transition state to give 4.9g. C: proposed undesired anion catalyzed Felkin transition state to give 4.9h. D: 
proposed desired anion catalyzed anti-Felkin transition state to give 4.9g. 
4.4.2. Ligand manipulations 
 To experimentally probe our proposed transition states, we explored subtle changes to the 
tridentate ligand 4.10 backbone. We observed in our proposed transition state (TS1, Figure 4.12) 
that a steric clash could arise between the methyl group on the nitrogen and the beta stereocenter 
on aldehyde 4.11. However, another possible anti-Felkin transition state can be imagined wherein 
that interaction is not present (TS2, Figure 4.12). To explore these possible transition states, we 
used the benzyl derivative of the tridentate ligand (TS3, Figure 4.12) to increase steric bulk at 
that position. We would expect that diastereoselectivity would decrease if the reaction was 
proceeding through TS1 or remain relatively the same (16:1 dr) if the reaction was proceeding 
through TS2. Interestingly, we found that the diastereoselectivity decreases to 1:5 using the 
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benzyl derivative of the tridentate ligand. This result is consistent with our proposed mechanistic 
pathway. 
 
Figure 4.12: TS1 represents the proposed anti-Felkin transition state. TS2 represents a plausible alternative 
anti-Felkin transition state. TS3 probes the steric effect of the nitrogen substituent in the transition state.  
4.5. Summary and outlook 
 We have discovered that anions can affect the diastereoselectivity of α-methyl-β-alkoxy 
aldehyde crotylation reactions. This discovery shows that in addition to reaction rate 
acceleration, inherent stereochemical challenges can be solved by tuning anion catalyst 
properties. Long standing challenges in the crotylation field, such as the anti-anti-anti 
diastereomer, now have a technically simple and cost effective method to introduce the desired 
stereochemistry. This work can have an immediate impact on non-aromatic polyketide synthesis 
to improve the syntheses of natural products such as zincophorin, calyculin A, and ionomycin 
(Figure 4.13). We have expanded the scope of accessible stereotetrad arrays which should allow 




Figure 4.13: Examples of natural products with challenging stereotetrad arrays. 
 Chiral anion catalysis of silane lewis acids is in its own right a highly intriguing 
discovery. Chiral anion catalysis opens up the possibility of using achiral ligands to activate 
silanes and using a chiral catalyst to impart all stereocontrol. Additionally, one could envision a 
silane lewis acid method wherein the catalytic anion is playing the role of both activator and 
chiral information carrier. Work towards these ideals will be discussed in Chapter 6.   
4.6. Experimental procedures 
General Information. All reactions were carried out under an inert atmosphere of argon in 
flame-dried glassware with magnetic stirring unless otherwise indicated.  Degassed solvents 
were purified by passage through an activated alumina column.  Et3N was distilled from CaH2; 
DBU was distilled from CaH2 onto 4 Å molecular sieves and stored under inert atmosphere.  All 
chloride and aldehyde substrates were purified immediately prior to use.  All other reagents were 
purchased from commercial sources and used without further purification unless otherwise 
noted.  Flash chromatography was performed with Silicycle SiliaFlash® P60 silica gel.  Thin-
layer chromatography (TLC) was carried out on glass backed silica gel TLC plates (250 nm) 
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from Silicycle; visualization by UV, phosphomolybdic acid (PMA), or Potassium Permanganate 
(KMnO4). 
Diastereomeric ratios for all compounds were determined by 
1
H NMR analysis of the 




Cdata were obtained using Bruker AVIII 500 (500 MHz) 
spectrometer and are reported in ppm.  
1
H NMR spectra were internally referenced to CDCl3 
(7.26 ppm); 
13
C NMR spectra were internally referenced to CDCl3 (77.23 ppm); Data are 
reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = triplet, m = multiplet, dd = 
doublet of doublets, ddd = doublet of doublet of doublets, ddt = doublet of doublet of triplets, td 
= triplet of doublets; coupling constant(s) in Hz; integration).  Infrared spectra were recorded on 
a Perkin-Elmer Spectrum Two (Diamond ATR) IR spectrometer.  Optical rotations were recorded 
on a Jasco DIP-1000 polarimeter.  HPLC analysis was carried out on an Agilent 1200 Series 
using a Chiralpak OD-H (250 x 4.5 mm ID) column. Mass Spectroscopy Data was obtained on a 
Waters XEVO G2-XS QToF mass spectrometer.   
4.6.1. Preparation of stereotetrad diastereomers 
 
To a flame dried vial containing (R,R)-4.10 ligand (62 mg, 0.25 mmol) and 4.16 (15.2 
mg, 0.0125 mmol), was added CH2Cl2 (1.50 mL).  The reaction mixture was cooled to 0 °C and 
DBU (114 mg, 0.75 mmol)  and cis-crotyltrichlorosilane (49 mg, 0.26 mmol) were sequentially 
added. The reaction mixture was warmed to room temperature and stirred for 2 hr. The reaction 
mixture was cooled to -78 °C and aldehyde 4.17 was added dropwise rinsing with CH2Cl2 (0.5 
mL). The reaction was allowed to warm to -30 °C and was stirred for 12 hr. After 12 hr, the 
reaction mixture was quenched by the addition of n-Bu4NF (65 mg, 0.25 mmol) and stirred at 0 
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°C for 1 hr. The reaction mixture was filtered through silica gel plug, rinsing with EtOAc. The 
filtrate was concentrated and resuspended in CH2Cl2 (2.0 mL), additional n-Bu4NF (65 mg, 0.25 
mmol) was added and stirred at 0 °C for 1 hr. The reaction mixture was filtered through a silica 
gel plug, rinsing with EtOAc. The filtrate was concentrated, and purified by buffered (pH 7) 
silica gel flash column chromatography (0-30% EtOAc:Hexanes) to afford diol 4.9a (41.0 mg, 





 +0.9318 º (c 1.0, CHCl3) 




H NMR (400 MHz, CDCl3) δ 7.32 – 7.15 (m, 5H), 5.73 (ddd, J = 17.5, 10.5, 7.3 Hz, 1H), 5.08 
– 4.98 (m, 2H), 3.96 (ddd, J = 9.3, 3.8, 2.1 Hz, 1H),  3.49 (t, J = 6.1 Hz, 1H), 2.84 (ddd, J = 13.8, 
10.1, 5.2 Hz, 2H), 2.63 (ddd, J = 13.7, 9.8, 6.6 Hz, 1H), 2.47 – 2.37 (m, 1H), 1.91- 1.80 (m, 1H), 
1.69 (dddd, J = 13.8, 10.3, 6.7, 3.8 Hz, 2H), 1.05 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 7.1 Hz, 3H). 
13
C NMR (500 MHz, CDCl3) δ 141.2, 128.4, 128.40, 125.8, 115.4, 78.2, 72.5, 40.8, 38.7, 35.8, 
32.8, 13.6, 11.7.  
HRMS (ESI+) calculated for C16H24O2 [M+H]
+
: 249.1855; found 249.1857. 
 
To a flame dried vial containing (R,R)-4.10 ligand (62 mg, 0.25 mmol) and n-Bu4NBr 
(4.0 mg, 0.0125 mmol), was added CH2Cl2 (1.50 mL).  The reaction mixture was cooled to 0 °C, 
DBU (114 mg, 0.75 mmol)  and cis-crotyltrichlorosilane (49 mg, 0.26 mmol) were sequentially 
added. The reaction mixture was warmed to room temperature and stirred for 2 hr. The reaction 
mixture was cooled to -78 °C and aldehyde 4.17 was added dropwise rinsing with CH2Cl2 (0.5 
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mL). The reaction was allowed to warm to -30 °C and was stirred for 12 hr. After 12 hr, the 
reaction mixture was quenched by the addition of n-Bu4NF (65 mg, 0.25 mmol) and stirred at 0 
°C for 1 hr. The reaction mixture was filtered through silica gel plug, rinsing with EtOAc. The 
filtrate was concentrated and resuspended in CH2Cl2 (2.0 mL), additional n-Bu4NF (65 mg, 0.25 
mmol) was added and stirred at 0 °C for 1 hr. The reaction mixture was filtered through a silica 
gel plug, rinsing with EtOAc. The filtrate was concentrated, and purified by buffered (pH 7) 
silica gel flash column chromatography (0-30% EtOAc:Hexanes) to afford diol 4.9b (38 mg, 





 -13.988 º (c 1.0, CHCl3) 




H NMR (500 MHz, CDCl3) δ 7.34 – 7.12 (m, 6H), 5.59 (ddd, J = 17.2, 10.3, 8.8 Hz, 1H), 5.19 
– 4.94 (m, 2H), 4.12 (q, J = 7.1 Hz, 1H), 3.83 (ddd, J = 8.6, 4.7, 2.0 Hz, 1H), 3.51 (dd, J = 9.5, 
1.9 Hz, 1H), 2.94 (s, 1H), 2.75 (ddd, J = 13.7, 9.7, 5.9 Hz, 1H), 2.64 (ddd, J = 13.8, 9.4, 6.5 Hz, 
1H), 2.38 – 2.23 (m, 1H), 2.04 (s, 1H), 1.95 – 1.80 (m, 1H), 1.77 – 1.63 (m, 3H), 1.34 – 1.18 (m, 
2H), 1.09 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 7.1 Hz, 3H). 
HRMS (ASAP+) calculated for C19H28O2Na [M+Na]
+
:271.1674; found 271.1673 
 
 (R,R)-4.10 (62.0 mg, 0.250 mmol) was dried overnight at 45C under vacuum. (R,R)-
4.10 and 4.16
 
(15.3 mg, 0.013 mmol) were dissolved in dry CH2Cl2 (1.30 mL) and cooled to 0C 
in an ice bath. DBU (0.11 mL, 0.750 mmol) was added, followed by trans-crotyltrichlorosilane 
(0.04 mL, 0.275 mmol) dropwise. The reaction was stirred for 1 hr while warming to room 
temperature. The reaction was cooled to -78C and aldehyde 4.17 (azeotroped with toluene 
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thrice) was added neat, dropwise, and rinsed with 0.05 mL dry CH2Cl2. The reaction was stirred 
for 12 hour at 0C. The reaction was quenched with 1 equivalent of 1M n-Bu4NF in THF, run 
through a silica gel plug, and concentrated. The product was redissolved in CH2Cl2 and cooled to 
0C. The residue was treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) and 
stirred 1 hr at 0 ºC. The crude mixture was run through a silica gel plug, concentrated, purified 
by silica gel column chromatography (0-30% EtOAc/Hexanes) to yield 4.9c (258 mg, 75% yield, 
>20:1 dr) as a clear oil. 
OR [α]D
24
 8.23 (c 0.1, CHCl3) 




H NMR (500 MHz, CH2Cl2) 
1
H NMR (400 MHz, Chloroform-d) δ 7.29 (tt, J = 7.0, 0.9 Hz, 
5H), 7.25 – 7.13 (m, 5H), 5.83 (ddd, J = 17.2, 10.3, 8.2 Hz, 1H), 5.16 – 5.03 (m, 2H), 3.93 – 3.84 
(m, 1H), 3.46 (dd, J = 8.3, 2.4 Hz, 1H), 2.73 – 2.46 (m, 5H), 2.31 (h, J = 7.2 Hz, 1H), 1.97 – 1.76 
(m, 5H), 1.11 (t, J = 7.2 Hz, 2H), 1.07 – 0.82 (m, 23H), 0.72 – 0.55 (m, 10H). 
HRMS (ASAP+) calculated for C22H38O2Si [M+Na]
+




To a flame dried vial containing (R,R)-4.10 ligand (62 mg, 0.25 mmol) and n-Bu4NBr 
(4.0 mg, 0.0125 mmol), was added CH2Cl2 (1.50 mL).  The reaction mixture was cooled to 0 °C 
and DBU (114 mg, 0.75 mmol)  and cis-crotyltrichlorosilane (49 mg, 0.26 mmol) were 
sequentially added. The reaction mixture was warmed to room temperature and stirred for 2 hr. 
The reaction mixture was cooled to -78 °C and aldehyde 4.17 was added dropwise rinsing with 
CH2Cl2 (0.5 mL). The reaction was allowed to warm to -30 °C and was stirred for 12 hr. After 12 
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hr, the reaction mixture was quenched by the addition of n-Bu4NF (65 mg, 0.25 mmol) and 
stirred at 0 °C for 1 hr. The reaction mixture was filtered through silica gel plug, rinsing with 
EtOAc. The filtrate was concentrated and resuspended in CH2Cl2 (2.0 mL), additional n-Bu4NF 
(65 mg, 0.25 mmol) was added and stirred at 0 °C for 1 hr. The reaction mixture was filtered 
through a silica gel plug, rinsing with EtOAc. The filtrate was concentrated, and purified by 
buffered (pH 7) silica gel flash column chromatography (0-30% EtOAc:Hexanes) to afford diol 






 -29.464 º (c 1.0, CHCl3) 
IR (ATR) 3302, 3082, 3063, 3025, 2970, 2937, 2864, 1641, 1603, 1495, 1454, 1382, 1259, 1175, 




H NMR (500 MHz, CDCl3) δ 7.33 – 7.14 (m, 10H), 5.72 – 5.58 (m, 1H), 5.21 – 5.10 (m, 2H), 
3.85 (dd, J = 8.8, 4.4 Hz, 1H), 3.44 (d, J = 9.5 Hz, 1H), 3.32 (s, 1H), 2.82 (ddd, J = 15.1, 9.9, 5.6 
Hz, 1H), 2.66 (ddd, J = 13.7, 9.6, 6.6 Hz, 1H), 2.33 – 2.20 (m, 2H), 2.01 – 1.87 (m, 1H), 1.74 – 
1.61 (m, 2H), 0.93 (dd, J = 6.9, 5.1 Hz, 6H). 
HRMS (ESI+) calculated for C19H28O2Na [M+Na]
+
:271.1674; found 271.1664 
 
 
To a flame dried vial containing (R,R)-4.10 ligand (62 mg, 0.25 mmol) and 4.16 (15.2 
mg, 0.0125 mmol), was added CH2Cl2 (1.50 mL).  The reaction mixture was cooled to 0 °C and 
DBU (114 mg, 0.75 mmol)  and cis-crotyltrichlorosilane (49 mg, 0.26 mmol) were sequentially 
added. The reaction mixture was warmed to room temperature and stirred for 2 hr. The reaction 
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mixture was cooled to -78 °C and aldehyde 4.11 (74 mg, 0.24 mmol) was added dropwise rinsing 
with CH2Cl2 (0.5 mL). The reaction was allowed to warm to -30 °C and was stirred for 12 hr. 
After 12 hr, the reaction mixture was quenched by the addition of n-Bu4NF (65 mg, 0.25 mmol) 
and stirred at 0 °C for 1 hr. The reaction mixture was filtered through silica gel plug, rinsing with 
EtOAc. The filtrate was concentrated and resuspended in CH2Cl2 (2.0 mL), additional n-Bu4NF 
(65 mg, 0.25 mmol) was added and stirred at 0 °C for 1 hr. The reaction mixture was filtered 
through a silica gel plug, rinsing with EtOAc. The filtrate was concentrated, and purified by 
buffered (pH 7) silica gel flash column chromatography (0-30% EtOAc:Hexanes) to afford diol 
4.9e (42.0 mg, 70% yield, >20:1 dr) as a light yellow oil. 
OR [α]D
23
 +45.1 º (c 1.0, CHCl3) 




H NMR (400 MHz, CDCl3) δ 7.33 – 7.25 (m, 2H), 7.25 – 7.13 (m, 3H), 5.91 (ddd, J = 17.4, 
10.6, 5.9 Hz, 1H), 5.22 – 5.10 (m, 2H), 3.71 (ddd, J = 8.8, 7.6, 2.8 Hz, 2H), 3.55 (dd, J = 9.1, 2.6 
Hz, 1H), 2.87 (ddd, J = 13.6, 10.5, 5.1 Hz, 1H), 2.71 (ddd, J = 13.7, 10.2, 6.3 Hz, 1H), 2.58 – 
2.45 (m, 2H), 1.92 (dddd, J = 13.4, 10.5, 6.3, 2.7 Hz, 1H), 1.81 – 1.66 (m, 2H), 1.01 (d, J = 6.9 
Hz, 3H), 0.83 (d, J = 6.9 Hz, 3H). 
13
C NMR (500 MHz, CDCl3) δ 142.8, 141.8, 128.6, 128.5, 125.8, 115.8, 78.9, 75.7, 40.8, 39.4, 
36.6, 31.8, 13.0, 10.2.  
HRMS (ESI+) calculated for C16H24O2 [M+Na]
+
: 271.1674; found 271.1679. 
 
To a flame dried vial containing (R,R)-4.10 ligand (62 mg, 0.25 mmol) and 4.16 (15.2 
mg, 0.0125 mmol), was added CH2Cl2 (1.50 mL).  The reaction mixture was cooled to 0 °C and 
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DBU (114 mg, 0.75 mmol)  and cis-crotyltrichlorosilane (49 mg, 0.26 mmol) were sequentially 
added. The reaction mixture was warmed to room temperature and stirred for 2 hr. The reaction 
mixture was cooled to -78 °C and aldehyde 4.17 was added dropwise rinsing with CH2Cl2 (0.5 
mL). The reaction was allowed to warm to -30 °C and was stirred for 12 hr. After 12 hr, the 
reaction mixture was quenched by the addition of n-Bu4NF (65 mg, 0.25 mmol) and stirred at 0 
°C for 1 hr. The reaction mixture was filtered through silica gel plug, rinsing with EtOAc. The 
filtrate was concentrated and resuspended in CH2Cl2 (2.0 mL), additional n-Bu4NF (65 mg, 0.25 
mmol) was added and stirred at 0 °C for 1 hr. The reaction mixture was filtered through a silica 
gel plug, rinsing with EtOAc. The filtrate was concentrated, and purified by buffered (pH 7) 
silica gel flash column chromatography (0-30% EtOAc:Hexanes) to afford diol 4.9f (41.0 mg, 





(R,R)-4.10 (62.0 mg, 0.250 mmol) was dried overnight at 45C under vacuum. (R,R)-
4.10 and 4.16
 
(15.3 mg, 0.013 mmol) were dissolved in dry CH2Cl2 (1.30 mL) and cooled to 0C 
in an ice bath. DBU (0.11 mL, 0.750 mmol) was added, followed by trans-crotyltrichlorosilane 
(0.04 mL, 0.275 mmol) dropwise. The reaction was stirred for 1.5 hours while warming to room 
temperature. The reaction was cooled to -78C and aldehyde 4.11 (azeotroped with toluene 
thrice) was added neat, dropwise, and rinsed with 0.05 mL dry CH2Cl2. The reaction was stirred 
for 1 hour at -30C. The reaction was warmed to 0C, quenched with 1 equivalent of 1M 
nBu4NF in THF, run through a silica gel plug, and concentrated. The product was redissolved in 
CH2Cl2 and cooled to 0C. The residue was treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 
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mmol, 2.00 equiv) and stirred 1 hr at 0 ºC. The crude mixture was run through a silica gel plug, 
concentrated, purified by preparatory TLC followed by silica gel column chromatography (0-
30% EtOAc/Hexanes) to yield diol 4.9g (17.4 mg, 30% yield, 16:1 dr) as a clear oil. 





 3.02 (c 0.1, CHCl3) 





H NMR (500 MHz, Chloroform-d) δ 7.34 – 7.29 (m, 2H), 7.26 – 7.18 (m, 3H), 5.90 (ddd, J = 
17.4, 10.5, 7.9 Hz, 1H), 5.20 – 5.10 (m, 2H), 3.74 (ddd, J = 8.9, 7.6, 2.7 Hz, 1H), 3.45 (dd, J = 
8.8, 3.1 Hz, 1H), 2.88 (ddd, J = 13.6, 10.4, 5.1 Hz, 1H), 2.71 (ddd, J = 13.6, 10.1, 6.3 Hz, 1H), 
2.58 – 2.50 (m, 1H), 1.98 – 1.89 (m, 1H), 1.80 – 1.72 (m, 1H), 1.73 – 1.65 (m, 1H), 1.13 (d, J = 
6.9 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 142.4, 138.2, 128.5, 128.4, 125.8, 116.6, 80.3, 75.6, 41.6, 40.4, 
36.5, 31.6, 17.3, 13.2. 
HRMS (ASAP+) calculated for C16H24O2 [M+H]
+
: 249.1855; found 249.1847 
 
Diol 4.9g (52.0 mg, 0.21 mmol) was dissolved in dimethoxypropane (1.4 mL) and CSA 
(2.4 mg, 0.01 mmol) was added to it. The reaction was stirred and monitored by TLC. After 
disappearance of starting material, the reaction was quenched with NaHCO3, diluted with EtOAc 
and H2O. The organic layer was extracted and washed with H2O once. The organic layer was 
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dried, filtered, concentrated and purified by silica gel column chromatography to yield acetonide 
4.9g (43 mg, 72% yield). 
OR [α]D
20
 +33.84° (c 0.5, CHCl3) 





H NMR (500 MHz, Chloroform-d)  
13
C NMR (400 MHz, CDCl3)  
HRMS (ASAP+) calculated for C19H28O2 [M+H]
+
: 289.2168; found 289.2164 
 
(R,R)-4.10 (62.0 mg, 0.250 mmol) was dried overnight at 45C under vacuum. (R,R)-
4.10 and n-Bu4NBr (4.0 mg, 0.013 mmol) were dissolved in dry CH2Cl2 (1.30 mL) and cooled to 
0C in an ice bath. DBU (0.11 mL, 0.750 mmol) was added, followed by trans-
crotyltrichlorosilane (0.04 mL, 0.275 mmol) dropwise. The reaction was stirred for 1.5 hours 
while warming to room temperature. The reaction was cooled to -78C and aldehyde 4.11 
(azeotroped with toluene thrice) was added neat, dropwise, and rinsed with 0.05 mL dry CH2Cl2. 
The reaction was stirred for 1 hour at -30C. The reaction was warmed to 0C, quenched with 1 
equivalent of 1M nBu4NF in THF, run through a silica gel plug, and concentrated. Product was 
purified by preparatory TLC followed by silica gel column chromatography (0-10% 
EtOAc/Hexanes) to yield protected diol 4.9h (37.0 mg, 60% yield, >20:1 dr) as a clear oil. 
OR [α]D
18
 +1.53º (c 1.0, CHCl3) 






H NMR (500 MHz, CH2Cl2) δ 7.35 – 7.30 (m, 2H), 7.25 – 7.17 (m, 4H), 5.91 (ddd, J = 17.2, 
10.3, 8.0 Hz, 1H), 5.18 – 5.07 (m, 2H), 3.85 (ddd, J = 8.2, 5.3, 3.1 Hz, 1H), 3.77 (dt, J = 9.2, 1.3 
Hz, 1H), 3.57 (d, J = 1.0 Hz, 1H), 2.66 – 2.55 (m, 2H), 2.35 – 2.26 (m, 1H), 2.05 (dddd, J = 13.8, 
10.2, 8.0, 5.8 Hz, 1H), 1.93 (dddd, J = 13.8, 10.4, 6.6, 5.3 Hz, 1H), 1.82 (qdd, J = 7.0, 3.1, 1.8 
Hz, 1H), 1.60 (s, 1H), 1.33 – 1.23 (m, 2H), 1.04 (d, J = 7.1 Hz, 3H), 1.01 – 0.92 (m, 12H), 0.64 
(q, J = 7.9 Hz, 6H). 
13
C NMR (126 MHz, CDCl3) δ 142.5, 141.7, 128.5, 128.2, 126.0, 114.5, 77.9, 73.9, 41.4, 36.8, 
35.9, 32.1, 16.5, 10.7, 7.0, 6.9, 5.0. 
HRMS (ASAP+) calculated for C22H38O2Si [M+H]
+
: 363.2719; found 363.2706 
 
Protected diol 4.9h (18.0 mg, 0.050 mmol) was dissolved in 0.80 mL CH2Cl2 and cooled 
to 0C. The solution was treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) 
and stirred 1 hr at 0 ºC.. The crude mixture was run through a silica gel plug and purified through 
column chromatography (0-40% EtOAc/Hexanes) to yield diol 4.9h as a white solid (9 mg, 72% 
yield, >20:1 dr). 
OR [α]D
21
 -1.34º (c 0.5, CHCl3) 




H NMR (500 MHz, Chloroform-d) δ 7.29 (td, J = 7.4, 1.3 Hz, 2H), 7.24 – 7.16 (m, 3H), 5.70 – 
5.60 (m, 1H), 5.20 – 5.12 (m, 2H), 3.66 (d, J = 9.5 Hz, 1H), 2.90 (ddd, J = 14.7, 10.1, 5.1 Hz, 
1H), 2.67 (ddd, J = 13.7, 9.8, 6.5 Hz, 1H), 2.25 (h, J = 6.9 Hz, 1H), 1.92 (dtd, J = 14.7, 9.6, 5.3 
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Hz, 1H), 1.82 (dd, J = 6.6, 3.5 Hz, 1H), 1.71 (s, 1H), 1.02 (d, J = 7.1 Hz, 3H), 0.93 (d, J = 6.7 
Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 142.4, 141.4, 128.5, 128.4, 125.8, 117.2, 75.7, 73.7, 42.6, 37.8, 
37.7, 32.8, 16.2, 10.3. 
HRMS (ASAP+) calculated for C16H24O2 [M+Na]
+
: 271.1674; found 271.1685 
 
Diol 4 (8 mg, 0.032 mmol) was dissolved in dimethoxypropane (0.42 mL) and CSA (0.5 mg, 
0.002 mmol) was added to it. The reaction was stirred and monitored by TLC. After 
disappearance of starting material, the reaction was quenched with NaHCO3, diluted with EtOAc 
and H2O. The organic layer was extracted and washed with H2O once. The organic layer was 
dried, filtered, concentrated and purified by silica gel column chromatography to yield acetonide 
5 (6 mg, 65% yield). 
OR [α]D
16
 -4.58 (c 0.2, CHCl3) 





H NMR (500 MHz, CH2Cl2δ 7.31 (dt, J = 6.8, 1.0 Hz, 1H), 7.28 (s, 1H), 7.24 – 7.15 (m, 3H), 
5.89 (ddd, J = 17.3, 10.4, 6.9 Hz, 1H), 5.14 – 4.92 (m, 2H), 3.52 (dd, J = 10.5, 4.5 Hz, 1H), 3.24 
(td, J = 7.1, 5.5 Hz, 1H), 2.86 (dt, J = 14.2, 7.3 Hz, 1H), 2.62 (dt, J = 13.8, 8.2 Hz, 1H), 2.28 (dt, 
J = 10.8, 6.6 Hz, 1H), 1.91 – 1.79 (m, 2H), 1.70 (td, J = 7.0, 4.5 Hz, 1H), 1.35 (d, J = 1.1 Hz, 




C NMR (400 MHz, CDCl3) δ 142.2, 142.2, 128.5, 128.3, 125.7, 113.4, 100.8, 74.3, 72.9, 38.6, 
37.1, 36.5, 32.3, 24.9, 23.9, 15.9, 11.6. 
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 CHAPTER 5: Construction of functionalized homoallylic tertiary alcohols 
via novel hexacoordinate allylsilicates 
5.1. Introduction 
A general method for the synthesis on enantioenriched tertiary alcohols represents a long-
standing challenge in organic chemistry.
1–4
 Several reports have used the asymmetric allylation 
of ketones
5–14
 to access these types alcohols
 
and our own group has shown the efficient allylation 
of certain  -diketones to furnish  -hydroxyketones enantioselectively15. Several groups have 
also attempted the allylation of  -diketones16–19 to access the highly sought after  -hydroxy 
ketone moiety. However, the allylation of  -diketones has often been plagued by poor 
enantioselectivity, regioselectivity, and over-allylation addition.
17
 Herein we report a six-
coordinate allylsilicate mediated method for nucleophilic addition to ketones,  -diketones and 
 -diketones. Using the Leighton group’s previously reported20 diaminophenol ligated allylsilane 
5.1, two different allylation mechanisms can be utilized (Figure 5.1).  The addition of a 
tetrabutylammonium anion catalyst results in transition state A, whereas addition of a dicarbonyl 
substrate and no catalyst results in transition state B. Through weakly coordinating anion 
catalysis, we can access the allylation of ketones and  -diketones, which can be biased to act as 
an activated ketone substrate. We also report the asymmetric and regioselective allylation of  -
diketones and  -diketones through a six-coordinate allylsilicate which intercepts the diketone’s 
keto-enol form for dual coordination. The practical development in the synthetic ease, scalability 
and efficiency of generating a diverse array of homoallylic tertiary alcohols and alcohol 
derivatives is to our knowledge, the first general method for the allylation of all three of the 




Figure 5.1: Proposed hexacoordinate allylsilicate transition states of ketones and diketones. 
 
5.2. Ketone allylation 
5.2.1. Initial ketone allylation results 
Having recently reported the discovery of weakly coordinating anions as catalyst for the 
allylsilylation reactions of aldehydes employing strained diaminophenol ligated allyl-silanes, we 
turned our focus to expanding the scope from aldehydes to a larger and more general array of 
carbonyl equivalents. Having studied the dramatic acceleration in the overall rate of aldehyde 
allylation using n-Bu4NBr, the first and most direct application of this method was toward the 
allylsilylation of ketones to access the historically elusive tertiary carbinol. Whereas a high 
degree of stereoselectivity may be expected in additions to simple aldehydes, as has been 
explained in the transition state analysis in Chapter 4, the same cannot be said of ketones. The 
aldehyde stereoselectivity mainly arises from the drastic difference in sterics that favors a 
hydrogen-ligand interaction over an alkyl group/ligand interaction.
21
 A ketone, by definition, 
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lacks a hydrogen and instead has two alkyl groups therefore the desired reaction pathway 




 It was known to us that the allylation of ketones using 1 in the absence of any catalyst 
resulted in low yields of product, even after extended reaction times and elevated reaction 
temperatures.  With the addition of only 5 mol% n-Bu4NBr, however, we were exceptionally 
pleased to see that the allylation of acetophenone proceeded at 23 ºC in 48 h and yielded the 
desired homoallylic tertiary alcohol in an 86% yield and 97% ee (entry 1, Table 5.1). This result, 
while exceptionally encouraging in its own right, also motivated us to explore the 
















5.2.2. Ketone substrate scope 
Table 5.1:Ketone scope. 
 



































Silane 5.3A was generated in situ via allyl chloride which then underwent ligand complexation and allylation of 
acetophenone. 
In particular, the extension to aliphatic ketones and its ability to distinguish between 
simple, non-functionalized carbonyls. The allylsilylation of 2-butanone (entry 2, Table 5.1), was 
performed and was able to give the product in 78% yield and 78% ee. This result exemplifies the 
unique ability of our system to distinguish between methyl and ethyl substituents, which are 
nearly indistinguishable in their stereoelectronic contribution when considering the closed, 6-
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membered transition state A (Figure 5.1). Having a one-pot procedure capable of distinguishing 
methyl and ethyl carbonyl substituents, we set out to explore a general understanding in the 
scope of ketones, with an emphasis on varied electronic and steric substituents. Electron 
withdrawing and electronic donating aromatic ketones performed exceptionally well as seen in 
entry 5 and entry 6. Furthermore, nonaromatic ketones, including benzylacetone, are efficiently 
allylated in good yields and selectivities, entry 3. Importantly, the generalizability of this method 
for the enantioselective allylsilylation of ketones with allyl halides as a late stage fragment 
coupling strategy was demonstrated in entry 4 with the allylation of acetophenone starting from 
the corresponding allyl chloride.   
5.2.3. Mechanistic analysis 
The catalysis of our weakly coordinating anions is facilitated by the remarkable ability of 
our strained, lewis acidic allylsilanes to accept the electron density of weakly-coordinating 
anions. Initially, this results in the rehybridization at silicon of 5.1 from tetrahedral geometry to 
trigonal pyramidal. Rehybridization from the tetracoordinate allylsilane 5.1 to a pentacoordinate 
anion-bound allylsilicate substantially increases the lewis acidic character of our silicon center 
and therefore renders the allylsilicate more reactive. The increased reactivity of the 
pentacoordinate anion-bound allylsilicate results in the rapid coordination of reactive carbonyls, 
inducing a second rehybridization to octahedral-like geometry and access to the highly reactive 
hexacoordinate allylsilicate seen in Transition State A (Figure 5.1). Rapid allyl transfer furnishes 
the allylsilylation product. This work has permitted us to expand the scope of our diaminophenol 
ligated allylsilane reagents from previously reported aldehydes to include the less reactive class 
of ketones.   
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Upon closer inspection of the mechanistic pathway, and with the ultimate goal of 
continued progress towards the development of a universal carbonyl allylation procedure, we 
predicted that not only simple carbonyls but functionalized carbonyls, including  - and  -
diketones, should be amenable to analogous catalysis as well.  In particular, we were deeply 
interested in the effect our weakly coordinating anions would have on the selectivity and rate of 
carbonyls that had the ability to chelate to our silane and access a transition state B like 
configuration (Figure 5.1). 
The particular relevance of this exploration comes from our understanding that mono-
coordination or chelation of a given dicarbonyl should result in an inversion of enantio- and 
diastereoselectivity. Traditional type-1 allyl and crotylsilylation reactions of monocarbonyls 
proceed through a closed, chair-like transition state where the enantioselectivity and 
diastereoselectivity are correlated to the size of the carbonyl substituents and the E/Z ratio of the 
crotyl reagent respectively (Figure 5.2A).  In the absence of any exogenous catalyst, we would 
expect a majority of dicarbonyls to proceed through a chelated pathway (Figure 5.2B).  -
diketones and  -diketones would form either 5- or 6-membered rings in their respective 
transition states.  If the presence of exogenous catalysts can promote the proposed 
stereochemical inversion for our dicarbonyls, implying a bias towards mono-coordination of the 
diketone, pathway A would act as the primary pathway, enabling an additional level of control 




Figure 5.2: Type-1 allyl and crotylsilylation reactions of A) monocarbonyl coordination and B) dicarbonyl 
coordination. C) Conditions enabling either of two pathways seen. 
The selectivity for simple ketones seen in Table 5.1 is consistent with the model of type-1 
crotylsilylation reactions as is seen in entries 7 and 8 where we observe the expected 
diastereoselectivity.  With the expected inversion in overall selectivity, following model B, we 
turned our focus to  - and  -diketones. Interestingly, the selectivity of  -diketones was not a 
simple and complete reversal in selectivity that was predicted. We attribute this difference to 
primarily two factors, namely (1) the conformational arrangement of acyclic  -diketones and (2) 
the equilibrium between keto and enol forms. 
5.3.  -diketone allylation 
5.3.1. Mechanistic hypothesis 
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We envision  -diketones as being the bridge between the two proposed mechanistic 
pathways and therefore can either go through pathway A, if catalyzed by an exogenous anion, or 
pathway B, if chelation of the second carbonyl oxygen takes place (Figure 5.2C).  To provide 
evidence for our mechanistic understanding of  -diketone reactivity, we compared the allylations 
of 2,3-butadione and 1,2-cyclohexadione. Both substrates undergo allylsilylation with high 
yields giving 98% and 88% respectively (entries 1 and 2, Table 5.3). The allylation product of 
1,2-cyclohexadione facilitates the excellent enantioselectivity of 85% as we are accustomed to 
when using the our diaminophenol ligated silane 5.1. The allylsilylation of 2,3-butadione 
provides an enantioenrichment of 34%, which is comparable to previously reported asymmetric 
allylations of 2,3-butadione. We attribute this difference to those factors enumerated before, 
namely the energetic cost of arranging the acyclic 2,3-butadione into the necessary orientation 
for substrate chelation, as well as the stereoelectronic contributions of the substituents being 
relatively similar in the relevant transition state. 1,2-cyclohexadione is conformationally 
constrained in the cyclohexyl ring such that both carbonyls are locked in the “s-cis” 
conformation and are therefore readily available to chelate to our allylsilane to form exclusively 
the substrate chelated, highly reactive 6-coordinate allylsilicate.  
In order to explore the possibility of tunability and to provide further evidence for our 
mechanistic hypothesis of  -diketones, we performed a screen of 2,3-butadione with anions 
known to have differing affinities for silanes (Table 5.2). Our goal was to see if we could bias our 
system from proceeding predominantly through pathway TS B to primarily the anion catalyzed, 
mono-coordinated pathway TS A  (Figure 5.2C). While addition of catalytic TBAB performed 
approximately as well as the catalyst free conditions (entries 1 and 2, Table 5.2), when we moved 
to fluoride containing anions, PF6 and BF4, we saw a progressive drop in ee (entries 3 and 4, 
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Table 5.2). While PF6 and BF4 are generally considered to be “non-coordinating” anions, when a 
Lewis acidic silicon center is present, the fluoro-philicity of silicon induces stronger binding of 





, but less so for Br
-
.  Additionally, upon a stoichiometric amount of BF4
-
 and 
running the reaction at 0 °C, we were able to accomplish the inversion in the overall 
stereoselectivity of these allylation reactions (entry 5, Table 5.2). This evidence is consistent with 
our model that these conditions promote the anion catalyzed allylation of acyclic  -diketones 
over the substrate chelated pathways.  
Table 5.2: Anion screen. 
 
Entry Catalyst X mol (%) Temp (ºC) ee (%) 
1 No cat 0 -40 34 
2 n-Bu4NBr 5 -40 35 
3 n-Bu4NPF6 5 -40 27 
4 n-Bu4NBF4 100 -40 10 
5 n-Bu4NBF4 100 0 -20 
 
5.3.2.  -diketones scope 
The allylation of 3-methyl-1,2-cyclohexadione was performed to gain a better 
understanding of the regioselectivity of our system (entry 3, Table 5.3). This  -diketone 
primarily exists as the more highly substituted enol and therefore we would expect a majority of 
allylation to take place at the C1 carbonyl. Satisfyingly, this reaction gave entry 3 in a yield of 
88% and a regioselectivity of 13:1 for the expected allylation product as well as providing a 
single diastereomer. Finally, to probe the importance of the keto-enol tautomerization and its 
effect on the overall rate of allylation, we explored the allylation of 1-phenyl-1,2-propanedione 
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(Entry 4, Table 5.3).  While the terminal methyl ketone has  -hydrogens amenable for 
enolization, initially indicating that allylation of the benzyl ketone to be the favored product, we 
still observe a majority of allylation taking place at the methyl ketone with a selectivity of 10:1. 
We believe this selectivity can be simply attributed to the differences in the rate of allylating 
aromatic and aliphatic carbonyls. Therefore, the selectivity of keto-enol conformations is 
important when comparing equally reactive ketones, but the difference in allylation rates 
between aromatic and aliphatic ketones outcompetes the keto-enol conformational equilibrium 
selectivity.  
Table 5.3:  -diketone substrate scope. 
 
Entry Product Yield (%) ee (%) rr 
1 
 
98 34 -- 
2 
 









42 -- 10:1 
 
5.4.  -diketone allylation 
5.4.1. Initial results 
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When approaching  -diketones however, we believed that the structural obstacles we saw 
with  -diketones would not be present. It has been widely reported, including from our group15, 
that  -diketones exist predominately in the cis-enolic form with the keto-oxygen participating in 
hydrogen bonding with the enol-oxygen.  This encouraged us that the allylation of  -diketones 
should proceed efficiently through pathway B. Satisfyingly, when reacting acetylacetone with 
allylsilane 1 for 12 hours at 0ºC we obtained our homoallylic  -hydroxyketone product, in a 93% 
yield and 98% ee (entry 1, Table 5.4). Strikingly, under conditions utilizing catalytic n-Bu4NBr 
in order to bias our substrate into monocarbonyl coordination and allylation, we failed to have 
any effect on the ee and only accomplished inhibiting the productive pathway, obtaining a 20% 
yield (entry 1, Table 5.4). These results are consistent with our hypothesis that in the case of 
acetylacetone, the  -carbonyl was playing a non-innocent role by effectively chelating to silicon 
and facilitating the rehybridization of silicon from the pentacoordinate allylsilicate 5.4 to a 
substrate-tethered, highly reactive hexacoordinate allylsilicate 5.5 (Figure 5.3A). Additionally, 
this also indicated that the substrate-chelated pathway is highly favored for  -diketones over the 
relatively unproductive intermediate of monocarbonyl coordination along with anion 





Figure 5.3: A) Proposed Pathway for  -diketones accessing hexacoordinate allylsilicate via chelation of both 
oxygens. B) Preparation of non-reactive hexacoordinate methylsilicate and proposed mode of anion inhibition 
of  -diketone reactions. 
5.4.2. Mechanistic investigations 
To further probe this mechanistic proposal, we endeavored to prepare a sample of the 
unreactive hexacoordinate methylsilicate 5.7 (Figure 5.3B). This would allow for possibility of 
spectroscopically observing a  -diketone-bound hexacoordinate silicate. We observed a single 
resonance at -160 ppm in the 
29
Si NMR, consistent with hexacoordinate silicates.  Upon addition 
of excess n-Bu4NBr, we observe a new resonance at -218 ppm in the 
29
Si NMR, which we 
attribute to the anion bound hexacoordinate silicate 5.9, and complete disappearance of the 
resonance attributed to 5.8. Therefore, we believe the presence of exogenous anions in reactions 
of  -diketones serve the role of inhibiting the effective overall rate of the reaction by reducing 
the amount of reactive hexacoordinate allylsilicate 5.5. We confirmed this by extending the 
reaction time of acetylacetone with catalytic n-Bu4NBr from 12 hours to 36 hours and saw a 
concurrent increase in yield from 20% to 39%, all the while maintaining the exceptionally high 
ee. Finally, the attempted allylation of 1,3- cyclohexadione, a  -diketone conformationally 
constrained such that chelation should not be possible, provided only trace allylation product, an 
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expected result of a non-chelated, non-catalyzed ketone allylation. This provides further evidence 
that the underlying mechanistic model of substrate activation of the allylsilane via chelation to 
the hexacoordinate allylsilicate as a valid pathway. 
5.4.3.  -diketone scope 
With generalized reaction conditions worked out, as well as a mechanistic model 
consistent with our understanding of highly reactive hexacoordinate silicates, we performed a 
general screen of interesting and commercially available  -diketones (Table 5.4). Symmetric 
diaryl and dialkyl  -diketones readily undergo allylation, all with excellent yields and high 
enantioselectivities (entries 1-4, Table 5.4). Allylation of an unsymmetric aryl-alkyl  -diketone 
gave entry 5 in a 93% yield and >20:1 regioselectivity The most important improvement of this 
methodology is the ability of this system to distinguish between unsymmetric dialkyl 
substituents, a limitation of many  -diketone allylation methodologies15. This fact is highlighted 
in entry 6, where we are able to obtain a regioselectivity of 5:1 for the methyl ketone allylation 
product over allylation at the tert-butyl ketone, a system that was indistinguishable in our 
previously reported 1
st
 generation  -diketone allylation methodology. Finally, to confirm the 
utility of this methodology as a possible late stage fragment coupling reaction for  -diketones, 
we performed a one-pot allylation of acetylacetone starting from the corresponding allyl chloride 




Table 5.4:  -diketone substrate scope. 
 






2  91 99 -- 
3 
 
95 96 -- 
4 
 
91 94 -- 
5 
 
93 -- >20:1 
6 
 




93 98 -- 
aYield in parentheses was obtained in the presence of TBAB as catalyst. bAllyltrichlorosilane was generated in 
situ via allyl chloride which then underwent ligand complexation and allylation of acetylacetone. 
5.5. Summary and outlook 
We have demonstrated significant progress towards a universal methodology for the 
construction of homoallylic tertiary alcohols via highly reactive hexacoordinate allylsilicates. We 
can perform allylsilylation reactions of ketones,  -diketones and  -diketones all starting from 
the same diaminophenol-ligated allyl silane generated in situ. Catalytic, weakly coordinating 
anions enable access to the necessary hexacoordinate allylsilicate which provides the sufficient 
rate acceleration for the allylsilylation reactions of aliphatic and aromatic ketones with high 
yields and enantioselectivities. Functionalized  -diketones access the corresponding 
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hexacoordinate allylsilicate via substrate chelation and rapidly undergo allyl transfer with not 
only high enantioselectivities, but also hitherto unseen regioselectivity of unsymmetrical  -
diketones in this system. The allylation of  -diketones can proceed through either an anion-
catalyzed pathway or chelation of both carbonyls. Overall the method allows for the protecting-
group-free, single-step synthesis of functionally and stereochemically complex products from 
readily available — and undifferentiated —  - and  -diketone starting materials. We have 
elucidated important aspects of the proposed mechanism of the hexacoordinate silicate allylation.  
Further work will include application of this methodology towards late stage fragment coupling 
of complex natural products. We envision biasing acyclic  -diketone allylsilylation reactions to 
proceed exclusively through one pathway such that we will be able to achieve the high 
enantioselectivities we expect from this ligand platform.  The mild reaction conditions, synthetic 
ease and general utility of this methodology in selectively constructing homoallylic alcohols 
from mono and dicarbonyl starting materials is a major step in the realization of a single method 
to construct any type of homoallylic alcohol. 
5.6. Experimental procedures 
5.6.1. General information 
All reactions were carried out under an inert atmosphere of argon in flame-dried glassware with 
magnetic stirring unless otherwise indicated.  Degassed solvents were purified by passage 
through an activated alumina column.  Et3N was distilled from CaH2; DBU was distilled from 
CaH2 onto 4 Å molecular sieves and stored under inert atmosphere.  All ketone,  -diketones and 
 -diketone substrates were purified immediately prior to use. All other reagents were purchased 
from commercial sources and used without further purification unless otherwise noted.  Flash 
chromatography was performed with Silicycle SiliaFlash® P60 silica gel.  Thin-layer 
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chromatography (TLC) was carried out on glass backed silica gel TLC plates (250 nm) from 
Silicycle; visualization by UV, phosphomolybdic acid (PMA), or Potassium Permanganate 
(KMnO4).     
Diastereomeric ratios for all compounds were determined by 
1
H NMR analysis of the unpurified 




C data were obtained using Bruker AVIII 500 (500 MHz) 
spectrometer and are reported in ppm.  
1
H NMR spectra were internally referenced to CDCl3 
(7.26 ppm); 
13
C NMR spectra were internally referenced to CDCl3 (77.23 ppm); Data are 
reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = triplet, m = multiplet, dd = 
doublet of doublets, ddd = doublet of doublet of doublets, ddt = doublet of doublet of triplets, td 
= triplet of doublets; coupling constant(s) in Hz; integration).  Infrared spectra were recorded on 
a Perkin-Elmer Spectrum Two (Diamond ATR) IR spectrometer.  Optical rotations were recorded 
on a Jasco DIP-1000 polarimeter.  HPLC analysis was carried out on an Agilent 1200 Series 
using a Chiralpak OD-H (250 x 4.5 mm ID) column.  Mass Spectroscopy Data was obtained on a 
Waters XEVO G2-XS QToF mass spectrometer.   
5.6.2. Allylation reactions of ketones  
General Procedure A for one-pot allylation or crotylation of ketones: A 2-dram vial, equipped 
with a stir bar, was charged with 5.2 (290 mg, 1.00 mmol, 1.05 equiv) n-Bu4NBr (16 mg, 0.050 
mmol, 0.052 equiv) and CH2Cl2 (10 mL) under Ar atmosphere. To the reaction mixture DBU 
(449 μL, 3.00 mmol, 3.15 equiv) was added dropwise via syringe. The reaction mixture was 
cooled to 0°C and allyltrichlorosilane (159 μL, 1.1 mmol, 1.1 equiv) is then added dropwise via 
syringe to the reaction mixture. The cooling bath was removed and the mixture was stirred 1 hr 
at room temperature. The silane solution was then re-cooled to 0 ºC and the ketone (0.95 mmol, 
1.0 eqiuv) was added.  The reaction was then conducted at 23 ºC for the indicated time. Upon 
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consumption of the ketone substrate, the reaction mixture was treated with n-Bu4NF (1M in THF, 
1.2 mL, 1.2 mmol, 1.2 equiv) and stirred 1 hr at 0ºC.  The mixture was then passed through a 
silica plug with EtOAc and concentrated to give the crude product, which was purified by flash 
column chromatography. 
General Procedure B for one-pot allylation or crotylation of ketones: A 2-dram vial, equipped 
with a stir bar, was charged with copper (I) bromide (7.2 mg, 0.050 mmol, 0.052 equiv) in an 
argon-atmosphere glove box. The vial was capped with a septum and transferred out of the glove 
box. The vessel was charged with CH2Cl2 (3 mL) and Et3N (195 μL, 1.40 mmol, 1.47 equiv) and 
n-Bu4NBr (16 mg, 0.050 mmol, 0.052 equiv). In a separate vial under Ar atmosphere, allyl 
chloride (1.00 mmol, 1.05 equiv), CH2Cl2 (2 mL), and Cl3SiH (121 μL, 1.20 mmol, 1.26 equiv) 
were sequentially added. To the cooled 0 ºC solution of CuBr, was added the allyl chloride 
solution dropwise via syringe. The allyl chloride vial was then rinsed with 1 mL CH2Cl2, this 
solution was added to the reaction flask, and the resulting mixture was stirred 2 hrs at 0 ºC.  A 
solution of the 5.2 (290 mg, 1.00 mmol, 1.05 equiv) and DBU (449 μL, 3.00 mmol, 3.15 equiv) 
in CH2Cl2 (2 mL + 0.5 mL rinse) was added dropwise via syringe to the reaction mixture.   The 
cooling bath was removed and the mixture was stirred 1 hr at room temperature. The silane 
solution was then re-cooled to 0 ºC and the ketone (0.95 mmol, 1.0 eqiuv) was added.  The 
reaction was then conducted at 23 ºC for the indicated time. Upon consumption of the ketone 
substrate, the reaction mixture was treated with n-Bu4NF (1M in THF, 1.2 mL, 1.2 mmol, 1.2 
equiv) and stirred 1 hr at 0ºC.  The mixture was then passed through a silica plug with EtOAc 






Prepared using Procedure A with acetophenone (111 mg, 0.95 mmol, 0.95 equiv).  Purified by 
silica gel flash column chromatography (0–10% EtOAc/Hexanes) to give the product as a clear 
oil (153 mg, 86% yield, 97% ee). 
[Daicel Chiracel AD-H, 96:4 Hexanes:IPA, 1.0 mL/min, 254 nm; t1= 8.06 min, t2= 11.64 min]. 
Spectral data were in agreement with reported values. 
(R)-3-methylhex-5-en-3-ol: 
 
Prepared using Procedure A with 2-butanone (68.5 mg, 0.95 mmol, 0.95 equiv).  Purified by 
silica gel flash column chromatography (0–10% EtOAc/Hexanes) to give the product as a clear 
oil (86.78 mg, 76% yield, 78% ee).  
[Daicel Chiracel OD-H, 98:2 Hexanes:IPA, 1 mL/min, 254 nm; t1= 9.55 min, t2= 10.33 min], 
Spectral data were in agreement with reported values. 
(R)-3-methyl-1-phenylhex-5-en-3-ol: 
 
Prepared using Procedure A with benzylacetone (91 mg, 1.0 mmol). Purified by silica gel flash 
column chromatography (5–15% EtOAc/Hexanes) to give the product as a pale yellow oil (162 
mg, 76% yield, 78% ee).  
[Daicel Chiracel OD-H, 95:5 Hexanes:IPA, 1 mL/min, 254 nm; t1= 7.51 min, t2=10.84 min], 





Prepared using Procedure B with acetophenone (111 mg, 0.95 mmol, 0.95 equiv).  Purified by 
silica gel flash column chromatography (0–10% EtOAc/Hexanes) to give the product as a clear 
oil (138 mg, 85% yield, 97% ee). 
[Daicel Chiracel AD-H, 96:4 Hexanes:IPA, 1.0 mL/min, 254 nm; t1= 8.06 min, t2= 11.64 min]. 
Spectral data were in agreement with reported values. 
(2S,3S)-3-methyl-2-phenylpent-4-en-2-ol: 
 
Prepared using Procedure A with acetophenone (111 mg, 0.95 mmol, 0.95 equiv).  Purified by 
silica gel flash column chromatography (0–10% EtOAc/Hexanes) to give the product as a clear 
oil (163 mg, 93% yield, >20:1 dr).  
Spectral data were in agreement with reported values. 
(2S,3R)-3-methyl-2-phenylpent-4-en-2-ol 
 
Prepared using Procedure A with acetophenone (111 mg, 0.95 mmol, 0.95 equiv).  Purified by 
silica gel flash column chromatography (0–10% EtOAc/Hexanes) to give the product as a clear 
oil (158 mg, 90% yield, >20:1 dr).  
Spectral data were in agreement with reported values.  
5.6.3. Allylation reactions of  -diketones 
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General Procedure C for one-pot allylation of  -diketones: A 2-dram vial, equipped with a stir 
bar, was charged with 5.2 (290 mg, 1.00 mmol, 1.05 equiv), and CH2Cl2 (10 mL) under Ar 
atmosphere. To the reaction mixture DBU (449 μL, 3.00 mmol, 3.15 equiv) was added dropwise 
via syringe. The reaction mixture was cooled to 0°C and allyltrichlorosilane (159 μL, 1.1 mmol, 
1.1 equiv) is then added dropwise via syringe to the reaction mixture. The cooling bath was 
removed and the mixture was stirred 1 hr at room temperature. The silane solution was then re-
cooled to -40 ºC and the  -diketone (0.95 mmol, 1.0 eqiuv) was added.  The reaction was then 
conducted at -40 ºC for the indicated time. Upon completion, the reaction mixture was treated 
with n-Bu4NF (1M in THF, 2.0 mL, 2.0 mmol, 2.0 equiv) and stirred 1 hr at -40 ºC.  The mixture 
was then passed through a silica plug with EtOAc and concentrated to give the crude product, 
which was purified by flash column chromatography. 
(S)-3-hydroxy-3-methylhex-5-en-2-one: 
 
Prepared using Procedure C with 2,3-butanedione (86.1 mg, 0.95 mmol) with a 12 hr reaction 
time at 0 ºC.  Purified by silica gel flash column chromatography (0–10% EtOAc/Hexanes) to 
give the product as a clear oil (125 mg, 98% yield, 34% ee). 
[Daicel Chiracel AD-H, 99:1 Hexanes:IPA, 0.75 mL/min, 210 nm; t1= 14.64 min, t2= 15.51 





Prepared using Procedure C with 1,2-cyclohexanedione (112 mg, 0.95 mmol) with a 12 hr 
reaction time at 0 ºC.  Purified by silica gel flash column chromatography (0–20% 
EtOAc/Hexanes) to give the product as a clear oil (136 mg, 88% yield, 85% ee). 
[Daicel Chiracel AD-H, 98:2 Hexanes:IPA, 1 mL/min, 210 nm; t1= 12.85 min, t2=13.85 min] 
Spectral data were in agreement with reported values.  
(2S)-2-allyl-2-hydroxy-6-methylcyclohexan-1-one 
 
Prepared using Procedure C with 1,2-cyclohexanedione (127.1 mg, 0.95 mmol) with a 12 hr 
reaction time at 0 ºC.  Purified by silica gel flash column chromatography (0–15% 
EtOAc/Hexanes) to give the product as a clear oil (148 mg, 88% yield, >20:1 dr, 13:1 rr). 
Spectral data were in agreement with reported values.  
(R)-2-hydroxy-2-methyl-1-phenylpent-4-en-1-one: 
 
Prepared using Procedure C with 1-phenylpropane-1,2-dione (148 mg, 0.95 mmol) with a 12 hr 
reaction time at 0 ºC.  Purified by silica gel flash column chromatography (0–20% 
EtOAc/Hexanes) to give the product as a clear oil (79.9 mg, 42% yield, 10:1 rr). 
Spectral data were in agreement with reported values.  
5.6.4. Allylation reactions of  -diketones 
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General Procedure D for catalyst-free one-pot allylation of  -diketones: A 2-dram vial, 
equipped with a stir bar, was charged with 5.2 (290 mg, 1.00 mmol, 1.05 equiv) and CH2Cl2 (10 
mL) under Ar atmosphere. To the reaction mixture DBU (449 μL, 3.00 mmol, 3.15 equiv) was 
added dropwise via syringe. The reaction mixture was cooled to 0°C and allyltrichlorosilane (159 
μL, 1.1 mmol, 1.1 equiv) is then added dropwise via syringe to the reaction mixture. The cooling 
bath was removed and the mixture was stirred 1 hr at room temperature. The silane solution was 
then re-cooled to -78 ºC and the  -diketone (0.95 mmol, 1.0 eqiuv) was added.  The reaction was 
then conducted at 0 ºC for the indicated time. Upon consumption of the  -diketone, the reaction 
mixture was treated with n-Bu4NF (1M in THF, 2.0 mL, 2.0 mmol, 2.0 equiv) and stirred 1 hr at 
0ºC.  The mixture was then passed through a silica plug with EtOAc and concentrated to give the 
crude product, which was purified by flash column chromatography. 
General Procedure E for one-pot allylation of  -diketones via in situ allyltrichlorosilane 
formation: A 2-dram vial, equipped with a stir bar, was charged with copper (I) bromide (7.2 mg, 
0.050 mmol, 0.052 equiv) in an argon-atmosphere glove box. The vial was capped with a septum 
and transferred out of the glove box. The vessel was charged with CH2Cl2 (3 mL) and Et3N (195 
μL, 1.40 mmol, 1.47 equiv) and n-Bu4NBr (16 mg, 0.050 mmol, 0.052 equiv). In a separate vial 
under Ar atmosphere, allyl chloride (1.00 mmol, 1.05 equiv), CH2Cl2 (2 mL), and Cl3SiH (121 
μL, 1.20 mmol, 1.26 equiv) were sequentially added. To the cooled 0 ºC solution of CuBr, was 
added the allyl chloride solution dropwise via syringe. The allyl chloride vial was then rinsed 
with 1 mL CH2Cl2, this solution was added to the reaction flask, and the resulting mixture was 
stirred 2 hrs at 0 ºC.  A solution of the 5.2 (290 mg, 1.00 mmol, 1.05 equiv) and DBU (449 μL, 
3.00 mmol, 3.15 equiv) in CH2Cl2 (2 mL + 0.5 mL rinse) was added dropwise via syringe to the 
reaction mixture.   The cooling bath was removed and the mixture was stirred 1 hr at room 
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temperature. The silane solution was then re-cooled to -78 ºC and the  -diketone (0.95 mmol, 
1.0 eqiuv) was added.  The reaction was then conducted at 0 ºC for the indicated time. Upon 
consumption of the  -diketone, the reaction mixture was treated with n-Bu4NF (1M in THF, 2.0 
mL, 2.0 mmol, 2.0 equiv) and stirred 1 hr at 0ºC.  The mixture was then passed through a silica 




Prepared using Procedure D with acetylacetone (97 mg, 095 mmol) with a 12 hr reaction time at 
0 ºC. Purified by silica gel flash column chromatography (0-10% EtOAc/Hexanes) to give the 
product as a pale yellow oil (137 mg, 96% yield, 98% ee). 
[Daicel Chiracel AD-H, 99:1 Hexanes:IPA, 0.75 mL/min, 210 nm; t1= 14.64 min, t2= 15.51 
min], Spectral data were in agreement with reported values. 
(S)-3-hydroxy-1,3-diphenylhex-5-en-1-one: 
 
Prepared using Procedure D with 1,3-diphenylpropane-1,3-dione (213 mg, 095 mmol) with a 12 
hr reaction time at 0 ºC. Purified by silica gel flash column chromatography (10% 
EtOAc/Hexanes) to give the product as an off white solid (242 mg, 91% yield, 99% ee). 
[Daicel Chiracel AD-H, 97:3 Hexanes:IPA, 1 mL/min, 254 nm; t1= 13.38 min, t2= 15.68 min], 





Prepared using Procedure D with 1,3-bis(4-bromophenyl)propane-1,3-dione (362 mg, 0.95 
mmol) with a 18 hr reaction time at 0 ºC. Purified by silica gel flash column chromatography 
(15% EtOAc/Hexanes) to give the product as an off white solid (386 mg, 91% yield, 94% ee). 
[Daicel Chiracel AD-H, 96:4 Hexanes:IPA, 1 mL/min, 254 nm; t1= 16.08 min, t2= 18.84 min], 
Spectral data were in agreement with reported values. 
(S)-3-hydroxy-3-methyl-1-phenylhex-5-en-1-one: 
 
Prepared using Procedure D with 1-phenylbutane-1,3-dione (154 mg, 0.95 mmol) with a 12 hr 
reaction time at 0 ºC. Purified by silica gel flash column chromatography (10% EtOAc/Hexanes) 
to give the product as an off white solid (190 mg, 93% yield, >20:1 rr). 
Spectral data were in agreement with reported values. 
(S)-5-hydroxy-2,2,5-trimethyloct-7-en-3-one: 
 
Prepared using Procedure D with 5,5-dimethylhexane-2,4-dione (135 mg, 0.95 mmol) with an 18 
hr reaction time at 0 ºC. Purified by silica gel flash column chromatography (10% 
EtOAc/Hexanes) to give the product as an off white solid (116 mg, 88% yield, 5:1 rr).  
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Spectral data were in agreement with reported values.  
(S)-4-hydroxy-4-methylhept-6-en-2-one: 
 
Prepared using Procedure E with acetylacetone (105 mg, 0.95 mmol) with a 12 hr reaction time 
at 0 ºC. Purified by silica gel flash column chromatography (0-15% EtOAc/Hexanes) to give the 
product as a pale yellow oil (132 mg, 93% yield, 98% ee).  
[Daicel Chiracel AD-H, 99:1 Hexanes:IPA, 0.75 mL/min, 210 nm; t1= 14.64 min, t2= 15.51 
min], Spectral data were in agreement with reported values. 
5.6.5. Mechanistic investigations of  -diketones 
Allylsilane 5.1: 
 
A 100-mL round bottom flask, equipped with a stir bar, was charged with 5.2 (290 mg, 1.00 
mmol, 1.05 equiv) and Et2O (20 mL) under N2 atmosphere. To the reaction mixture DBU (449 
μL, 3.00 mmol, 3.15 equiv) was added dropwise via syringe. The reaction mixture was cooled to 
0°C and allyltrichlorosilane (159 μL, 1.1 mmol, 1.1 equiv) is then added dropwise via syringe to 
the reaction mixture. The cooling bath was removed and the mixture was stirred 1 hr at room 
temperature. Stirring was suspended and the entire solution was transferred to a new 100mL 
round bottom flask via syringe equipped with a filter to remove the precipitated DBU•HCl salts. 
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The volatiles (Et2O) were removed by under vacuum to afford 5.1 as a clear viscous oil which 
was analyzed without further purification.  
1
H NMR (500 MHz, CDCl3) δ 7.23-7.18 (m, 1H), 6.90 – 6.84 (m, 1H), 6.82 (t, J = 7.5 Hz, 1H), 
5.95 (ddt, J = 16.9, 10.1, 7.8 Hz, 1H), 5.16 – 5.07 (m, 1H), 5.04 – 4.95 (m, 1H), 4.23 (d, J = 15.6 
Hz, 1H), 3.69 (d, J = 15.7 Hz, 1H), 2.54 – 2.42 (m, 1H), 2.47 (s, 3H), 2.13 (ddd, J = 10.5, 9.0, 
3.3 Hz, 1H), 2.06 – 1.90 (m, 4H), 1.74 – 1.63 (m, 2H), 1.39 (s, 9H), 1.26 – 1.15 (m, 1H), 1.14 – 
1.03 (m, 2H), 0.86 – 0.73 (m, 1H); 
13
C NMR (126 MHz, CDCl3) δ 152.9, 139.6, 135.9, 132.0, 
130.2, 129.3, 127.2, 125.9, 121.6, 120.5, 115.7, 64.9, 62.6, 54.7, 49.0, 47.5, 38.1, 34.9, 32.3, 
30.3, 30.1, 30.0, 30.0, 29.9, 29.6, 29.3, 25.0, 24.8, 24.3, 19.8, 18.9; 
29




A 100-mL round bottom flask, equipped with a stir bar, was charged with 5.2 (290 mg, 1.00 
mmol, 1.05 equiv) and Et2O (20 mL) under N2 atmosphere. To the reaction mixture DBU (449 
μL, 3.00 mmol, 3.15 equiv) was added dropwise via syringe. The reaction mixture was cooled to 
0°C and methyltrichlorosilane (121 μL, 1.2 mmol, 1.2 equiv) is then added dropwise via syringe 
to the reaction mixture. The cooling bath was removed and the mixture was stirred 1 hr at room 
temperature. Stirring was suspended and the entire solution was transferred to a new 100mL 
round bottom flask via syringe equipped with a filter to remove the precipitated DBU•HCl salts. 
The volatiles (Et2O) were removed by under vacuum to afford methylsilane 5.7 as a clear viscous 




H NMR (500 MHz, CDCl3) δ 7.19 (ddd, J = 7.8, 1.8, 0.7 Hz, 1H), 6.97 – 6.72 (m, 3H), 4.23 (d, 
J = 15.6 Hz, 1H), 3.71 (d, J = 15.7 Hz, 1H), 2.51 – 2.35 (m, 4H), 2.20 – 2.09 (m, 2H), 2.09 – 
2.00 (m, 1H), 1.99 – 1.88 (m, 1H), 1.79 – 1.60 (m, 3H), 1.39 (d, J = 8.9 Hz, 12H), 1.15 – 1.04 
(m, 3H), 0.87 – 0.71 (m, 1H), 0.44 (s, 3H); 
29
Si NMR (99 MHz, CDCl3) δ -7.62 
Hexacoordinate Methylsilicate (5.8): 
 
Acetylacetone (102 μL, 1.00 mmol, 1.00 equiv) was added dropwise to a solution of 
methylsilane 5.7 (1.0 mmol, 1.0 equiv) in 2.0 mL of CDCl3 to produce hexacoordinate 
methylsilicate 5.8 which was analyzed without further purification. 
1
H NMR (500 MHz, CDCl3 δ 7.25 – 7.04 (m, 5H), 6.89 – 6.74 (m, 5H), 6.72 – 6.61 (m, 2H), 
5.46 (s, 6H), 4.02 (tdd, J = 19.7, 8.4, 4.6 Hz, 2H), 3.71 – 3.58 (m, 2H), 3.56 – 3.52 (m, 2H), 3.43 
(q, J = 7.0 Hz, 11H), 2.72 – 2.56 (m, 3H), 2.38 (t, J = 14.4 Hz, 5H), 2.36 – 2.24 (m, 4H), 2.21 
(ddt, J = 12.1, 9.5, 4.3 Hz, 11H), 2.12 (d, J = 8.3 Hz, 2H), 2.09 (s, 5H), 2.00 (s, 35H), 1.98 – 1.92 
(m, 2H), 1.83 – 1.75 (m, 2H), 1.72 – 1.63 (m, 10H), 1.64 – 1.52 (m, 2H), 1.43 – 1.22 (m, 42H), 
1.16 (t, J = 7.0 Hz, 20H), 1.08 (s, 3H), 0.95 – 0.84 (m, 2H), 0.36 – 0.25 (m, 8H), 0.27 – 0.19 (m, 
2H). 
29
Si NMR (99 MHz, CDCl3) δ -160.71 




n-Bu4NBr (1.6 g, 5.00 mmol, 5.00 equiv) was added to a solution of hexacoordinate 
methylsilicate 5.8 (1.00 mmol, 1.00 equiv) in CDCl3 to produce anion bound hexacoordinate 
methylsilicate 5.9, which was analyzed without further purification. 
1
H NMR (500 MHz, CDCl3) δ 7.23-7.18 (m, 1H), 6.90 – 6.84 (m, 1H), 6.82 (t, J = 7.5 Hz, 1H), 
5.95 (ddt, J = 16.9, 10.1, 7.8 Hz, 1H), 5.16 – 5.07 (m, 1H), 5.04 – 4.95 (m, 1H), 4.23 (d, J = 15.6 
Hz, 1H), 3.69 (d, J = 15.7 Hz, 1H), 2.54 – 2.42 (m, 1H), 2.47 (s, 3H), 2.13 (ddd, J = 10.5, 9.0, 
3.3 Hz, 1H), 2.06 – 1.90 (m, 4H), 1.74 – 1.63 (m, 2H), 1.39 (s, 9H), 1.26 – 1.15 (m, 1H), 1.14 – 
1.03 (m, 2H), 0.86 – 0.73 (m, 1H); 
29
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 CHAPTER 6: New methods for carbon-carbon and carbon-hydrogen 
bond formation  
6.1. Introduction 
With an eye towards the future of drug development, specifically in the context of 
polyketide total synthesis, we want to expand our synthetic toolbox to facilitate efficient 
modification and construction of new targets. One way in which we foresee accomplishing this 
goal is by diversifying the coupling partners we can incorporate in complex fragment unions. We 
strive to re-imagine the bond disconnection strategies of challenging targets in order to further 
their development as viable therapeutics.  
The new found reactivity of six-coordinate silicates has opened the pathway for a variety 
of high utility reactions. Herein we report progress towards accessing functionality of alkynes 
and allenes. We also envisage an alternative strategy for the installation of chiral alcohols using 
chiral silane complexes as reducing agents. Furthermore we have designed attractive catalytic 
alternatives to traditional aldol chemistry to access the same products in high yields and 
selectivities.  
6.2. Propargylation  
6.2.1. Challenges associated with propargylations 
 Homopropargylic alcohols are key building blocks for natural product synthesis. Alkynes 
are high utility functional group handles which would greatly benefit from new methods of 
installation. Addition of allenyl-metals to carbonyl electrophiles is an attractive way to generate 
homopropargylic alcohols. One major drawback of this method is poor regioselectivity which is 
attributed to metallotropic rearrangement of the allenyl-metal species either upon isolation or 
under reaction conditions (Figure 6.1).
1,2
 Another limitation that has restricted the widespread 
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 have endeavored to tackle these limitations, there still remains no 
user-friendly, asymmetric, and general propargylations protocol.  
 
Figure 6.1: Rearrangement of allenyltrichlorsilanes and propargyltrichlorosilanes. 
 We endeavored to address the outlined limitations in a two-fold approach. First, the 
allenyltrichlorosilane formation and silane ligand complexation will be telescoped into a one-pot 
reaction (Figure 6.2). As part of the telescoping process, metal catalysts will be screened to 
optimize allenyltrichlorosilane formation over propargyltrichlorosilane formation. Obviating the 
need for isolation of the highly sensitive silane will limit metallotropic rearrangement thus 
providing the desired regioselectivity. Furthermore, we predict that using an anion-catalyzed 
mechanistic pathway analogous to that previously described will expand the scope of propargyl 




Figure 6.2: Proposed one-pot propargylation and allenation reactions. 
6.2.2. Allenyltrichlorosilane formation 
  Similar to the Benkeser-Furuya reaction, propargyl halides react with trichlorosilane and 
a base at elevated temperature give a mixture of propargyl trichlorosilane and 
allenyltrichlorosilane.
4
 Kobayashi and co-workers have performed beautiful studies on the 
formation and subsequent isomerization occurring during this process.
4
 They determined that 
isomerization between propargyltrichlorosilane and allenyltrichlorosilane can occur during 
distillation (96-109°C), therefore negating both thermal reaction conditions and isolation as  
viable strategies for obtaining these species. Upon examination of metal salts to catalyze the 
silylation of propargyl chloride, it was found that Cu(I) salts favor the formation of 
propargyltrichlorosilane by way of an SN2 mechanism; whereas Ni(II) salts favor the formation 
of allenyltrichlorosilane by way of an SN2’ mechanism.
4
 With this information in hand, we began 
telescoping our proposed reaction.  
 Initial attempts at a one-pot propargylations resulted in a 16% yield of the 
homopropargylic alcohol 6.2 as a single species (entry 1, Table 6.1). Although a low yield was 
obtained, we were able to chemoselectively obtain the propargyl alcohol rather than the allenyl 
alcohol. It was found that increasing the reaction time of the nickel catalyzed silylation was 
preferable (entry 2, Table 6.1). Similarly, going to the more reactive propargyl bromide substrate 
increased the yield from 20 to 30% (entry 3, Table 6.1). Despite these modest improvements, the 
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reaction was still stalling during the silylation process. It was observed that trichlorosilane 
(boiling point = 31.8 ºC) was evaporating from the reaction mixture before being consumed to 
form the desired allenyl trichlorosilane. We were able to improve the yield by portion-wise 
addition of trichlorosilane over 48h which increased conversion of the primary step, even with 
the less reactive propargyl chloride starting material (entry 4, Table 6.1). Extended reaction times 
for the ligand complexation further improved product yield to furnish 6.2 in 61% yield and 92% 
ee (entry 5, Table 6.1).  
Table 6.1: Propargylation optimization. 
 
6.2.3. Propargylation scope 
We began by exploring the substitution patterns of propargyl chlorides and their effects 
on chemoselectively forming allenyl trichlorosilanes (Table 6.2). We have been able to form the 
homopropargylic alcohol 6.2 in 62% yield and 92% ee as one major product. When 3-chloro-3-
methyl-1-butyne was subjected to reaction conditions using Ni(acac)2 as the metal catalyst a 
mixture of allenyl and propargyl products were obtained. However, using copper bromide as the 
catalyst we were able to form the disubstituted allene trichlorosilane and obtain the propargyl 
product 6.3 in 78% yield. The boost in selectivity is thought to arise from the fact that tertiary 
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alkynyl halides are bulky enough to shut down the SN2 mechanism, leaving the SN2’ pathway as 
the only viable mechanism. Starting from a chiral propargyl chloride we were able to obtain the 
desired product 6.4 in a 3:1 dr with a 60% yield. These three examples provide an excellent proof 
of concept that a broad scope of propargyl chlorides can be targeted to selectively give the 
homopropargylic alcohol of choice without the need to isolate and purify the corresponding 
allenyl trichlorosilane.  
Table 6.2: Propargyl chloride scope. 
 
6.2.4. Future work of propargylations 
We have employed our understanding of highly reactive six-coordinate silane chemistry 
to access a challenging reaction type and solve key problems that have limited this chemistry. 
Future work will focus on expanding the scope to allenylcarbinols which are useful as precursors 
of tetrahydrofuran subunits of polyethers.
2
 We also are working to examine allenyl 
trichlorosilane stereochemistry and how it affects the diastereoselectivity of the product. In order 
to explore this area further, we will start from both chiral and achiral propargyl halides and 
examine the diastereoselectivity of the resulting products. An exciting area of study will also 
involve the use of metal catalysts with chiral ligands to form enantiopure allenes in situ. Further 
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effort will also be spent investigating the scope of carbonyl substrates that are tolerated in the 
reaction. 
6.3. Reduction 
6.3.1. Background and motivation 
 Asymmetric reduction of carbonyls to give chiral alcohols is a highly sought-after 
transformation. Stoichiometric reactions give good selectivity yet are costly and inefficient 
especially for industrial use.
7
 Most recent focus has been on the development of new catalytic 
methods.
7–10
 The Noyori reduction is well established and successful yet has its limitations.
11,12
 
Most catalytic methods involve transition metal catalysts and high temperatures and pressures 
and are plagued by substrate limitations.
13
 In particular, enantioselective hydrogenation of 
simple, unfunctionalized ketones has remained difficult.
14
 Asymmetric hydrosilylations have also 
been explored with ruthenium catalysts as the activator.
15
 Our goal is to develop a mild, catalytic, 
transition metal free hydrosilylation of carbonyls.  
6.3.2. Initial results 
During the development and optimization of the one-pot propargylations procedure 
(section 6.2), it was noted that use of excess trichlorosilane led to formation of primary alcohols 
from aldehydes. It was hypothesized that free trichlorosilane is able to complex with the trident 
ligand 6.1 to form complex 6.5, which subsequently hydrosilylates the coordinated aldehyde 




Figure 6.3: Proposed mechanism of alcohol formation. 
We envisioned using this new-found reactivity to asymmetrically reduce ketones. We 
began with stoichiometric reductions of aldehydes and ketones with ligand 6.1, which can be 
recycled. We saw this as a way to take advantage of the high stereoselectivities associated with 
stoichiometric reactions while still being cost affective and atom-economical. Initially we have 
been able to reduce hydrocinnamaldehyde to 3-phenyl-1-propanol in 63% yield (Table 6.3). 
Realizing our vision, we were able to reduce benzylacetone in 55% yield and 54% ee. This result 
illustrates an asymmetric reduction of a simple, unfunctionalized ketone. The reaction was also 
able to impart relatively high levels of selectivity between sterically similar functional groups.  
Table 6.3: Reduction scope. 
 
6.3.3. Future work 
 We have discovered a use for our in situ generated, highly reactive strained silane 
complexes. Initial results indicate a promising role for strained silanes to play in solving key 
challenges in the asymmetric reduction field. Development of an achiral, strained silane, which 
can efficiently reduce aldehydes, would provide an attractive alternative to metal hydride 
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reducing agents. In particular, we see this method as being highly controlled and chemoselective. 
Further work will be done on expanding the scope of our asymmetric ketone reduction as well as 
optimizing the reaction. We are interested in examining the role of chiral anion catalysts in 
reducing ketones. Alternatively, we are also interested in using the chiral silane complex 6.5 
catalytically for reductions. Ultimately, we want to expand this work to be able to reduce 
ketimines to yield the desired unprotected secondary amines in high yields and selectivities. 
6.4. Beta-ketoaldehyde allylation  
 As discussed in Chapter 5, dicarbonyl compounds can react with allyl silanes through a 
dual-coordination pathway, which activates the silane through a similar mechanism to the anion 
catalysis previously described. We have also shown that chiral anions can directly interact with 
silicon species to impart chiral information on a reaction (Chapter 4). We therefore hypothesize 
that it is possible to promote allylation of a coordinated dicarbonyl substrate through chiral anion 
catalysis (Figure 6.4). The reaction proposed in figure 6.4 would be a catalytic alternative to 




Figure 6.4: Proposed chiral anion catalysis. 
6.4.1. Previous synthesis attempts 
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The allylation of beta-ketoaldehydes
19
 to obtain homoallylic alcohols is virtually 
unknown in the literature and an asymmetric variant has yet to be reported. Beta-ketoaldehydes 
(BKAs) are notoriously difficult as substrates for nucleophilic addition due to the fact that the 
aldehyde primarily exists in its enolic form. Despite the challenges associated with allylating 
BKAs, the resulting beta-hydroxy ketone products are of high utility. It is, therefore, a 
worthwhile endeavor to undertake in order to provide an attractive alternative to aldol chemistry. 
6.4.2. Initial results 
 It was thought that a BKA sodium salt would be a more reactive substrate than its 
protonated counterpart. The sodium salt should react with a trichlorosilane to form NaCl and the 
desired silicate as a thermodynamically favored process. Therefore we chose to begin our 
allylation studies with BKA 6.7 in order to accelerate BKA coordination, as well as provide a 
stable, user-friendly starting material to handle. Excitingly, the addition of allyltrichlorsilane and 
6.7 resulted in the desired homoallylic alcohol product 6.8 in 73% yield (Scheme 6.1). 
 
Scheme 6.1: Allylation of BKA 6.7. 
 Moving on to examine if a chiral anion could catalyze the proposed trichlorosilane 
mediated pathway, the chiral anion 6.9 was added. We were pleased to observe formation of 6.8 
in 54% yield and 83% ee (Scheme 6.2). This proof of concept result represents, to the best of our 




Scheme 6.2: Asymmetric allylation of BKA 6.8. 
6.4.3. Unsymmetrical BKA allylation scope 
 With a promising proof of concept result in hand we went on to explore the scope of 
anion catalyzed BKA allylation. However, we immediately identified a problem with the 
reaction. We were unable to obtain usable enantioselectivity for additional substrates. Simply 
moving from 6.7 to 6.10 the ee dropped from 83% to 0% (Scheme 6.3). Extensive reaction 
condition manipulation involving solvent switches, temperature variation, proportion changes, 
and catalyst loading were fruitless in improving enantioselectivity. 
 
Scheme 6.3: Allylation of BKA 6.10. 
 Our optimization work, although lacking in providing enantioselectivity, did show that a 
wide variety of BKAs could be allylated in good yields under the reaction conditions. Herein we 
386 
 
report the racemic allylation and crotylation of BKAs (Table 6.4). Both aromatic and alkyl 
substituted BKAs are well tolerated. Alpha-substituted beta-ketoaldehydes can also be employed 
to generate stereotriads in a single step. 
Table 6.4: Racemic BKA scope. 
 
6.4.4. Proposed mechanistic hypothesis 
 We can explain the discrepancies between the allylation of 6.7 and 6.10 by delving into 
the mechanism of the reaction. As was proposed in Figure 6.4 (subsection 6.4.1), each BKA 
coordinates with the silane in a bidentate fashion for the reaction to proceed. In effect, each 
reaction is forming a unique strained silane complex whose reactivity is going to be directly 
affected by the sterics and electronics of the BKA substrate. In order for the anion to have chiral 
control over the reaction kx->>k0, therefore it is hypothesized that for 6.10 kx-<k0 thereby 
rendering the reaction product racemic. Increasing catalyst loading leads to more of the dianion 
G thereby slowing kx down even further. With the described mechanistic limitations, the only 
viable path forward for the enantioselective allylation of BKAs is to design a new chiral catalyst 
that out competes the background reaction. 
6.5. Anion catalyzed allylations 
6.5.1. Mechanistic prediction 
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 In the case of BKA allylations we need to find a way to increase the rate of the anion 
catalyzed pathway in order to achieve enantioselectivity; however that is not the case for other 
dicarbonyl substrates. We suggest that we can use substrate control to slow down the chiral 
anion-free pathway thus biasing the reaction in favor of our desired mechanistic pathway. We 
imagined that alpha-diketones and beta-diketones would be ideal substrates to test this 
hypothesis.  
6.5.2. Preliminary results 
 1,2-cyclohexanedione and allyltrichlorosilane were chosen as the model substrates for 
this reaction. Simply mixing 1,2-cyclohexanedione and allyltrichlorosilane together in the 
presence of 6.9 unsurprisingly yielded no product. Similarly to the BKA reactions, the diketones 
need an activator to accelerate the rate of coordination to the silane. 1,2-cyclohexanedione exists 
in equilibrium between its keto and enol forms. Addition of a base can weaken the O-H bond 
strength of the enol form thus providing the oxygen atom with more electron density. A more 
electron rich oxygen will more readily coordinate to the silane which loses a chloride to form the 
base-HCl salt. 1,2-cyclohexanedione was pre-stirred with triethylamine and then added to 
allyltrichlorosilane and 6.9. This reaction readily facilitated 6.12 in 61% yield and 49% ee 
(Scheme 6.4). 
 
Scheme 6.4: Allylation of 1,2-cyclohexanedione.  
 Optimization of reaction conditions entailed examining catalyst loading, reaction time, 
and reaction temperature (Table 6.5). Lowering the reaction temperature and increasing the 
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catalyst loading did improve ee to 65% but at a cost to the yield (entry 1, Table 6.5). Raising the 
temperature to 23 °C dramatically reduced enantiomeric excess to 15 % while recovering the 
yield to 52% (entry 2, Table 6.5). The best conditions obtained thus far arose lowering the 
catalyst loading to 1% and extending the reaction time to 48h which furnished 6.12 in 55% yield 
and 56% ee. Lower catalyst loadings increase the rate of reaction by minimizing sequestration of 
silane and catalyst as the dianion species.  
Table 6.5: Reaction optimization. 
 
 We have been able to extend this method to acyclic substrates such as 1,2-butadione 
(Scheme 6.5). As discussed in Chapter 5, the selective mono-allylation of 1,2-butadione has been 
an unmet challenge in the literature. Herein we report the successful synthesis 6.13 in 66% yield 
and 98% ee.  
 
Scheme 6.5: Allylation of 1,2-butadione. 
 We have also been able to enantioselectively allylate alpha-hydroxyketones and beta-
diketones in good yields and selectivities. The allylation of alpha-hydroxyketones creates a chiral 
quaternary center as well as a 1,2-diol. Starting from the racemic alpha-hydroxyketone, 6.14 was 
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synthesized in 47% yield and 73% ee (Scheme 6.6). Allylation of 1,3-Diphenyl-1,3-
propanedione gives the beta-hydroxyketone 6.15 in a 72% yield and 80% ee (Scheme 6.7). The 
allylation of beta-diketones would suggest that straining the silane into a 5-membered ring, as 
results in the alpha-diketone and alpha-hydroxyketone reactions, is not necessary to achieve the 
needed reactivity. The variety of different carbonyl equivalents that can be utilized in this 
chemistry is encouraging for application towards an asymmetric, universal anion-catalyzed 
allylation methodology. 
 
Scheme 6.6: Synthesis of 6.13. 
 
Scheme 6.7: Synthesis of 6.14. 
 
6.5.3. Control experiments and mechanistic comments 
 In order to probe the mechanistic hypotheses outlined in subsection 6.5.1, certain control 
reactions were performed. Both chiral anion 6.9 and triethylamine are necessary in order for the 
reaction to proceed enantioselectively (Figure 6.5A). Another plausible mechanism is by way of 
silane lewis base catalysis
20,21
 by either triethylamine or 6.9. If our reaction was going through a 
lewis base catalyzed mechanism, we would expect facile allylation of benzaldehyde to give the 
homoallylic alcohol.
22
 However, under reaction condition, both with and without triethylamine, 
no allylation product was observed (Figure 6.5B). Another characteristic of Lewis base catalyzed 
reaction is that they are not tolerant of alkyl substrates due to unproductive silylchlorohydrin 
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formation (Figure 3.5, Chapter 3), whereas our methodology can clearly tolerate alkyl-
substituted substrates. These results lead us to believe that the anion-catalyzed mechanism we 
have proposed is chemically distinct from the Lewis base catalyzed allylations previously 
reported. 
 
Figure 6.5: A: Control experiments for the anion catalyzed allylation reaction. B: Control reactions for lewis 
base catalyzed aldehyde allylations. 
 As a way to test our hypothesis that the key to achieving enantioselectivity was due to 
substrate control to slow down the chiral anion-free pathway, we examined the allylation beta-
hyrdoxyaldehydes and of protonated beta-ketoaldehydes. Indeed allylation of salicylaldehyde 
proceeded smoothly to yield the desired homoallylic alcohol 6.16 in 96% yield as a racemic 
mixture (Figure 6.6A). Similarly, protonated BKA 6.10a gave a complex mixture of products 
some of which was the desired product 6.11, which also ended up being racemic (Figure 6.6B). 
These results would suggest that going to more sterically hindered diketone substrates helps bias 




Figure 6.6: A: Beta-hydroxyaldehyde allylation. B: Protonated BKA 6.10a allylation. 
6.5.4. Conclusion and future directions 
 Overall we have developed a new method for the organocatalytic, asymmetric allylation 
of alpha-diketones, beta-diketones, and alpha-hydroxyketones; which furnishes high utility 
synthetic building blocks. We have been able to utilize catalyst loadings as low as 1 mol% while 
retaining yield and enantioselectivity. It has also been shown that the anion-catalyzed allylation 
mechanism is functionally distinct from previously reported Lewis base catalyzed allylations. 
 Further work in this area will focus on catalyst structural manipulations to examine which 
structural features are necessary for activity and stereocontrol. We also are interested in 
quantifying the lewis acidity silane intermediates the reaction is generating. We hope to isolate 
and characterize the intermediates in our catalytic cycle to further our mechanistic understanding 
and apply our knowledge to new problems. 
6.6. Anion catalyzed decarboxylative aldols 
6.6.1. Background 
 A common way nature forms carbon-carbon bonds, particularly in the biosynthesis of 
polyketides, is through a decarboxylative Claisen condensation with malonic acid half 
thioesters.
23
 Nature’s chemistry has inspired many groups to pursue catalytic enantioselective 
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aldol reactions of carboxylic acid derivatives.
24–29
 In particular, the Shair group has used malonic 
acid half thioesters as nucleophile equivalents in enantioselective aldols (Scheme 6.8).  
 
Scheme 6.8: Shair’s thioester aldol reaction.
26
 
 We were inspired by nature’s biosynthesis of polyketides as well as by the beautiful work 
previously done in this field to pursue an anion catalyzed decarboxylative aldol. We saw an 
opportunity to apply the new found anion catalyzed six-coordinate silane intermediate as a 
transition metal-free method for enantioselective aldol reactions.  
6.6.2. Mechanistic prediction 
We envision using beta-ketoacids as a nucleophile source to react with aldehydes to form 
key carbon-carbon bonds (Figure 6.8). The silyl enol ether 6.21 can be generated in situ via 
Lewis acid activation of 6.19 with silcon tetrachloride and loss of CO2 and HCl. Once 6.21 is 
formed, we propose coordination of the chiral anion (X*) and the aldehyde leads to nucleophilic 
addition though a closed six-membered transition state. Finally, once fluoride is added to quench 
the reaction the aldol product 6.23 is released.  
 
Figure 6.7: Proposed mechanism of an anion catalyzed decarboxylative aldol wherein X* denotes the chiral 
anion. 
6.6.3. Initial results 
 6.19 and SiCl4 were pre-stirred for 30 minutes before addition of 6.9 and 
hydrocinnamaldehyde. Upon isolation and purification of the reaction mixture two major 
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products were isolated: the desired product 6.23 and acetophenone (Scheme 6.9). We were 
pleased to observe that in the un-optimized reaction the aldol was able proceed in 24% yield and 
most strikingly in 89% ee. Again we are seeing high levels of enantioselectivity being imparted 
from the chiral anion catalyst 6.9. The presence of acetophenone would suggest that 
decarboxylation is taking place to generate intermediate 6.21, however, under the reaction 
conditions described full conversion to 6.22 is not occurring. We are confident that further 
examination of the reaction intermediates by NMR will elucidate both mechanistic details as 
well as ideal optimization conditions to induce higher yields. 
 
Scheme 6.9: Anion catalyzed decarboxylative aldol of 6.19 and hydrocinnamaldehyde. 
6.6.4. Future work 
 Optimization and scope studies are currently ongoing for the newly developed anion 
catalyzed decarboxylative aldol reaction. In particular, we are interested in examining alpha-
substituted beta-ketoacids to generate either E- or Z- silyl enol ethers. If the proposed reaction 
intermediate 6.20 is correct, only the E-silyl enol ether should be able to form (Figure 6.7). This 
experiment would provide mechanistic insight; additionally the reaction should provide high 
levels of stereocontrol. An anion catalyzed decarboxylative aldol has adapted nature’s approach 
to polyketide synthesis for use in a flask. This method is technically simple with broad utility in a 
wide range of both industrial and academic applications. 
6.7. Summary and outlook 
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 The synthetic methods reported in this chapter do not simply provide new ways to control 
challenging carbon-carbon and carbon-hydrogen bond connections, but also promote creativity 
for the synthesis of new compounds. Accessing new reactivity allows for the development of 
novel bond disconnection strategies, as highlighted in the 22 step synthesis of spongistatin 1 
analogs
30
. With the powerful synthetic tools described in this chapter, we hope to develop 
striking new ways to synthesize natural product derived drug candidates. 
 I see anion catalysis as the future of silicon chemistry. One of the key advantages of using 
silicon is that it is cheap and readily available. Being able to use stoichiometric silicon and a 
chiral catalyst for activation is the ideal we have been striving for. I want to further employ this 
idea on a variety of new substrates to continue expanding to the utility and scope of this 
chemistry. Future targets include epoxide openings, nazarov cyclizations, and functionalization 
of masked diketones, such as pyrazoles. I also see imines and free amines as exciting functional 
groups for use in this type of chemistry. In particular, the asymmetric reduction and allylation of 
ketimines to give chiral amines would have great utility.  
6.8. Experimental procedures and characterization 
General Information. All reactions were carried out under an inert atmosphere of argon in 
flame-dried glassware with magnetic stirring unless otherwise indicated.  Degassed solvents 
were purified by passage through an activated alumina column.  Et3N was distilled from CaH2; 
DBU was distilled from CaH2 onto 4 Å molecular sieves and stored under inert atmosphere.  All 
chloride and aldehyde substrates were purified immediately prior to use.  All other reagents were 
purchased from commercial sources and used without further purification unless otherwise 
noted.  Flash chromatography was performed with Silicycle SiliaFlash® P60 silica gel.  Thin-
layer chromatography (TLC) was carried out on glass backed silica gel TLC plates (250 nm) 
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from Silicycle; visualization by UV, phosphomolybdic acid (PMA), or Potassium Permanganate 
(KMnO4). 
Diastereomeric ratios for all compounds were determined by 
1
H NMR analysis of the 




Cdata were obtained using Bruker AVIII 500 (500 MHz) 
spectrometer and are reported in ppm.  
1
H NMR spectra were internally referenced to CDCl3 
(7.26 ppm); 
13
C NMR spectra were internally referenced to CDCl3 (77.23 ppm); Data are 
reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = triplet, m = multiplet, dd = 
doublet of doublets, ddd = doublet of doublet of doublets, ddt = doublet of doublet of triplets, td 
= triplet of doublets; coupling constant(s) in Hz; integration).  Infrared spectra were recorded on 
a Perkin-Elmer Spectrum Two (Diamond ATR) IR spectrometer.  Optical rotations were recorded 
on a Jasco DIP-1000 polarimeter.  HPLC analysis was carried out on an Agilent 1200 Series 
using a Chiralpak OD-H (250 x 4.5 mm ID) column. Mass Spectroscopy Data was obtained on a 
Waters XEVO G2-XS QToF mass spectrometer.   
6.8.1. Preparation of homopropargylic alcohols 
 
A 2-dram vial, equipped with a stir bar, was charged with nickel(II) acetylacetonate (25.7 
mg, 0.010 mmol, 0.014 equiv) in an argon-atmosphere glove box. The vial was capped with a 
septum and transferred out of the glove box. The vessel was charged with CH2Cl2 (3 mL) and 
Et3N (195 μL, 1.40 mmol, 1.47 equiv) and n-Bu4NBr (16 mg, 0.050 mmol, 0.052 equiv). In a 
separate vial under Ar atmosphere, propargyl chloride (73 μL, 1.00 mmol, 1.05 equiv), CH2Cl2 (2 
mL), and Cl3SiH (121 μL, 1.20 mmol, 1.26 equiv) were sequentially added. To the cooled 0 ºC 
solution of Ni(acac)2, was added the propargyl chloride solution dropwise via syringe. The 
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propargyl chloride vial was then rinsed with 1 mL CH2Cl2, this solution was added to the 
reaction flask, and the resulting mixture was stirred for 5 hr. An additional portion of Cl3SiH (20 
μL, 0.20 mmol, 0.26 equiv) was added and the mixture was stirred for a total of 48 hrs at 0 ºC.  A 
solution of the (R,R)-6.1 (290 mg, 1.00 mmol, 1.05 equiv) and DBU (449 μL, 3.00 mmol, 3.15 
equiv) in CH2Cl2 (2 mL + 0.5 mL rinse) was added dropwise via syringe to the reaction mixture.  
The cooling bath was removed and the mixture was stirred 5 hr at room temperature.  The silane 
solution was then re-cooled to –78 ºC and hydrocinnamaldehyde (125 μL, 0.95 mmol, 1.00 
eqiuv) was added.  The reaction was then conducted at 0 ºC for 12 hr. Upon consumption of the 
aldehyde, the reaction mixture was treated with n-Bu4NF (1M in THF, 2.0 mL, 2.0 mmol, 2.0 
equiv) and stirred 1 hr at 0ºC.  The mixture was then passed through a silica plug with EtOAc 
and concentrated to give the crude product, which was purified by flash column chromatography 
(0–30% EtOAc/Hexanes) to give the product 6.2 as a pale yellow oil (101 mg, 61% yield, 92% 
ee).  
[Daicel Chiracel OD-H, 95:5 Hexanes:IPA, 1 mL/min, 254 nm; t1= 15.94 min, t2=10.75 min]. 
1
H NMR (500 MHz, CDCl3) δ 7.37 –7.08 (m, 5H),3.83-3.70 (m, 1H), 2.86-2.63(m, 2H), 2.50 –
2.24 (m, 2H), 2.05 (t, J= 2.6 Hz, 1H), 1.96 (d, J= 5.2 Hz, 1H), 1.90-1.82 (m, 2H). 
13
C NMR (125 
MHz, CDCl3) δ 141.8, 128.7, 128.6, 126.1, 80.9, 71.2, 69.3, 38.0, 32.1, 27.7. Other spectral data 




A 2-dram vial, equipped with a stir bar, was charged with nickel(II) acetylacetonate (25.7 
mg, 0.010 mmol, 0.014 equiv) in an argon-atmosphere glove box. The vial was capped with a 
septum and transferred out of the glove box. The vessel was charged with CH2Cl2 (3 mL) and 
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Et3N (195 μL, 1.40 mmol, 1.47 equiv) and n-Bu4NBr (16 mg, 0.050 mmol, 0.052 equiv). In a 
separate vial under Ar atmosphere, 3-chloro-3-methyl-1-butyne (112 μL, 1.00 mmol, 1.05 equiv), 
CH2Cl2 (2 mL), and Cl3SiH (121 μL, 1.20 mmol, 1.26 equiv) were sequentially added. To the 
cooled 0 ºC solution of Ni(acac)2, was added the propargyl chloride solution dropwise via 
syringe. The propargyl chloride vial was then rinsed with 1 mL CH2Cl2, this solution was added 
to the reaction flask, and the resulting mixture was stirred for 5 hr. An additional portion of 
Cl3SiH (20 μL, 0.20 mmol, 0.26 equiv) was added and the mixture was stirred for a total of 48 
hrs at 0 ºC.  A solution of the (R,R)-6.1 (290 mg, 1.00 mmol, 1.05 equiv) and DBU (449 μL, 3.00 
mmol, 3.15 equiv) in CH2Cl2 (2 mL + 0.5 mL rinse) was added dropwise via syringe to the 
reaction mixture.  The cooling bath was removed and the mixture was stirred 5 hr at room 
temperature.  The silane solution was then re-cooled to –78 ºC and hydrocinnamaldehyde (125 
μL, 0.95 mmol, 1.00 eqiuv) was added.  The reaction was then conducted at 0 ºC for 12 hr. Upon 
consumption of the aldehyde, the reaction mixture was treated with n-Bu4NF (1M in THF, 2.0 
mL, 2.0 mmol, 2.0 equiv) and stirred 1 hr at 0ºC.  The mixture was then passed through a silica 
plug with EtOAc and concentrated to give the crude product, which was purified by flash column 
chromatography (0–25% EtOAc/Hexanes) to give the product 6.3 as a pale yellow oil (149 mg, 




A 2-dram vial, equipped with a stir bar, was charged with nickel(II) acetylacetonate (25.7 
mg, 0.010 mmol, 0.014 equiv) in an argon-atmosphere glove box. The vial was capped with a 
septum and transferred out of the glove box. The vessel was charged with CH2Cl2 (3 mL) and 
Et3N (195 μL, 1.40 mmol, 1.47 equiv) and n-Bu4NBr (16 mg, 0.050 mmol, 0.052 equiv). In a 
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separate vial under Ar atmosphere, 3-chloro-1-butyne (88.5 mg, 1.00 mmol, 1.05 equiv), CH2Cl2 
(2 mL), and Cl3SiH (121 μL, 1.20 mmol, 1.26 equiv) were sequentially added. To the cooled 0 
ºC solution of Ni(acac)2, was added the propargyl chloride solution dropwise via syringe. The 
propargyl chloride vial was then rinsed with 1 mL CH2Cl2, this solution was added to the 
reaction flask, and the resulting mixture was stirred for 5 hr. An additional portion of Cl3SiH (20 
μL, 0.20 mmol, 0.26 equiv) was added and the mixture was stirred for a total of 48 hrs at 0 ºC.  A 
solution of the (R,R)-6.1 (290 mg, 1.00 mmol, 1.05 equiv) and DBU (449 μL, 3.00 mmol, 3.15 
equiv) in CH2Cl2 (2 mL + 0.5 mL rinse) was added dropwise via syringe to the reaction mixture.  
The cooling bath was removed and the mixture was stirred 5 hr at room temperature.  The silane 
solution was then re-cooled to –78 ºC and hydrocinnamaldehyde (125 μL, 0.95 mmol, 1.00 
eqiuv) was added.  The reaction was then conducted at 0 ºC for 12 hr. Upon consumption of the 
aldehyde, the reaction mixture was treated with n-Bu4NF (1M in THF, 2.0 mL, 2.0 mmol, 2.0 
equiv) and stirred 1 hr at 0ºC.  The mixture was then passed through a silica plug with EtOAc 
and concentrated to give the crude product, which was purified by flash column chromatography 
(0–30% EtOAc/Hexanes) to give the product 6.4 as a pale yellow oil (108 mg, 60% yield, 3:1 
dr). Spectral data were in agreement with reported values.
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6.8.2. Reduction of aldehydes and ketones 
3-phenyl-1-propanol: 
 
A flame dried 2-dram vial, equipped with a stir bar, was charged with (R,R)-6.1 (73.0 mg, 
0.25 mmol, 1.00 equiv) and dissolved in dry CH2Cl2 (2.0 mL) under Ar atmosphere. The reaction 
mixture was cooled to 0 °C and DBU (112 μL, 0.75 mmol, 3.00 equiv) was added dropwise via 
syringe followed by trichlorosilane (30 μL, 0.30 mmol, 1.20 equiv). The cooling bath was 
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removed and the resulting mixture was stirred 1 hr at room temperature. The silane solution was 
then re-cooled to 0 ºC and hydrocinnamaldehyde (32 μL, 0.24 mmol, 0.95 eqiuv) was added. The 
reaction was then conducted at 0 ºC for 12 hr. Upon consumption of the aldehyde, the reaction 
mixture was treated with n-Bu4NF (1M in THF, 0.30 mL, 0.30 mmol, 1.20 equiv) and stirred 1 hr 
at 0ºC. The mixture was then passed through a silica plug with EtOAc and concentrated to give 
the crude product, which was purified by flash column chromatography (0–20% 
EtOAc/Hexanes) to give the product 3-phenyl-1-propanol as a pale yellow oil (20 mg, 63% 





A flame dried 2-dram vial, equipped with a stir bar, was charged with (R,R)-6.1 (73.0 mg, 
0.25 mmol, 1.00 equiv) and dissolved in dry CH2Cl2 (2.0 mL) under Ar atmosphere. The reaction 
mixture was cooled to 0 °C and DBU (112 μL, 0.75 mmol, 3.00 equiv) was added dropwise via 
syringe followed by trichlorosilane (30 μL, 0.30 mmol, 1.20 equiv). The cooling bath was 
removed and the resulting mixture was stirred 1 hr at room temperature. The silane solution was 
then re-cooled to 0 ºC and benzylacetone (36 μL, 0.24 mmol, 0.95 eqiuv) was added. The 
reaction was then conducted at 0 ºC for 12 hr. Upon consumption of the ketone, the reaction 
mixture was treated with n-Bu4NF (1M in THF, 0.30 mL, 0.30 mmol, 1.20 equiv) and stirred 1 hr 
at 0ºC. The mixture was then passed through a silica plug with EtOAc and concentrated to give 
the crude product, which was purified by flash column chromatography (0–20% 
EtOAc/Hexanes) to give the product 4-phenylbutan-2-ol as a pale yellow oil (20 mg, 55% yield, 
54% ee). Spectral data were in agreement with reported values.
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A flame dried 2-dram vial, equipped with a stir bar, was charged with allyltrichlorosilane 
(25 μL, 0.25 mmol, 1.00 equiv) and dissolved in dry CH2Cl2 (2.0 mL) under Ar atmosphere. The 
reaction mixture was cooled to -78 °C and 6.9 (15 mg, 0.013 mmol, 0.05 equiv) was added in a 
single portion followed by BKA sodium salt 6.7 (50 mg, 0.25 mmol, 1.00 equiv). The reaction 
was allowed to warm to -40 °C and was subsequently stirred for 12 h. Upon consumption of the 
BKA, the reaction mixture was treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 
equiv) and stirred 1 hr at 0ºC. The mixture was then passed through a silica plug with EtOAc and 
concentrated to give the crude product, which was purified by flash column chromatography (0–
15% EtOAc/Hexanes) to give the product 6.8 as a pale yellow oil (30 mg, 54% yield, 83% ee). 
1
H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 8.9 Hz, 2H), 6.95 (d, J = 8.9 Hz, 3H), 5.96 – 5.84 (m, 
1H), 5.20 – 5.12 (m, 2H), 4.62 (ddd, J = 7.2, 5.6, 1.7 Hz, 1H), 3.88 (d, J = 1.0 Hz, 4H), 3.47 (dd, 
J = 16.9, 7.4 Hz, 1H), 3.25 (dd, J = 17.0, 5.8 Hz, 1H), 2.71 – 2.62 (m, 1H), 2.62 – 2.53 (m, 1H). 








A flame dried 2-dram vial, equipped with a stir bar, was charged with allyltrichlorosilane 
(25 μL, 0.25 mmol, 1.00 equiv) and dissolved in dry CH2Cl2 (2.0 mL) under Ar atmosphere. The 
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reaction mixture was cooled to -78 °C and 6.9 (15 mg, 0.013 mmol, 0.05 equiv) was added in a 
single portion followed by BKA sodium salt 6.10 (43 mg, 0.25 mmol, 1.00 equiv). The reaction 
was allowed to warm to -40 °C and was subsequently stirred for 12 h. Upon consumption of the 
BKA, the reaction mixture was treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 
equiv) and stirred 1 hr at 0ºC. The mixture was then passed through a silica plug with EtOAc and 
concentrated to give the crude product, which was purified by flash column chromatography (0–
15% EtOAc/Hexanes) to give the product 6.11 as a pale yellow oil (36 mg, 76% yield, 0% ee). 




A flame dried 2-dram vial, equipped with a stir bar, was charged with allyltrichlorosilane 
(25 μL, 0.25 mmol, 1.00 equiv) and dissolved in dry CH2Cl2 (2.0 mL) under Ar atmosphere. The 
BKA sodium salt (38 mg, 0.25 mmol, 1.00 equiv) was added in a single portion. The reaction 
was subsequently stirred for 12 h. Upon consumption of the BKA, the reaction mixture was 
treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) and stirred 1 hr at -30ºC. 
The mixture was then passed through a silica plug with EtOAc and concentrated to give the 
crude product, which was purified by flash column chromatography (0–20% EtOAc/Hexanes) to 
give the product as a pale yellow oil (30 mg, 76% yield, 3:1:1dr). Spectral data were in 




A flame dried 2-dram vial, equipped with a stir bar, was charged with allyltrichlorosilane 
(25 μL, 0.25 mmol, 1.00 equiv) and dissolved in dry CH2Cl2 (2.0 mL) under Ar atmosphere. The 
BKA sodium salt (38 mg, 0.25 mmol, 1.00 equiv) was added in a single portion. The reaction 
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was subsequently stirred for 12 h. Upon consumption of the BKA, the reaction mixture was 
treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) and stirred 1 hr at 0ºC. The 
mixture was then passed through a silica plug with EtOAc and concentrated to give the crude 
product, which was purified by flash column chromatography (0–20% EtOAc/Hexanes) to give 








6.8.4. Anion catalyzed dicarbonyl allylations 
 
A flame dried vial, equipped with a stir bar, was charged with allyltrichlorosilane (40 μL, 
0.28 mmol, 1.10 equiv) and dissolved in dry CH2Cl2 (1.75 mL) under Ar atmosphere. 6.9 (15 
mg, 0.013 mmol, 0.05 equiv) was added to the reaction mixture. In a separate flame dried vial, 
equipped with a stir bar, 1,2-cyclohexanedione (28 mg, 0.25 mmol, 1.00 equiv) and Et3N (35 μL, 
0.25 mmol, 1.00 equiv) in CH2Cl2 (0.50 mL) were stirred for 5 min. The allyltrichlorosilane 
mixture was cooled to -78 °C and the 1,2-cyclohexanedione mixture was added dropwise via 
syringe rinsing with CH2Cl2 (0.25 mL). The reaction was allowed to warm to -40 °C and was 
subsequently stirred for 2 h. Upon consumption of the starting material, the reaction mixture was 
treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) and stirred 1 hr at -40 ºC. 
The mixture was then passed through a silica plug with EtOAc and concentrated to give the 
crude product, which was purified by flash column chromatography (0–20% EtOAc/Hexanes) to 
give the product 6.12 as a pale yellow oil (24 mg, 61% yield, 49% ee). Spectral data were in 




A flame dried vial, equipped with a stir bar, was charged with allyltrichlorosilane (40 μL, 
0.28 mmol, 1.10 equiv) and dissolved in dry CH2Cl2 (1.75 mL) under Ar atmosphere. 6.9 (15 
mg, 0.013 mmol, 0.05 equiv) was added to the reaction mixture. In a separate flame dried vial, 
equipped with a stir bar, 2,3-butadione (22 μL, 0.25 mmol, 1.00 equiv) and Et3N (35 μL, 0.25 
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mmol, 1.00 equiv) in CH2Cl2 (0.50 mL) were stirred for 5 min. The allyltrichlorosilane mixture 
was cooled to -78 °C and the 2,3-butadione mixture was added dropwise via syringe rinsing with 
CH2Cl2 (0.25 mL). The reaction was allowed to warm to -40 °C and was subsequently stirred for 
1 h. Upon consumption of the starting material, the reaction mixture was treated with n-Bu4NF 
(1M in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) and stirred 1 hr at -40 ºC. The mixture was then 
passed through a silica plug with EtOAc and concentrated to give the crude product, which was 
purified by flash column chromatography (0–10% EtOAc/Hexanes) to give the product 6.13 as a 





A flame dried vial, equipped with a stir bar, was charged with allyltrichlorosilane (40 μL, 
0.28 mmol, 1.10 equiv) and dissolved in dry CH2Cl2 (1.75 mL) under Ar atmosphere. 6.9 (15 
mg, 0.013 mmol, 0.05 equiv) was added to the reaction mixture. In a separate flame dried vial, 
equipped with a stir bar, acetoin (22 μL, 0.25 mmol, 1.00 equiv) and Et3N (35 μL, 0.25 mmol, 
1.00 equiv) in CH2Cl2 (0.50 mL) were stirred for 5 min. The allyltrichlorosilane mixture was 
cooled to -78 °C and the acetoin mixture was added dropwise via syringe rinsing with CH2Cl2 
(0.25 mL). The reaction was allowed to warm to -40 °C and was subsequently stirred for 1 h. 
Upon consumption of the starting material, the reaction mixture was treated with n-Bu4NF (1M 
in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) and stirred 1 hr at -40 ºC. The mixture was then passed 
through a silica plug with EtOAc and concentrated to give the crude product, which was purified 
by flash column chromatography (0–10% EtOAc/Hexanes) to give the product 6.14 as a pale 
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A flame dried vial, equipped with a stir bar, was charged with allyltrichlorosilane (40 μL, 
0.28 mmol, 1.10 equiv) and dissolved in dry CH2Cl2 (1.75 mL) under Ar atmosphere. 6.9 (15 
mg, 0.013 mmol, 0.05 equiv) was added to the reaction mixture. In a separate flame dried vial, 
equipped with a stir bar, 1,3-diphenyl-1,3-propanedione (56 mg, 0.25 mmol, 1.00 equiv) and 
Et3N (35 μL, 0.25 mmol, 1.00 equiv) in CH2Cl2 (0.50 mL) were stirred for 5 min. The 
allyltrichlorosilane mixture was cooled to -78 °C and the 1,3-diphenyl-1,3-propanedione mixture 
was added dropwise via syringe rinsing with CH2Cl2 (0.25 mL). The reaction was allowed to 
warm to -40 °C and was subsequently stirred for 1 h. Upon consumption of the starting material, 
the reaction mixture was treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) 
and stirred 1 hr at -40 ºC. The mixture was then passed through a silica plug with EtOAc and 
concentrated to give the crude product, which was purified by flash column chromatography (0–
10% EtOAc/Hexanes) to give the product 6.15 as a pale yellow oil (48 mg, 72% yield, 80% ee). 




A flame dried vial, equipped with a stir bar, was charged with allyltrichlorosilane (40 μL, 
0.28 mmol, 1.10 equiv) and dissolved in dry CH2Cl2 (1.75 mL) under Ar atmosphere. 6.9 (15 
mg, 0.013 mmol, 0.05 equiv) was added to the reaction mixture. In a separate flame dried vial, 
equipped with a stir bar, salicylaldehyde (35 μL, 0.25 mmol, 1.00 equiv) and Et3N (35 μL, 0.25 
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mmol, 1.00 equiv) in CH2Cl2 (0.50 mL) were stirred for 5 min. The allyltrichlorosilane mixture 
was cooled to -78 °C and the salicylaldehyde mixture was added dropwise via syringe rinsing 
with CH2Cl2 (0.25 mL). The reaction was allowed to warm to -40 °C and was subsequently 
stirred for 12 h. Upon consumption of the starting material, the reaction mixture was treated with 
n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) and stirred 1 hr at -40 ºC. The mixture 
was then passed through a silica plug with EtOAc and concentrated to give the crude product, 
which was purified by flash column chromatography (0–25% EtOAc/Hexanes) to give the 




6.8.5. Anion catalyzed decarboxylative aldol 
 
A flame dried vial, equipped with a stir bar, was charged with silicon tetrachloride (32 
μL, 0.28 mmol, 1.10 equiv) and 6.9 (15 mg, 0.013 mmol, 0.05 equiv) in dry CH2Cl2 (0.50 mL) 
under Ar atmosphere. In a separate flame dried vial, equipped with a stir bar, 6.19 (41 mg, 0.25 
mmol, 1.00 equiv) was suspended in CH2Cl2 (1.50 mL). The silicon tetrachloride solution was 
added to the suspension and the reaction mixture was stirred for 1 hr. Hydrocinnamaldehyde (33 
μL, 0.25 mmol, 1.00 eqiuv) was then added and reaction was allowed to stir for 12 hr. the 
reaction mixture was treated with n-Bu4NF (1M in THF, 0.50 mL, 0.50 mmol, 2.00 equiv) and 
stirred 1 hr at 0 ºC. The mixture was then passed through a silica plug with EtOAc and 
concentrated to give the crude product, which was purified by flash column chromatography (0–
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25% EtOAc/Hexanes) to give the product 6.23 as a pale yellow oil (15 mg, 24% yield, 89% ee). 
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